"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0429016 S,049-305-965-002-13X,2000-08-01,2000,US 105551,1999-05-24,,,Lamp housing,,,Cohen; Fred,MINKA LIGHTING INC (1999-10-14),https://lens.org/049-305-965-002-13X,Design Right,yes,3,1,1,1,0,,,D26 67;;D26 72,1,0,,,"Rockscapes lighting catalog, Nov. 1996, p. 28, wall lantern, #WC193-8-V.",UNKNOWN
2,AU,A,AU 2001/029047 A,155-733-161-648-609,2001-05-30,2001,AU 2001/029047 A,2000-11-14,US 16558199 P;;US 69689300 A;;US 0031295 W,1999-11-15,Method and apparatus for network deception/emulation,,FRED COHEN,COHEN FRED,,https://lens.org/155-733-161-648-609,Patent Application,no,0,0,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L29/06;;H04L29/12,,0,0,,,,DISCONTINUED
3,EP,A1,EP 3863634 A1,006-690-403-410-012,2021-08-18,2021,EP 19804825 A,2019-10-11,US 201862744958 P;;IB 2019001105 W,2018-10-12,LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM,,STRONGBRIDGE DUBLIN LTD,COHEN FRED,,https://lens.org/006-690-403-410-012,Patent Application,yes,0,0,3,3,0,A61K31/496;;A61K45/06;;A61P5/38;;A61P5/42;;A61P5/28;;A61K31/496;;A61K45/06,A61K31/496;;A61K45/06;;A61P5/28;;A61P5/38;;A61P5/42,,0,0,,,,PENDING
4,DE,B1,DE 1639373 B1,055-240-287-553-727,1971-10-21,1971,DE R0047834 A,1968-01-19,US 61067067 A,1967-01-20,HALBLEITERBAUELEMENT MIT ERHOEHTER WIDERSTANDSFAEHIGKEIT GEGEN SEKUNDAERDURCHBRUCH UND VERFAHREN ZUM HERSTELLEN EINES SOLCHEN HALBLEITERBAUELEMENTES,,RCA CORP,COHEN FRED,,https://lens.org/055-240-287-553-727,Patent Application,no,0,0,6,6,0,H01L29/00;;H01L29/0813;;H01L29/66303;;H01L29/0813;;H01L29/66303;;H01L29/00,H01L29/73;;H01L21/331;;H01L29/00;;H01L29/08,,1,0,,,None,EXPIRED
5,US,S,US D0706920 S,132-632-315-464-769,2014-06-10,2014,US 201229431990 F,2012-09-12,US 201229431990 F,2012-09-12,Ceiling fan motor housing,,COHEN FRED;;AIR COOL IND CO LTD,COHEN FRED,AIR COOL INDUSTRIAL CO. LTD (2012-08-20),https://lens.org/132-632-315-464-769,Design Right,no,0,1,1,1,0,,,2304;;D23/411,0,0,,,,ACTIVE
6,US,B1,US 7107347 B1,119-999-561-070-159,2006-09-12,2006,US 69689300 A,2000-10-26,US 69689300 A;;US 16558199 P,1999-11-15,Method and apparatus for network deception/emulation,"A number of innovations in the field of networking are disclosed. These techniques use multiple address translation to achieve effective deceptions, emulations, extended private networks and related goals. A further embodiment using a deception network having a number of different actual computer systems each performing emulation where deceived datagrams are routed to an actual machine that is particularly able to perform the desired emulation. The invention allows the emulation to receive a datagram just at it would appear at an external access point, operate on that datagram and return a datagram which is then passed through a deception wall using multiple address translations.",COHEN FRED,COHEN FRED,MANAGEMENT ANALYTICS INC (2014-07-05),https://lens.org/119-999-561-070-159,Granted Patent,yes,12,92,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L9/32;;H04L12/24;;H04L29/06;;H04L29/12,709/229;;709/218;;709/223;;713/201;;713/202;;713/200,38,5,064-845-554-764-907;;067-664-665-735-064;;000-179-897-447-096;;022-350-828-151-078;;018-860-141-942-004,10.1109/risp.1992.213257;;10.1016/s0167-4048(98)80099-0;;10.1016/s0167-4048(99)80115-1;;10.1016/1353-4858(96)83738-x;;10.1016/s1353-4858(00)90001-1,"Hasenstein, M.; Diplomarbeit, IP Network Address Translation, http:www.suse.de/~mha/HyperNews/get/linux-ip-nat.html (1997) 32 pages.;;Microsoft TechNet; SNA Open Gateway Architecture, http://www.microsoft.com/TechNet/sna/technote/soga.asp, pp. 1-20.;;Gateways, http://www.sohointer.net, 15 pages.;;ComSoft Knowledge Share; http://www.vicomsoft.com/knowledge/reference/firewalls1.html, pp. 1-10.;;Microsoft Windows 2000 Server Documentation http://www.windows.com/windows2000/en/server/help/sag<SUB>-</SUB>rras-ch2-adv<SUB>-</SUB>11.htm, 1 page.;;Cisco IOS Network Address Translation (NAT) http://www.ieng.com/warp/public/701/60.html, pp. 1-9.;;ENTERASYS Networks, Network Address Translation, http://www.enterasys.com/products/whitepapers/ssr/network-trans/ pp. 1-6.;;Winkler, J.R., A Unix Prototype For Intrusiion And Anomaly Detection In Secure Networks, Proceedings, National Computer Security Conference, Washington D.C. Oct. 1990, Planning Research Corp.;;Sebring, M.M, et al. Expert Systems In Intrusion Detection; A Case-Study, Proceedings of the 11<SUP>th </SUP>National Computer Security Conference, 1988, pp. 74-81.;;Debar, H., et al. A Neural Network Component For An Intrusion Detection System, Proceedings of the 1992 IEEE Computer Society Symposium on Research in Security and Privacy, Cedex, France, 1992 pp. 240-250.;;Dowell, C., et al. The ComputerWatch Data Reduction Tool, Proceedings of the 13<SUP>th </SUP>National Computer Security Conference, 1990, pp. 99-108.;;Snapp, S.R. et al, DIDS (Distributed Intrusion Detection System)-Motivation, Architecture, And An Early Prototype, Proceedings of the 14<SUP>th </SUP>National Computer Security Conference, 1991, pp. 167-176.;;Tener, William T., Discovery; An Exret System In The Commerical Data Security Environment., Originally presented at the Fourth IFIP Symposium on Information Systems Security, Monte Carlo, 1986. Also appeared in Security and Protection in Information Systems, ed. Andre Grissonanche, pp. 261-268. 1989 Elsevieer Science Publishers, B.V. (North Holland) pp. 45-53 as submitted.;;Smapp, S.R. Signature Analysis And Communication Issues In A Distributed Intrusion Detection System, 1991, Committee in Charge, submitted in partial satisfaction of the requirements for Master of Science in Computer Science at the University of California Davis pp. 1-40.;;Avritzer, A. et al., Reliability Testing Of Rule-Based Systems, 1996 International Symposium on Software Reliability Engineering, White Plains, N.Y., Oct. 30-Nov. 2, (7 pages).;;Venter, H.S. et al. ""Data Packet Intercepting on the Internet: How and Why? A Closer look at Existing Data Packet-Intercepting Tools"" Computers & Security. International Journal Devoted to the Study of Technical and Financial Aspects of Computer Security, Elsevier Science Publishers. Amsterdam, NL vol. 17, No. 8, 1998, pp. 683-692, XP004150446 ISSN: 0167-4048.;;Cohen F., ""Simulating Cyber Attacks, Defences, and Consequences"" Computers & Security, International Journal Devoted to the Study of Technical and Financial Aspects of Computer Security, Elsevier Science Publishers. Amsterdam, NL, vol. 18, No. 6, 1999, pp. 479-518, XP004178853 ISSN: 0167-4048.;;Bellovin (1992) ""There Be Dragons."" Proceedings of the Third Usenix UNIX Security Symposium. Baltimore (Sep. 1992). World Wide Web at http://www.research.att.com/~smb/papers/dragon.pdf.;;Cheswick et al. (1991) ""An Evening with Berferd: In Which a Cracker is Lured, Endured and Studied"". World Wide Web at http://www.deter.com/unix/papers/berferd<SUB>-</SUB>cheswick.pdf.;;Cisco Systems Inc. (1999) ""Cisco IOS Network Address Translation (NAT)"" World Wide Web at http://www.ieng.com/warp/public/701/60.html. pp. 1-9 of 9.;;Cohen (1992) ""Operating System Protection Through Program Evolution Computers and Security"", World Wide Web at http://all.net/books/IP/evolve.html. pp. 1-22 of 22.;;Cohen (1996) ""A Note on Detecting Tampering with Audit Trails IFIP-TC11"" Computers and Security. World Wide Web at http://www.all.net/books/audit/audmod.html. pp. 1-10 of 10.;;Cohen (1996) ""A Note On Distributed Coordinated Attacks"". World Wide Web at http://www.all.net/books/dca/background.html. p. 1 of 1.;;Cohen (1996) ""Internet Holes-Incident at All.Net"". Network Security Magazine, Apr. 1996. World Wide Web at http://all.net/journal/netsec/1996-04.html. p. 1-11 of 11 total.;;Cohen (1996) ""Internet Holes-Internet Lightning Rods"" Network Security Magazine, (Jul. 1996). World Wide Web at http://all.net/journal/netsec/1996-07-2.html. pp. 1-5 of 5.;;Cohen (1996) ""Internet Holes-The Human Element"" Network Security Magazine, Mar. 1996. World Wide Web at http://all.net/journal/netsec/1996-03.html. pp. 1-5 of 5.;;Cohen (1996) ""National Info-Sec Technical Baseline-Intrusion Detection and Response"" World Wide Web at http://www.all.net/journal/ntb/ids.html. pp. 1-21 of 21.;;Cohen (1996) ""Why is thttpd Secure?"" Computers and Security. World Wide Web at http://www.all.net/journal/white/whitepaper.html. pp. 1-11 of 11 total.;;Cohen (1998) ""National InfoSec Technical Baseline-At the Intersection of Security, Networking, and Management"" World Wide Web at http://www.all.net/journal/ntb/nsm.html. pp. 1-17 of 17.;;ENTERASYS Networks (2000) ""Network Address Translation"" World Wide Web at http://www.enterasys.com/product/whitepapers/ssr/network-trans/. pp. 1-6 of 6.;;Hasenstein (1997) ""DIPLOMARBEIT: IP Network Address Translation"" World Wide Web at http://www.suse.de/~mha/linux-ip-nat/diplom/. 32 pages.;;MICROSOFT Corporation (2000) ""Microsoft TechNet: SNA Open Gateway Architecture"" World Wide Web at http://www.microsoft.com/TechNet/sna/technote/soga.asp. pp. 1-20.;;MICROSOFT Corporation (2000) ""Microsoft Windows 2000 Server Documentation"" World Wide Web at http://www.windows.com/windows2000/en/server/help/sag<SUB>-</SUB>rras-ch2-adv<SUB>-</SUB>11.htm. p. 1 of 1.;;Six Sigma Networks (2000) ""Types of Internet Gateways"" World Wide Web at http://www.sohointer.net/team/gateways.htm, pp. 1-15 of 15 total.;;VICOM Technology Ltd. (2000) ""ViComSoft Knowledge Share Firewall: Q & A"". World Wide Web at http://www.vicomsoft.com/knowledge/reference/firewalls1.html. pp. 1-10 of 10.;;Cohen (1985) ""Algorithmic Authentication of Identification."" Information Age, V7, #1 (Jan. 1985), pp. 35-41.;;Cohen (1998) ""Managing Network Security: The Unpredictability Defense."" Located on the World Wide Web at http://all.net/journal/netsec/1998-04.html. Fred Cohen & Associates, Apr. 1998.;;Cohen et al. (1998) ""A Preliminary Classification Scheme for Information System Threats, Attacks, and Defenses; A Cause and Effect Model; and Some Analysis Based on That Model."" Located on the World Wide Web at http://all.net/journal/ntb/cause-and-effect.html. Sandia National Laboratories, Sep. 1998.",EXPIRED
7,US,B2,US 7516227 B2,187-368-781-389-036,2009-04-07,2009,US 46330106 A,2006-08-08,US 46330106 A;;US 69689300 A;;US 16558199 P,1999-11-15,Method and apparatus for network deception/emulation,"A number of innovations in the field of networking are disclosed. These techniques use multiple address translation to achieve effective deceptions, emulations, extended private networks and related goals. A further embodiment using a deception network having a number of different actual computer systems each performing emulation where deceived datagrams are routed to an actual machine that is particularly able to perform the desired emulation. The invention allows the emulation to receive a datagram just at it would appear at an external access point, operate on that datagram and return a datagram which is then passed through a deception wall using multiple address translations.",COHEN FRED,COHEN FRED,COHEN FRED (2019-10-16);;MANAGEMENT ANALYTICS INC (2014-07-05),https://lens.org/187-368-781-389-036,Granted Patent,yes,17,40,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L9/32;;H04L29/06;;H04L29/12,709/228;;709/220;;709/224;;713/202,38,4,064-845-554-764-907;;067-664-665-735-064;;000-179-897-447-096;;018-860-141-942-004,10.1109/risp.1992.213257;;10.1016/s0167-4048(98)80099-0;;10.1016/s0167-4048(99)80115-1;;10.1016/s1353-4858(00)90001-1,"Hasenstein, M.; Diplomarbeit, IP Network Address Translation, http:www.suse.de/~mha/HyperNews/get/linux-ip-nat.html (1997) 32 pages.;;Microsoft TechNet; SNA Open Gateway Architecture, http://www.microsoft.com/TechNet/sna/technote/soga.asp, pp. 1-20.;;Gateways, http://www.sohointer.net, 15 pages.;;ComSoft Knowledge Share; http://www.vicomsoft.com/knowledge/reference/firewalls 1.html, pp. 1-10.;;Microsoft Windows 2000 Server Documentation http://www.windows.com/windows2000/en/server/help/sag-rras-ch2-adv-11.htm, 1 page.;;Cisco IOS Network Address Translation (NAT) http://www.ieng.com/warp/public/701/60.html, pp. 1-9.;;Enterasys Networks, Network Address Translation, http://www.enterasys.com/products/whitepapers/ssr/network-trans/ pp. 1-6.;;Winkler, J.R., A Unix Prototype for Intrusion and Anomaly Detection In Secure Networks, Proceedings, National Computer Security Conference, Washington D.C. Oct. 1990, Planning Research Corp.;;Sebring, M.M, et al. Expert Systems in Intrusion Detection; A Case-Study, Proceedings of the 11th National Computer Security Conference, 1998, pp. 74-81.;;Debar, H., et al. A Neural Network Component For An Intrusion Detection System, Proceedings of the 1992 IEEE Computer Society Symposium on Research in Security and Privacy, Cedex, France, 1992 pp. 204-250.;;Dowell, C., et al. The ComputerWatch Data Reduction Tool, Proceedings of the 13th National Computer Security Conference, 1990, pp. 99-108.;;Snapp, S.R. et al, DIDS (Distributed Intrusion Detection System) - Motivation, Architecture, And An Early Prototype, Proceedings of the 14th National Computer Security Conference, 1991, pp. 167-176.;;Tener, William T., Discovery; An Exret System in the Commercial Data Security Environment., Originally presented at the Fourth IFIP Symposium on Information Systems Security, Monte Carlo, 1986. Also appeared in Security and Protection in Information Systems, ed. Andre Grissonanche, pp. 261-68. 1989 Elsevieer Science Publishers, B.V. (North Holland) pp. 45-53 as submitted.;;Snapp, S.R. Signature Analysis and Communication Issues In A Distributed Intrusion Detection System, 1991, Committee in Charge, submitted in partial satisfaction of the requirements for Master of Science in Computer Science at the University of California Davis pp. 1-40.;;Avritzer, A. et al., Reliability Testing of Rule-Based Systems, 1996 International Symposium on Software Reliability Engineering, White Plains, N.Y., Oct. 30-Nov. 2. (7 pages).;;Venter, H.S. et al. ""Data Packet Intercepting on the Internet: How and Why? A Closer look at Existing Data Packet-Intercepting Tools"" Computers & Security. International Journal Devoted to the Study of Technical and Financial Aspects of Computer Security, Elsevier Science Publishers. Amsterdam, NL vol. 17, No. 8, 1998, pp. 683-692, XP004150446 ISSN: 0167-4048.;;Cohen F., ""Simulating Cyber Attacks, Defences, and Consequences"" Computers & Security, International Journal Devoted to the Study of Technical and Financial Aspects of Computer Security, Elsevier Science Publishers. Amsterdam, NL, vol. 18, No. 6, 1999, pp. 479-518, XP004178853 ISSN: 0167-4048.;;Bellovin (1992) ""There Be Dragons."" Proceedings of the Third Usenix UNIX Security Symposium. Baltimore (Sep. 1992). World Wide Web at http://www.research.att.com/~smb/papers/dragon.pdf.;;Cheswick et al. (1991) ""An Evening with Berferd: In Which a Cracker is Lured, Endured, and Studied"". World Wide Web at http://www.deter.com/unix/papers/berferd-cheswick.pdf.;;Cisco Systems Inc. (1999) ""Cisco IOS Network Address Translation (NAT)"" World Wide Web at http://www.ieng.com/warp/public/701/60.html. pp. 1-9 of 9.;;Cohen (1992) ""Operating System Protection Through Program Evolution Computers and Security"". World Wide Web at http://all.net/books/IP/evolve.html. pp. 1-22 of 22.;;Cohen (1996) ""A Note on Detecting Tampering with Audit Trails IFIP-TC11"" Computers and Security. World Wide Web at http://www.all.net/books/audit/audmod.html. pp. 1-10 of 10.;;Cohen (1996) ""A Note on Distributed Coordinated Attacks"". World Wide Web at http://www.all.net/books/dca/background.html. p. 1 of 1.;;Cohen (1996) ""Internet Holes - Incident at All.Net"", Network Security Magazine, Apr., 1996. World Wide Web at http://all.net/journal/netsec/1996-04,html. pp. 1-11 of 11 total.;;Cohen (1996) ""Internet Holes - Internet Lightning Rods"" Networks Security Magazine, (Jul., 1996), World Wide Web at http://all.net/journal/netsec/1996-07-2.html. pp. 1-5 of 5.;;Cohen (1996) ""Internet Holes - The Human Element"" Network Security Magazine, Mar., 1996. World Wide Web at http://all.net/journal/netsec/1996-03.html. pp. 1-5 of 5.;;Cohen (1996) ""National Info-Sec Technical Baseline - Intrusion Detection and Response"" World Wide Web at http://www.all.net/journal/ntb/ids.html. pp. 1-21 of 21.;;Cohen (1996) ""Why is thttpd Secure?"" Computers and Security. World Wide Web at http://ww.all.net/journal/white/whitepaper.html. pp. 1-11 of 11 total.;;Cohen (1998) ""National InfoSec Technical Baseline - At the Intersection of Security, Networking, and Management"" World Wide Web at http://www.all.net/journal/ntb/nsm.html. pp. 1-17 of 17.;;Enterasys Networks (2000) ""Network Address Translation"" World Wide Web at http://www.enterasys.com/products /whitepapers/ssr/network-trans/. pp. 1-6 of 6.;;Hasenstein (1997) ""Diplomarbeit: IP Network Address Translation"" World Wide Web at http://www.suse.de/~mha/linux-ip-nat/diplom/. 32 pages.;;Microsoft Corporation (2000) ""Microsoft TechNet: SNA Open Gateway Architecture"" World Wide Web at http://www.microsoft.com/TechNet/sna/technote/soga.asp. pp. 1-20.;;Microsoft Corporation (2000) ""Microsoft Windows 2000 Servers Documentation"" World Wide Web at http://www.windows.com/windows2000/en/server/help/sag-rras-ch2-adv-11.htm. p. 1 of 1.;;Six Sigma Networks (2000) ""Types of Internet Gateways"" World Wide Web at http://www.sohointer.net/learn/gataways.htm, pp. 1-15 of 15 total.;;Vicom Technology Ltd. (2000) ""ViComSoft Knowledge Share Firewall: Q & A"". World Wide Web at http://www.vicomsoft.com/knowledge/reference/firewalls1.html. pp. 1-10 of 10.;;Cohen (1985) ""Algorithmic Authentication of Identification."" Information Age, V7, #1 (Jan. 1985), pp. 35-41.;;Cohen (1998) ""Managing Network Security: The Unpredictability Defense."" Located on the World Wide Web at http://all.net/journal/netsec/1998-04.html. Fred Cohen & Associates, Apr. 1998.;;Cohen et al. (1998) ""A Preliminary Classification Scheme for Information System Threats, Attacks, and Defenses; A Cause and Effect Model; and Some Analysis Based on That Model."" Located on the World Wide Web at http://all.net/journal/ntb/cause-and-effect.html. Sandia National Laboratories, Sep. 1998.",EXPIRED
8,EP,A2,EP 1290847 A2,066-366-857-189-537,2003-03-12,2003,EP 00993131 A,2000-11-14,US 0031295 W;;US 16558199 P;;US 69689300 A,1999-11-15,METHOD AND APPARATUS FOR NETWORK DECEPTION/EMULATION,,COHEN FRED,COHEN FRED,,https://lens.org/066-366-857-189-537,Patent Application,yes,0,0,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L29/06;;H04L29/12,,0,0,,,,DISCONTINUED
9,WO,A3,WO 2001/037510 A3,086-424-081-954-77X,2002-02-21,2002,US 0031295 W,2000-11-14,US 16558199 P;;US 69689300 A,1999-11-15,METHOD AND APPARATUS FOR NETWORK DECEPTION/EMULATION,"A number of innovations in the field of networking are disclosed. These techniques use multiple address translation to achieve effective deceptions, emulations, extended private networks and related goals. A further embodiment using a deception network having a number of different actual computer systems each performing emulation where deceived datagrams are routed to an actual machine that is particularly able to perform the desired emulation. The invention allows the emulation to receive a datagram just as it would appear at an external access point, operate on that datagram and return a datagram which is then passed through a deception wall using multiple address translations.",COHEN FRED,COHEN FRED,,https://lens.org/086-424-081-954-77X,Search Report,yes,0,0,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L29/06;;H04L29/12,,2,2,067-664-665-735-064;;000-179-897-447-096,10.1016/s0167-4048(98)80099-0;;10.1016/s0167-4048(99)80115-1,"VENTER H S ET AL: ""Data Packet Intercepting on the Internet: How and Why? A Closer Look at Existing Data Packet-Intercepting Tools"", COMPUTERS & SECURITY. INTERNATIONAL JOURNAL DEVOTED TO THE STUDY OF TECHNICAL AND FINANCIAL ASPECTS OF COMPUTER SECURITY, ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM, NL, vol. 17, no. 8, 1998, pages 683 - 692, XP004150446, ISSN: 0167-4048;;COHEN F: ""Simulating Cyber Attacks, Defences, and Consequences"", COMPUTERS & SECURITY. INTERNATIONAL JOURNAL DEVOTED TO THE STUDY OF TECHNICAL AND FINANCIAL ASPECTS OF COMPUTER SECURITY, ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM, NL, vol. 18, no. 6, 1999, pages 479 - 518, XP004178853, ISSN: 0167-4048",PENDING
10,CA,A,CA 827846 A,109-274-347-007-000,1969-11-18,1969,CA 827846D A,,CA 827846T A,,SEMICONDUCTOR DEVICES,,RCA CORP,COHEN FRED,,https://lens.org/109-274-347-007-000,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
11,US,S,US D0429834 S,172-367-955-928-37X,2000-08-22,2000,US 10539999 F,1999-05-24,US 10539999 F,1999-05-24,Lamp housing,,MINKA LIGHTING INC,COHEN FRED,MINKA LIGHTING INC (1999-10-19),https://lens.org/172-367-955-928-37X,Design Right,yes,3,1,1,1,0,,,D26/72;;2605,0,0,,,,EXPIRED
12,US,A1,US 2021/0220352 A1,170-919-397-656-532,2021-07-22,2021,US 202117226640 A,2021-04-09,IB 2019001105 W;;US 201862744958 P,2018-10-12,LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM,"Disclosed are methods for treating for treating congenital adrenal hyperplasia or primary aldosteronism in a subject in need thereof, comprising administering a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said subject. Also disclosed are compositions comprising a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer for use in treating a disease or condition associated with congenital adrenal hyperplasia or primary aldosteronism.",STRONGBRIDGE DUBLIM LTD,COHEN FRED,,https://lens.org/170-919-397-656-532,Patent Application,yes,0,0,3,3,0,A61K31/496;;A61K45/06;;A61P5/38;;A61P5/42;;A61P5/28;;A61K31/496;;A61K45/06,A61K31/496;;A61K45/06,,8,6,095-146-600-587-756;;089-929-134-684-340;;010-645-872-815-401;;084-190-130-640-661;;097-957-714-121-219;;029-231-028-743-924,10494456;;10.1016/s0006-3223(99)00081-5;;pmc9376294;;10.3389/fendo.2022.934675;;35979433;;10.1016/s0149-2918(96)80017-8;;8829014;;10.4158/ep.14.7.889;;18996819;;23313950;;10.1097/maj.0b013e31827ad893;;10.1016/j.tem.2008.01.006;;18314347,"Jacobs et al., ""Late-onset congenital adrenal hyperplasia: a treatable cause of anxiety"", 1999, Society of Biological Psychiatry, 46, pgs. 856-859 (Year: 1999);;Auchus et al., ""2S,4R-Ketoconazole Is The Relevant Enantiomer Of Ketoconazole For Cortisol Synthesis Inhibition: Steroidogenic P450s Inhibition Involves Multiple Mechanisms"", 2018, Endocrine Society, Presented Abstract (Year: 2018);;Barbot et al., ""Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia"", 2022, Frontiers in Endocrinology, 13, pgs. 01-10 (Year: 2022);;Campbell et al., ""Metformin: a new oral biguanide"", 1996, Clinical Therapeutics, 18, pgs. 360-371 (Year: 1996);;Mapas-Dimaya et al., ""Metformin-responsive classic salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a case report"", 2008, Endocrine Practice, 14, Abstract Only (Year: 2008);;Kashiwagi et al., ""Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone"", 2013, The American Journal of the Medical Sciences, 345, Abstract Only (Year: 2013);;Rossi et al., ""Primary aldosteronism: cardiovascular, renal and metabolic implications"", 2008, Trends in Endocrinology and Metabolism, 19, pgs. 88-90 (Year: 2008);;Sonino et al., ""Effect of short-term ketoconazole administration in primary aldosteronism"", 1988, Medical Science Research, 16, pgs. 535-536. (Year: 1988)",PENDING
13,US,A1,US 2007/0115993 A1,058-122-109-330-493,2007-05-24,2007,US 46330106 A,2006-08-08,US 46330106 A;;US 69689300 A;;US 16558199 P,1999-11-15,METHOD AND APPARATUS FOR NETWORK DECEPTION/EMULATION,"A number of innovations in the field of networking are disclosed. These techniques use multiple address translation to achieve effective deceptions, emulations, extended private networks and related goals. A further embodiment using a deception network having a number of different actual computer systems each performing emulation where deceived datagrams are routed to an actual machine that is particularly able to perform the desired emulation. The invention allows the emulation to receive a datagram just at it would appear at an external access point, operate on that datagram and return a datagram which is then passed through a deception wall using multiple address translations.",COHEN FRED,COHEN FRED,COHEN FRED (2019-10-16);;MANAGEMENT ANALYTICS INC (2014-07-05),https://lens.org/058-122-109-330-493,Patent Application,yes,6,32,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L12/56;;H04L29/06;;H04L29/12,370/392;;370/401,0,0,,,,EXPIRED
14,US,A,US 3448354 A,124-540-632-296-73X,1969-06-03,1969,US 3448354D A,1967-01-20,US 61067067 A,1967-01-20,SEMICONDUCTOR DEVICE HAVING INCREASED RESISTANCE TO SECOND BREAKDOWN,,RCA CORP,COHEN FRED,,https://lens.org/124-540-632-296-73X,Granted Patent,no,7,7,6,6,0,H01L29/00;;H01L29/0813;;H01L29/66303;;H01L29/0813;;H01L29/66303;;H01L29/00,H01L21/331;;H01L29/00;;H01L29/73;;H01L29/08,317/235,0,0,,,,EXPIRED
15,US,S,US D0707345 S,111-762-651-085-542,2014-06-17,2014,US 201229432007 F,2012-09-12,US 201229432007 F,2012-09-12,Fan blade iron,,COHEN FRED;;AIR COOL IND CO LTD,COHEN FRED,AIR COOL INDUSTRIAL CO. LTD (2012-08-20),https://lens.org/111-762-651-085-542,Design Right,no,0,1,1,1,0,,,2304;;D23/411,0,0,,,,ACTIVE
16,US,S,US D0447264 S,129-063-711-421-749,2001-08-28,2001,US 11593199 F,1999-12-22,US 11593199 F,1999-12-22,Lamp housing,,MINKA LIGHTING INC,COHEN FRED,MINKA LIGHTING INC (2000-04-24),https://lens.org/129-063-711-421-749,Design Right,yes,2,1,1,1,0,,,D26/72;;2605,4,0,,,"Home Lighting & Accessories, lamps at lower left of p. 128, Mar. 1998.*;;Home Lighting & Accessories, lamp at center of p. 68, Mar. 1998.*;;Minka Lighting, Inc.; The Great Outdoors: Collection of Outdoor Lighting, Minka Lavery; Jan. 29, 1999; pp. 16, 17; ML99-2-ON; Minka Lighting, Inc.; U.S.A.;;Minka Lighting Inc.; Metropolitan; Jul. 30, 1998; p. 139; Metro 98; Minka Lighting, Inc.; U.S.A.",EXPIRED
17,US,A,US 4696029 A,059-863-440-264-574,1987-09-22,1987,US 80824985 A,1985-12-12,US 80824985 A,1985-12-12,Telephone traffic load control system,"A system for controlling the initiation of voting telephone calls by controlling character generators at a group of affiliated television broadcast stations through a control center which receives real-time feedback of telephone voting traffic data from polling terminals at telephone central offices and utilizes this information to regulate visual stimuli broadcast by the television station. The control center initiates polling traffic by causing associated character generators at the affiliate transmitter to produce the desired message displays across the TV screen. The control center monitors the polling call traffic at each central office until it determines that the traffic being generated has reached a level which is not within the traffic-handling capabilities of that particular central office switching machines. It then sends messages which cause the character generators at the local affiliate to reduce the frequency and/or duration of the message until the traffic generated has dropped to a level which is within the traffic handling capabilities of the central office, whereupon the frequency and/or duration is again increased.",TELESCIENCES INC,COHEN FRED,TELESCIENCES INC. MOUNT LAUREL NJ A CORP. OF NJ (1985-11-29),https://lens.org/059-863-440-264-574,Granted Patent,yes,8,59,1,1,0,H04H60/33;;H04H60/33;;H04M3/36;;H04M3/36;;H04M3/46;;H04M3/46;;H04M3/465;;H04M3/465;;H04M2203/1041;;H04M2203/1041,H04H1/00;;H04H60/33;;H04M3/36;;H04M3/46,379/92;;379/93;;379/112;;379/138;;358/85;;455/2,2,0,,,"PCT application, WO 85/03830, AT&T, Method and Apparatus for Subscription Broadcast , 8/29/85.;;Yankee Group, Telco Pay Per View System , Report No. 83 1, 6/83.",EXPIRED
18,US,S,US D0706917 S,071-553-349-314-551,2014-06-10,2014,US 201229431999 F,2012-09-12,US 201229431999 F,2012-09-12,Combined ceiling fan and light kit,,COHEN FRED;;AIR COOL IND CO LTD,COHEN FRED,AIR COOL INDUSTRIAL CO. LTD (2012-08-20),https://lens.org/071-553-349-314-551,Design Right,no,0,6,1,1,0,,,2304;;D23/385;;D23/377,0,0,,,,ACTIVE
19,WO,A1,WO 2020/074958 A1,136-470-253-102-928,2020-04-16,2020,IB 2019001105 W,2019-10-11,US 201862744958 P,2018-10-12,LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM,"Disclosed are methods for treating congenital adrenal hyperplasia or primary aldosteronism in a subject in need thereof, comprising administering a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said subject. Also disclosed are compositions comprising a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer for use in treating a disease or condition associated with congenital adrenal hyperplasia or primary aldosteronism.",STRONGBRIDGE DUBLIN LTD,COHEN FRED,,https://lens.org/136-470-253-102-928,Patent Application,yes,18,0,3,3,0,A61K31/496;;A61K45/06;;A61P5/38;;A61P5/42;;A61P5/28;;A61K31/496;;A61K45/06,A61K31/496;;A61K45/06;;A61P5/28;;A61P5/38;;A61P5/42,,6,3,130-315-332-577-675;;025-511-502-551-980;;022-035-025-657-69X,1835031;;10.1155/2010/670960;;10.1186/1687-9856-2010-670960;;20652035;;pmc2905899;;10.1021/jm00093a015;;1495014,"SONINO N ET AL: ""Effect of short-term ketoconazole administration in primaryaldosteronism"", MEDICAL SCIENCE RESEARCH, ELSEVIER APPLIED SCIENCE, BARKING, GB, vol. 16, no. 10, 1 January 1988 (1988-01-01), pages 535 - 536, XP009518510, ISSN: 0269-8951;;AGUILAR DIOSDADO M ET AL: ""Traitement de l'hyperaldostéronisme primaire par le kétoconazole - [Treatment of primary hyperaldosteronism with ketoconazole]"", PRESSE MEDICALE, PRESSE MEDICALE, PARIS, FR, vol. 20, no. 30, 28 September 1991 (1991-09-28), pages 1456, XP009518512, ISSN: 0755-4982;;KARENJ LOECHNER ET AL: ""Alternative Strategies for the Treatment of Classical Congenital Adrenal Hyperplasia: Pitfalls and Promises"", INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 2010, no. 1, 8 June 2010 (2010-06-08), pages 670960, XP021109266, ISSN: 1687-9856, DOI: 10.1186/1687-9856-2010-670960;;JACQUES ET AL.: ""Enantiomers, Racemates and Resolutions"", 1981, WILEY;;ROTSTEIN ET AL., J. MED. CHEM., vol. 35, no. 15, 1992, pages 2818 - 25;;FARHADIMALEKI: ""A new spectrophotometric method for the determination of ketoconazole based on the oxidation reactions"", ANALYTICAL SCIENCES, vol. 17, 2001, pages i867 - i869",PENDING
20,US,S,US D0427714 S,005-369-685-797-237,2000-07-04,2000,US 10540199 F,1999-05-24,US 10540199 F,1999-05-24,Lighting fixture backplate,,MINKA LIGHTING INC,COHEN FRED,MINKA LIGHTING INC (2000-04-24),https://lens.org/005-369-685-797-237,Design Right,yes,1,1,1,1,0,,,D26/142;;2699,0,0,,,,EXPIRED
21,WO,A3,WO 2009/026589 A3,043-012-547-334-302,2009-04-23,2009,US 2008/0074257 W,2008-08-25,US 95745507 P,2007-08-23,METHOD AND/OR SYSTEM FOR PROVIDING AND/OR ANALIZING AND/OR PRESENTING DECISION STRATEGIES,A method and/or system that can be implemented on a computing device or tables or board game or otherwise uses a rule set to evaluate data about a situation and actors in order to provide advice regarding strategies for influencing actors and/or other outputs.,COHEN FRED,COHEN FRED,,https://lens.org/043-012-547-334-302,Search Report,yes,5,0,7,7,0,G06Q30/02;;G06T11/206;;G06Q30/02;;G06T11/206;;G06Q10/067,G06F17/00;;G06F19/00,,0,0,,,,PENDING
22,US,S,US D0706921 S,065-284-190-232-596,2014-06-10,2014,US 201229431996 F,2012-09-12,US 201229431996 F,2012-09-12,Fan blade iron,,COHEN FRED;;AIR COOL IND CO LTD,COHEN FRED,AIR COOL INDUSTRIAL CO. LTD (2012-08-20),https://lens.org/065-284-190-232-596,Design Right,no,0,2,1,1,0,,,2304;;D23/411,0,0,,,,ACTIVE
23,WO,A2,WO 2001/037510 A2,163-529-468-181-291,2001-05-25,2001,US 0031295 W,2000-11-14,US 16558199 P;;US 69689300 A,1999-11-15,METHOD AND APPARATUS FOR NETWORK DECEPTION/EMULATION,"A number of innovations in the field of networking are disclosed. These techniques use multiple address translation to achieve effective deceptions, emulations, extended private networks and related goals. A further embodiment using a deception network having a number of different actual computer systems each performing emulation where deceived datagrams are routed to an actual machine that is particularly able to perform the desired emulation. The invention allows the emulation to receive a datagram just as it would appear at an external access point, operate on that datagram and return a datagram which is then passed through a deception wall using multiple address translations.",COHEN FRED,COHEN FRED,,https://lens.org/163-529-468-181-291,Patent Application,yes,0,10,7,14,0,H04L61/25;;H04L63/0218;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L63/1441;;H04L63/0218;;H04L63/1491;;H04L61/25;;H04L61/00,H04L12/24;;H04L29/06;;H04L29/12,,0,0,,,,PENDING
24,WO,A2,WO 2009/026589 A2,039-578-285-356-410,2009-02-26,2009,US 2008/0074257 W,2008-08-25,US 95745507 P,2007-08-23,METHOD AND/OR SYSTEM FOR PROVIDING AND/OR ANALIZING AND/OR PRESENTING DECISION STRATEGIES,A method and/or system that can be implemented on a computing device or tables or board game or otherwise uses a rule set to evaluate data about a situation and actors in order to provide advice regarding strategies for influencing actors and/or other outputs.,COHEN FRED,COHEN FRED,,https://lens.org/039-578-285-356-410,Patent Application,yes,0,14,7,7,0,G06Q30/02;;G06T11/206;;G06Q30/02;;G06T11/206;;G06Q10/067,G06F17/00;;G06F19/00,,0,0,,,,PENDING
25,US,A1,US 2007/0156814 A1,057-506-340-424-026,2007-07-05,2007,US 59172506 A,2006-11-01,US 59172506 A;;US 75523805 P,2005-12-30,Method and/or system for providing and/or analyzing influence strategies,A method and/or system that can be implemented on a computing device or tables or board game or otherwise uses a rule set to evaluate data about a situation and actors in order to provide advice regarding strategies for influencing actors and/or other outputs.,COHEN FRED,COHEN FRED,MANAGEMENT ANALYTICS INC (2014-07-05),https://lens.org/057-506-340-424-026,Patent Application,yes,3,3,2,2,0,G06Q50/20;;G06Q50/20,G06F15/16,709/204,0,0,,,,ACTIVE
26,US,A1,US 2023/0351414 A1,096-140-285-072-726,2023-11-02,2023,US 202318144625 A,2023-05-08,US 202318144625 A;;US 202117236898 A;;US 19801108 A;;US 95745507 P,2007-08-23,METHOD AND/OR SYSTEM FOR PROVIDING AND/OR ANALYZING AND/OR PRESENTING DECISION STRATEGIES,A method and/or system that can be implemented on a computing device or tables or board game or otherwise uses a rule set to evaluate data about a situation and actors in order to provide advice regarding strategies for influencing actors and/or other outputs.,MAN ANALYTICS INC,COHEN FRED,MANAGEMENT ANALYTICS INC (2014-07-05),https://lens.org/096-140-285-072-726,Patent Application,yes,0,0,7,7,0,G06Q30/02;;G06T11/206;;G06Q30/02;;G06T11/206;;G06Q10/067,G06Q30/02;;G06Q10/067;;G06T11/20,,0,0,,,,PENDING
27,US,A1,US 2002/0125665 A1,070-980-008-873-064,2002-09-12,2002,US 9375002 A,2002-03-08,US 9375002 A;;US 27508501 P,2001-03-12,Rollable support for luggage,"
   A rollable support assembly for luggage includes a pair of longitudinal adjustable in length supports having ends terminating in curved end portions so that the major length of the supports rests against the underside of the luggage while the end portions wrap around the corners of the luggage. Additionally, a pair of transverse cross braces which are adjustable in length and incorporate a separate end piece at one end that fits around the luggage corner to terminate adjacent the side thereof. One end of each brace rollably supports a swivel wheel while the opposite end supports a wheel having a fixed axis. Fastening means are employed for fixly securing the supports and the braces to the luggage in appropriate areas such as when the luggage is hard or soft and has a rigid bottom, rigid or soft sides, or a combination of both. Spacers accommodate fitting of the component parts to the luggage. The supports may be placed inside the luggage with the wheeled braces carried on the outside thereof. 
",COHEN FRED,COHEN FRED,,https://lens.org/070-980-008-873-064,Patent Application,yes,0,13,1,1,0,A45C5/14;;A45C13/001;;B62B5/0083;;B62B2202/24;;B62B2206/02;;B62B2301/252;;A45C7/0031;;A45C13/385;;A45C5/14;;A45C13/001;;B62B2206/02;;B62B5/0083;;B62B2301/252;;B62B2202/24;;A45C7/0031;;A45C13/385,A45C5/14;;B62B5/00,280/35;;280/47.26,0,0,,,,DISCONTINUED
28,US,A,US 5174289 A,036-017-114-520-889,1992-12-29,1992,US 57853690 A,1990-09-07,US 57853690 A,1990-09-07,Pacing systems and methods for control of the ventricular activation sequence,"Apparatus and methods for improving the ventricular activation sequence of the heart by pacing at an advantageous selected ventricular location to achieve shortening of the QRS complex or pacing at multiple advantageous selected ventricular locations, either simulataneously or with a programmed delay or delays between firings, to achieve shortening of the QRS complex in combination with producing a desirable and efficient ventricular motion. During a cardiac cycle initiated by intrinsic cardiac activity, stimulating impulses may be directed to advantageous selected locations of the ventricles by employing intrinsic cardiac signals to trigger the stimulating impulses, either simultaneously or with a programmed delay or delays between the sensed event or events and firing event or events, to provide improved mechanical and electrical ventricular function.",COHEN FRED M,COHEN FRED M,,https://lens.org/036-017-114-520-889,Granted Patent,yes,11,382,1,2,0,A61N1/056;;A61N1/365;;A61N1/368;;A61N1/056;;A61N1/365;;A61N1/368,A61N1/05;;A61N1/365;;A61N1/368,128419PG,0,0,,,,EXPIRED
29,US,A1,US 2016/0014067 A1,014-662-496-804-601,2016-01-14,2016,US 201514797909 A,2015-07-13,US 201514797909 A;;US 201462023410 P,2014-07-11,"SYSTEMS, APPARATUSES, AND METHODS FOR PRESENTING CONTACTS BY PROJECT","A method for addressing message recipients is disclosed, including enabling a user to select a project, displaying recipients related to the selected project, wherein each recipient has at least one address, and enabling the user to select individual recipients to add their addresses to a recipients field of the message. The method may further include selecting a group related to the message, wherein the group includes at least one member arranged in an order based on their respective roles within the selected group and wherein the members have at least one address, displaying the at least one of members according to the arrangement, and enabling a user to select a member of the group to add the member's address to the recipients field of the message.",COHEN FRED J,COHEN FRED J,ZS18 LLC (2021-07-01),https://lens.org/014-662-496-804-601,Patent Application,yes,21,0,3,3,0,G06Q10/10;;G06F16/9535;;H04L51/42;;G06Q10/10;;G06F16/9535;;H04L51/42,G06F3/0482;;H04L12/58;;G06F3/0484;;G06F17/30,,0,0,,,,ACTIVE
30,US,B2,US 9149640 B2,150-026-587-110-959,2015-10-06,2015,US 201213544926 A,2012-07-09,US 201213544926 A,2012-07-09,Pacing systems for treating functional ventricular conduction abnormalities of intrinsic origin incorporating improved electrocardiographic acquisition apparatus and methods,"Therapeutic implantable cardiac pacing systems incorporating improved electrocardiographic acquisition systems for the purpose of ventricular pacing during wide QRS complexes of intrinsic origin, in order to narrow the QRS complex in patients where QRS narrowing is achievable and improving ventricular function in all patients with wide QRS complexes including those where QRS shortening does not result. These pacing systems are employed to increase coronary artery flow and electrode position is employed to improve ventricular motion in the treatment of functional ventricular abnormalities caused by wide QRS complexes.",COHEN FRED MICHAEL,COHEN FRED MICHAEL,,https://lens.org/150-026-587-110-959,Granted Patent,yes,5,0,2,2,0,A61N1/365;;A61N1/056;;A61N1/36592;;A61B5/349;;A61N1/365;;A61N1/056;;A61B5/349;;A61N1/36592,A61N1/365;;A61B5/0452;;A61N1/05,,0,0,,,,ACTIVE
31,US,A1,US 2014/0012343 A1,057-839-915-154-318,2014-01-09,2014,US 201213544926 A,2012-07-09,US 201213544926 A,2012-07-09,Pacing Systems for Treating Functional Ventricular Conduction Abnormalities of Intrinsic Origin Incorporating Improved Electrocardiographic Acquisition Apparatus and Methods,"Therapeutic implantable cardiac pacing systems incorporating improved electrocardiographic acquisition systems for the purpose of ventricular pacing during wide ORS complexes of intrinsic origin, in order to narrow the QRS complex in patients where QRS narrowing is achievable and improving ventricular function in all patients with wide QRS complexes including those where ORS shortening does not result. These pacing systems are employed to increase coronary artery flow and electrode position is employed to improve ventricular motion in the treatment of functional ventricular abnormalities caused by wide ORS complexes.",COHEN FRED MICHAEL,COHEN FRED MICHAEL,,https://lens.org/057-839-915-154-318,Patent Application,yes,3,2,2,2,0,A61N1/365;;A61N1/056;;A61N1/36592;;A61B5/349;;A61N1/365;;A61N1/056;;A61B5/349;;A61N1/36592,A61N1/365,607/17,0,0,,,,ACTIVE
32,US,A,US 4599081 A,174-093-184-397-490,1986-07-08,1986,US 43040382 A,1982-09-30,US 43040382 A,1982-09-30,Artificial heart valve,An artificial heart valve of turbine-like construction includes a rotor that translates and rotates to cause a plurality of rotor blades to either occlude or unocclude spaces between adjacent ones of a plurality of stator blades.,COHEN FRED M,COHEN FRED M,,https://lens.org/174-093-184-397-490,Granted Patent,yes,12,66,3,4,0,A61F2/2409;;A61F2/2421;;Y10T137/7839;;Y10T137/7859;;Y10T137/7859;;A61F2/2421;;A61F2/2409;;F16K15/035,A61F2/24,623/2;;137/512.1;;137/516.11;;623/3,0,0,,,,EXPIRED
33,WO,A1,WO 1984/001282 A1,165-476-591-315-589,1984-04-12,1984,US 8301526 W,1983-09-30,US 43040382 A,1982-09-30,ARTIFICIAL HEART VALVE,"An artificial heart valve (10) of turbine-like construction includes a rotor that translates and rotates about central axis (17) to cause a plurality of rotor blades (36) to either occlude or unocclude spaces between adjacent ones of a plurality of stator blades (12, 14) all fixedly connected at their proximal ends to a central stator hub (16) with stator blades (14) connected at their distal ends to a rigid orifice ring (18) carrying a suture ring (32).",COHEN FRED MICHAEL,COHEN FRED MICHAEL,,https://lens.org/165-476-591-315-589,Patent Application,yes,9,10,3,4,0,A61F2/2409;;A61F2/2421;;Y10T137/7839;;Y10T137/7859;;Y10T137/7859;;A61F2/2421;;A61F2/2409;;F16K15/035,A61F2/24,F2V VR10          VR10;;U1S S1035,0,0,,,,PENDING
34,US,A,US 5267560 A,176-376-968-816-529,1993-12-07,1993,US 99777592 A,1992-12-28,US 99777592 A;;US 57853690 A,1990-09-07,Methods for control of the ventricular activation sequence,"Apparatus and methods for improving the ventricular activation sequence of the heart by pacing at an advantageous selected ventricular location to achieve shortening of the QRS complex or pacing at multiple advantageous selected ventricular locations, either simultaneously or with a programmed delay or delays between firings, to achieve shortening of the QRS complex in combination with producing a desirable and efficient ventricular motion. During a cardiac cycle initiated by intrinsic cardiac activity, stimulating impulses may be directed to advantageous selected locations of the ventricles by employing intrinsic cardiac signals to trigger the stimulating impulses, either simultaneously or with a programmed delay or delays between the sensed event or events and firing event or events, to provide improved mechanical and electrical ventricular function.",COHEN FRED M,COHEN FRED M,,https://lens.org/176-376-968-816-529,Granted Patent,yes,11,268,1,2,0,A61N1/056;;A61N1/365;;A61N1/368;;A61N1/368;;A61N1/056;;A61N1/365,A61N1/05;;A61N1/365;;A61N1/368,607/25,14,9,022-452-791-944-126;;170-916-680-091-940;;097-926-734-083-107;;096-119-305-315-785;;025-429-492-793-368;;108-325-952-787-413;;025-429-492-793-368;;005-439-332-255-441;;050-956-262-048-283,10.1136/hrt.45.1.56;;pmc482489;;7459166;;10.1111/j.1540-8159.1986.tb05367.x;;2419840;;10.1016/0002-9149(84)90312-6;;6741799;;709767;;10.1161/01.cir.58.6.1123;;2459670;;10.1111/j.1540-8159.1988.tb03969.x;;10.1111/j.1540-8159.1987.tb05928.x;;2436173;;2459670;;10.1111/j.1540-8159.1988.tb03969.x;;10.1111/j.1540-8159.1988.tb06306.x;;2463544;;2463549;;10.1111/j.1540-8159.1988.tb06311.x,"Lipman et al.: Clinical Electrocardiography 9th Ed. York Medical Book Publishers, pp. 11 13, 16 19, 171 and 172 (1984).;;Langley: Outline of Physiology, 2nd Ed.; McGraw Hill Book Co. pp. 54 55, 182 and 260 (1965).;;Richards et al.: Relation Between QT Interval & Heart Rate, Bo Heart J. 45: pp. 56 61 (1981).;;Puddu et al.: The O T Sensitive Cybernetic Pacemaker: A New Rate on an Old Parameter p. 9: pp. 108 123 (1986).;;Jonnslagehla et al.: An Exponential Formula for Heart Rate Dependence of OT Internal During Exercise and Cardiac Paring in Humans: Reevaluation of Bazitts Formula Am. J. Cardiol., 54 pp. 103 108 (1984).;;Biscott et al.: Hidden Death in Cardiac Myapathy: Rob. of Hadycarbia dependent repolarization changes, Am. Heart J. 99: pp. 625 629 (1980).;;Cantor et al.: Septolic Time Intervals in Children: Normal Standards for Clinical Use Circulation, 58 No. 6 pp. 1123 1129 (1978).;;Stangl et al.: Influence of AU Synchrony on the Plasma Levels of Atrial Natriuretic Peptide (ANP) in Patients with Total AU Block Pace, 11: pp. 1176 181 (1988).;;Walton et al.: Platinum Pacemaker Electrodes: Original and Effects of the Electrode Tissue Interface Impidana PACE, 10 pp. 87 99 (1987).;;Stangl et al.: Influence of AU Synchrony on the Plasma Levels of Atrial Natrueretic Peptide (ANP) in Patients with Total AU Block PACE, 11: pp. 1176 1181 (1988).;;Buyeredorf et al.: Studies of the Tissue Reaction Induced by Transvenoye Pacemaker Electrodes. I. Microscopic Examination of the Extent of Connective Tissue Around the Electrode Tip in the Human Right Ventricle, PACE 11 pp. 1753 1759 (1988).;;Walton et al.: In Vitro Estimation of the Electrical Performance of Bipolar Pacing Electrode Systems, p. 11: pp. 1791 1796 (1988).;;Parsonnet et al.: Adaptive Ratio Pacing Heart Disease Update, 5: pp. 97 109 (1989).;;Willins et al. The Conduction System of the Heart Lin & Erbiger, pp. 377 392 (1976).",EXPIRED
35,US,B2,US 10397159 B2,055-890-643-291-933,2019-08-27,2019,US 201514797909 A,2015-07-13,US 201514797909 A;;US 201462023410 P,2014-07-11,"Systems, apparatuses, and methods for presenting contacts by project","A method for addressing message recipients is disclosed, including enabling a user to select a project, displaying recipients related to the selected project, wherein each recipient has at least one address, and enabling the user to select individual recipients to add their addresses to a recipients field of the message. The method may further include selecting a group related to the message, wherein the group includes at least one member arranged in an order based on their respective roles within the selected group and wherein the members have at least one address, displaying the at least one of members according to the arrangement, and enabling a user to select a member of the group to add the member's address to the recipients field of the message.",COHEN FRED J,COHEN FRED J,ZS18 LLC (2021-07-01),https://lens.org/055-890-643-291-933,Granted Patent,yes,22,0,3,3,0,G06Q10/10;;G06F16/9535;;H04L51/42;;G06Q10/10;;G06F16/9535;;H04L51/42,G06Q10/10;;G06F16/9535;;H04L12/58,,0,0,,,,ACTIVE
36,US,A,US 5351792 A,100-918-302-094-140,1994-10-04,1994,US 16566493 A,1993-12-13,US 16566493 A,1993-12-13,Wheeled stackable luggage,"A piece of luggage in the form of a suitcase of a rectangular configuration having a flat top, a flat bottom and flat sides. Four wheels are mounted at the corners of the bottom. Elongated rigid arcuate members are mounted on the corners of the suitcase and each extends from the top of the suitcase to a plane beyond the bottom of the suitcase to protect the wheels. The top of the suitcase is formed of a soft fabric material with a zippered portion to permit access to the interior of the suitcase. A pull strap and a carrying handle are provided. A rigid plastic tray is mounted inside the suitcase and engages the bottom and the sides to provide strength and rigidity to the suitcase.",COHEN FRED E,COHEN FRED E,,https://lens.org/100-918-302-094-140,Granted Patent,yes,9,28,1,1,0,A45C5/14;;A45C5/14,A45C5/14,190 18A;;190/37;;280/47.34,0,0,,,,EXPIRED
37,AU,A,AU 1983/022626 A,003-733-484-143-62X,1984-04-24,1984,AU 1983/022626 A,1983-09-30,US 43040382 A;;US 8301526 W,1982-09-30,ARTIFICIAL HEART VALVE,,COHEN F M,MICHAEL COHEN FRED,,https://lens.org/003-733-484-143-62X,Patent Application,no,0,0,1,4,0,,,,0,0,,,,DISCONTINUED
38,US,A1,US 2020/0195597 A1,026-516-955-570-411,2020-06-18,2020,US 201916550806 A,2019-08-26,US 201916550806 A;;US 201514797909 A;;US 201462023410 P,2014-07-11,"SYSTEMS, APPARATUSES, AND METHODS FOR PRESENTING CONTACTS BY PROJECT","A method for addressing message recipients is disclosed, including enabling a user to select a project, displaying recipients related to the selected project, wherein each recipient has at least one address, and enabling the user to select individual recipients to add to their addresses to a recipients field of the message. The method may further include selecting a group related to the message, wherein the group includes at least one member arranged based on their respective roles within the group and wherein the members have at least one address, displaying the at least one of members according to the arrangement, and enabling a user to select a member of the group to add the member's address to the recipients field of the message.",COHEN FRED J,COHEN FRED J,,https://lens.org/026-516-955-570-411,Patent Application,yes,0,0,3,3,0,G06Q10/10;;G06F16/9535;;H04L51/42;;G06Q10/10;;G06F16/9535;;H04L51/42,H04L12/58;;G06F16/9535;;G06Q10/10,,0,0,,,,DISCONTINUED
39,US,B1,US 6267778 B1,069-317-251-092-608,2001-07-31,2001,US 29009799 A,1999-04-12,US 29009799 A,1999-04-12,Pacing systems for treating functional ventricular conduction abnormalities of intrinsic origin,"Therapeutic implantable cardiac pacing systems incorporating electrocardiographic acquisition and QRS discrimination circuitry, for the purpose of ventricular pacing during wide QRS complexes of intrinsic origin, in order to narrow the QRS complex. Resultant narrowing of the QRS complex increases coronary artery flow and electrode position is employed to improve ventricular motion in the treatment of functional ventricular abnormalities caused by wide QRS complexes.",COHEN FRED MICHAEL,COHEN FRED MICHAEL,,https://lens.org/069-317-251-092-608,Granted Patent,yes,13,39,1,1,0,A61N1/365;;A61N1/365,A61N1/365;;A61N1/372,607/9,0,0,,,,EXPIRED
40,US,A,US 6116390 A,055-231-540-901-955,2000-09-12,2000,US 19331698 A,1998-11-16,US 19331698 A;;US 6558897 P,1997-11-18,Wheeled stackable luggage,Wheeled luggage having a container of soft fabric adapted for stacking with other similar containers such as suitcases or the like. The container has at least three wheels mounted on the bottom to provide stability when rolled over a supporting surface. A selected pair of wheels extend beyond the rear periphery of the container so that the container may be pulled in a tilted position as well as pulled along on the wheels. The non-selected wheel is swiveled so that the suitcase may be easily maneuvered when it is pulled along the supporting surface in a non-tilted position. A handle device may be either a leash-type strap detachably connected to a connection at one end of the container and/or a rigid handle may be telescopically arranged on the container with or without a pivot. A pouch may be provided on the container for insertably receiving and storing the strap.,COHEN; FRED E.,COHEN FRED E,,https://lens.org/055-231-540-901-955,Granted Patent,yes,19,27,1,1,0,A45C5/14;;A45C5/14;;A45C2005/142;;A45C2005/142,A45C5/14,190 18A;;190/24;;190/115;;190/127,0,0,,,,EXPIRED
41,EP,A1,EP 0120960 A1,099-865-219-690-857,1984-10-10,1984,EP 83903637 A,1983-09-30,US 43040382 A,1982-09-30,ARTIFICIAL HEART VALVE.,"Une valvule cardiaque artificielle (10) ayant une construction semblable à une turbine comprend un rotor qui possède un mouvement de translation et de rotation autour d'un axe central (17) pour faire en sorte que plusieurs aubes (36) du rotor ferment ou ouvrent des espaces définis entre une pluralité d'aubes (12, 14) adjacentes d'un stator et rattachées de manière fixe par leurs extrémités proximales à un moyeu central de stator (16), les aubes de stator (14) étant rattachées par leurs extrémités distales à un anneau rigide d'orifice (18) portant un anneau de suture (32).",COHEN FRED MICHAEL,COHEN FRED MICHAEL,,https://lens.org/099-865-219-690-857,Patent Application,yes,0,0,3,4,0,A61F2/2409;;A61F2/2421;;Y10T137/7839;;Y10T137/7859;;Y10T137/7859;;A61F2/2421;;A61F2/2409;;F16K15/035,A61F2/24,,0,0,,,,DISCONTINUED
42,US,A,US 4756394 A,142-731-790-885-139,1988-07-12,1988,US 93134686 A,1986-11-17,US 93134686 A;;US 85593386 A,1986-04-25,Expandable hand luggage with wheels and separable compartments,"Expandable luggage which includes a case forming a first compartment and having a hinged cover, and a collapsible bag located at the top of the case and forming a second compartment to provide additional packing space when required. A removable panel is also attached to the top of the case, and the panel forms a pocket for the collapsible bag when the second compartment is not in use.",COHEN FRED E,COHEN FRED E,,https://lens.org/142-731-790-885-139,Granted Patent,yes,22,102,1,1,0,A45C7/0068;;A45C7/0068;;A45C5/14;;A45C5/14;;A45C7/0086;;A45C7/0086;;Y10S190/903;;Y10S190/903,A45C5/14;;A45C7/00,190 18A;;190/103;;190/107;;190/108;;190/110;;190/112;;190/116;;190/903;;150/111;;383/2;;383/37,0,0,,,,EXPIRED
43,US,S,US D0745655 S,170-302-340-614-235,2015-12-15,2015,US 201429495845 F,2014-07-03,US 201429495845 F,2014-07-03,Ceiling fan motor housing,,YOUNGO LTD,PICKETT MARK;;COHEN FRED,YOUNGO LIMITED (2014-06-23),https://lens.org/170-302-340-614-235,Design Right,no,0,16,1,1,0,,,2304;;D23/411,0,0,,,,ACTIVE
44,US,S,US D0434873 S,182-848-654-365-729,2000-12-05,2000,US 10554099 F,1999-05-27,US 10554099 F,1999-05-27,Lamp support arm,,MINKA LIGHTING INC,JASPERS-FAYER JAN;;COHEN FRED,MINKA LIGHTING INC (1999-03-11),https://lens.org/182-848-654-365-729,Design Right,yes,2,3,1,1,0,,,D26/155;;2699,0,0,,,,EXPIRED
45,AU,A,AU 1995/018432 A,119-038-874-871-325,1995-09-11,1995,AU 1995/018432 A,1995-02-13,US 20038794 A;;US 9501815 W,1994-02-23,Method and compositions for increasing the serum half-life of pharmacologically active agents,,CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/119-038-874-871-325,Patent Application,no,0,0,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,PENDING
46,EP,A1,EP 0802798 A1,167-582-993-236-228,1997-10-29,1997,EP 95910249 A,1995-02-13,US 9501815 W;;US 20038794 A,1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS,,CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/167-582-993-236-228,Patent Application,yes,0,0,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,DISCONTINUED
47,US,A1,US 2015/0004873 A1,179-850-091-358-780,2015-01-01,2015,US 201414285056 A,2014-05-22,US 201414285056 A;;US 201361839725 P,2013-06-26,SPRING-ACTUATED APPENDAGE FOR STUFFED ANIMAL AND METHOD FOR USE,"A stuffed animal includes a body and an appendage attached to the body. The appendage includes an elongate bi-stable spring element movable between a first extended position that is straight and a second articulated position that forms a loop. The stuffed animal further includes a material covering the body appendage. Deflecting the surface of the bi-stable spring element, such as by lightly rapping it, causes the spring element to move to the second articulated position and wrap the appendage around an object, such as a wrist, a child's bed rail, or stroller bar. The stuffed animal hangs from the object by the appendage, and will stay attached until pulled off, thereby preventing the accidental loss of the animal.",COILY Q TOYS LLC,SCHECTER FRED;;COHEN ALLISON C,COILY-Q TOYS LLC (2014-05-19),https://lens.org/179-850-091-358-780,Patent Application,yes,6,12,1,1,0,A63H3/36;;A63H3/36;;Y10T29/49826;;Y10T29/49826,A63H3/46,446/376;;29/428,0,0,,,,DISCONTINUED
48,MX,A,MX 9603570 A,013-602-915-162-762,1997-03-29,1997,MX 9603570 A,1995-02-13,US 9501815 W;;US 20038794 A,1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS.,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/013-602-915-162-762,Patent Application,no,0,0,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,PENDING
49,WO,A1,WO 1995/022992 A1,196-967-487-293-51X,1995-08-31,1995,US US9501815,1995-02-13,"US 08/2/000,387",1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY  ACTIVE AGENTS,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",CHIRON CORPORATION,"BLANEY, Jeffrey, M.;;COHEN, Fred",,https://lens.org/196-967-487-293-51X,Patent Application,yes,0,0,1,1,0,,A61K47/48,,0,0,,,,UNKNOWN
50,US,A,US 2900610 A,061-257-864-605-645,1959-08-18,1959,US 50948655 A,1955-05-19,US 50948655 A,1955-05-19,Variable impedance transformer,,ALLEN RICHARD W;;FRED COHEN,ALLEN RICHARD W;;FRED COHEN,,https://lens.org/061-257-864-605-645,Granted Patent,no,9,14,1,1,0,H01P5/04;;H01P5/04,H01P5/04,,0,0,,,,EXPIRED
51,WO,A2,WO 1995/022992 A2,108-881-087-051-571,1995-08-31,1995,US 9501815 W,1995-02-13,US 20038794 A,1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/108-881-087-051-571,Patent Application,no,0,17,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,PENDING
52,US,A,US 4523722 A,134-963-332-475-928,1985-06-18,1985,US 49023783 A,1983-04-29,US 49023783 A,1983-04-29,Adjustable display apparatus,"Adjustable display apparatus comprising a pair of laterally spaced side supporting elements, each having an elongated front leg, an elongated rear leg, an upper section joined to the upper ends of the front and rear legs, and a lower section joined to the front and rear legs near the lower ends thereof. Elongated support bars are removably connected to the upper and lower sections of the supporting elements and are positioned near the rear legs of the supporting elements. A pair of support panels, such as aperture boards, are secured to the rear portions of the support bars to provide a mounting surface extending between the supporting elements. The support panels are overlapped at their inner ends and are removably connected together at their overlapped portions. Laterally adjustable display racks are removably mounted in vertically spaced relation on the support panels and are laterally adjusted to extend across the support panels from one supporting element to the other. Laterally adjustable connecting members extend from the lower portion of one supporting element to the other and are removably secured at their ends thereto. The length of the display apparatus can easily be adjusted without disassembling the display apparatus by merely changing the amount of overlap of the support panels and the lengths of the display racks and the connecting members.",MELROSE DISPLAYS INC,COHEN MELVIN;;DUYNE FRED V,MELROSE DISPLAYS INC. A CORP. OF NJ (1983-04-11),https://lens.org/134-963-332-475-928,Granted Patent,yes,12,25,1,1,0,A47F5/13;;A47F5/13,A47F5/13,211/175;;211/134;;211/186;;211/189;;108/102,0,0,,,,EXPIRED
53,US,A,US 5714142 A,172-304-546-781-292,1998-02-03,1998,US 66437296 A,1996-06-13,US 66437296 A;;US 20038794 A,1994-02-23,Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",BLANEY; JEFFREY M.;;COHEN; FRED,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/172-304-546-781-292,Granted Patent,yes,4,93,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,424/85.2;;424/85.4;;514/11;;514/16;;514/262;;514/274;;514/335;;514/368;;514/421;;514/423;;514/460;;514/471;;514/567;;514/568;;514/571;;514/620;;514/626;;514/737;;514/772;;514/776,21,17,023-369-815-076-327;;011-446-596-152-115;;017-995-237-741-41X;;053-520-692-346-012;;020-673-657-530-893;;024-808-900-957-207;;049-958-587-173-262;;016-805-375-097-267;;009-695-593-077-151;;035-423-646-570-26X;;012-910-666-741-568;;012-931-162-405-715;;081-053-022-793-900;;035-597-127-661-864;;020-627-669-761-683;;014-096-450-877-748;;096-473-294-934-485,8385339;;pmc46146;;10.1073/pnas.90.7.2618;;6170997;;10.1016/s0021-9258(19)40032-x;;2153133;;2172276;;10.1210/jcem-71-5-1265;;10.1038/nbt1291-1326;;1367763;;10.1073/pnas.88.13.5572;;pmc51919;;2062838;;10.3109/10731198909118282;;2819254;;10.1210/jcem-68-6-1141;;2498384;;3220661;;10.1111/j.1399-3011.1988.tb00675.x;;10.1016/0009-2797(90)90034-k;;2393944;;1868115;;10.1021/bc00008a001;;3076166;;3343226;;10.1016/s0021-9258(18)69122-7;;2565017;;10.1021/jm00381a018;;3919186;;10.1016/0022-1759(83)90164-3;;6345677;;10.1016/0731-7085(91)80172-6;;1817672,"Bickel et al., Pharmacologic effects in vivo in brain by vector mediated peptide drug delivery, Proc. Natl. Acad. Sci., USA 90:2618 2622 (1993).;;Brouwer et al., Competitive inhibition of thyroxine binding to transthyretin by monohydroxy metabolites of 3,4,3 ,4 tetrachlorobiphenyl, Chemosphere 20(7 9):1257 1262 (1990).;;Cavalieri et al., The effects of drugs on the distribution and metabolism of thyroid hormones, Pharmacological Reviews 33(2):55 80 (1981).;;Divino et al., Receptor mediated uptake and internalization of transthyretin, J. Biol. Chem. 265(3):1425 1429 (1990).;;Divino et al., Transthyretin Receptors on Human Astrocytoma Cells, J. Clin. Endocrin. Metab. 71(5):1265 1268 (1990).;;Edgington et al., The anatomy of access: Peptide drug delivery, Bio/Technology 9:1327 1331 (Dec. 1991).;;Leamon et al., Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis, Proc. Natl. Acad. Sci., USA 88:5572 5576 (1991).;;Mao et al., Superoxide dismutase: Improving its pharmacological properties by conjugation with human serum albumin, Biomat., Art. Cells, Art. Org. 17:229 244 (1989).;;Munro et al., Drug competition for thyroxine binding to transthyretin (prealbumin): Comparison with effects on thyroxine binding globulin, J. Clin. Endocrin. Metabol. 68(6):1141 1147 (1989).;;Ogino, Chemical modification of superoxide dismutase, Int. J. Peptide Protein Res. 32:153 159 (1988).;;Van Den Berg, Interaction of chlorinated phenols with thyroxine binding sites of human transthyretin, albumin and thyroid binding globulin, Chem. Biol. Interactions 76:63 75 (1990).;;Arano et al., A Novel Bifunctional Metabolizable Linker for the Conjugation of Antibodies with Radionuclides, Bioconjugate Chem. 2:71 76 (1991).;;Bank, Effects of Polyhalogenated Aromatic Hydrocarbons on Vitamin A Catabolism and the Regulation of Vitamin A Homeostatis in Rats (Hydrocarbons), Database: Dissertation Abstracts AN:AAI9013852 (1989).;;Bhattacharya et al., Homogeneous Enzyme Immunoassay of Thyroxine and Triiodothyronine Using Glucose 6 phosphate Dehydrogenase and Horse Radish Peroxidase, Indian Journal of Experimental Biology 26:990 992 (1988).;;Blondeau et al., Characterization of the Thyroid Hormone Transport System of Isolated Hepatocytes, The Journal of Biological Chemistry 263(6):2685 2692 (1988).;;Busche et al., Preparation and Utility of a Radioiodinated Analogue of Daunomycin in the Study of Multidrug Resistance, Mol. Pharmacol. 35(4): 414 421 (1989).;;McKinney et al., Molecular Interactions of Toxic Chlorinated Dibenzo p dioxins and Dibenzofurans with Thyroxine Binding Prealbumin, J. Med. Chem. 28:375 381 (1985).;;Melhus, Studies of the Vitamin A Transporting Protein Complex Retinol Binding Protein Transthyretin, Database: Dissertation Abstracts AN: AAIC220221 (1990).;;Nichols, Molecular Genetic Studies of Autosomal Dominant, Systemic Amyloidosis (Amyloidosis), Database: Disssertation Abstracts AN: AAI9020740 (1989).;;Place et al., A Colorimetric Immunoassay Based on an Enzyme Inhibitor Method, J. Immunol. Methods 61(2):209 216 (1983).;;van den Berg et al., A New Radioimmunoassay for the Determiniation of the Angiotensin converting Enzyme Inhibitor Perindopril and its Active Metabolite in Plasma and Urine: Advantages of a Lysine Derivative as Immunogen to Improve the Assay Specificity, J. Pharm. Biomed. Anal. 9(7):517 524 (1991).",EXPIRED
54,US,S,US D0426914 S,047-347-812-143-452,2000-06-20,2000,US 10539299 F,1999-05-24,US 10539299 F,1999-05-24,Lamp support arm,,MINKA LIGHTING INC,JASPERS-FAYER JAN;;COHEN FRED,MINKA LIGHTING INC (1999-10-19),https://lens.org/047-347-812-143-452,Design Right,yes,0,0,1,1,0,,,D26/155;;2699,2,0,,,"Hinkley lighting catalog, 1990, p. 49, wall lantern #2945.;;Home Lighting and Accessories,Mar. 1996, p. 153, lamp arm.",EXPIRED
55,US,S,US D0426911 S,031-853-697-726-505,2000-06-20,2000,US 105565,1999-05-27,,,Lighting fixture backplate,,,Jaspers-Fayer; Jan;;Cohen; Fred,MINKA LIGHTING INC (1999-10-19),https://lens.org/031-853-697-726-505,Design Right,yes,1,0,1,1,0,,,D26142,1,0,,,"Murray Feiss lighting catalog, Mar. 1995, p. 119, wall lamp base, #VS2401.",UNKNOWN
56,WO,A8,WO 1995/022992 A8,029-022-029-282-938,2002-02-14,2002,US 9501815 W,1995-02-13,US 20038794 A,1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/029-022-029-282-938,Patent Application,no,0,0,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,PENDING
57,CA,A1,CA 2184002 A1,155-815-668-044-977,1995-08-31,1995,CA 2184002 A,1995-02-13,US 20038794 A,1994-02-23,METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS,"Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.",CHIRON CORP,BLANEY JEFFREY M;;COHEN FRED,,https://lens.org/155-815-668-044-977,Patent Application,no,0,0,8,8,0,A61K47/545;;A61K47/545;;A61K47/54;;A61K47/54,A61K47/48,,0,0,,,,DISCONTINUED
58,US,S,US D0428662 S,062-161-872-362-866,2000-07-25,2000,US 10553399 F,1999-05-27,US 10553399 F,1999-05-27,Lamp housing,,MINKA LIGHTING INC,JASPERS-FAYER JAN;;COHEN FRED,MINKA LIGHTING INC (1999-10-19),https://lens.org/062-161-872-362-866,Design Right,yes,3,0,1,1,0,,,D26/67;;2605,0,0,,,,EXPIRED
59,AU,A,AU 1971/034414 A,133-434-353-052-270,1973-04-19,1973,AU 1971/034414 A,1971-10-11,US 9147770 A,1970-11-20,HEAT EXCHANGE DEVICE,,BAXTER LABORATORIES INC,LEONARD RONALD JAMES;;COHEN FRED MICHAEL,,https://lens.org/133-434-353-052-270,Patent Application,no,0,0,17,17,0,A61M5/44;;A61M5/44;;A61M2205/366;;A61M2205/366;;F28D9/0025;;F28D9/0025;;Y10S165/399;;Y10S165/399,A61M5/44;;F28D9/00,,0,0,,,,EXPIRED
60,AU,A,AU 1998/068712 A,091-949-241-570-242,1998-10-20,1998,AU 1998/068712 A,1998-03-20,US 82819597 A;;US 9806065 W,1997-03-21,"Substrates useful in both aqueous and organic media, and associated methods of preparation and use",,CHIRON CORP,ZUCKERMANN RONALD N;;COHEN FRED E,,https://lens.org/091-949-241-570-242,Patent Application,no,0,0,2,2,0,C07H21/00;;C07K1/04;;C07K1/042;;C07K1/047,C07H21/00;;C07K1/04,,0,0,,,,PENDING
61,US,A,US 2642389 A,157-514-093-241-358,1953-06-16,1953,US 20379650 A,1950-12-30,US 20379650 A,1950-12-30,Treating method for high-boiling esters,,STANDARD OIL DEV CO,COHEN CHARLES A;;KNOTH JR FRED,,https://lens.org/157-514-093-241-358,Granted Patent,no,6,7,1,1,0,C07C67/56;;C07C67/56,C07C67/48;;C07C69/34;;C07C69/80,,0,0,,,,EXPIRED
62,US,A,US 5878373 A,016-413-001-187-003,1999-03-02,1999,US 76172496 A,1996-12-06,US 76172496 A,1996-12-06,System and method for determining three-dimensional structure of protein sequences,"The present invention pertains to a system and method for predicting the protein fold of a target amino acid residue sequence of unknown protein structure. A target sequence is represented by a sequence of residue variability types that utilizes positional variability information present in an associated family of homologous sequences to the target sequence. The use of the positional variability information increases the likelihood of matching the target sequence with a known protein structure. In a first preferred embodiment, a target sequence is mapped into a sequence of residue variability types that are based on the solubility variability present between amino acid residues in homologous sequences. In a second preferred embodiment, each residue variability type represents a cluster of residue types at each position of aligned sets of homologous protein sequences. Each distinct cluster represents a pattern of residue variability at various positions in sets of homologous protein sequences. The sequence of residue variability types is aligned with one or more environment strings, each of which represents a known protein structure in accordance with the degree of surface exposure for each amino acid position in the protein's structure. The alignment is performed using a threading procedure that determines a score for each alignment indicating the compatibility of the sequence to the structure. The protein structure associated with the highest score is deemed to be the most analogous structure to the target sequence.",UNIV CALIFORNIA,COHEN FRED E;;DEFAY THOMAS R,REGENTS OF THE UNIVERSITY OF CALIFORNIA (1996-11-19);;REGENTS OF THE UNIVERSITY OF COALIFORNIA (1996-12-02),https://lens.org/016-413-001-187-003,Granted Patent,yes,2,61,1,1,0,C07K1/00;;G16B15/00;;G16B30/00;;G16B40/00;;G16B15/20;;G16B30/10;;C07K1/00;;G16B30/00;;G16B15/00;;G16B40/00;;G16B15/20;;G16B30/10,G16B15/20;;C07K1/00;;G06F17/30;;G16B30/10;;G16B40/00,702/22;;702/19,1,1,032-100-076-165-506,10.1016/s0092-8240(05)80077-1;;10.1007/bf02459635;;1591533,"Chan, S.C. et al A Survey of Multiple Sequence Comparison Methods Bulletin of Mathematical Biology, vol. 54, No. 4, pp. 563 598, 1992.",EXPIRED
63,WO,A1,WO 1998/042730 A1,059-728-509-797-60X,1998-10-01,1998,US 9806065 W,1998-03-20,US 82819597 A,1997-03-21,"SUBSTRATES USEFUL IN BOTH AQUEOUS AND ORGANIC MEDIA, AND ASSOCIATED METHODS OF PREPARATION AND USE","Novel functionalized substrates are provided having a surface which is hydrophilic in a first state and hydrophobic in a second state, so that the substrate can be used in either aqueous or organic media. The substrate surface contains a plurality of hydrophilic sites which can be readily protected and deprotected. In use, generally, a fraction of the sites are protected, leaving the remainder available for participating in organic synthetic processes to be conducted using organic reagents and solvents, e.g., solid phase organic synthesis of ligands which may or may not be oligomeric. Following synthesis, the protected hydrophilic sites are deprotected, regenerating the substrate surface in hydrophilic form for use with aqueous reagents, e.g., in screening and/or separation procedures to be conducted in aqueous media.",CHIRON CORP,ZUCKERMANN RONALD N;;COHEN FRED E,,https://lens.org/059-728-509-797-60X,Patent Application,yes,1,5,2,2,0,C07H21/00;;C07K1/04;;C07K1/042;;C07K1/047,C07H21/00;;C07K1/04,,3,1,040-934-438-052-076,10.1002/pola.1992.080300823,"R ARSHADY & F FALLAH: ""Amphiphilic gels for peptide synthesis"", JOURNAL OF POLYMER SCIENCE, POLYMER CHEMISTRY EDITION., vol. 30, no. 8, 1992, NEW YORK US, pages 1705 - 1716, XP000286978;;CHEMICAL ABSTRACTS, vol. 123, no. 13, 25 September 1995, Columbus, Ohio, US; abstract no. 170151, XP002074984;;CHEMICAL ABSTRACTS, vol. 102, no. 6, 11 February 1985, Columbus, Ohio, US; abstract no. 46635, R ARSHADY: ""A new synthetic approach for the preparation of polymer supports based on beaded copolymers of styren and 2,4,5-trichlorophenyl acrylate: synthesis and swelling behavior off poly(styrene-co-acrylamide) resins"" XP002074985",PENDING
64,WO,A1,WO 1997/003193 A1,063-840-869-093-256,1997-01-30,1997,US 9611438 W,1996-07-09,US 87195 P,1995-07-11,NOVEL FACTOR VIII:C POLYPEPTIDE ANALOGS WITH ALTERED METAL-BINDING PROPERTIES,"Factor VIII:C polypeptide analogs are provided that are native Factor VIII:C polypeptides that contain modifications wherein the modifications comprise the alteration of the metal-binding properties of the molecule. Nucleic acid molecules encoding Factor VIII:C polypeptide analogs, vectors and host cells containing such nucleic acid molecules are also provided. Further provided are analog complexes that contain at least two such analogs. Methods of producing the analog, the analog complex, the nucleic acids, vectors, and host cells are also provided as well as methods of using such compositions for prevention or treatment of active Factor VIII:C polypeptide deficiencies.",CHIRON CORP;;HUNG DAVID T;;COHEN FRED E,HUNG DAVID T;;COHEN FRED E,,https://lens.org/063-840-869-093-256,Patent Application,yes,1,44,2,2,0,A61K38/00;;C07K14/755,A61K38/00;;C07K14/755;;C12N15/12,,1,1,051-090-392-372-016,7552743;;10.1038/nsb0995-740,"PAN ET AL: ""PROPOSED STRUCTURE OF THE A DOMAINS OF FACTOR VIII BY HOMOLOGY MODELLING"", NATURE STRUCTURAL BIOLOGY, vol. 2, no. 8, September 1995 (1995-09-01), pages 740 - 744, XP000611617",PENDING
65,DE,C2,DE 1639373 C2,113-372-881-378-681,1978-11-09,1978,DE R0047834 A,1968-01-19,US 61067067 A,1967-01-20,DE 1639373 C2,,"RCA CORP., NEW YORK, N.Y. (V.ST.A.)","COHEN, FRED, SOUTH PLAINFIELD, N.J. (V.ST.A.)",,https://lens.org/113-372-881-378-681,Granted Patent,no,0,0,6,6,0,H01L29/00;;H01L29/0813;;H01L29/66303;;H01L29/0813;;H01L29/66303;;H01L29/00,H01L29/73;;H01L21/331;;H01L29/00;;H01L29/08,,0,0,,,,EXPIRED
66,US,A,US 5284829 A,000-368-472-475-422,1994-02-08,1994,US 79856591 A,1991-11-26,US 79856591 A,1991-11-26,Synthetic tetrapeptides for the prevention of schistosome parasite infection,"The invention relates to synthetic tetrapeptides that contain a peptide blocking group at the amino terminus and an enzyme inhibitor at the carboxy terminus, and their use in the prevention of schistosome parasite infection.",UNIV CALIFORNIA,MCKERROW JAMES H;;COHEN FRED E,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1991-11-25),https://lens.org/000-368-472-475-422,Granted Patent,yes,3,27,1,1,0,A61K38/55;;C07K5/0827;;A61K38/55;;C07K5/0827,A61K38/00;;A61K38/55;;C07K5/08,514/18;;514/19;;514/846;;514/969;;530/323;;530/330;;530/331,6,4,058-500-306-157-410;;057-869-303-179-108;;053-343-932-681-545;;148-177-635-945-35X,10.1021/bi00747a032;;4797992;;10.1126/science.2511631;;2511631;;3882713;;10.1016/s0021-9258(19)83680-3;;10.1016/s0021-9258(18)37688-9;;3166457,"Powers, J. C. and Tuhy, P. M., Biochemistry 12, 4767 4774 (1973).;;Cherfas, J., Science 246, 1242 1232 (1989).;;McKerrow, J. H., Pino Heiss, S., Lindquist, R. and Werb, Z. Journal of Biological Chemistry, 160, 3703 3707 (1985).;;Newport, G. R., McKerrow, J. H., Hedstrom, R., Petitt, M. McGarrigle, L. Barr, P. J. and Agabian, N., Journal of Biological Chemistry 263, 13179 13184 (1988).;;McKerrow, J. H., Skanari, J., Brown, M., Brindley, P., Railey, J., Weiss, N., and Resnick, S. D., Models in Dermatology, vol. 4, 276 284 (1989).;;Amiri, F., Cohen, F. E., Gregoret, L. M., Aldape, K., Railey, J., and McKerrow, J. H., Abstrcts of the 20th Annual Meetings for the Keystone Symposia on Molecular and Cellular Biology (1991).",EXPIRED
67,AU,A,AU 1996/064558 A,046-536-814-748-881,1997-02-10,1997,AU 1996/064558 A,1996-07-09,US 87195 P;;US 9611438 W,1995-07-11,Novel factor viii:c polypeptide analogs with altered metal-binding properties,,CHIRON CORP,HUNG DAVID T;;COHEN FRED E,,https://lens.org/046-536-814-748-881,Patent Application,no,0,0,2,2,0,A61K38/00;;C07K14/755,A61K38/00;;C07K14/755;;C12N15/12,,0,0,,,,PENDING
68,DK,B,DK 138162 B,072-448-751-984-985,1978-07-24,1978,DK 568171 A,1971-11-19,US 9147770 A,1970-11-20,Varmeveksler.,,BAXTER TRAVENOL LAB,LEONARD RONALD JAMES;;COHEN FRED MICHAEL,,https://lens.org/072-448-751-984-985,Patent Application,no,0,0,17,17,0,A61M5/44;;A61M5/44;;A61M2205/366;;A61M2205/366;;F28D9/0025;;F28D9/0025;;Y10S165/399;;Y10S165/399,A61M5/44;;F28D9/00,,0,0,,,,EXPIRED
69,CH,A,CH 538658 A,063-522-017-662-486,1973-06-30,1973,CH 1650171 A,1971-11-11,US 9147770 A,1970-11-20,"Wärmeaustauscher, insbesondere zum Wärmeaustausch zwischen Blut und einem Wärme- oder Kälteträger",,BAXTER LABORATORIES INC,RONALD JAMES LEONARD;;FRED MICHAEL COHEN,,https://lens.org/063-522-017-662-486,Granted Patent,no,0,0,17,17,0,A61M5/44;;A61M5/44;;A61M2205/366;;A61M2205/366;;F28D9/0025;;F28D9/0025;;Y10S165/399;;Y10S165/399,A61M5/44;;F28D9/00,,0,0,,,,EXPIRED
70,CA,A,CA 942291 A,195-152-909-964-51X,1974-02-19,1974,CA 124923 A,1971-10-12,US 9147770 A,1970-11-20,HEAT EXCHANGE DEVICE WITH CONVOLUTED HEAT TRANSFER WALL,,BAXTER LABORATORIES INC,LEONARD RONALD J;;COHEN FRED M,,https://lens.org/195-152-909-964-51X,Granted Patent,no,0,0,17,17,0,A61M5/44;;A61M5/44;;A61M2205/366;;A61M2205/366;;F28D9/0025;;F28D9/0025;;Y10S165/399;;Y10S165/399,A61M5/44;;F28D9/00,257-15,0,0,,,,EXPIRED
71,US,A,US 1618171 A,137-314-695-490-202,1927-02-22,1927,US 61639823 A,1923-02-01,US 61639823 A,1923-02-01,Unit power truck,,LEWIS COHEN LOUIS;;FULTON SMALL FRED,LEWIS COHEN LOUIS;;FULTON SMALL FRED,,https://lens.org/137-314-695-490-202,Granted Patent,no,0,0,1,1,0,B61F3/04;;B61F3/04,B61F3/04,,0,0,,,,EXPIRED
72,US,A1,US 2004/0168173 A1,135-747-290-913-810,2004-08-26,2004,US 67860903 A,2003-10-03,US 67860903 A;;US 41628502 P;;US 38082402 P;;US 16558199 P,1999-11-15,Method and apparatus providing deception and/or altered execution of logic in an information system,"
   A method and/or system and/or apparatus providing deception and/or execution alteration in an information system. In specific embodiments, deceptions and/or protections are provided by intercepting and/or modifying operation of one or more system calls of an operating system. 
",SANDIA NAT LABS,COHEN FRED;;ROGERS DEANNA T;;NEAGOE VICENTIU,NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA LLC (2017-05-01);;SANDIA NATIONAL LABORATOARIES CALIFORNIA (2004-02-17),https://lens.org/135-747-290-913-810,Patent Application,yes,8,62,2,14,0,G06F21/52;;G06F21/55;;G06F21/52;;G06F21/55,G06F9/00;;G06F21/00,71931,0,0,,,,EXPIRED
73,US,B2,US 7437766 B2,109-766-777-650-136,2008-10-14,2008,US 67918603 A,2003-10-03,US 67918603 A;;US 41628502 P,2002-10-03,Method and apparatus providing deception and/or altered operation in an information system operating system,"A method and/or system and/or apparatus providing deception and/or execution alteration in an information system. In specific embodiments, deceptions and/or protections are provided by intercepting and/or modifying operation of one or more system calls of an operating system.",SANDIA NAT LAB,COHEN FRED;;ROGERS DEANNA T;;NEAGOE VICENTIU,SANDIA NATIONAL LABORATORIES CALIFORNIA (2004-02-26),https://lens.org/109-766-777-650-136,Granted Patent,yes,9,41,2,14,0,G06F21/52;;G06F21/52;;G06F9/468;;G06F9/468;;G06F21/554;;G06F21/554;;G06F2221/2123;;G06F2221/2123,H04L29/00;;G06F9/46;;G06F21/00;;H04L9/00,726/26;;713/164,14,1,096-013-066-403-298,10.1109/cmpsac.2002.1045129,"Cohen (1985) ""Algorithmic Authentication of Identification."" Information Age, V7, #1 (Jan. 1985), pp. 35-41.;;Cohen (1992) ""Operating System Protection through Program Evolution, Computers and Security"". World Wide Web at http://www.all.net/books/IP/evolve.html. pp. 1-22 of 22.;;Cohen (1995) ""A Note on Detecting Tampering with Audit Trails, IFIP-TC11-Computers and Security"". World Wide Web at http://www.all.net/books/audit/audmod.html. pp. 1-10 of 10.;;Cohen (1998) ""A Note on the Role of Deception in Information Protection"". World Wide Web at http://www.all.net/journal/deception/deception.html. pp. 1-23 of 23.;;Cohen (2000) ""Models of Practical Defenses Against Computer Viruses"". World Wide Web at http://all.net/books/integ/vmodels.html. pp. 1-12 of 12.;;Cohen et al. (1998) ""A Preliminary Classification Scheme for Information System Threats, Attacks, and Defenses; A Cause and Effect Model; and Some Analysis Based on That Model."" Located on the World Wide Web at http://all.net/journal/ntb/cause-and-effect.html. Sandia National Laboratories, Sep. 1998. 1-74 of 74.;;Cohen et al. (2001) ""Red Teaming Experiments with Deception Technologies"". World Wide Web at http://www.all.net/journal/deception/experiments/experiments.html. pp. 1-30 of 30.;;Javitz et al. (1994) ""The NIDES Statistical Component Description and Justification,"" Annual Report, A010, Mar. 1994.;;Michael (2002) ""On the Response Policy of Software Decoys: Conducting Computer Based Deception in the Cyber Battlespace,"" Proceedings of the 26<SUP>th </SUP>Annual Computer Software and Applications Conference, Oxford, England, Aug. 2002.;;Michael et al. (2001) ""Intelligent Software Decoys,"" Proceedings of the Monterey Workshop on Engineering Automation for Software-Intensive Integration, Monterey, CA, Jun. 2001. pp. 178-187.;;Michael et al. (2002) ""Software Decoys: Intrusion, Detection and Countermeasures,"" Proceedings of the 2002 IEEE Workshop on Information Assurance, West Point, NY, Jun. 2002. pp. 130-138.;;Michael et al. (2003) ""An Experiment in Software Decoy Design,"" Proceedings of the IFIP 18<SUP>th </SUP>International Information Security Conference, Athens, Greece, May 2003. pp. 1-12 of 12.;;Pomerantz (1999) ""System Calls"" The Linux Kernal Module Programming Guide. World Wide Web at http://www.tldp.org/LDP/lkmpg/node20.html. pp. 1-5 of 5.;;Spitzner (2003) ""Honeypots: Definitions and Value of Honeypots,"" World Wide Web at http://www.trackinghackers.com/papers/honeypots.html. pp. 1-5 of 5.",INACTIVE
74,US,B2,US 7296274 B2,109-955-287-167-46X,2007-11-13,2007,US 67860903 A,2003-10-03,US 67860903 A;;US 41628502 P;;US 38082402 P;;US 16558199 P,1999-11-15,Method and apparatus providing deception and/or altered execution of logic in an information system,"A method and/or system and/or apparatus providing deception and/or execution alteration in an information system. In specific embodiments, deceptions and/or protections are provided by intercepting and/or modifying operation of one or more system calls of an operating system.",SANDIA NAT LAB,COHEN FRED;;ROGERS DEANNA T;;NEAGOE VICENTIU,NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA LLC (2017-05-01);;SANDIA NATIONAL LABORATOARIES CALIFORNIA (2004-02-17),https://lens.org/109-955-287-167-46X,Granted Patent,yes,9,64,2,14,0,G06F21/52;;G06F21/55;;G06F21/52;;G06F21/55,G06F3/00;;G06F9/00;;G06F9/44;;G06F9/46;;G06F13/00;;G06F21/00,719/315;;719/313;;713/182,14,1,096-013-066-403-298,10.1109/cmpsac.2002.1045129,"Cohen (1985) ""Algorithmic Authentication of Identification."" Information Age, V7, #1 (Jan. 1985), pp. 35-41.;;Cohen (1992) ""Operating System Protection through Program Evolution, Computers and Security"". World Wide Web at http://www.all.net/books/IP/evolve.html. pp. 1-22 of 22.;;Cohen (1995) ""A Note on Detecting Tampering with Audit Trails, IFIP-TC11-Computers and Security"", World Wide Web at http://www.all.net/books/audit/audmod.html. pp. 1-10 of 10.;;Cohen (1998) ""A Note on the Role of Deception in Information Protection"", World Wide Web at http://www.all.net/journal/deception/deception.html. pp. 1-23 of 23.;;Cohen (2000) ""Models of Practical Defenses Against Computer Viruses"". World Wide Web at http://www.all.net/books/integ/vmodels.html. pp. 1-12 of 12.;;Cohen et al. (1998) ""A Preliminary Classification Scheme for Information System Threats, Attacks, and Defenses; A Cause and Effect Model; and Some Analysis Based on That Model."" Located on the World Wide Web at http://www.all.net/journal/ntb/cause-and-effect.html. Sandia National Laboratories, Sep. 1998. 1-74 of 74.;;Cohen et al. (2001) ""Red Teaming Experiments with Deception Technologies"". World Wide Web at http://www.all.net/journal/deception/experiments/experiments.html. pp. 1-30 of 30.;;Javitz et al. (1994) ""The NIDES Statistical Component Description and Justification,"" Annual Report, A010, Mar. 1994.;;Michael (2002) ""On the Response Policy of Software Decoys: Conducting Computer Based Deception in the Cyber Battlespace,"" Proceedings of the 26<SUP>th </SUP>Annual Computer Software and Applications Conference, Oxford, England, Aug. 2002.;;Michael et al. (2001) ""Intelligent Software Decoys,"" Proceedings of the Monterey Workshop on Engineering Automation for Software-Intensive Integration, Monterey, CA, Jun. 2001. pp. 178-187.;;Michael et al. (2002) ""Software Decoys: Intrusion, Detection and Countermeasures,"" Proceedings of the 2002 IEEE Workshop on Information Assurance, West Point, NY, Jun. 2002. pp. 130-138.;;Michael et al. (2003) ""An Experiment in Software Decoy Design,"" Proceedings of the IFIP 18<SUP>th </SUP>International Information Security Conference, Athens, Greece, May 2003. pp. 1-12 of 12.;;Pomerantz (1999) ""System Calls"" The Linux Kernal Module Programming Guide. World Wide Web at http://www.tldp.org/LDP/lkmpg/node20.html. pp. 1-5 of 5.;;Spitzner (2003) ""Honeypots: Definitions and Value of Honeypots,"" World Wide Web at http://www.trackinghackers.com/papers/honeypots.html. pp. 1-5 of 5.",INACTIVE
75,US,A1,US 2005/0076237 A1,013-858-875-386-540,2005-04-07,2005,US 67918603 A,2003-10-03,US 67918603 A;;US 41628502 P,2002-10-03,Method and apparatus providing deception and/or altered operation in an information system operating system,"A method and/or system and/or apparatus providing deception and/or execution alteration in an information system. In specific embodiments, deceptions and/or protections are provided by intercepting and/or modifying operation of one or more system calls of an operating system.",SANDIA NAT LABS,COHEN FRED;;ROGERS DEANNA T;;NEAGOE VICENTIU,SANDIA NATIONAL LABORATORIES CALIFORNIA (2004-02-26),https://lens.org/013-858-875-386-540,Patent Application,yes,8,77,2,14,0,G06F21/52;;G06F21/52;;G06F9/468;;G06F9/468;;G06F21/554;;G06F21/554;;G06F2221/2123;;G06F2221/2123,G06F9/46;;G06F21/00;;H04L9/00,713/201,0,0,,,,EXPIRED
76,UY,A,UY 32925 A,092-913-638-928-304,2011-04-29,2011,UY 32925 A,2010-10-01,US 24764209 P,2009-10-01,COMPOSICIONES DE CORTICOSTEROIDES DE ADMINISTRACIÓN ORAL,Composiciones de corticosteroides de administración oral. Método para tratar una afección asociada con la inflamación del tracto gastrointestinal en un individuo. El método comprende administrarle al individuo que lo necesita una composición farmacéutica de la presente invención.,EURAND INC,VENKATESH GOPI M;;STEPHEN PERRETT;;FRED COHEN,,https://lens.org/092-913-638-928-304,Patent Application,no,0,0,103,103,0,A61K9/0065;;A61K31/56;;A61K31/573;;A61K31/58;;A61K45/06;;A61K47/34;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K31/569;;A61K45/06;;A61K9/0065;;A61K31/58;;A61K31/56;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/04;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P37/02;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/56;;A61K31/573;;A61P29/00;;A61K9/0056;;A61K9/2054;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K31/569;;A61K45/06;;A61K9/0065;;A61K9/0053;;A61K31/56;;A61K9/08;;A61K31/58;;A61K47/38,A61K31/56;;A61K9/00;;A61K9/20;;A61K47/00;;A61K47/40;;A61P1/00,,0,0,,,,DISCONTINUED
77,AR,A1,AR 078499 A1,196-384-747-591-544,2011-11-09,2011,AR P100103589 A,2010-10-01,US 24764209 P,2009-10-01,COMPOSICIONES DE CORTICOSTEROIDES DE ADMINISTRACION ORAL,"Composiciones de corticosteroides de administracion oral. Método para tratar una afeccion asociada con la inflamacion del tracto gastrointestinal en un individuo. El método comprende administrarle al individuo que lo necesita una composicion farmacéutica de la presente. Reivindicacion 1: Una composicion farmacéutica solida caracterizada porque comprende 20 mg o menos de un corticosteroide, donde la composicion no presenta una actividad sistémica significativa como glucocorticoide o como mineralocorticoide después de una administracion oral, donde la composicion farmacéutica solida se desintegra en 60 segundos en un fluido de saliva simulada cuando se la evalua usando la prueba de desintegracion de la USP . Reivindicacion 3: La composicion farmacéutica solida de la reivindicacion 1, caracterizada porque dicho corticosteroide se selecciona del grupo que consiste en la budesonida, la fluticasona, la flunisolida, la ciclesonida, la mometasona, la beclometasona y sales, solvatos y ésteres de éstas. Reivindicacion 4: La composicion farmacéutica solida de la reivindicacion 1, caracterizada porque también comprende un agente adhesivo. Reivindicacion 5: La composicion farmacéutica solida de la reivindicacion 4, caracterizada porque el agente adhesivo se selecciona del grupo que consiste en el complejo de sulfato de aluminio y sacarosa, el quitosán y sus derivados, la polivinilpirrolidona, la metilcelulosa, la carboximetilcelulosa de sodio, la hidroxipropil celulosa, los poliacrilatos entrecruzados o no entrecruzados, los poliacrilatos entrecruzados, los poliacrilatos ácidos entrecruzados o no entrecruzados, los homopolímeros o los copolímeros de ácido poliacrílico, los copolímeros de metacrilato de aminoalquilo, los copolímeros de ácido metacrílico y metacrilato de metilo, los copolímeros de acrilato de alquilo y metacrilato de alquilo, los copolímeros de metacrilato de amonio, los homopolímeros o los copolímeros de carbomero, las gomas basadas en polisacáridos hidrofílicos, las maltodextrinas, los geles de goma de alginato entrecruzada, los polímeros de vinilo policarboxilado, las pectinas, las gomas xantana, el ácido algínico, los ácidos algínicos modificados y combinaciones de éstos. Reivindicacion 6: La composicion farmacéutica solida de la reivindicacion 1, caracterizada porque también comprende un desintegrante seleccionado del grupo que consiste en la crospovidona, el glicolato de almidon de sodio, la carboximetil celulosa entrecruzada, la hidroxilpropilcelulosa con un grado de sustitucion bajo, el manitol, el xilitol, el sorbitol, el maltol, el maltitol, la lactosa, la sacarosa, la maltosa y combinaciones de éstos. Reivindicacion 9: La composicion farmacéutica solida de la reivindicacion 1, caracterizada porque también comprende al menos un agente antifungico. Reivindicacion 12: La composicion farmacéutica solida de la reivindicacion 1, caracterizada porque también comprende al menos un agente antiviral. Reivindicacion 15: La composicion farmacéutica de la reivindicacion 1, caracterizada porque la composicion farmacéutica toma la forma de una tableta de desintegracion oral (ODT). Reivindicacion 16: La composicion farmacéutica de la reivindicacion 15, caracterizada porque la ODT comprende las partículas de la droga y gránulos de dispersion rápida, donde las partículas de la droga comprenden el corticosteroide y los gránulos de dispersion rápida comprenden un desintegrante y un alcohol de azucar y/o un sacárido. Reivindicacion 35: Una composicion farmacéutica líquida sustancialmente no acuosa caracterizada porque comprende un corticosteroide y un líquido farmacéuticamente aceptable. Reivindicacion 42: La composicion farmacéutica líquida de la reivindicacion 35, caracterizada porque, después de la administracion al paciente, dicha composicion sufre un incremento en la viscosidad al tomar contacto con la mucosa del tracto gastrointestinal del paciente, donde el tiempo de residencia del corticosteroide en la mucosa del tracto intestinal es prolongado. Reivindicacion 46: La composicion farmacéutica líquida de la reivindicacion 39, caracterizada porque el agente de cambio de fase es un polímero seleccionado del grupo que consiste en la poli(N-isopropilacrilamida), el poli(etilenglicol-(DL-ácido láctico-co-ácido glicolico)-etilenglicol) y mezclas de éstos.",EURAND INC,VENKATESH GOPI M;;PERRETT STEPHEN;;COHEN FRED,,https://lens.org/196-384-747-591-544,Patent Application,no,0,0,103,103,0,A61K9/0065;;A61K31/56;;A61K31/573;;A61K31/58;;A61K45/06;;A61K47/34;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K31/569;;A61K45/06;;A61K9/0065;;A61K31/58;;A61K31/56;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/04;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P37/02;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/56;;A61K31/573;;A61P29/00;;A61K9/0056;;A61K9/2054;;A61K9/0056;;A61K9/006;;A61K9/06;;A61K31/569;;A61K45/06;;A61K9/0065;;A61K9/0053;;A61K31/56;;A61K9/08;;A61K31/58;;A61K47/38,,,0,0,,,,PENDING
78,BR,A,BR 9712874 A,010-991-508-157-82X,2000-02-01,2000,BR 9712874 A,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,Proteìnas solúveis,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",TTHE UNIVERSITY OF CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/010-991-508-157-82X,Patent Application,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,DISCONTINUED
79,CN,A,CN 101958433 A,116-236-540-445-463,2011-01-26,2011,CN 201010236571 A,2010-07-16,US 50418109 A,2009-07-16,Center-tapped battery and power distribution system for same,"A battery for a power distribution system includes a cell assembly having a positive terminal and a negative terminal that together provide a relative battery DC voltage. A neutral tap is electrically connected to the cell assembly between the positive and negative terminals, splitting the voltage into positive and negative voltages. The positive terminal is at a positive DC voltage greater than the neutral tap. The negative voltage is at a negative DC voltage less than the neutral tap. The relative battery DC voltage is greater than each of the relative voltages between the neutral tap and each of the positive and negative DC voltages.",HAMILTON SUNDSTRAND CORP,FRED COHEN;;CHENG-YI LU;;JOHN METCALF KENNETH,"PRATT + WHITNEY ROCKETDYNE, INC. (2014-11-06);;HAMILTON SUNDSTRAND SPACE SYSTEMS INTERNATIONAL IN (2012-10-24);;HAMMILLTONSONDESTLAND INC. (2014-11-06)",https://lens.org/116-236-540-445-463,Patent Application,no,6,1,5,5,0,H01M10/425;;H01M2200/103;;Y02E60/10;;H01M50/578;;H01M50/543;;H01M50/204;;H01M50/574;;H01M10/425;;H01M2200/103;;H01M50/543;;H01M50/578;;H01M50/204;;H01M50/574,H01M10/42;;H01M50/204;;H01M50/543;;H01M50/574;;H02J7/00,,0,0,,,,DISCONTINUED
80,US,A,US 5750361 A,002-148-473-749-331,1998-05-12,1998,US 55682395 A,1995-11-02,US 55682395 A,1995-11-02,Formation and use of prion protein (PRP) complexes,"Prion protein (PrP) peptides having at least one .alpha.-helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrP.sup.C) to form a complex having characteristics of the scrapie isoform (PrP.sup.Sc). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrP.sup.C are disclosed, as well as methods for assaying PrP.sup.Sc.",UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1996-01-19),https://lens.org/002-148-473-749-331,Granted Patent,yes,1,161,8,9,10,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,435/23;;435/24;;435/6;;435/188;;435/325;;436/2;;436/164;;436/181;;530/350;;536/23.1,26,26,094-151-950-903-210;;079-975-646-187-852;;019-152-320-543-606;;075-153-632-804-911;;068-081-491-144-943;;160-355-055-007-555;;067-313-970-172-320;;098-437-772-799-455;;176-308-122-338-207;;011-376-059-746-38X;;008-313-176-340-390;;036-893-407-568-640;;020-408-698-836-349;;025-425-047-205-849;;145-273-325-748-677;;092-861-108-562-622;;084-688-053-652-033;;071-653-349-970-151;;016-387-612-950-657;;040-095-621-513-788;;133-220-740-974-327;;018-649-764-477-571;;105-374-999-563-144;;145-273-325-748-677;;026-113-275-066-629;;056-484-231-172-156,10.1093/infdis/154.3.518;;3090160;;10.1016/s0140-6736(61)92008-6;;10.1073/pnas.88.21.9578;;pmc52761;;1946372;;10.1001/jama.265.7.880;;1992185;;10.1001/jama.1991.03460070062043;;10.1038/209794a0;;5922150;;10.1073/pnas.85.18.6617;;3137571;;pmc282028;;10.1073/pnas.89.22.10940;;pmc50458;;1438300;;5661299;;10.1126/science.161.3839.388;;10.1016/s0140-6736(59)92081-1;;pmc1033012;;10.1136/jnnp.51.9.1113;;3066847;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;10.1038/370471a0;;7913989;;1167884;;10.1093/infdis/131.2.104;;10.1021/bi00013a006;;7703230;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;pmc46182;;10.1073/pnas.90.7.2793;;8464892;;10.1016/0092-8674(83)90168-x;;6418385;;1719082;;2574076;;10.1016/0092-8674(89)90608-9;;8448158;;10.1021/bi00059a016;;10.1016/0092-8674(95)90236-8;;7553876;;3138115;;10.1111/j.1432-1033.1988.tb14246.x;;10.1006/jmbi.1995.0395;;7542350;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;3755672;;10.1089/dna.1986.5.315;;8030949;;10.1111/j.1749-6632.1994.tb38918.x,"Barry, R., et al., Monoclonal Antibodies to the Cellular and Scrapie Prion Proteins, The Journal of Infectious Diseases, vol. 154, No. 3, pp. 518 521, (Sep. 1986).;;Chandler, R.L., et al., Encephalopathy in Mice Produced by Inoculation with Scrapie Brain Material, The Lancet, 1:1378 1379, (Jun. 24, 1961).;;Chien, C., et al., The two hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest, Proc. Natl. Acad. Sci. USA, 88:9578 9582, (Nov. 1991).;;Fradkin, J., et al., Creutzfeldt jakob Disease in Pituitary Growth Hormone Recipients in the United States, JAMA, 265, No. 7, 880 884.;;Gajdusek, D.C., et al., Experimental Transmission of a Kuru like Syndrome to Chimpanzees, Nature, 209:794 796.;;Gabizon, R., et al., Immunoaffinity purification and neutralization of scrapie prion infectivity, Proc. Natl. Acad. Sci. USA, 85:6617 6621, (Sep. 1988).;;Gassett, M., et al., Predicted helical regions of the prion protein when synthesized as peptides form amyloid, Proc. natl. Acad. Sci. USA, 89:10940 10944 (Nov. 1992).;;Gibbs, C.J., et al., Creutzfeldt Jakob Disease (Spongiform Encephalopathy): Transmission to the Chimpanzee, Science, 161:388 389 (Jul. 1968).;;Hadlow, W.J., et al., Scrapie and Kuru, The Lancet, 2:289 290, (Sep. 5, 1959).;;Harries Jones, R., et al., Creutzfeld Jakob disease in England and Wales, 1980 1984: a case control study of potential risk factors, Journal of Neurology, Neurosurgery, and Psychiatry, 51:1113 1119, (1988).;;Kascsak, R., et al., Mouse Polyclonal and Monoclonal Antibody to Scrapie Associated Fibril Proteins, Journal of Virology, vol. 61, No. 12, 3688 3693, (Dec. 1987).;;Kocisko, David, A., et al., Cell free formation of protease resistant prion protein, Nature, 370:471 474, (Aug. 1994).;;Marsh, R.F., et al., Comparison of Scrapie and Transmissible Mink Encephalopathy in Hamsters. II. Clinical Signs, Pathology, and Pathogenesis, The Journal of Infectious Diseases, vol. 131, No. 2, 104 110, (Feb. 1975).;;Nguyen, J., et al., Prion Protein Peptides Induce Helix to Sheet Conformational Transitions, Biochemistry, 34:4186 4192, (1995).;;Pan, K., et al., Conversion of helices in sheets features in the formation of the scrapie prion proteins, Proc. Natl. Acad. Sci. USA, 90:10962 10966, (Dec. 1993).;;Prusiner, S.B., et al., Attempts to restore scrapie prion infectivity after exposure to protein denaturants, Proc. Natl. Aca. Sci. USA, 90:2793 2797, (Apr. 1993).;;Prusiner, S.B., et al., Scrapie Prions Aggregate to Form Amyloid like Birefringent Rods, Cell, 35:349 358, (Dec. 1983).;;Rogers, M., et al., Epitope Mapping of the Syrian Hamster Prion Protein Utilizing Chimeric and Mutant Genes in a Vaccinia Virus Expression System, The Journal of Immunology, 147, No. 10, 3568 3574, (Nov. 1991).;;Scott, M., et al., Transgenic Mice Expressing Hamster Prion Protein Produce Species Specific Scrapie Infectivity and Amyloid Plaques, Cell, 59:847 857, (Dec. 1989).;;Stahl, N., et al., Structural Studies of the Scrapie Prion Protein Using Mass Spectrometry and Amino Acid Sequencing, Biochemistry, 32:1991 2002, (1993).;;Telling, G.C., et al., Prion Propagation in Mice Expressing Human and Chimeric PrP Transgenes Implicates the Interaction of Cellular PrP with Another Protein, Cell, 83:79 90, (Oct. 1995).;;Turk, E., et al., Purification and properties of the cellular and scrapie hamster prion proteins, J. Eur. Biochem., 176:21 30, (1988).;;Zhang H., et al., Conformational Transitions in Peptides Containing Two Putative Helices of the Prion Protein, J. Mol. Biol., 250:514 526, (1995).;;Pan et al., Conversion of Alpha Helices into Beta Sheets Features in the Formation of the Scrapie Prion Proteins, Proceedings of the National Academy of Science, USA., vol. 90, Dec., 1993, pp. 10962 10966.;;Kretzschmar et al., Molecular Cloning of a Human Prion Protein cDNA, DNA, vol. 5, No. 4, 1986, pp. 315 324.;;Caughey et al., Scrapie Associated PrP Accumulation and its Inhibition: Revisiting the Amyloid Glycosaminoglycan Connection, Annals of Trhe New York Academy of Sciences, vol. 724, Jun. 6, 1994, pp. 290 294.",EXPIRED
81,US,A,US 5834593 A,006-010-136-863-129,1998-11-10,1998,US 74094796 A,1996-11-05,US 74094796 A,1996-11-05,Soluble form of PrPSC which is insoluble in native form,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrP.sup.Sc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrP.sup.Sc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1997-01-06),https://lens.org/006-010-136-863-129,Granted Patent,yes,7,10,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;G01N33/50;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,530/350;;530/356;;435/6;;435/7.1;;435/2.3;;435/72.3;;435/236,40,40,030-933-842-811-33X;;128-409-538-126-285;;053-448-149-112-579;;035-962-611-930-846;;071-772-765-956-684;;037-396-041-244-359;;066-770-445-200-618;;032-960-893-528-071;;003-886-900-367-313;;013-611-786-677-405;;124-044-208-767-130;;068-848-244-364-149;;022-200-622-890-023;;067-313-970-172-320;;023-493-590-815-122;;036-893-407-568-640;;003-457-262-300-943;;016-433-962-751-839;;029-357-080-653-794;;071-702-926-691-637;;080-099-660-695-667;;025-425-047-205-849;;145-273-325-748-677;;028-998-298-813-221;;084-688-053-652-033;;000-980-702-414-096;;018-140-225-646-696;;071-653-349-970-151;;062-530-475-276-156;;022-122-233-681-403;;027-138-347-946-535;;017-710-636-685-708;;000-821-465-292-284;;009-430-338-941-439;;049-024-377-972-593;;018-649-764-477-571;;011-125-677-786-665;;117-805-985-794-328;;047-448-067-269-41X;;105-374-999-563-144,1400445;;10.1016/s0021-9258(19)36613-x;;0001400445;;1908208;;pmc183450;;10.1128/aem.57.6.1669-1674.1991;;1375461;;10.1016/s0006-291x(05)80038-5;;10.1016/s0021-9258(18)46854-8;;7961704;;1373228;;10.1038/356577a0;;2822260;;10.1016/0092-8674(87)90646-5;;1678278;;10.1021/bi00245a003;;10.1016/1074-5521(95)90087-x;;8807814;;10.1016/s0140-6736(96)90638-8;;8609775;;7909169;;10.1126/science.7909169;;10.1002/j.1460-2075.1996.tb00467.x;;8635458;;pmc450028;;10.1016/s0021-9258(18)68879-9;;3350818;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;10.1073/pnas.89.22.10940;;pmc50458;;1438300;;8419912;;pmc45587;;10.1073/pnas.90.1.1;;10.1038/370471a0;;7913989;;7913747;;pmc44354;;10.1073/pnas.91.15.7139;;10.1016/s1359-0278(96)00007-7;;9162135;;9079359;;pmc386505;;10.1073/pnas.83.17.6372;;3462700;;8611544;;10.1021/bi952965e;;3085093;;10.1073/pnas.83.8.2310;;pmc323286;;10.1021/bi00013a006;;7703230;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;10.1021/bi00269a050;;6818988;;10.1016/0092-8674(83)90168-x;;6418385;;10.1016/0092-8674(84)90533-6;;6432339;;8700211;;10.1038/382180a0;;0008700211;;1719082;;10.1073/pnas.90.8.3182;;pmc46263;;8475059;;10.1016/s0021-9258(20)80725-x;;8104185;;10.1093/protein/2.1.69;;2908139;;1338978;;pmc2142161;;10.1002/pro.5560010804;;10.1016/0092-8674(87)90150-4;;2444340;;10.1073/pnas.87.21.8262;;pmc54935;;1978322;;10.1083/jcb.129.1.121;;7698979;;pmc2120366;;3138115;;10.1111/j.1432-1033.1988.tb14246.x;;10.1016/s0140-6736(96)91412-9;;8598754;;10.1073/pnas.93.14.7279;;pmc38974;;8692983;;1968226;;10.1038/343669a0;;10.1006/jmbi.1995.0395;;7542350,"Shigematsu et al. J. Biol. Chem. 267(30):21329 37, Oct. 25, 1992.;;Strandberg et al. Appl. Environ. Microbiol. 57(6):1669 74, Jun. 1991.;;Tabliavini et al. Biochem. Biophys. Res. Comm. 184(3):1398 1404, May 15, 1992.;;Zhang et al. J. Biol. Chem. 269(45):27799 27802 Nov. 11, 1994.;;H. B u eler et al Normal development of mice lacking the neuronal cell surface PrP protein Nature 356 , 577 582 (1992).;;K. R. Thomas et al. Site directed mutagenesis by gene targeting in mouse embryo derived stem cells, Cell 51 :503 512 (1987).;;B.W. Caughey, et al., Secondary structure analysis of the scrapie associated protein PrP 27 30 in water by infrared spectroscopy, Biochemistry 30 , 7672 7680 (1991).;;B. Caughey, et al., Aggretates of scrapie associated prion protein induce the cell free conversion of protease sensitive prion protein to the protease resistant state, J. Chem. Biol. 2 , 807 817 (1995).;;G. Chazot, et al., New variant of Creutzfeldt Jakob disease in a 26 year old French man, Lancet 347 :1181 (1996).;;F.E. Cohen, et al., Structural clues to prion replication, Science 264 :530 531 (1994).;;M. Fischer, et al., Prion protein (PrP) with amino proximal deletions restoring susceptibility of PrP knockout mice to scrapie, EMBO J. 15 (6):1255 64 (1996).;;R. Gabizon, et al., Properties of scrapie prion protein Liposomes, J. Biol. Chem. 263 :4950 4955 (1988).;;J. Gabriel et al., Molecular cloning of a candidate chicken prion protein, Proc. Natl. Acad. Sci. USA 89 :9097 9101 (1992).;;M. Gasset, et al., Predicted helical regions of the prion protein when synthesized as peptides form amyloid, Proc. Natl. Acad. Sci. USA 89 :10940 10944 (1992).;;M. Gasset, et al., Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity, Proc. Natl. Acad. Sci. USA 90 :1 5 (1993).;;D.A. Kocisko, et al., Cell free formation of protease resistant prion protein, Nature 370 , 471 474 (1994).;;Z. Huang, et al., Proposed three dimensional structure for the cellular prion protein, Proc. Natl. Acad. Sci. USA 91 :7139 7143 (1994).;;Z. Huang, et al., Scrapie prions: a three dimensional model of an infectious fragment, Folding & Design 1 :13 19 (1995).;;C. Locht, et al., Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent, Proc. Natl. Acad. Sci. USA 83: 6372 6276 (1986).;;I. Mehlhorn, et al., High level expression and characterization of a purified 152 residue polypeptide of the prion protein, Biochemistry 35 :5528 5537 (1996).;;R.K. Meyer, et al., Separation and properties of cellular and scrapie prion proteins, Proc. Natl. Acad. Sci. USA 83 :2310 2314 (1986).;;J. Nguyen, et al., Prion protein peptides induce helix to sheet conformational transitions, Biochemistry 34 :4186 4192 (1995).;;K.M. Pan, et al., Conversion of helices into sheets features in the formation of the scrapie prion proteins, Proc. Natl. Acad. Sci. USA 90 :10962 10966 (1993).;;S.B. Prusiner, et al., Further purification and characterization of scrapie prions, Biochemistry 21 :6942 6950 (1982).;;S.B. Prusiner, et al., Scrapie prions aggregate to form amyloid like birefringent rods, Cell 35 (2) :349 358 (1983).;;S.B. Prusiner, et al., Purification and structural studies of a major scrapie prion protein, Cell 38 :127 134 (1984).;;R. Riek, et al., NMR structure of the mouse prion protein domain PrP(121 231), Nature 382 :180 182 (1996).;;M. Rogers, et al., Epitope mapping of the syrian hamster prion protein utilizing chimeric and mutant genes in a vaccinia virus expression system, J. Immunol. 147:3568 3574 (1991).;;M. Rogers, et al., Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells, Proc. Natl. Acad. Sci. USA 90 :3182 3186 (1993).;;J. Safar, et al., Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein, J. Biol. Chem. 268 :20276 20284 (1993).;;M. Scott, et al., Prion protein gene expression in cultured cells, Protein Engineering 2 :69 76 (1988).;;M.R. Scott, et al., Chimeric prion protein expression in cultured cells and transgenic mice, Protein Sci. 1:986 997 (1992).;;N. Stahl, et al., Scrapie prion protein contains a phosphatidylinositol glycolipid, Cell 51 :229 240 (1987).;;A. Taraboulos, et al., Acquisition of protease resistance by prion proteins in scrapie infected cells does not require asparagine linked glycosylation, Proc. Natl. Acad. Sci. USA 87 :8262 6.;;A. Taraboulos, et al., Cholesterol depletion and modification of COOH terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform, J. Cell Biol. 129:121 132 (1995).;;E. Turk, et al., Purification and properties of the cellular and scrapie hamster prion proteins, Eur. J. Biochem. 176:21 30 (1988).;;R.G. Will, et al., New variant of Creuzfeldt Jacob disease in the UK, Lancet 347 , 921 925 (1996).;;R. A. Williamson, et al., Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein, Proc. Natl. Acad. Sci. USA 93 :7279 7282 (1996).;;C.S. Yost, et al., Non hydrophobic extracytoplasmic determinant of stop transfer in the prion protein, Nature 343 :669 672 (1990).;;H, Zhang, et al., Conformational transitions in peptides containing two putative helices of the prion protein, J. Mol. Biol. 250 :514 526 (1995).",EXPIRED
82,US,A1,US 2004/0162994 A1,045-543-465-267-738,2004-08-19,2004,US 43828503 A,2003-05-13,US 43828503 A;;US 38082402 P;;US 41628502 P,2002-05-13,Method and apparatus for configurable communication network defenses,"
   A method and/or system providing and/or indicating configurable and selectable strategies for responding to data units. 
",SANDIA NAT LAB,COHEN FRED;;CARATHIMAS ANTHONY GEORGE;;THOMAS ERIC DANIEL,SANDIA NATIONAL LABORATORIES (2003-12-05),https://lens.org/045-543-465-267-738,Patent Application,yes,25,96,1,14,0,H04L63/0227;;H04L63/1441;;H04L63/1491;;H04L61/00;;H04L2101/663;;H04L2101/604;;H04L63/1441;;H04L63/1491;;H04L63/0227;;H04L61/00;;H04L2101/604;;H04L2101/663,H04L29/06;;H04L29/12,713/201,0,0,,,,DISCONTINUED
83,AU,A,AU 1997/026694 A,121-579-056-459-279,1998-05-29,1998,AU 1997/026694 A,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,Soluble proteins,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/121-579-056-459-279,Patent Application,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,EXPIRED
84,PT,E,PT 1012162 E,006-472-550-434-211,2003-04-30,2003,PT 97918634 T,1997-04-15,US 74094796 A,1996-11-05,PROTEINAS SOLUVEIS,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;MURAMOTO TAMAKI;;COHEN FRED E,,https://lens.org/006-472-550-434-211,Granted Patent,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;G01N33/50;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,EXPIRED
85,AU,A,AU 1996/064861 A,059-708-031-393-025,1997-02-10,1997,AU 1996/064861 A,1996-07-09,US 102595 P;;US 9611444 W,1995-07-11,Novel factor viii:c polypeptide analogs with altered protease sites,,CHIRON CORP,HUNG DAVID T;;COHEN FRED E;;INNIS MICHAEL,,https://lens.org/059-708-031-393-025,Patent Application,no,0,0,2,2,0,A61K38/00;;C07K14/755,A61K38/00;;C07K14/755;;C12N15/12,,0,0,,,,PENDING
86,EP,A1,EP 1012162 A1,179-878-741-790-327,2000-06-28,2000,EP 97918634 A,1997-04-15,US 9706227 W;;US 74094796 A,1996-11-05,SOLUBLE PROTEINS,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/179-878-741-790-327,Patent Application,yes,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,EXPIRED
87,WO,A1,WO 1997/016728 A1,192-084-371-317-562,1997-05-09,1997,US 9617462 W,1996-10-28,US 55682395 A,1995-11-02,FORMATION AND USE OF PRION PROTEIN (PrP) COMPLEXES,"Prion protein (PrP) peptides having at least one α-helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrPc) to form a complex having characteristics of the scrapie isoform (PrPSc). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrPc are disclosed, as well as methods for assaying PrPSc.",UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/192-084-371-317-562,Patent Application,yes,1,34,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,4,3,145-273-325-748-677;;026-113-275-066-629;;056-484-231-172-156,10.1073/pnas.90.23.10962;;7902575;;pmc47901;;3755672;;10.1089/dna.1986.5.315;;8030949;;10.1111/j.1749-6632.1994.tb38918.x,"PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA., December 1993, Vol. 90, PAN et al., ""Conversion of Alpha-helices into Beta-sheets Features in the Formation of the Scrapie Prion Proteins"", pages 10962-10966.;;DNA, 1986, Vol. 5, No. 4, KRETZSCHMAR et al., ""Molecular Cloning of a Human Prion Protein cDNA"", pages 315-324.;;ANNUALS OF THE NEW YORK ACADEMY OF SCIENCE, 06 June 1994, Vol. 724, CAUGHEY et al., ""Scrapie-associated PrP Accumulation and its Inhibition: Revisiting the Amyloid-glycosaminoglycan Connection"", pages 290-295.;;See also references of EP 1007964A4",PENDING
88,WO,A1,WO 1998/020022 A1,183-476-579-513-34X,1998-05-14,1998,US 9706227 W,1997-04-15,US 74094796 A,1996-11-05,SOLUBLE PROTEINS,"The invention includes deleting codon segments from DNA expressing a native protein in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/183-476-579-513-34X,Patent Application,yes,2,2,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,A61K38/00;;A61K45/00;;A61P25/00;;G01N33/50;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,4,4,030-933-842-811-33X;;128-409-538-126-285;;053-448-149-112-579;;035-962-611-930-846,1400445;;10.1016/s0021-9258(19)36613-x;;0001400445;;1908208;;pmc183450;;10.1128/aem.57.6.1669-1674.1991;;1375461;;10.1016/s0006-291x(05)80038-5;;10.1016/s0021-9258(18)46854-8;;7961704,"JOURNAL OF BIOL. CHEM., 25 October 1992, Vol. 267, No. 30, SHIGEMATSU et al., ""Expression of Human Soluble Tissue Factor in Yeast and Enzymatic Properties of Its Complex with Factor VIIa"", pages 21329-21337.;;APPLIED ENVIRON. MICROBIOL., June 1991, Vol. 56, No. 6, STRANDBERG et al., ""Factors Influencing Inclusion Body Formation in Production of a Fused Protein in Escherichia Coli"", pages 1669-1674.;;BIOCHEM. BIOPHYS. RES. COMM., 15 May 1992, Vol. 184, No. 3, TAGLIAVINI et al., ""A Soluble form of Prion Protein in Human Cerebrospinal Fluid"", pages 1398-1404.;;JOURNAL OF BIOL. CHEM., 11 November 1994, Vol. 269, No. 45, ZHANG et al., ""Proteolytic Processing and Secretion of Human Beta-Amyloid Precursor Protein in Yeast"", pages 27799-27802.",PATENTED
89,US,A1,US 2011/0012435 A1,013-361-971-509-754,2011-01-20,2011,US 50418109 A,2009-07-16,US 50418109 A,2009-07-16,CENTER-TAPPED BATTERY AND POWER DISTRIBUTION SYSTEM FOR SAME,"A battery for a power distribution system includes a cell assembly having a positive terminal and a negative terminal that together provide a relative battery DC voltage. A neutral tap is electrically connected to the cell assembly between the positive and negative terminals, splitting the voltage into positive and negative voltages. The positive terminal is at a positive DC voltage greater than the neutral tap. The negative voltage is at a negative DC voltage less than the neutral tap. The relative battery DC voltage is greater than each of the relative voltages between the neutral tap and each of the positive and negative DC voltages.",COHEN FRED;;LU CHENG-YI;;METCALF KENNETH JOHN,COHEN FRED;;LU CHENG-YI;;METCALF KENNETH JOHN,AEROJET ROCKETDYNE OF DE INC (2012-09-30);;HAMILTON SUNDSTRAND SPACE SYSTEMS INTERNATIONAL INC (2012-08-31);;HAMILTON SUNDSTRAND CORPORATION (2012-05-21),https://lens.org/013-361-971-509-754,Patent Application,yes,20,13,5,5,0,H01M10/425;;H01M2200/103;;Y02E60/10;;H01M50/578;;H01M50/543;;H01M50/204;;H01M50/574;;H01M10/425;;H01M2200/103;;H01M50/543;;H01M50/578;;H01M50/204;;H01M50/574,H01H9/54;;H01M50/204;;H01M50/543;;H01M50/574,307/139;;429/178,0,0,,,,DISCONTINUED
90,AU,B2,AU 720533 B2,105-390-021-760-61X,2000-06-01,2000,AU 1997/026694 A,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,Soluble proteins,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/105-390-021-760-61X,Granted Patent,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,2,2,035-962-611-930-846;;053-448-149-112-579,10.1016/s0021-9258(18)46854-8;;7961704;;1375461;;10.1016/s0006-291x(05)80038-5,THE JOURNAL OF BIOLOGICAL CHEM V 269 NO45 (94) P27799-27802;;BIOCHEMICAL AND BIOPHYSICAL RES COMM 184 (3) (92) P1398-1404,EXPIRED
91,NZ,A,NZ 335103 A,132-437-656-798-325,2000-10-27,2000,NZ 33510397 A,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,Soluble proteins,"The deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein that mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/132-437-656-798-325,Patent Application,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,A61K38/00;;A61K45/00;;A61P25/00;;G01N33/50;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,PENDING
92,EP,A1,EP 1007964 A1,045-465-647-832-047,2000-06-14,2000,EP 96938699 A,1996-10-28,US 9617462 W;;US 55682395 A,1995-11-02,FORMATION AND USE OF PRION PROTEIN (PrP) COMPLEXES,,UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/045-465-647-832-047,Patent Application,yes,0,0,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,0,0,,,,DISCONTINUED
93,DK,T3,DK 1012162 T3,069-224-846-862-402,2003-03-10,2003,DK 97918634 T,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,Opløselige proteiner,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/069-224-846-862-402,Granted Patent,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,EXPIRED
94,ES,T3,ES 2186886 T3,199-040-054-087-011,2003-05-16,2003,ES 97918634 T,1997-04-15,US 74094796 A,1996-11-05,PROTEINAS SOLUBLES.,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/199-040-054-087-011,Granted Patent,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,A61K38/00;;A61K45/00;;A61P25/00;;G01N33/50;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,EXPIRED
95,EP,B1,EP 1012162 B1,005-421-618-871-72X,2002-11-13,2002,EP 97918634 A,1997-04-15,US 9706227 W;;US 74094796 A,1996-11-05,SOLUBLE PROTEINS,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/005-421-618-871-72X,Granted Patent,yes,3,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,6,0,,,"T MURAMOTO ET AL.: ""Recombinant scrapie-like prion protein of 106 amino acids is soluble "" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, no. 26, 24 December 1996 (1996-12-24), pages 15457-15462, XP002135435 NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US ISSN: 0027-8424;;N STAHL ET AL.: ""Identification of glycoinositol phospholipid linked and truncated forms of scrapie prion protein"" BIOCHEMISTRY., vol. 29, no. 38, 25 September 1990 (1990-09-25), pages 8879-8884, XP002135436 AMERICAN CHEMICAL SOCIETY. EASTON, PA., US ISSN: 0006-2960;;JOURNAL OF BIOL. CHEM., 25 October 1992, Vol. 267, No. 30, SHIGEMATSU et al., ""Expression of Human Soluble Tissue Factor in Yeast and Enzymatic Properties of Its Complex with Factor VIIa"", pages 21329-21337.;;APPLIED ENVIRON. MICROBIOL., June 1991, Vol. 56, No. 6, STRANDBERG et al., ""Factors Influencing Inclusion Body Formation in Production of a Fused Protein in Escherichia Coli"", pages 1669-1674.;;BIOCHEM. BIOPHYS. RES. COMM., 15 May 1992, Vol. 184, No. 3, TAGLIAVINI et al., ""A Soluble form of Prion Protein in Human Cerebrospinal Fluid"", pages 1398-1404.;;JOURNAL OF BIOL. CHEM., 11 November 1994, Vol. 269, No. 45, ZHANG et al., ""Proteolytic Processing and Secretion of Human Beta-Amyloid Precursor Protein in Yeast"", pages 27799-27802.",EXPIRED
96,CA,A1,CA 2235670 A1,076-695-412-658-652,1997-05-09,1997,CA 2235670 A,1996-10-28,US 55682395 A;;US 9617462 W,1995-11-02,FORMATION AND USE OF PRION PROTEIN (PRP) COMPLEXES,"Prion protein (PrP) peptides having at least one .alpha.-helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrPc) to form a complex having characteristics of the scrapie isoform (PrPSc). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrPc are disclosed, as well as methods for assaying PrPSc.",UNIV CALIFORNIA,COHEN FRED E;;KANEKO KIYOTOSHI;;PRUSINER STANLEY B,,https://lens.org/076-695-412-658-652,Patent Application,no,0,0,1,9,10,,C07K7/08;;C07K14/47;;G01N33/53;;G01N33/543,,0,0,,,,DISCONTINUED
97,CA,A1,CA 2268354 A1,117-978-417-448-369,1998-05-14,1998,CA 2268354 A,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,SOLUBLE PROTEINS,"The invention includes deleting codon segments from DNA expressing a native protein in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein.",UNIV CALIFORNIA,MURAMOTO TAMAKI;;PRUSINER STANLEY B;;COHEN FRED E,,https://lens.org/117-978-417-448-369,Patent Application,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,DISCONTINUED
98,US,A1,US 2004/0153574 A1,149-830-480-868-593,2004-08-05,2004,US 43825303 A,2003-05-13,US 43825303 A;;US 38082402 P;;US 41628502 P,2002-05-13,Method and apparatus for specifying communication indication matching and/or responses,"
   A method and/or system providing and/or indicating configurable and selectable strategies for responding to data units. 
",SANDIA NAT LAB,COHEN FRED;;CARATHIMAS ANTHONY GEORGE;;THOMAS ERIC DANIEL,SANDIA NATIONAL LABORATORIES (2003-12-05),https://lens.org/149-830-480-868-593,Patent Application,yes,2,16,1,14,0,H04L61/00;;H04L2101/663;;H04L2101/604;;H04L61/00;;H04L2101/604;;H04L2101/663,H04L29/12,709/245,0,0,,,,DISCONTINUED
99,EP,A3,EP 2276093 A3,168-975-598-276-194,2012-04-11,2012,EP 10251279 A,2010-07-16,US 50418109 A,2009-07-16,Center-tapped battery and power distribution system for same,"A battery for a power distribution system includes a cell assembly having a positive terminal (14) and a negative terminal (16) that together provide a relative battery DC voltage. A neutral tap (12) is electrically connected to the cell assembly between the positive and negative terminals, splitting the voltage into positive and negative voltages. The positive terminal is at a positive DC voltage greater than the neutral tap. The negative voltage is at a negative DC voltage less than the neutral tap. The relative battery DC voltage is greater than each of the relative voltages between the neutral tap and each of the positive and negative DC voltages.
",HAMILTON SUNDSTRAND CORP,COHEN FRED;;LU CHENG-YI;;METCALF KENNETH JOHN,"AEROJET ROCKETDYNE OF DE, INC. (2015-02-11);;HAMILTON SUNDSTRAND SPACE SYSTEMS INTERNATIONAL, I (2013-01-02)",https://lens.org/168-975-598-276-194,Search Report,yes,5,0,5,5,0,H01M10/425;;H01M2200/103;;Y02E60/10;;H01M50/578;;H01M50/543;;H01M50/204;;H01M50/574;;H01M10/425;;H01M2200/103;;H01M50/543;;H01M50/578;;H01M50/204;;H01M50/574,H01M50/204;;H01M50/543;;H01M50/574,,0,0,,,,DISCONTINUED
100,AU,A,AU 1996/076012 A,019-998-600-460-118,1997-05-22,1997,AU 1996/076012 A,1996-10-28,US 55682395 A;;US 9617462 W,1995-11-02,Formation and use of prion protein (prp) complexes,,UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/019-998-600-460-118,Patent Application,no,0,1,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,0,0,,,,EXPIRED
101,EP,A4,EP 1012162 A4,111-490-025-626-413,2000-06-28,2000,EP 97918634 A,1997-04-15,US 9706227 W;;US 74094796 A,1996-11-05,SOLUBLE PROTEINS,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/111-490-025-626-413,Search Report,no,1,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,2,2,022-270-055-020-323;;072-934-992-479-262,pmc26426;;10.1073/pnas.93.26.15457;;8986833;;1980209;;10.1021/bi00490a001,"T MURAMOTO ET AL.: ""Recombinant scrapie-like prion protein of 106 amino acids is soluble"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, no. 26, 24 December 1996 (1996-12-24), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 15457 - 15462, XP002135435, ISSN: 0027-8424;;N STAHL ET AL.: ""Identification of glycoinositol phospholipid linked and truncated forms of scrapie prion protein"", BIOCHEMISTRY., vol. 29, no. 38, 25 September 1990 (1990-09-25), AMERICAN CHEMICAL SOCIETY. EASTON, PA., US, pages 8879 - 8884, XP002135436, ISSN: 0006-2960",EXPIRED
102,US,A1,US 2004/0148521 A1,020-936-931-467-711,2004-07-29,2004,US 43825103 A,2003-05-13,US 43825103 A;;US 38082402 P;;US 41628502 P,2002-05-13,Method and apparatus for invisible network responder,"
   A method and/or system providing and/or indicating configurable and selectable strategies for responding to data units. 
",SANDIA NAT LAB,COHEN FRED;;CARATHIMAS ANTHONY GEORGE;;THOMAS ERIC DANIEL,SANDIA NATIONAL LABORATORIES (2003-07-21),https://lens.org/020-936-931-467-711,Patent Application,yes,6,58,1,14,0,H04L63/0263;;H04L63/1466;;H04L63/1491;;H04L2101/663;;H04L2101/604;;H04L61/00;;H04L63/1466;;H04L63/1491;;H04L63/0263;;H04L61/00;;H04L2101/604;;H04L2101/663,H04L29/06;;H04L29/12,713/201;;709/246,0,0,,,,DISCONTINUED
103,EP,A2,EP 2276093 A2,025-584-429-720-73X,2011-01-19,2011,EP 10251279 A,2010-07-16,US 50418109 A,2009-07-16,Center-tapped battery and power distribution system for same,"A battery for a power distribution system includes a cell assembly having a positive terminal (14) and a negative terminal (16) that together provide a relative battery DC voltage. A neutral tap (12) is electrically connected to the cell assembly between the positive and negative terminals, splitting the voltage into positive and negative voltages. The positive terminal is at a positive DC voltage greater than the neutral tap. The negative voltage is at a negative DC voltage less than the neutral tap. The relative battery DC voltage is greater than each of the relative voltages between the neutral tap and each of the positive and negative DC voltages.
",HAMILTON SUNDSTRAND CORP,COHEN FRED;;LU CHENG-YI;;METCALF KENNETH JOHN,"AEROJET ROCKETDYNE OF DE, INC. (2015-02-11);;HAMILTON SUNDSTRAND SPACE SYSTEMS INTERNATIONAL, I (2013-01-02)",https://lens.org/025-584-429-720-73X,Patent Application,yes,1,0,5,5,0,H01M10/425;;H01M2200/103;;Y02E60/10;;H01M50/578;;H01M50/543;;H01M50/204;;H01M50/574;;H01M10/425;;H01M2200/103;;H01M50/543;;H01M50/578;;H01M50/204;;H01M50/574,H01M50/204;;H01M50/543;;H01M50/574,,0,0,,,,DISCONTINUED
104,WO,A1,WO 1997/003195 A1,064-237-181-931-143,1997-01-30,1997,US 9611444 W,1996-07-09,US 102595 P,1995-07-11,NOVEL FACTOR VIII:C POLYPEPTIDE ANALOGS WITH ALTERED PROTEASE SITES,"Factor VIII:C polypeptide analogs are provided that are native Factor VIII:C polypeptides that contain amino acid modifications at one or more amino acid residues adjacent an Arg residue, provided that the Arg residue is not at a Factor VIII:C activation site. Such modifications create one or more Arg-Pro or Pro-Arg linkages. Nucleic acid molecules encoding Factor VIII:C polypeptide analogs, vectors and host cells containing such nucleic acid molecules are also provided. Additional modifications include the creation of a tripeptide having the formula P3-P2-P1, wherein P3 is a residue selected from the group consisting of Phe, Glu, and Pro; P2 is any amino acid residue except Ser and P2 is not Leu335 and is not Asn1720; and P1 is Arg. Other modifications include substitutions at the non-activating Arg residues occurring at positions Arg336, Arg1719 and/or Arg1721. Further provided are analog complexes that contain at least two such analogs. Methods of producing the analogs, the analog complexes, nucleic acids encoding the same, vectors, and host cells are also provided as well as methods of using such compositions for prevention or treatment of active Factor VIII:C polypeptide deficiencies.",CHIRON CORP;;HUNG DAVID T;;COHEN FRED E;;INNIS MICHAEL,HUNG DAVID T;;COHEN FRED E;;INNIS MICHAEL,,https://lens.org/064-237-181-931-143,Patent Application,yes,3,47,2,2,3,A61K38/00;;C07K14/755,A61K38/00;;C07K14/755;;C12N15/12,,0,0,,,,PENDING
105,BR,A,BR 9611428 A,178-547-210-143-814,2000-10-24,2000,BR 9611428 A,1996-10-28,US 55682395 A;;US 9617462 W,1995-11-02,Formação e uso complexos de proteìnas de priÈnio (prp),"<B>FORMAçãO E USO DE COMPLEXOS DE PROTEìNA DE PRIÈNIO (PrP)<D> Peptídeos de proteína de priónio (PrP) tendo pelo menos um domínio <244>-helicoidal e formando uma conformação de espira aleatória em soluções aquosas ligam PrP celular (PrP^ c^) para formar um complexo tendo características do isoform de scrapie (PrP^ sc^). Os processos para selecionar compostos capazes de inibir ou diminuir a ligação de peptídeos de PrP a PrP^ c^ são revelados, bem como processos para ensaiar PrP^ sc^.",UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/178-547-210-143-814,Patent Application,no,0,0,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,0,0,,,,DISCONTINUED
106,AT,T1,AT E227736 T1,018-600-636-571-857,2002-11-15,2002,AT 97918634 T,1997-04-15,US 74094796 A;;US 9706227 W,1996-11-05,LÖSLICHE PROTEINE,"The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrPSc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrPSc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;MURAMOTO TAMAKI,,https://lens.org/018-600-636-571-857,Granted Patent,no,0,0,17,36,0,A61K38/00;;C07K14/00;;C07K14/47;;C07K16/18;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;A61K38/00;;C07K16/18;;C07K14/47,G01N33/50;;A61K38/00;;A61K45/00;;A61P25/00;;A61P25/16;;A61P25/28;;C07K14/00;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/15;;G01N33/53,,0,0,,,,DISCONTINUED
107,AU,B2,AU 715659 B2,019-217-404-171-306,2000-02-10,2000,AU 1996/076012 A,1996-10-28,US 55682395 A;;US 9617462 W,1995-11-02,Formation and use of prion protein (PrP) complexes,,UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/019-217-404-171-306,Granted Patent,no,0,0,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,2,2,145-273-325-748-677;;026-113-275-066-629,10.1073/pnas.90.23.10962;;7902575;;pmc47901;;3755672;;10.1089/dna.1986.5.315,PROC. NATL. ACAD. SC. USA 1993 VOL 90 PP 10962-10966;;DNA 1986 VOL 5 NO 4 PP 315-324,EXPIRED
108,EP,A4,EP 1007964 A4,086-928-574-278-828,2000-07-26,2000,EP 96938699 A,1996-10-28,US 9617462 W;;US 55682395 A,1995-11-02,FORMATION AND USE OF PRION PROTEIN (PrP) COMPLEXES,,UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E,,https://lens.org/086-928-574-278-828,Search Report,no,1,0,8,9,0,C07K14/47;;C07K14/47;;C07K16/18;;C07K16/18;;G01N33/6896;;G01N33/6896;;G01N2800/2828;;G01N2800/2828;;Y10T436/25875;;Y10T436/25875,G01N33/53;;C07K14/47;;C07K16/18;;C12N15/09;;G01N33/566;;G01N33/68,,7,6,025-425-047-205-849;;038-924-423-892-012;;124-031-488-079-144;;006-912-422-780-810;;042-671-215-802-23X;;068-344-586-358-356,10.1021/bi00013a006;;7703230;;10.1016/0378-1119(95)00064-d;;7622046;;7907586;;10.1016/s0021-9258(17)37129-6;;10.1073/pnas.90.20.9678;;pmc47633;;8105481;;8270104;;10.1093/infdis/167.3.602;;8440932,"NGUYEN J ET AL: ""PRION PROTEIN PEPTIDES INDUCE ALPHA-HELIX TO BETA-SHEET CONFORMATIONAL TRANSITIONS"", BIOCHEMISTRY, 1 January 1995 (1995-01-01), XP002071225;;WINDL O ET AL: ""A candidate marsupial PrP gene reveals two domains conserved in mammalian PrP proteins"", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 159, no. 2, 4 July 1995 (1995-07-04), pages 181 - 186, XP004042203, ISSN: 0378-1119;;DE GIOIA, LUCA ET AL.: ""CONFORMATIONAL POLYMORPHISM OF THE AMYLOIDOGENIC AND NEUROTOXIC PEPTIDE HOMOLOGOUS TO RESIDUES 106-126 OF THE PRION PROTEIN"", J BIOL CHEM ( 1994 ) 269(11) 7859-62, XP002138201;;TAGLIAVINI, FABRIZIO ET AL.: ""SYNTHETIC PEPTIDE HOMOLOGOUS TO PRION PROTEIN RESIDUES 106-147 FORM AMYLOID-LIKE FIBRILS IN VITRO"", PROC NATL ACAD SCI U S A ( 1993 ) 90(20) 9678-82, XP002138202;;KASCSAK R J ET AL: ""THE ROLE OF ANTIBODIES TO PRP IN THE DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES"", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION,CH,BASEL, vol. 80, 1 January 1993 (1993-01-01), pages 141 - 151, XP002036865;;PRUSINER S B ET AL: ""IMMUNOLOGIC AND MOLECULAR BIOLOGIC STUDIES OF PRION PROTEINS IN BOVINE SPONGIFORM ENCEPHALOPATHY"", JOURNAL OF INFECTIOUS DISEASES,US,CHICAGO, IL, vol. 167, 1 March 1993 (1993-03-01), pages 602 - 613, XP002036867, ISSN: 0022-1899;;See also references of WO 9716728A1",DISCONTINUED
109,JP,A,JP 2011024413 A,176-208-247-192-40X,2011-02-03,2011,JP 2010160209 A,2010-07-15,US 50418109 A,2009-07-16,BATTERY FOR POWER DISTRIBUTION SYSTEM AND METHOD OF SUPPLYING DC VOLTAGE USING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a battery which does not cause arc discharge and short-circuit even in an environment where an atmospheric pressure is low. <P>SOLUTION: An enclosure 18 of the battery 10 accommodates a first cell assembly 20 and a second cell assembly 22. A negative electrode side 30 of the first cell assembly 20 is connected to a center tap 32 electrically. A positive electrode side 28 of the second cell assembly 22 is connected to the center tap 32 electrically. A center tap connection point 32 is connected to a neutral terminal 12 electrically. The neutral terminal 12 is grounded. A positive DC voltage in a positive terminal is higher than a voltage in the neutral terminal. A negative DC voltage in the negative terminal is lower than a voltage in the neutral terminal. A battery DC voltage is greater than each of a potential difference between a voltage in the neutral terminal and a positive DC voltage, and a potential difference between a voltage in the neutral terminal and a negative DC voltage. <P>COPYRIGHT: (C)2011,JPO&INPIT",HAMILTON SUNDSTRAND CORP,COHEN FRED;;LU CHENG-YI;;METCALF KENNETH JOHN,,https://lens.org/176-208-247-192-40X,Patent Application,no,9,0,5,5,0,H01M10/425;;H01M2200/103;;Y02E60/10;;H01M50/578;;H01M50/543;;H01M50/204;;H01M50/574;;H01M10/425;;H01M2200/103;;H01M50/543;;H01M50/578;;H01M50/204;;H01M50/574,H02J7/00;;H01M10/44;;H01M50/204;;H01M50/543;;H01M50/574,,0,0,,,,DISCONTINUED
110,CA,A1,CA 2318477 A1,054-340-287-556-954,1999-08-26,1999,CA 2318477 A,1999-02-05,US 2695798 A;;US 15105798 A;;US 9902580 W,1998-02-20,ASSAY FOR SPECIFIC STRAINS OF MULTIPLE DISEASE RELATED CONFORMATIONS OF A PROTEIN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;SAFAR JIRI G,,https://lens.org/054-340-287-556-954,Patent Application,no,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,DISCONTINUED
111,WO,A2,WO 2004/042023 A2,112-247-925-717-309,2004-05-21,2004,US 0334811 W,2003-10-31,US 42304102 P;;US 45457603 P,2002-11-01,STEM CELL LIBRARIES,"A stem cell library is created by genetically modifying stem cells with nucleic acids encoding polypeptides which can promote stem cell differentiation into specific cell types. Alternatively, the stem cell library is exposed to an externally added factor that promotes stem cell differentiation into a desired cell line, e.g., neuronal or muscle. The library is used to determine the effect of the encoded protein on the differentiation process. The library is also used to produce nucleic acids for insertion into embryonic stem cells to produce transfected embryonic stem cells. The nucleic acids are inserted into a locus that permits widespread expression of the encoded polypeptide in animals produced from blastocysts that incorporate the transfected cells. Non-human chimeric animals produced by combining blastocysts derived from animal models of human disease and embryonic stem cells transfected with molecules from the library provide an in vivo system for therapeutic design.",FIVE PRIME THERAPEUTICS INC;;ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,,https://lens.org/112-247-925-717-309,Patent Application,yes,0,16,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;G01N33/00,,0,0,,,,PENDING
112,AU,A,AU 1991/082990 A,112-593-013-219-915,1992-02-04,1992,AU 1991/082990 A,1991-07-15,US 55376090 A;;US 9104971 W,1990-07-13,"PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 OR 9",,UNIV CALIFORNIA,COHEN FRED A;;NISSENSON ROBERT A;;STREWLER GORDON J,,https://lens.org/112-593-013-219-915,Patent Application,no,0,0,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,0,0,,,,EXPIRED
113,CN,A,CN 1040793 A,187-474-523-628-267,1990-03-28,1990,CN 89101333 A,1989-03-10,US 16808788 A,1988-03-11,METHOD FOR PREPARING URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDEN FRED R,,https://lens.org/187-474-523-628-267,Patent Application,no,0,3,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
114,AU,B2,AU 667662 B2,169-993-079-142-237,1996-04-04,1996,AU 1991/082990 A,1991-07-15,US 55376090 A;;US 9104971 W,1990-07-13,"Parathyroid hormone analogues modified at positions 3, 6 or 9",,UNIV CALIFORNIA,COHEN FRED A;;NISSENSON ROBERT A;;STREWLER GORDON J,,https://lens.org/169-993-079-142-237,Granted Patent,no,3,0,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,0,0,,,,EXPIRED
115,CA,A1,CA 2087190 A1,066-735-824-427-237,1992-01-14,1992,CA 2087190 A,1991-07-15,US 55376090 A,1990-07-13,PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS,"2087190 9200753 PCTABS00010 The present invention relates polypeptide analogs which have agonist or antagonist or tissue selection properties relative to parathyroid hormone (PTH), parathyroid hormone-like protein (PLP) or parathyroid-related protein (PTHrP). The serine amino acid at position 3, the glutamine amino acid at position 6, the histidine amino acid at position 9 or combinations thereof are substituted by other natural or synthetic amino acids. Preferably, a human PTH fragment of about 34 amino acids is sufficient for pharmacological activity. These polypeptides are useful as agonists or antagonists in the treatment of a human being for disease conditions of cancer, osteoporosis, hypercalcemia, or hyperparathyroid disease conditions. The invention also concerns a method of performing certain assays using the modified peptides, and based on the results of the assays falling within preset limits, selecting those modified peptides which shall be useful in the treatment of disease conditions.",UNIV CALIFORNIA,COHEN FRED E;;NISSENSON ROBERT A;;STREWLER GORDON J,,https://lens.org/066-735-824-427-237,Patent Application,no,0,0,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,0,0,,,,DISCONTINUED
116,EP,A4,EP 1057022 A4,078-383-436-951-319,2001-05-30,2001,EP 99906769 A,1999-02-05,US 9902580 W;;US 2695798 A;;US 15105798 A,1998-02-20,ASSAY FOR SPECIFIC STRAINS OF MULTIPLE DISEASE RELATED CONFORMATIONS OF A PROTEIN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/078-383-436-951-319,Search Report,no,5,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,4,4,042-671-215-802-23X;;025-425-047-205-849;;124-031-488-079-144;;068-344-586-358-356,8270104;;10.1021/bi00013a006;;7703230;;7907586;;10.1016/s0021-9258(17)37129-6;;10.1093/infdis/167.3.602;;8440932,"KASCSAK R J ET AL: ""THE ROLE OF ANTIBODIES TO PRP IN THE DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES"", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION,CH,BASEL, vol. 80, 1993, pages 141 - 151, XP002036865;;NGUYEN J ET AL: ""PRION PROTEIN PEPTIDES INDUCE ALPHA-HELIX TO BETA-SHEET CONFORMATIONAL TRANSITIONS"", BIOCHEMISTRY, 1995, pages 4186 - 4192, XP002071225;;GIOIA DE L ET AL: ""CONFORMATIONAL POLYMORPHISM OF THE AMYLOIDOGENIC AND NEUROTOXIC PEPTIDE HOMOLOGOUS TO RESIDUES 106-126 OF THE PRION PROTEIN"", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 11, 18 March 1994 (1994-03-18), pages 7859 - 7862, XP000887214, ISSN: 0021-9258;;PRUSINER S B ET AL: ""IMMUNOLOGIC AND MOLECULAR BIOLOGIC STUDIES OF PRION PROTEINS IN BOVINE SPONGIFORM ENCEPHALOPATHY"", JOURNAL OF INFECTIOUS DISEASES,US,CHICAGO, IL, vol. 167, 1 March 1993 (1993-03-01), pages 602 - 613, XP002036867, ISSN: 0022-1899",EXPIRED
117,AT,T1,AT E244889 T1,178-087-403-360-466,2003-07-15,2003,AT 99906769 T,1999-02-05,US 2695798 A;;US 15105798 A;;US 9902580 W,1998-02-20,ASSAY FÜR SPEZIFISCHE STÄMME VON MIT MEHREREN KRANKHEITEN ZUSAMMENHÄNGENDEN PROTEINKONFORMATIONEN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/178-087-403-360-466,Granted Patent,no,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,DISCONTINUED
118,WO,B1,WO 2004/042023 B1,174-595-457-207-980,2004-10-21,2004,US 0334811 W,2003-10-31,US 42304102 P;;US 45457603 P,2002-11-01,STEM CELL LIBRARIES,"A stem cell library is created by genetically modifying stem cells with nucleic acids encoding polypeptides which can promote stem cell differentiation into specific cell types. Alternatively, the stem cell library is exposed to an externally added factor that promotes stem cell differentiation into a desired cell line, e.g., neuronal or muscle. The library is used to determine the effect of the encoded protein on the differentiation process. The library is also used to produce nucleic acids for insertion into embryonic stem cells to produce transfected embryonic stem cells. The nucleic acids are inserted into a locus that permits widespread expression of the encoded polypeptide in animals produced from blastocysts that incorporate the transfected cells. Non-human chimeric animals produced by combining blastocysts derived from animal models of human disease and embryonic stem cells transfected with molecules from the library provide an in vivo system for therapeutic design.",FIVE PRIME THERAPEUTICS INC;;ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,,https://lens.org/174-595-457-207-980,Patent Application,no,0,0,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;G01N33/00,,0,0,,,,PENDING
119,WO,A1,WO 1999/042829 A1,094-004-858-951-949,1999-08-26,1999,US 9902580 W,1999-02-05,US 2695798 A;;US 15105798 A,1998-02-20,ASSAY FOR SPECIFIC STRAINS OF MULTIPLE DISEASE RELATED CONFORMATIONS OF A PROTEIN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA;;PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/094-004-858-951-949,Patent Application,yes,3,21,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68;;G01N33/53,,0,0,,,,PATENTED
120,AU,B2,AU 753331 B2,156-939-314-157-174,2002-10-17,2002,AU 1999/026602 A,1999-02-05,US 2695798 A;;US 15105798 A;;US 9902580 W,1998-02-20,Assay for specific strains of multiple disease related conformations of a protein,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/156-939-314-157-174,Granted Patent,no,1,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,EXPIRED
121,AU,A1,AU 2003/287429 A1,045-462-107-850-531,2004-06-07,2004,AU 2003/287429 A,2003-10-31,US 42304102 P;;US 45457603 P;;US 0334811 W,2002-11-01,STEM CELL LIBRARIES,,FIVE PRIME THERAPEUTICS INC,ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,,https://lens.org/045-462-107-850-531,Patent Application,no,0,0,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;G01N33/00,,0,0,,,,DISCONTINUED
122,US,A,US 5849695 A,170-349-764-734-634,1998-12-15,1998,US 97246693 A,1993-01-13,US 97246693 A,1993-01-13,Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals,"The present invention relates polypeptide analogs which have agonist or antagonist or tissue selection properties relative to parathyroid hormone (PTH), parathyroid hormone-like protein (PLP) or parathyroid-related protein (PTHrP). The serine amino acid at position 3, the glutamine amino acid at position 6, the histidine amino acid at position 9 or combinations thereof are substituted by other natural or synthetic amino acids. Preferably, a human PTH fragment of about 34 amino acids is sufficient for pharmacological activity. These polypeptides are useful as agonists or antagonists in the treatment of a human being for disease conditions of cancer, osteoporosis, hypercalcemia, or hyperparathyroid disease conditions. The invention also concerns a method of performing certain assays using the modified peptides, and based on the results of the assays falling within preset limits, selecting those modified peptides which shall be useful in the treatment of disease conditions.",UNIV CALIFORNIA,COHEN FRED E;;NISSENSON ROBERT A;;STREWLER GORDON J,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1993-01-13),https://lens.org/170-349-764-734-634,Granted Patent,yes,5,101,1,1,0,A61K38/29;;C07K14/635;;C07K14/635;;A61K38/29,A61K38/00;;A61K38/29;;C07K14/635,514/12;;530/307;;530/324;;530/399,2,0,,,"Schulz et al, Principles of Protein Structure, pp. 14 16, Springer Verlag (NY), 1979.;;Chorev et al, pp. 621 626 in Peptide Chemistry 1987, edited by Shiba et al. (Protein Res. Found., Osaka) 1988.",EXPIRED
123,BR,A,BR 9908059 A,108-164-163-950-236,2002-01-08,2002,BR 9908059 A,1999-02-05,US 2695798 A;;US 15105798 A;;US 9902580 W,1998-02-20,Método de análise para espécies especìficas de conformações de uma proteìna relacionadas a várias doenças,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/108-164-163-950-236,Patent Application,no,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,DISCONTINUED
124,US,A1,US 2015/0311240 A1,015-469-827-530-687,2015-10-29,2015,US 201414263630 A,2014-04-28,US 201414263630 A,2014-04-28,DEEP WELL PHOTODIODE FOR NIR IMAGE SENSOR,"An active pixel image sensor includes a photodiode structure which enables high near-infrared modulation transfer function and high quantum efficiency, with low pinning voltage for a medium- to large-size pixel. The photodiode includes a shallow photodiode region and a deep photodiode region both of a first dopant type, where the length of the shallow photodiode region is larger than the length of the deep photodiode region; and a shallow depleting region and a deep depleting region both of a second dopant type. The deep depleting region surrounds the deep photodiode region on at least two opposite sides.",SONY CORP;;PIXIM INC,COHEN MURIEL;;BRADY FRED;;AYERS THOMAS R;;HWANG SUNGIN,PIXIM INC (2014-05-07);;SONY CORPORATION (2014-05-07),https://lens.org/015-469-827-530-687,Patent Application,yes,1,2,3,3,0,H01L27/1463;;H01L27/1464;;H01L27/1461;;H01L27/14607;;H01L27/14649;;H01L27/14689;;H01L27/14612;;H04N25/75;;H01L27/1464;;H01L27/1461;;H01L27/14607;;H01L27/14649;;H01L27/14689;;H01L27/14612;;H01L27/1463;;H04N25/75,H04N5/378;;H01L27/146,,0,0,,,,DISCONTINUED
125,US,A1,US 2002/0001817 A1,099-050-106-386-632,2002-01-03,2002,US 90186501 A,2001-07-09,US 90186501 A;;US 15105798 A;;US 2695798 A;;US 80453697 A,1997-02-21,Assay for specific strains of multiple disease related conformations of a protein,"
   Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample. 
",PRUSINER STANLEY B.;;SAFAR JIRI G.;;COHEN FRED E.,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1998-10-16),https://lens.org/099-050-106-386-632,Patent Application,yes,0,5,2,104,0,C07K14/47;;C07K14/47;;C07K14/4711;;C07K14/4711;;C07K16/2872;;C07K16/2872;;G01N33/6896;;G01N33/6896;;G01N33/56983;;G01N33/56983;;G01N33/6893;;G01N33/6893;;G01N2500/00;;G01N2500/00;;G01N2800/2828;;G01N2800/2828;;G01N2800/52;;G01N2800/52,C07K14/47;;C07K16/28;;G01N33/569;;G01N33/68,435/7.1;;X43596;;436/501;;436/518;;436/538;;436/542;;530/388.85;;530/403;;X53035,0,0,,,,EXPIRED
126,EP,A4,EP 0539491 A4,080-858-799-364-592,1994-03-23,1994,EP 91913697 A,1991-07-15,US 55376090 A,1990-07-13,EP 0539491 A4,,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,"COHEN, FRED, A.;;NISSENSON, ROBERT, A.;;STREWLER, GORDON, J.",,https://lens.org/080-858-799-364-592,Search Report,no,0,0,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,0,0,,,,DISCONTINUED
127,EP,A1,EP 0539491 A1,196-799-030-981-697,1993-05-05,1993,EP 91913697 A,1991-07-15,US 55376090 A,1990-07-13,"PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9.","Analogues polypeptidiques présentant des propriétés de sélection d'agonistes ou d'antagonistes ou de tissus vis à vis de la parathormone (PTH), une protéine analogue à la parathormone (TAP) ou un e protéine apparentée à la parathyroïde (PaPTH). On remplace l'acide aminé de sérine en position 3, l'acide aminé de glutamine en position 6, l'acide aminé d'histidine en position 9 ou des combinaisons de ceux-ci par d'autres acides aminés naturels ou synthétiques. De préférence un fragment de PTH humaine d'environ 34 acides aminés est suffisant pour une activité pharmacologique. Ces polypeptides sont utiles comme agonistes ou antagonistes dans le traitement d'un patient souffrant d'états pathologiques relatifs au cancer, à l'ostéoporose, l'hypercalcémie, ou des états pathologiques d'hyperparathyroïdie. L'invention concerne également un procédé permettant de réaliser certains dosages utilisant les peptides modifiés, et basé sur les résultats des dosages situés dans des limites prédéterminées, et permettant de sélectionner les peptides modifiés utiles dans le traitement d'états pathologiques.",UNIV CALIFORNIA,COHEN FRED A;;NISSENSON ROBERT A;;STREWLER GORDON J,,https://lens.org/196-799-030-981-697,Patent Application,yes,0,1,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,1,0,,,See references of WO 9200753A1,DISCONTINUED
128,WO,A1,WO 1992/000753 A1,046-954-531-472-098,1992-01-23,1992,US 9104971 W,1991-07-15,US 55376090 A,1990-07-13,"PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9","The present invention relates polypeptide analogs which have agonist or antagonist or tissue selection properties relative to parathyroid hormone (PTH), parathyroid hormone-like protein (PLP) or parathyroid-related protein (PTHrP). The serine amino acid at position 3, the glutamine amino acid at position 6, the histidine amino acid at position 9 or combinations thereof are substituted by other natural or synthetic amino acids. Preferably, a human PTH fragment of about 34 amino acids is sufficient for pharmacological activity. These polypeptides are useful as agonists or antagonists in the treatment of a human being for disease conditions of cancer, osteoporosis, hypercalcemia, or hyperparathyroid disease conditions. The invention also concerns a method of performing certain assays using the modified peptides, and based on the results of the assays falling within preset limits, selecting those modified peptides which shall be useful in the treatment of disease conditions.",UNIV CALIFORNIA,COHEN FRED A;;NISSENSON ROBERT A;;STREWLER GORDON J,,https://lens.org/046-954-531-472-098,Patent Application,yes,4,37,7,7,0,A61K38/00;;A61P3/00;;C07K14/635,A61K38/22;;A61K38/00;;A61P3/00;;C07K14/635,,3,2,001-200-065-153-108;;117-849-268-598-353,10.1016/s0021-9258(18)52390-5;;1846369;;10.1530/acta.0.1000398;;6287783,"Journal of Biological Chemistry, Volume 266, No. 3, issued 25 January 1991, F.E. COHEN et al., ""Analogues of Parathyroid Hormone Modified at Positions 3 and 6"", pages 1997-2004, see entire document.;;Acta Endocrinologica, Volume 100, No. 3, issued July 1982, R. ZONEFRATI et al., ""Parathyroid hormone bioassay using human kidney cortical cells in primary culture"", pages 398-405, see Abstract.;;G. SCHULZ et al., ""Principles of Protein Structure"", published 1979 by Springer-Verlag (N.Y.), see pages 14-16.",PENDING
129,EP,A1,EP 1057022 A1,042-054-644-653-953,2000-12-06,2000,EP 99906769 A,1999-02-05,US 9902580 W;;US 2695798 A;;US 15105798 A,1998-02-20,ASSAY FOR SPECIFIC STRAINS OF MULTIPLE DISEASE RELATED CONFORMATIONS OF A PROTEIN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/042-054-644-653-953,Patent Application,yes,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,EXPIRED
130,AU,A,AU 1999/026602 A,030-694-488-482-194,1999-09-06,1999,AU 1999/026602 A,1999-02-05,US 2695798 A;;US 15105798 A;;US 9902580 W,1998-02-20,Assay for specific strains of multiple disease related conformations of a protein,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/030-694-488-482-194,Patent Application,no,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,0,0,,,,EXPIRED
131,US,B2,US 6617119 B2,048-412-821-382-222,2003-09-09,2003,US 90186501 A,2001-07-09,US 90186501 A;;US 15105798 A;;US 2695798 A;;US 80453697 A,1997-02-21,Assay for specific strains of multiple disease related conformations of a protein,"
    Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample. 
",UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1998-10-16),https://lens.org/048-412-821-382-222,Granted Patent,yes,29,5,2,104,0,C07K14/47;;C07K14/47;;C07K14/4711;;C07K14/4711;;C07K16/2872;;C07K16/2872;;G01N33/6896;;G01N33/6896;;G01N33/56983;;G01N33/56983;;G01N33/6893;;G01N33/6893;;G01N2500/00;;G01N2500/00;;G01N2800/2828;;G01N2800/2828;;G01N2800/52;;G01N2800/52,C07K14/47;;C07K16/28;;G01N33/569;;G01N33/68,435/7.1;;435/5,72,66,032-639-807-972-918;;094-151-950-903-210;;014-148-181-267-301;;005-850-596-269-193;;045-852-186-095-143;;008-361-725-760-125;;032-409-974-407-058;;071-772-765-956-684;;010-340-295-705-917;;043-451-517-284-388;;051-983-761-228-799;;009-634-866-826-666;;160-355-055-007-555;;092-243-535-113-700;;016-460-593-452-975;;124-031-488-079-144;;005-660-743-204-705;;176-338-940-727-172;;085-775-046-873-737;;059-738-485-647-998;;042-671-215-802-23X;;008-313-176-340-390;;085-249-959-101-256;;057-365-548-975-242;;011-420-014-056-604;;071-702-926-691-637;;080-099-660-695-667;;025-425-047-205-849;;075-063-886-919-023;;089-809-753-101-267;;145-273-325-748-677;;068-344-586-358-356;;084-688-053-652-033;;071-653-349-970-151;;062-530-475-276-156;;022-122-233-681-403;;100-008-124-958-029;;068-199-496-216-938;;036-132-403-154-882;;011-893-397-956-06X;;013-632-974-151-972;;040-095-621-513-788;;056-110-055-044-019;;018-649-764-477-571;;019-996-997-217-159;;117-805-985-794-328;;037-972-679-811-175;;047-972-910-013-153;;045-004-628-002-521;;044-514-652-212-530;;057-799-710-450-507;;049-386-580-031-527;;070-212-620-817-702;;082-769-963-808-57X;;039-423-978-088-280;;050-502-584-407-676;;061-073-993-636-580;;018-045-380-856-970;;001-028-737-447-618;;017-503-246-228-198;;050-218-564-306-685;;066-008-054-592-592;;028-998-298-813-221;;042-832-204-720-604;;051-030-294-918-658;;038-763-843-781-541,10.1038/382779a0;;8752271;;10.1093/infdis/154.3.518;;3090160;;2873895;;10.1016/0092-8674(86)90662-8;;2865330;;10.1099/0022-1317-66-11-2471;;10.1126/science.6815801;;6815801;;1351607;;10.1016/0140-6736(92)92431-e;;2025705;;pmc1669149;;10.1136/bmj.302.6780.824;;1373228;;10.1038/356577a0;;1368228;;10.1038/nbt0292-163;;2222355;;10.1111/j.1445-5994.1990.tb01322.x;;10.1136/jnnp.55.11.1094;;1469410;;pmc1015303;;10.1016/s0140-6736(05)64378-4;;8691941;;10.1073/pnas.85.18.6617;;3137571;;pmc282028;;142303;;10.1126/science.142303;;8419831;;10.1056/nejm199302043280520;;7907586;;10.1016/s0021-9258(17)37129-6;;10.1126/science.1439789;;1439789;;8400968;;pmc1678637;;10.1136/bmj.307.6903.517;;7916462;;pmc44760;;10.1073/pnas.91.19.9126;;10.1246/bcsj.66.3565;;8270104;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;2430521;;10.1128/aac.30.3.409;;pmc180570;;10.1006/bbrc.1993.2373;;7902706;;6414721;;10.1016/0092-8674(83)90207-6;;8611544;;10.1021/bi952965e;;3085093;;10.1073/pnas.83.8.2310;;pmc323286;;10.1021/bi00013a006;;7703230;;2859120;;10.1016/0092-8674(85)90333-2;;1363897;;pmc2142104;;10.1002/pro.5560011014;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;10.1093/infdis/167.3.602;;8440932;;10.1016/0092-8674(83)90168-x;;6418385;;1719082;;10.1073/pnas.90.8.3182;;pmc46263;;8475059;;10.1016/s0021-9258(20)80725-x;;8104185;;1969126;;10.1212/wnl.40.3_part_1.513;;9771749;;10.1038/2654;;10.1016/0304-5102(93)80133-f;;8798909;;10.1016/0378-4347(95)00541-2;;10.1212/wnl.40.1.110;;1967489;;8448158;;10.1021/bi00059a016;;pmc49762;;1354357;;10.1073/pnas.89.16.7620;;3138115;;10.1111/j.1432-1033.1988.tb14246.x;;1810710;;10.1007/978-3-642-76540-7_2;;10.1073/pnas.93.14.7279;;pmc38974;;8692983;;pmc110372;;9765500;;10.1128/jvi.72.11.9413-9418.1998;;9197331;;10.1128/cdli.3.4.470-471.1996;;8807215;;pmc170369;;10.1128/jvi.66.4.2096-2101.1992;;pmc289000;;1347795;;10.1099/0022-1317-73-2-329;;1531675;;10.1038/383685a0;;8878476;;10.1016/s0140-6736(97)24002-x;;8996424;;1812788;;10.1016/0003-2697(91)90093-9;;8696966;;10.1016/s0959-440x(96)80089-3;;10.1038/36337;;9363892;;10.1021/bi952501g;;8639594;;7913759;;10.1098/rstb.1994.0037;;10.1006/bbrc.1993.2495;;8267575;;10.1021/bi00096a024;;8218290;;pmc6151859;;1346338;;10.1056/nejm199202133260704;;pmc26354;;8986762;;10.1073/pnas.93.26.15051;;10.1021/bi00269a050;;6818988;;9121579;;10.1038/386564b0;;10.1038/386564a0;;10.1101/gad.10.14.1736;;8698234;;10.1126/science.274.5295.2079;;8953038,"Alpatova, N.M., et al. ""Comparison of Electrochemical Behavior of Heteropolyacids in Solution and Immobilized in a Conducting Polymer Film"" Chemical Abstracts, vol. 121, No. 16, Oct. 17, 1994.;;Anderson et al., (1996) ""Transmission dynamics and epidemiology and BSE in British cattle,"" Nature 382: 779-88.;;Barry, R.A., et al., (1986) ""Monoclonal Antibodies to the Cellular and Scrapie Prion Proteins,"" Journal of Infectious Diseases 154:518-521.;;Basler et al., (1986) ""Scrapie and Cellular PrP Isoforms Are Encoded by the Same Chromosomal Gene,"" Cell 46: 417-28.;;Bendheim, et al., (1984) ""Characterization of Antisera Against Scrapie-Associated Fibrils (SAF) from Affected Hamster and Cross-Reactivity with SAF from Scrapie-Affected Mice and from Patients with Creutzfeldt-Jacob Disease,"" J. Gen. Virol. 66:2471-2478.;;Bolton et al., (1992) ""Identification of a Protein That Purifies with the Scrapie Prion,"" Science 218:1309-11.;;Brown et al., (1992) """"Friendly Fire' in Medicine: Hormones, Homografts, and Creutzfeldt-Jakob Disease,"" Lancet 340:24-27.;;Buchanan et al., (1991) ""Mortality, Neoplasia, and Creutzfeldt-Jakob Disease in Patients Treated with Human Pituitary Growth Hormone in the United Kingdom"", BMJ 302:824-828.;;Bueler et al., (1992), ""Normal Development and Behavior of Mice Lacking the Neuronal Cell-surface PrP Protein,"" Nature 356:577-582.;;Carter, et al., (1992) ""High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment,"" Biotechnology 10:163-7.;;Cochius et al., (1990) ""Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin,"" Aust. N.Z. J. Med. 20:592-593.;;Cochius et al., (1992) ""Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin: A Second Case,"" J. Neurol. Neurosurg. Psychiatry 55:1094-1095.;;Collinge, et al., (1996) ""Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease,"" Lancet 348: 56.;;Gabizon, R., et al., ""Immunoaffinity Purification and Neutralization of Scrapie Prion Infectivity"" Proc. Natl. Acad. Sci. USA, vol. 85, Sep. 1988, pp. 6617-6621.;;Gajdusek, D.C., (1977) ""Unconventional Viruses and the Origin and Disappearance of Kuru,"" Science 197:943-960.;;Gibbs, Jr. et al., (1993) ""Creutzfeldt-Jakob Disease Infectivity of Growth Hormone Derived from Human Pituitary Glands,"" N. Engl. J. Med. 328:358-359.;;Gioia et al. (1994) ""Conformational Polymorphism of the Amyloidogenic and Neurotoxic Peptide Homologous to Residues 106-126 of the Prion Protein."" Journal of Biological Chemistry, vol. 269(11):7859-7862.;;Goldfarb et al., (1992) ""Fatal Familial Insomnia and Familial Creutzfeldt-Jakob Disease: Disease Phenotype Determined by a DNA Polymorphism,"" Science 258:806-808.;;Healy et al., ""Creutzfeldt-Jakob Disease After Pituitary Gonadotrophins: The Prion is the Problem,"" BMJ (1993) 307:517-518.;;Hsiao et al., (1994) ""Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein,"" Proc.National Acad. Sci. USA 91:9126-30.;;Kamada, M., et al., ""Dispersion and Fixation of 12-Tungstophosphate Anion on a Silica Surface Modified with Silane Agents Having an Amine Group and Their Catalytic Properties"" Bull. Chem. Soc. JPN., vol. 66, Dec. 1993, pp. 3565-3570.;;Kascsak et al. (1993) ""The Role of Antibodies to PRP in the Diagnosis of Transmissible Spongiform Encephalopathies."" Developments in Biological Standardization, Ch, Basel, vol. 80:141-151.;;Kascsak, R.J., et al., (1987) ""Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins"" Journal of Virology 61:3688-3693.;;Kimberlin, R.H., et al. ""Suppression of Scrapie Infection In Mice by Heteropolyanion 23, Dextran Sulfate, and Some Other Polyanions"" Antimicrobial Agents and Chemotherapy, vol. 30, No. 3, Sep. 1986, pp. 409-413.;;Lasmezas et al., (1993) ""Recombinant Human Growth Hormone and Insulin-Like Growth Factor I Induce PRP Gene Expression in PC12 Cell,"" Biochem. Biophys. Res. Commun. 196:1163-1169.;;McKinley et al., (1983) ""A Protease-Resistant Protein is a Structural Component of the Scrapie Prion,"" Cell 35:57-62.;;Mehlhorn et al., (1996) ""High-Level Expression and Characterization of a Purified 142-Residue Polypeptide of the Prion Protein,"" Biochemistry 35:5528-37.;;Meyer et al., (1986) ""Separation and Properties of Cellular and Scrapie Prion Proteins,"" Proc. Natl. Acad. Sci. USA 83:2310-2314.;;Nguyen et al., (1986) ""Prion Protein Peptides Induce Alpha-helix to Beta-Sheet Conformational Transitions."" Biochemistry, pp. 4186-4192.;;Oesch, et al., (1985) ""A Cellular Gene Encodes Scrapie PrP 27-30 Protein,"" Cell 40:735-46.;;Pan, et al., (1992) ""Purification and Properties of the Cellular Prion Protein from Syrian Hamster Brain,"" Protein Sci. 1:1343-1352.;;Pan, et al., (1993) ""Conversion of a alpha-helices into beta-sheets features in the formation of the scrapie prion proteins,"" Proc. Natl. Acad. Sci. USA 90:10962-66.;;Prusiner et al. (1993) ""Immunologic and Molecular Biologic Studies of Prion Proteins in Bovine Spongiform Encephalopathy."" Journal of Infectious Diseases, vol. 167:602-613.;;Prusiner, S.B. et al., ""Biology of Prions,"" The Molecular and Genetic Basis of Neurological Disease, 2nd Edition, Chap. 7, pp. 103-143.;;Prusiner, S.B., et al., (1983) ""Scrapie prions aggregate to form amyloid-like birefringent rods,"" Cell 35:349-58.;;Rogers et al., (1991) ""Epitope Mapping of the Syrian Hamster Prion Protein Utilizing Chimeric and Mutant Genes in a Vaccinia Virus Expression System,"" J. Immunol. 147:3568-74.;;Rogers, et al., (1993) ""Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells,"" Proc. Natl. Acad. Sci. USA 90:3182-6.;;Safar et al. J., (1993) ""Conformational Transitions, Dissociation, and Unfolding of Scrapie Amyloid (Prion) Protein,"" J. Biol. Chem. 268:20276-84.;;Safar, et al., (1990) ""Scrapie-associated precursor proteins: Antigenic relationship between species and immunocytochemical localization in normal, scrapie, and Creutzfeldt-Jakob disease brains,"" Neurology 40:513-7.;;Safar, J., et al., ""Eight Prion Strains Have PrPSc Molecules With Different Conformations"" Nature Medicine, vol. 4, No. 10, Oct. 1998, pp. 1157-1165.;;Saidkhanov, S.S., et al. ""Changes in Catalytic Properties of 12-Heteropolyacids in Reaction of Dihydrogen Evolution From Water Induced By Their Immobilization on Anion-Exchange Polymers"" Journal of Molecular Catalysis, vol. 21, 1983, pp. 365-373.;;Schmerr, Mary Jo et al., (1996) ""Improvements in a Competition Assay to Detect Scrapie Prion Protein by Capillary Eletrophoresis"", Journal of Chromatography b 681:29-35.;;Serban et al, (1990) ""Rapid Detection of Creuzfeldt-Jakob Disease and Scrapie Prion Proteins,"" Neurology 40:110-7.;;Stahl et al., (1993) ""Structural Studies of the Scrapie Prion Protein Using Mass Spectrometry and Amino Acid Sequencing,"" Biochemistry 32:1991-2002.;;Taraboulos et al., (1992) ""Regional Mapping of Prion Proteins in Brain,"" Proc. Natl. Acad. Sci. USA 89:7620-7624.;;Turk, et al., (1988) ""Purification and Properties of the Cellular and Scrapie Hamster Prion Proteins,"" Eur. J. Biochem. 176:21-30.;;Wilesmith and Wells, (1991) ""Bovine Spongiform Encephalopathy,"" Curr. Topics Microbiol. Immunol. 172 21-38.;;Wilesmith, ""Bovine Spongiform Encephalopathy,"" Methods in Molecular Medicines: Prion Diseases, pp. 155-173.;;Williamson, et al., (1996) ""Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein,"" Proc. Natl. Acad. Sci. USA 93:7279-82.;;Williamson, R.A. et al., (1998) ""Mapping the prion protein using recombinant antibodies"", J. Virol. 72(11):9413-9418.;;Xu, Y., et al., (1997) ""Cryptic and regulatory epitopes in CD13/Aminopeptidase N"", Exp. Hematol. 25:521-529.;;Yokoyama, Takashi, et al., (1996) ""Immunoreactivity of Specific Epitopes of PrPSc is Enhanced by Pretreatment in a Hydrated Autoclave"", Clinical and Diagnostic Laboratory Immunology 3(4):470-471.;;Bessen et al. (1992) ""Biochemical and Physical Properties of the Prion Protein from Two Strains of the Transmissible Mink Encephalopathy Agent."" J. Virol. 66(4):2096-2101.;;Bessen et al. (1992) ""Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters."" J. Gen. Virol. 73:329-334.;;Collinge et al. (1996) ""Molecular analysis of prion strain variation and the aetiology of ""new variant' CJD."" Nature 383:685-690.;;Hill et al. (1997) ""Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy."" The Lancet 349:99-100.;;Karlsson et al. (1991) ""Analysis and isolation of human transferrin receptor using the OKT-9 monoclonal antibody covalently crosslinked to magnetic beads"" Anal. Biochem. 199:219-222.;;Kelly (1996) ""Alternative conformations of amyloidogenic proteins govern their behavior."" Curr. Op. Struct. Biol. 6:11-17.;;Korth et al. (1997) ""Prion (PrPSc)-specific epitope defined by a monoclonal antibody"" Nature 390:74-77.;;Lai et al. (1996) ""The Acid-Mediated Denaturation Pathway of Transthyretin Yields a Conformational Intermediate that Can Self-Assemble into Amyloid."" Biochem.35:6470-6482.;;Marsh et al. (1994) ""Physiochemical and biological characterization of distinct strains of the transmissible mink encephalopathy agent."" Phil. Tran. R. Soc. Lond. B. 343:413-414 .;;Max, E.E. (1999) ""Immunoglobulins: Molecular Genetics"" in: Fundamental Immunology, Fourth Ed., Paul, W.F., ed., Lippincott-Raven Publishers, Philadelphia, PA, pp. 142-143.;;McCutchen et al. (1993) ""Intermolecular Disulfide Linkages are not Required for Transthyretin Amyloid Fibril Formation in vitro."" Biochem. Biophys. Res. Comm. 197(2):415-421.;;McCutchen et al. (1993) ""Transthyretin Mutation Leu-55-Pro Significantly Alters Tetramer Stability and Increases Amyloidogenicity."" Biochem32:12119-12127.;;Medori et al. (1992) ""Fatal Familial Insomnia, a Prion Disease with a mutation at codon 178 of the prion protein gene."" N. Engl. J. Med. 326:444-449.;;Milroy et al. (1996) ""Inhibiting transthyretin amyloid fribril formation via protein stabilization."" Proc. Natl. Acad. Sci. USA 93:15051-15056.;;Prusiner et al. (1997) ""The prion diseases of humans and animals"" in: The Molecular and Genetic Basis of Neurological Disease, 2nd ed., Rosenberg et al., eds. Butterworth-Heinemann, Chapter 9.;;Prusiner et al. (1982) ""Further Purification and Characterization of Scrapie Prions."" Biochem. 21:6942-6950.;;Setchel, C.H. (1985) ""Magnetic separations in biotechnology-A Review"" J. Chem. Tech. Biotechnol. 35B:175-182.;;Somerville et al. (1997) ""Biochemical typing of scrapie strains."" Nature 386(6625):564.;;Telling et al. (1996) ""Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice."" Genes Devel. 10:1736-1750.;;Telling et al. (1996) ""Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity."" Science 274:2079-2082.",EXPIRED
132,AU,A8,AU 2003/287429 A8,037-414-514-117-840,2004-06-07,2004,AU 2003/287429 A,2003-10-31,US 42304102 P;;US 45457603 P;;US 0334811 W,2002-11-01,Stem cell libraries,,FIVE PRIME THERAPEUTICS INC,CHU KETTING;;COHEN FRED;;WILLIAMS LEWIS T;;ZHANG HONGBING,,https://lens.org/037-414-514-117-840,Patent Application,no,0,0,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;G01N33/00,,0,0,,,,DISCONTINUED
133,WO,A3,WO 2004/042023 A3,035-608-755-277-370,2004-09-10,2004,US 0334811 W,2003-10-31,US 42304102 P;;US 45457603 P,2002-11-01,STEM CELL LIBRARIES,"A stem cell library is created by genetically modifying stem cells with nucleic acids encoding polypeptides which can promote stem cell differentiation into specific cell types. Alternatively, the stem cell library is exposed to an externally added factor that promotes stem cell differentiation into a desired cell line, e.g., neuronal or muscle. The library is used to determine the effect of the encoded protein on the differentiation process. The library is also used to produce nucleic acids for insertion into embryonic stem cells to produce transfected embryonic stem cells. The nucleic acids are inserted into a locus that permits widespread expression of the encoded polypeptide in animals produced from blastocysts that incorporate the transfected cells. Non-human chimeric animals produced by combining blastocysts derived from animal models of human disease and embryonic stem cells transfected with molecules from the library provide an in vivo system for therapeutic design.",FIVE PRIME THERAPEUTICS INC;;ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETTING;;COHEN FRED,,https://lens.org/035-608-755-277-370,Search Report,yes,0,0,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;G01N33/00,,8,8,042-950-042-270-088;;117-584-041-009-963;;103-508-533-667-548;;094-551-569-203-760;;115-302-710-997-014;;107-775-700-457-735;;019-800-915-764-072;;026-380-376-241-189,11130972;;10.1007/s003350010208;;11110684;;10.1182/blood.v96.13.4132;;11335111;;10.1016/s0925-4773(01)00331-8;;10.1073/pnas.92.5.1292;;7877970;;pmc42505;;9593468;;10.1016/s0145-2126(97)00133-1;;10.1016/s0006-8993(02)02550-7;;12020853;;11996042;;10.1016/s0142-9612(01)00329-5;;11925932,"KOHLHEPP ET AL.: ""ROSA26 Mice Carry a Modifier of Min-Induced Mammary and Intestinal Tumor Development"", MAMMALIAN GENOME, vol. 11, 2000, pages 1058 - 1062, XP002977294;;BRANDON ET AL.: ""WNT Signaling Modulates the Diversification of Hematopoietic Cells"", BLOOD, vol. 96, no. 13, 15 December 2000 (2000-12-15), pages 4132 - 4141, XP002977295;;LAKO ET AL.: ""Characterisation of MNT Gene Expression During the Differentiation of Murine Embryonic Stem Cells in Vitro:Role of WNT3 in Enhancing Haemtopoietic Differentiation"", MECHANISMS OF DEVELOPMENT, vol. 103, 2001, pages 49 - 59, XP002977296;;GASSMANN ET AL.: ""Maintenance of an Extrachromosomal Plasmid Vector in Mouse Embyonic Stem Cells"", PROC. NATL. ACAD. SCI. USA, vol. 92, February 1995 (1995-02-01), pages 1292 - 1296, XP002064504;;AHMED ET AL.: ""Gene Transfer of Alpha Interferon Into Hematopoietic Stem Cells"", LEUKEMIA RESEARCH, vol. 22, no. 2, 1998, pages 119 - 124, XP002977297;;DECKEL ET AL.: ""Altered Neuronal Nitric Oxide Synthase Expression Contributes to Disease Progression in Huntingon's Disease Transgenic Mice"", BRAIN RESEARCH, vol. 939, 2002, pages 76 - 86, XP002977298;;WEBER ET AL.: ""Formation of Cartilage Matrix Proteins by BMP-Transfected Murine Mesenchymal Stem Cells Encapsulated in a Novel Class of Alginates"", BIOMATERIALS, vol. 23, 2002, pages 2003 - 2013, XP004345246;;SATO ET AL.: ""Cloned Transgenic Mouse Fetuses from Embryonic Stem Cells"", HUMAN CELL, vol. 14, no. 4, December 2001 (2001-12-01), pages 301 - 304, XP002977299",PENDING
134,EP,B1,EP 1057022 B1,080-064-053-084-40X,2003-07-09,2003,EP 99906769 A,1999-02-05,US 9902580 W;;US 2695798 A;;US 15105798 A,1998-02-20,ASSAY FOR SPECIFIC STRAINS OF MULTIPLE DISEASE RELATED CONFORMATIONS OF A PROTEIN,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/080-064-053-084-40X,Granted Patent,yes,8,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/53;;G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68,,4,0,,,"KASCSAK R J ET AL: ""THE ROLE OF ANTIBODIES TO PRP IN THE DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES"" DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION,CH,BASEL, vol. 80, 1993, pages 141-151, XP002036865;;NGUYEN J ET AL: ""PRION PROTEIN PEPTIDES INDUCE ALPHA-HELIX TO BETA-SHEET CONFORMATIONAL TRANSITIONS"" BIOCHEMISTRY, 1995, pages 4186-4192, XP002071225;;GIOIA DE L ET AL: ""CONFORMATIONAL POLYMORPHISM OF THE AMYLOIDOGENIC AND NEUROTOXIC PEPTIDE HOMOLOGOUS TO RESIDUES 106-126 OF THE PRION PROTEIN"" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 11, 18 March 1994 (1994-03-18), pages 7859-7862, XP000887214 ISSN: 0021-9258;;PRUSINER S B ET AL: ""IMMUNOLOGIC AND MOLECULAR BIOLOGIC STUDIES OF PRION PROTEINS IN BOVINE SPONGIFORM ENCEPHALOPATHY"" JOURNAL OF INFECTIOUS DISEASES,US,CHICAGO, IL, vol. 167, 1 March 1993 (1993-03-01), pages 602-613, XP002036867 ISSN: 0022-1899",EXPIRED
135,US,A1,US 2006/0035373 A1,117-625-120-225-187,2006-02-16,2006,US 384004 A,2004-12-06,US 384004 A;;US 0334811 W;;US 42304102 P;;US 45457603 P,2002-11-01,Stem cell libraries,"A stem cell library is created by genetically modifying stem cells with nucleic acids encoding polypeptides which can promote stem cell differentiation into specific cell types. Alternatively, the stem cell library is exposed to an externally added factor that promotes stem cell differentiation into a desired cell line, e.g., neuronal or muscle. The library is used to determine the effect of the encoded protein on the differentiation process. The library is also used to produce nucleic acids for insertion into embryonic stem cells to produce transfected embryonic stem cells. The nucleic acids are inserted into a locus that permits widespread expression of the encoded polypeptide in animals produced from blastocysts that incorporate the transfected cells. Non-human chimeric animals produced by combining blastocysts derived from animal models of human disease and embryonic stem cells transfected with molecules from the library provide an in vivo system for therapeutic design.",ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETING;;COHEN FRED,ZHANG HONGBING;;WILLIAMS LEWIS T;;CHU KETING;;COHEN FRED,FIVE PRIME THERAPEUTICS INC (2005-08-31),https://lens.org/117-625-120-225-187,Patent Application,yes,2,18,7,7,0,C12N5/0606;;C12N5/0606,A01K67/00;;A01K67/033;;C12N/;;C12N5/00;;C12N5/02;;C12N5/0735;;C12N15/85;;C40B40/02;;G01N33/00,435/366;;435/455,0,0,,,,DISCONTINUED
136,ES,T3,ES 2203073 T3,182-392-832-688-932,2004-04-01,2004,ES 99906769 T,1999-02-05,US 2695798 A;;US 15105798 A,1998-02-20,DOSIFICADO PARA CEPAS ESPECIFICAS DE CONFORMACIONES DE UNA PROTEINA RELACIONADAS CON VARIAS ENFERMEDADES.,Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of proteas resistant disease related protein in a sample and by subtracting that amount from the total amount of a disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of protein in a sample.,UNIV CALIFORNIA,PRUSINER STANLEY B;;SAFAR JIRI G;;COHEN FRED E,,https://lens.org/182-392-832-688-932,Granted Patent,no,0,0,15,104,0,G01N33/56983;;G01N33/6893;;G01N33/6896;;G01N2800/52;;G01N33/6896;;G01N2800/2828,G01N33/537;;G01N33/566;;G01N33/569;;G01N33/68;;G01N33/53,,0,0,,,,EXPIRED
137,CA,A1,CA 3216107 A1,026-813-929-105-349,2022-11-03,2022,CA 3216107 A,2022-04-25,US 202163179632 P;;US 2022/0026163 W,2021-04-26,PROCESS FOR SYNTHESIZING APREMILAST,"Provided herein are processes for synthesizing apremilast comprising reacting 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1 -amine or a salt thereof to form apremilast. Also provided are processes for isolating apremilast from the reaction mixture, as described herein.",AMGEN INC,BEAVER MATTHEW G;;COHEN CAROLYN;;LANGILLE NEIL FRED;;SPADA SIMONE,,https://lens.org/026-813-929-105-349,Patent Application,no,0,0,7,7,0,C07D209/48;;C07B2200/13;;C07D209/48,C07D209/48,,0,0,,,,PENDING
138,AU,A1,AU 2008/221358 A1,185-343-436-820-821,2008-09-04,2008,AU 2008/221358 A,2008-02-28,US 90439307 P;;US 2008/0055361 W,2007-02-28,Indenoisoquinolinone analogs and methods of use thereof,,INOTEK PHARMACEUTICALS CORP,COHEN FRED;;WANG XIAOJING;;JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG,,https://lens.org/185-343-436-820-821,Patent Application,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
139,BR,A2,BR PI0808054 A2,186-886-362-276-540,2019-09-24,2019,BR PI0808054 A,2008-02-28,US 2008/0055361 W;;US 90439307 P,2007-02-28,análogos de indenoisoquinolinona e métodos de uso dos mesmos,,INOTEK PHARMACEUTICALS CORP,DUY-PHONG PHAM-HUU;;FRED COHEN;;PRAKASH JAGTAP;;XIAOJING WANG,,https://lens.org/186-886-362-276-540,Patent Application,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
140,AR,A1,AR 125097 A1,006-726-484-413-46X,2023-06-07,2023,AR P220101066 A,2022-04-25,US 202163179632 P,2021-04-26,PROCESO PARA LA SÍNTESIS DE APREMILAST,"En el presente documento, se proporcionan procesos para la síntesis de apremilast, que comprenden hacer reaccionar anhídrido 3-acetamidoftálico y (S)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etan-1-amina o una sal de la misma para formar apremilast. También se proporcionan procesos para el aislamiento de apremilast de la mezcla de reacción, tal como se describe en el presente documento. Reivindicación 1: Un proceso de preparación de apremilast, que comprende: mezclar (1) una primera solución que comprende anhídrido 3-acetamidoftálico (Compuesto A) o una sal del mismo en un primer disolvente y (2) una segunda solución que comprende (S)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etan-1-amina (Compuesto B) o una sal de la misma en un segundo disolvente para formar apremilast en una mezcla de reacción; y añadir agua a la mezcla de reacción para aislar el apremilast. Reivindicación 46: Un proceso para el aislamiento de apremilast de una mezcla de reacción que comprende apremilast en bruto y DMSO, que comprende: a. enfriar dicha mezcla de reacción hasta una temperatura de 0ºC a 50ºC para formar una solución enfriada; b. añadir agua a dicha solución enfriada; c. precipitar apremilast de dicha solución formada en la Etapa (b) para formar apremilast precipitado; y d. aislar dicho apremilast precipitado. Reivindicación 50: Un proceso de preparación de apremilast, que comprende: a. mezclar (1) una primera solución que comprende anhídrido 3-acetamidoftálico (Compuesto A) en un primer disolvente y (2) una segunda solución que comprende (S)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etan-1-amina (Compuesto B) o una sal de la misma en un segundo disolvente para formar apremilast en una mezcla de reacción, en donde el mezclado se produce en un aparato de proceso continuo; y b. aislar dicho apremilast de dicha mezcla de reacción, en donde dicho aislamiento comprende: i. enfriar la mezcla de reacción hasta una temperatura de 0ºC a 50ºC; ii. añadir agua a la mezcla de reacción enfriada; iii. precipitar apremilast de la mezcla de la Etapa (ii); y iv. aislar dicho apremilast precipitado. Reivindicación 51: Un proceso de preparación de apremilast cristalino, que comprende: a. mezclar (1) una primera solución que comprende anhídrido 3-acetamidoftálico (Compuesto A) en un primer disolvente y (2) una segunda solución que comprende (S)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etan-1-amina (Compuesto B) o una sal de la misma en un segundo disolvente para formar apremilast en una mezcla de reacción, en donde el mezclado se produce en un aparato de proceso continuo; y b. aislar apremilast cristalino de dicha mezcla de reacción mediante cristalización continua y filtración paralela.",AMGEN INC,BEAVER MATTHEW G;;COHEN CAROLYN;;LANGILLE NEIL FRED;;SPADA SIMONE,,https://lens.org/006-726-484-413-46X,Patent Application,no,0,0,7,7,0,C07D209/48;;C07B2200/13;;C07D209/48,C07D209/48,,0,0,,,,PENDING
141,MX,A,MX 2009009183 A,027-681-062-611-752,2009-09-07,2009,MX 2009009183 A,2008-02-28,US 90439307 P;;US 2008/0055361 W,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF.,"The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.",INOTEK PHARMACEUTICALS CORP,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/027-681-062-611-752,Patent Application,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
142,EP,A4,EP 2117545 A4,019-066-549-111-894,2010-10-20,2010,EP 08731015 A,2008-02-28,US 2008/0055361 W;;US 90439307 P,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,,INOTEK PHARMACEUTICALS CORP,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/019-066-549-111-894,Search Report,no,3,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
143,US,B2,US 7495023 B2,052-398-472-170-868,2009-02-24,2009,US 8462605 A,2005-03-18,US 8462605 A;;US 43171403 A;;US 44905803 P;;US 37936602 P,2002-05-08,Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use,"The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.",UNIV CALIFORNIA,COHEN FRED E;;DU XIAOHUI;;GUO CHUN;;MCKERROW JAMES H,,https://lens.org/052-398-472-170-868,Granted Patent,yes,8,0,4,4,0,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04;;Y02A50/30;;C07D231/06;;C07D333/22;;C07D333/28;;C07D207/48;;C07D409/04;;C07C337/08;;C07C281/14;;C07D307/52;;C07D209/14,A61K31/38;;C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/12;;C07D333/22;;C07D333/28;;C07D409/04,514/438;;514/444;;514/471;;549/75;;549/59;;549/494,51,28,062-350-984-634-013;;178-013-384-166-577;;005-482-130-426-664;;042-727-381-384-539;;057-573-054-361-386;;013-193-773-103-18X;;039-077-761-573-008;;002-506-912-050-125;;036-253-100-974-235;;075-573-265-542-251;;076-167-449-391-93X;;041-154-523-615-098;;017-317-426-021-523;;052-204-810-048-112;;135-952-116-372-337;;029-577-913-376-360;;022-060-119-090-641;;093-172-251-224-928;;016-965-590-400-911;;020-557-508-678-60X;;095-494-997-872-520;;102-558-589-605-337;;077-713-109-619-565;;074-634-934-978-109;;036-106-121-932-843;;005-299-952-499-816;;032-445-852-432-704;;017-120-753-722-184,2055300;;10.1016/0014-4894(91)90006-i;;8670136;;10.1042/bj3150085;;pmc1217200;;10.1021/jm9805790;;10354402;;10.1016/s0014-827x(97)00011-6;;9604315;;10785560;;10.1016/s0223-5234(00)00131-8;;10.1021/jm00283a023;;5539756;;11238649;;10.4049/jimmunol.166.6.4020;;8026412;;10.1111/j.1528-1157.1994.tb02486.x;;10.1002/(sici)1098-2299(199902)46:2<112::aid-ddr4>3.0.co;2-n;;10.1084/jem.188.4.725;;9705954;;pmc2213346;;10.1016/0166-6851(93)90086-d;;8459830;;376848;;10.1021/jm00193a020;;10353643;;10.1016/s0968-0896(99)00008-5;;10.1016/0166-6851(92)90050-t;;1620157;;10.1021/jo01079a008;;10.1016/s0968-0896(99)00004-8;;10353642;;11848867;;10.1021/cr950025u;;10.1021/jm00017a002;;7650671;;9503475;;10.1006/phrs.1997.0250;;10.1006/expr.1995.1033;;7895837;;10997933;;10.1016/s0040-4020(00)00882-6;;10.1021/ja981792o;;11849701;;10.1016/s0166-6851(01)00438-8;;11342060;;10.1016/s0167-4838(00)00297-1;;10.1073/pnas.96.20.11015;;10500116;;pmc34234;;9736544;;10.1128/aac.42.9.2254;;pmc105801;;915918;;10.1021/jm00221a034,"Stone et al., 1976, CAS: 84:54228.;;Shaar et al., 1975, CAS: 83:173023.;;Zhou et al., 2000, CAS: 133: 207771.;;Lukevics et al., 1996, CAS: 124: 193285.;;Daiku et al., 1995, CAS: 122: 187591.;;Kumari et al., 1994, CAS: 121:57592.;;Deng et al., 1981, CAS: 95: 132756.;;Umar et al. , 1969, CAS: 70: 2052.;;Duca et al., 1952, CAS: 46: 39723.;;Schuler et al., 1952, CAS: 46: 6397.;;Bonaldo, Myrna C., et al.; Characterization and Expression of Proteases during Trypanosoma cruzi Metacyclogenesis; Experimental Prasitology 1991 pp. 44-51 vol. 73.;;Bromme, Dieter, et al.; ""Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors""; Biochem. J. 1996 pp. 85-89 vol. 315.;;Castineiras et al., ""Structural and spectral characterization of two 1-phenyl-1,2-propanedione bis{N(4)-alkylthiosemicarbazones}"" CAS Accession No. 132:78174 (1999) (Abstract).;;Cerecetto, Hugo, et al.; ""1,2,5-Oxadiazole N-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs: Structure-Activity Relationships""; J. Med. Chem. 1999 pp. 1941-1950 vol. 42.;;Cerecetto, Hugo, et al.; ""Synthesis and anti-trypanosomal activity of novel 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives""; II Farmaco 1998 pp. 89-94 vol. 53.;;Cerecetto, Hugo, et al.; ""Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives Structure-activity relationships""; Eur. J. Med. Chem. 2000 pp. 343-350 vol. 35.;;Cheng et al., ""A preliminary note on the relation between structure and antischistosomal activity of nitrofurazones"" CAS Accession No. 59:75319 (1963) (Abstract).;;Colwell et al., ""Preparation and antimalarial activity of compounds related to dypnone guanylhydrazone"" CAS Accession No. 74:64038 (1971) (Abstract).;;Das, Lopamudra, et al.; ""Successful Therapy of Lethal Murine Visceral Leishmaniasis with Cystatin Involves Up-Regulation of Nitric Oxide and a Favorable T Cell Response""; The Journal of Immunology 2000 pp. 4020-4028.;;Dimmock et al., ""Some aryl semicarbazones possessing anticonvulsant activities"" CAS Accession No. 123:297 (1995) (Abstract).;;Dimmock, J.R., et al.; ""Anticonvulsant Activities of 4-Bromobenzaldehyde Semicarbazone""; Epilepsia 1994 pp. 648-655 vol. 35 No. 3.;;Dimmock, Jonathan R., et al.; ""Anticonvulsant Activities of 4-(4'-Fluorophenoxy) Benzaldehyde Semicarbazone""; Drug Development Research 1999 pp. 112-125 vol. 46.;;Engel, Juan C., et al.; ""Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection""; J. Exp. Med. 1998 pp. 725-734 vol. 188 No. 4.;;Harth, Guenter, et al.; ""Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi""; Molecular and Biochemical Parasitology 1993 pp. 17-24 vol. 58.;;Humphlett et al., ""Antimalarials. IX. Antitubercular drugs. 1. Preparation of ketones from gamma-diethylaminobutyronitrile and aromatic grignard reagents and their conversion to diamides"" CAS Accession No. 43:109 (1949) (Abstract).;;Iskander et al., ""Coordination compounds of hydrazine derivatives with transition metals. XIX. Redox reactions of copper (II) salts with thiosemicarbazide and hydrazine-s-methyl dithiocarboxylate Schiff bases"" CAS Accession No. 94:113576 (1981) (Abstract).;;Jain et al., ""Possible antiamebic agents"" CAS Accession No. 54:56152 (1960) ( Abstract).;;Kachru et al., ""Search for new amebicides. I"" CAS Accession No. 52:34983 (1958) (Abstract).;;Klayman et al., ""2-acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents"" CAS Accession No. 91:151061 (1979) (Abstract).;;May et al., ""Attempts to find new antimalarials. XV. Phenanthrene. 31. Amino alcohols of the typ CH(OH) CH2NR2 derived from 3-chloro-6-acetylphenanthrene"" CAS Accession No. 41:3632 (1947) (Abstract).;;McKerrow, James H., et al.; ""Cysteine Protease Inhibitors as Chemotherapy for Parasitic Infections""; Bioorganic & Medicinal Chemistry 1999 pp. 639-644 vol. 7.;;Meirelles, Maria Nazareth L., et al.; Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro; Molecular Biochemical Parasitology 1992 pp. 175-184 vol. 52.;;Nerurkar et al., ""beta-arylglutaconic acids. IV. Synthesis of crotono- and valerolactones ofbeta-arylglutaconic and glutaric acids"" CAS Accession No. 55:37886 (1961) (Abstract).;;Olson, Jed E., et al.; ""Antimalarial Effects in Mice of Orally Administered Peptidyl Cysteine Protease Inhibitors""; Bioorganic & Medicinal Chemistry 1999 pp. 633-638 vol. 7.;;Otto, Hans-Hartwig, et al.; ""Cysteine Proteases and Their Inhibitors""; Chem. Rev. 1997 pp. 133-171 vol. 97.;;Palmer, James, T., et al.; ""Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors""; J. Med. Chem. 1995 pp. 3193-3196 vol. 38.;;Pandeya, S.N., et al.; ""Anticonculsant Activity of Thioureido Derivatives of Acetophenone Semicarbazone""; Pharmacological Research 1998 pp. 17-22 vol. 37 No. 1.;;Posenthal, Philip, J., et al.; ""Plasmodium falciparum: Effects of Proteinase Inhibitors on Globin Hydrolysis by Cultured Malaria Parasites""; Experimental Parasitology 1995 pp. 272-281 vol. 80.;;Prescott, ""Thiosemicarbazones and hydrazonse of alpha-methylchalcone as potential chemotherapeutic agents"" CAS Accession No. 83:126292 (1975) (Abstract).;;Ramu, Kumar, et al.; ""In Vivo Metabolism and Mass Balance of 4-[4-Fluorophenoxy] Benzaldehyde Semicarbazone in Rats""; Drug Metabolism and Disposition 2000 pp. 1153-1161 vol. 28 No. 10.;;Roush, William R., et al.; ""Design, Synthesis and Evaluation of D-Homophenylalanyl Epoxysuccinate Inhibitors of the Trypanosomal Cysteine Protease Cruzain""; Tetrahedron 2000 pp. 9747-9762 vol. 56.;;Roush, William R., et al.; ""Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases""; J. Am. Chem. Soc. 1998 pp. 10994-10995 vol. 120.;;Saijid, M., et al.; ""Cysteine proteases of parasitic organisms""; Molecular & Biochemical Parasitology 2002 pp. 1-21 vol. 120.;;Salvati, Luca, et al.; ""No donors inhibit Leishmania infantum cysteine proteinase activity""; Biochimica et Biophysica Acta 2001 pp. 357-366 vol. 1545.;;Sawhney et al., ""Synthesis of possible amebicides"" CAS Accession No. 54:56188 (1960) (Abstract).;;Sawhney et al., ""Synthesis of possible amebicides"" CAS Accession No. 60:60564 (1964) (Abstract).;;Selzer, Paul M., et al.; ""Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target""; Proc. Natl. Acad. Sci. 1999 pp. 11015-11022 vol. 96.;;Semenov, Andrey, et al.; ""Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors""; Antimicrobial Agents and Chemotherapy 1998 pp. 2254-2258 vol. 42 No. 9.;;Sharma et al., ""Synthesis of possible amebicides. VII"" CAS Accession No. 54:38933 (1960) (Abstract).;;Warren, James D., et al.; ""4-Substituted Semicarbazones of Mono- and Dichlorobenzaldehydes as Antihypertensive Agents""; Journal of Medicinal Chemistry 1977 pp. 1520-1521 vol. 20 No. 11.;;Zsolnai, ""Attempts to discover new fungistats. VIII. Antimicrobial activity of new compounds containing an arylazomethylene group"" CAS Accession No. 63:83741 (1965) (Abstract).",INACTIVE
144,CN,A,CN 101674832 A,098-580-919-994-135,2010-03-17,2010,CN 200880006557 A,2008-02-28,US 2008/0055361 W;;US 90439307 P,2007-02-28,Indenoisoquinolinone analogs and methods of use thereof,"The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.",INOTEK PHARMACEUTICALS CORP,PRAKASH JAGTAP;;DUY-PHONG PHAM-HUU;;FRED COHEN;;XIAOJING WANG,,https://lens.org/098-580-919-994-135,Patent Application,no,0,1,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
145,ZA,B,ZA 200905741 B,050-830-470-046-596,2010-06-30,2010,ZA 200905741 A,2009-08-18,US 90439307 P,2007-02-28,Indenoisoquinolinone analogs and methods of use thereof,,INOTEK PHARMACEUTICALS CORP,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/050-830-470-046-596,Granted Patent,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A01N/;;A61K/,,0,0,,,,ACTIVE
146,US,A1,US 2004/0014801 A1,011-913-194-618-277,2004-01-22,2004,US 43171403 A,2003-05-08,US 43171403 A;;US 44905803 P;;US 37936602 P,2002-05-08,Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use,"
   The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L. 
",UNIV CALIFORNIA,COHEN FRED E;;DU XIAOHUI;;GUO CHUN;;MCKERROW JAMES H,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2003-07-23),https://lens.org/011-913-194-618-277,Patent Application,yes,4,23,4,4,0,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04;;Y02A50/30;;C07D231/06;;C07D333/22;;C07D333/28;;C07D207/48;;C07D409/04;;C07C337/08;;C07C281/14;;C07D307/52;;C07D209/14,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04,514/406;;548/379.4;;X564 2;;564/34;;514/582;;X51459,0,0,,,,EXPIRED
147,US,A1,US 2005/0182121 A1,117-067-513-461-638,2005-08-18,2005,US 8462605 A,2005-03-18,US 8462605 A;;US 43171403 A;;US 44905803 P;;US 37936602 P,2002-05-08,Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use,"The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.",UNIV CALIFORNIA,COHEN FRED E;;DU XIAOHUI;;GUO CHUN;;MCKERROW JAMES H,,https://lens.org/117-067-513-461-638,Patent Application,yes,8,3,4,4,0,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04;;Y02A50/30;;C07D231/06;;C07D333/22;;C07D333/28;;C07D207/48;;C07D409/04;;C07C337/08;;C07C281/14;;C07D307/52;;C07D209/14,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04,514/406;;514/581;;514/590;;548/379.4;;564/20;;564/34,0,0,,,,EXPIRED
148,WO,A3,WO 2008/106619 A3,187-915-259-677-203,2008-11-27,2008,US 2008/0055361 W,2008-02-28,US 90439307 P,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,"The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.",INOTEK PHARMACEUTICALS CORP;;JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/187-915-259-677-203,Search Report,yes,2,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A01N43/38;;A61K31/47;;A01N43/42,,1,1,021-532-992-430-520,10.1124/jpet.103.048934;;12606624,"CHIARUGI A. ET AL.: ""Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase 1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia"", JPET, 20 February 2003 (2003-02-20), pages 1 - 31, XP008116453",PENDING
149,WO,A2,WO 2008/106619 A2,053-854-653-270-22X,2008-09-04,2008,US 2008/0055361 W,2008-02-28,US 90439307 P,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,"The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.",INOTEK PHARMACEUTICALS CORP;;JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/053-854-653-270-22X,Patent Application,yes,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/4745,,0,0,,,,PENDING
150,EP,A1,EP 4330230 A1,183-808-109-738-091,2024-03-06,2024,EP 22724285 A,2022-04-25,US 202163179632 P;;US 2022/0026163 W,2021-04-26,PROCESS FOR SYNTHESIZING APREMILAST,,AMGEN INC,BEAVER MATTHEW G;;COHEN CAROLYN;;LANGILLE NEIL FRED;;SPADA SIMONE,,https://lens.org/183-808-109-738-091,Patent Application,yes,0,0,7,7,0,C07D209/48;;C07B2200/13;;C07D209/48,C07D209/48,,0,0,,,,PENDING
151,CA,A1,CA 2677046 A1,172-192-113-928-451,2008-09-04,2008,CA 2677046 A,2008-02-28,US 90439307 P;;US 2008/0055361 W,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,"The present invention relates to Indenoisoquinolinone Analogs, compositio ns comprising an effective amount of an Indenoisoquinolinone Analog and meth ods for treating or preventing an inflammatory disease, a reperfusion injury , diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative dise ase, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuro pathy, erectile dysfunction or urinary incontinence, comprising administerin g to a subject in need thereof an effective amount of an Indenoisoquinolinon e Analog.",INOTEK PHARMACEUTICALS CORP,COHEN FRED;;WANG XIAOJING;;JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG,,https://lens.org/172-192-113-928-451,Patent Application,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/4745,,0,0,,,,DISCONTINUED
152,TW,A,TW 202308995 A,188-461-618-107-441,2023-03-01,2023,TW 111115570 A,2022-04-25,US 202163179632 P,2021-04-26,Process for synthesizing apremilast,"Provided herein are processes for synthesizing apremilast comprising reacting 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine or a salt thereof to form apremilast. Also provided are processes for isolating apremilast from the reaction mixture, as described herein.",AMGEN INC,BEAVER MATTHEW G;;COHEN CAROLYN;;LANGILLE NEIL FRED;;SPADA SIMONE,,https://lens.org/188-461-618-107-441,Patent of Addition,no,0,0,7,7,0,C07D209/48;;C07B2200/13;;C07D209/48,C07D209/48;;C07C45/63;;C07C49/84,,0,0,,,,PENDING
153,EP,A2,EP 2117545 A2,153-509-334-452-761,2009-11-18,2009,EP 08731015 A,2008-02-28,US 2008/0055361 W;;US 90439307 P,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,,INOTEK PHARMACEUTICALS CORP,JAGTAP PRAKASH;;PHAM-HUU DUY-PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/153-509-334-452-761,Patent Application,yes,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,A61K31/47;;A01N43/38;;A01N43/42,,0,0,,,,DISCONTINUED
154,KR,A,KR 20090115879 A,121-310-564-465-542,2009-11-09,2009,KR 20097019954 A,2008-02-28,US 90439307 P,2007-02-28,INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF,"The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.",INOTEK PHARMACEUTICALS CORP,JAGTAP PRAKASH;;PHAM HUU DUY PHONG;;COHEN FRED;;WANG XIAOJING,,https://lens.org/121-310-564-465-542,Patent Application,no,0,0,17,17,0,C07D221/18;;C07D401/12;;C07D401/14;;C07D405/12;;C07D491/04;;C07D491/10;;A61P13/00;;A61P13/12;;A61P15/00;;A61P15/10;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/10;;A61P35/00;;A61P39/06;;A61P9/00;;A61P9/04;;A61P9/10;;C07D221/18;;C07D491/06;;A61K31/47;;A01N43/38;;C07D221/18;;C07D491/10;;C07D401/12;;C07D405/12;;C07D491/04;;C07D401/14,C07D221/18;;A01N43/38;;A61K31/47;;C07D491/06,,0,0,,,,DISCONTINUED
155,US,A1,US 2022/0348542 A1,092-023-232-057-903,2022-11-03,2022,US 202217728575 A,2022-04-25,US 202217728575 A;;US 202163179632 P,2021-04-26,PROCESS FOR SYNTHESIZING APREMILAST,"Provided herein are processes for synthesizing apremilast comprising reacting 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine or a salt thereof to form apremilast. Also provided are processes for isolating apremilast from the reaction mixture, as described herein.",AMGEN INC,BEAVER MATTHEW G;;COHEN CAROLYN;;LANGILLE NEIL FRED;;SPADA SIMONE,AMGEN INC (2021-08-09),https://lens.org/092-023-232-057-903,Patent Application,yes,1,0,7,7,0,C07D209/48;;C07B2200/13;;C07D209/48,C07D209/48,,0,0,,,,PENDING
156,US,B2,US 6897240 B2,117-205-915-976-725,2005-05-24,2005,US 43171403 A,2003-05-08,US 43171403 A;;US 44905803 P;;US 37936602 P,2002-05-08,Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use,"The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.",UNIV CALIFORNIA,COHEN FRED E;;DU XIAOHUI;;GUO CHUN;;MCKERROW JAMES H,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2003-07-23),https://lens.org/117-205-915-976-725,Granted Patent,yes,4,10,4,4,0,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04;;Y02A50/30;;C07D231/06;;C07D333/22;;C07D333/28;;C07D207/48;;C07D409/04;;C07C337/08;;C07C281/14;;C07D307/52;;C07D209/14,C07C281/14;;C07C337/08;;C07D207/48;;C07D209/14;;C07D231/06;;C07D307/52;;C07D333/22;;C07D333/28;;C07D409/04,514/582;;514/590;;514/238.7;;564/18;;564/20;;564/34;;544/162,41,25,062-350-984-634-013;;178-013-384-166-577;;042-727-381-384-539;;005-482-130-426-664;;057-573-054-361-386;;039-077-761-573-008;;036-253-100-974-235;;002-506-912-050-125;;075-573-265-542-251;;076-167-449-391-93X;;017-317-426-021-523;;052-204-810-048-112;;029-577-913-376-360;;022-060-119-090-641;;093-172-251-224-928;;016-965-590-400-911;;095-494-997-872-520;;020-557-508-678-60X;;077-713-109-619-565;;102-558-589-605-337;;074-634-934-978-109;;036-106-121-932-843;;005-299-952-499-816;;032-445-852-432-704;;017-120-753-722-184,2055300;;10.1016/0014-4894(91)90006-i;;8670136;;10.1042/bj3150085;;pmc1217200;;10.1016/s0014-827x(97)00011-6;;9604315;;10.1021/jm9805790;;10354402;;10785560;;10.1016/s0223-5234(00)00131-8;;11238649;;10.4049/jimmunol.166.6.4020;;10.1002/(sici)1098-2299(199902)46:2<112::aid-ddr4>3.0.co;2-n;;8026412;;10.1111/j.1528-1157.1994.tb02486.x;;10.1084/jem.188.4.725;;9705954;;pmc2213346;;10.1016/0166-6851(93)90086-d;;8459830;;10353643;;10.1016/s0968-0896(99)00008-5;;10.1016/0166-6851(92)90050-t;;1620157;;10.1016/s0968-0896(99)00004-8;;10353642;;11848867;;10.1021/cr950025u;;10.1021/jm00017a002;;7650671;;9503475;;10.1006/phrs.1997.0250;;10997933;;10.1006/expr.1995.1033;;7895837;;10.1021/ja981792o;;10.1016/s0040-4020(00)00882-6;;11849701;;10.1016/s0166-6851(01)00438-8;;11342060;;10.1016/s0167-4838(00)00297-1;;10.1073/pnas.96.20.11015;;10500116;;pmc34234;;9736544;;10.1128/aac.42.9.2254;;pmc105801;;915918;;10.1021/jm00221a034,"Iskander et al., 1981,CAS: 94:1135.*;;Klayman et al. , 1979, CAS: 91:151061.*;;Prescott, 1975, CAS: 83:126292.*;;Colwell et al., 1971,CAS:74:64038.*;;Zsolnai, 1965, CAS:63:83741.*;;Castineiras et al., 1999, CAS: 132:78174.*;;Sawhney et al., 1964, CAS:60:60564.*;;Cheng et al. , 1963, CAS:59:75319.*;;Nerurkar et al., 1961, CAS:55:37886.*;;Sawhney et al., 1960,CAS:54:56188.*;;Jain et al., 1960CAS:54:56152.*;;Sharma et al., 1960,CAS: 54:38933.*;;Kachru et al., 1958 CAS:52:34983.*;;Humphlett et al., 1949, CAS: 43:10934*;;May et al., 1947,CAS: 41:3632.*;;Dimmock et al., 1995, CAS: 123:297.*;;Bonaldo, Myrna C., et al.; Characterization and Expression of Proteases during Trypanosoma cruzi Metacyclogenesis; Experimental Prasitology 1991 pp. 44-51 vol. 73.;;Bromme, Dieter, et al.; ""Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors""; Biochem. J. 1996 pp. 85-89 vol. 315.;;Cerecetto, Hugo, et al.; ""Synthesis and anti-trypanosomal activity of novel 5 -nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives""; Il Farmaco 1998 pp. 89-94 vol. 53.;;Cerecetto, Hugo, et al.; ""1,2,5-Oxadiazole N-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs: Structure-Activity Relationships""; J. Med. Chem. 1999 pp. 1941-1950 vol. 42.;;Cerecetto, Hugo, et al.; ""Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5 -nitrothiophene-2-carboxaldehyde semicarbazone derivatives Structure-activity relationships""; Eur. J. Med. Chem. 2000 pp. 343-350 vol. 35.;;Das, Lopamudra, et al.; ""Successful Therapy of Lethal Murine Visceral Leishmaniasis with Cystatin Involves Up-Regulation of Nitric Oxide and a Favorable T Cell Response""; The Journal of Immunology 2000 pp. 4020-4028.;;Dimmock, Jonathan R., et al.; ""Anticonvulsant Activities of 4-(4<SUP>1</SUP>-Fluorophenoxy) Benzaldehyde Semicarbazone""; Drug Development Research 1999 pp. 112-125 vol. 46.;;Dimmock, J.R., et al.; ""Anticonvulsant Activities of 4-Bromobenzaldehyde Semicarbazone""; Epilepsia 1994 pp. 648-655 vol. 35 No. 3.;;Engel, Juan C., et al.; ""Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection""; J. Exp. Med. 1998 pp. 725-734 vol. 188 No. 4.;;Harth, Guenter, et al.; ""Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi""; Molecular and Biochemical Parasitology 1993 pp. 17-24 vol. 58.;;McKerrow, James H., et al.; ""Cysteine Protease Inhibitors as Chemotherapy for Parasitic Infections""; Bioorganic & Medicinal Chemistry 1999 pp. 639-644 vol. 7.;;Meirelles, Maria Nazareth L., et al.; Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro; Molecular Biochemical Parasitology 1992 pp. 175-184 vol. 52.;;Olson, Jed E., et al.; ""Antimalarial Effects in Mice of Orally Administered Peptidyl Cysteine Protease Inhibitors""; Bioorganic & Medicinal Chemistry 1999 pp. 633-638 vol. 7.;;Otto, Hans-Hartwig, et al.; ""Cysteine Proteases and Their Inhibitors""; Chem. Rev. 1997 pp. 133-171 vol. 97.;;Palmer, James T., et al.; ""Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors""; J. Med. Chem. 1995 pp. 3193-3196 vol. 38.;;Pandeya, S.N., et al.; ""Anticonculsant Activity of Thioureido Derivatives of Acetophenone Semicarbazone""; Pharmacological Research 1998 pp. 17-22 vol. 37 No. 1.;;Ramu, Kumar, et al.; ""In Vivo Metabolism and Mass Balance of 4-[4-Fluorophenoxy] Benzaldehyde Semicarbazone in Rats""; Drug Metabolism and Disposition 2000 pp. 1153-1161 vol. 28 No. 10.;;Posenthal, Philip, J., et al.; ""Plasmodium falciparum: Effects of Proteinase Inhibitors on Globin Hydrolysis by Cultured Malaria Parasites""; Experimental Parasitology 1995 pp. 272-281 vol. 80.;;Roush, William R., et al.; ""Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases""; J. Am. Chem. Soc. 1998 pp. 10994-10995 vol. 120.;;Roush, William R., et al.; ""Design, Synthesis and Evaluation of D-Homophenylalanyl Epoxysuccinate Inhibitors of the Trypanosomal Cysteine Protease Cruzain""; Tetrahedron 2000 pp. 9747-9762 vol. 56.;;Saijid, M., et al.; ""Cysteine proteases of parasitic organisms""; Molecular & Biochemical Parasitology 2002 pp. 1-21 vol. 120.;;Salvati, Luca, et al.; ""NO donors inhibit Leishmania infantum cysteine proteinase activity""; Biochimica et Biophysica Acta 2001 pp. 357-366 vol. 1545.;;Selzer, Paul M., et al.; ""Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target""; Proc. Natl. Acad. Sci. 1999 pp. 11015-11022 vol. 96.;;Semenov, Andrey, et al.; ""Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors""; Antimicrobial Agents and Chemotherapy 1998 pp. 2254-2258 vol. 42 No. 9.;;Warren, James D., et al; ""4-Substituted Semicarbazones of Mono- and Dichlorobenzaldehydes as Antihypertensive Agents""; Journal of Medicinal Chemistry 1977 pp. 1520-1521 vol. 20 No. 11.",EXPIRED
157,KR,B1,KR 970002229 B1,014-154-653-173-487,1997-02-26,1997,KR 890702114 A,1989-11-13,US 16808788 A;;US 8900875 W,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXY ANHYDRIDES,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL P;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/014-154-653-173-487,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D277/20;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
158,HU,D0,HU 891841 D0,125-991-952-596-861,1990-04-28,1990,HU 184189 A,1989-03-03,US 16808788 A,1988-03-11,PROCESS FOR PREPARATION OF AMINO-ACID-N-CARBOXY-ANHYDRIDES PROTECTED WITH URETHANE GROUP,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM DEAN;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/125-991-952-596-861,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
159,EP,A1,EP 0986396 A1,199-881-763-584-666,2000-03-22,2000,EP 98926042 A,1998-05-18,US 9810104 W;;US 86816297 A;;US 7660698 A,1997-06-02,PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/199-881-763-584-666,Patent Application,yes,0,0,8,9,24,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,0,0,,,,DISCONTINUED
160,AU,A,AU 1998/077967 A,016-902-630-011-489,1998-12-21,1998,AU 1998/077967 A,1998-05-18,US 86816297 A;;US 7660698 A;;US 9810104 W,1997-06-02,Prion protein modulator factor (ppmf) and prion resistant animals,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/016-902-630-011-489,Patent Application,no,0,0,8,9,0,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,0,0,,,,EXPIRED
161,DK,A,DK 564489 A,137-544-714-903-927,1989-11-10,1989,DK 564489 A,1989-11-10,US 16808788 A;;US 8900875 W,1988-03-11,URETHANBESKYTTEDE AMINOSYRE-N-CARBOXYANHYDRIDER,,BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/137-544-714-903-927,Patent Application,no,0,0,2,39,0,,C07D263/44;;C07D277/34;;C07K1/04;;C07K1/06,,0,0,,,,EXPIRED
162,HU,A,HU T52488 A,110-702-543-152-321,1990-07-28,1990,HU 184189 A,1989-03-03,US 16808788 A,1988-03-11,PROCESS FOR PRODUCING AMINO-ACID-N-CARBOXY-ANHYDRIDES PROTECTED WITH URETHANE GROUPS,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM DEAN;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/110-702-543-152-321,Unknown,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D277/20;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
163,AT,T1,AT E108438 T1,161-280-998-609-167,1994-07-15,1994,AT 89903412 T,1989-03-03,US 16808788 A,1988-03-11,URETHAN GESCHÜTZTE AMINOSÄUREN-N- CARBOXYANHYDRIDE.,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/161-280-998-609-167,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,DISCONTINUED
164,PT,B,PT 89961 B,011-517-888-406-207,1994-04-29,1994,PT 8996189 A,1989-03-09,US 16808788 A,1988-03-11,PROCESSO PARA A PREPARACAO DE N-CARBOXIANIDRIDOS DE AMINOACIDOS PROTEGIDOS POR URETANO,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/011-517-888-406-207,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
165,DD,A5,DD 280322 A5,142-427-752-288-513,1990-07-04,1990,DD 32645189 A,1989-03-10,US 16808788 A,1988-03-11,VERFAHREN ZUR HERSTELLUNG URETHANGESCHUETZTER AMINOSAEURE-N-CARBOXYANHYDRIDE ODER N-THIOCARBOXYANHYDRIDE,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PH;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/142-427-752-288-513,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
166,EP,A1,EP 1290004 A1,095-252-880-570-981,2003-03-12,2003,EP 01935592 A,2001-05-15,US 0115832 W;;US 57298000 A,2000-05-16,METHOD OF IDENTIFYING CRITICAL POINTS WITHIN PROTEIN-PROTEIN INTERACTIONS,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/095-252-880-570-981,Patent Application,yes,0,0,3,3,2,C12N15/1055;;C07H17/00;;C07K14/47;;G01N33/6896,C07H17/00;;C07K14/47;;C12N15/10;;G01N33/68,,1,0,,,See references of WO 0187911A1,DISCONTINUED
167,HU,B,HU 205091 B,099-254-523-523-663,1992-03-30,1992,HU 184189 A,1989-03-03,US 16808788 A,1988-03-11,PROCESS FOR PRODUCING AMINO ACID-N-CARBOXYANHYDRIDES PROTECTED WITH URETHANE GROUP,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM DEAN;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/099-254-523-523-663,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D277/20;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
168,WO,A1,WO 1989/008643 A1,032-216-592-483-61X,1989-09-21,1989,US 8900875 W,1989-03-03,US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide, and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/032-216-592-483-61X,Patent Application,yes,1,11,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,2,1,179-899-288-668-878,10.1002/macp.1977.021780401,"Kricheldorf, Makromolecular Chemie, 178, 905-939, published 1977.;;See also references of EP 0357750A4",PATENTED
169,CA,A1,CA 2287848 A1,082-141-958-970-691,1998-12-10,1998,CA 2287848 A,1998-05-18,US 86816297 A;;US 7660698 A;;US 9810104 W,1997-06-02,PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS,"A protein designated Prion Protein Modulator Factor (PPMF) is disclosed which protein is an auxiliary factor in prion replication. PPMF is primarily characterized by its ability to bind to PrPC and facilitate a conformational change from PrPC to PrPSc. A discontinuous epitope on PrPC comprising residues 172, 215 and 219 of human PrPC binds PPMF which is encoded by a nucleotide sequence derived from an organism selected from the group consisting of cow, sheep, mouse, hamster and human. In converting PrPC to PrPSc the PPMF forms a PRPC/PrPSc complex and is a rate limiting compound in the formation of that complex. Molecules, including antibodies, which bind PPMF or its epitope on PrPC are useful in the treatment of prion disease. Pharmacophores of the PrPC epitope are disclosed as are useful therapeutics and pharmacophores of the PPMF surface which binds PrPC. Animals resistant to prion disease are taught as are genes for producing such animals. Assay systems are disclosed which use PPMF to amplify PrPSc in sample being tested.",UNIV CALIFORNIA,PRUSINER STANLEY B;;KANEKO KIYOTOSHI;;COHEN FRED E;;JAMES THOMAS L,,https://lens.org/082-141-958-970-691,Patent Application,no,0,0,8,9,24,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,0,0,,,,DISCONTINUED
170,DE,T2,DE 68916722 T2,097-859-400-437-844,1994-11-03,1994,DE 68916722 T,1989-03-03,US 8900875 W;;US 16808788 A,1988-03-11,URETHAN GESCHÜTZTE AMINOSÄUREN-N-CARBOXYANHYDRIDE.,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/097-859-400-437-844,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
171,EP,A4,EP 0357750 A4,024-047-332-447-554,1991-01-30,1991,EP 89903412 A,1989-03-03,US 8900875 W;;US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.","BIORESEARCH, INC.","FULLER, WILLIAM, D.;;COHEN, MICHAEL, PHILLIP;;NAIDER, FRED, R.;;GOODMAN, MURRAY",,https://lens.org/024-047-332-447-554,Search Report,no,2,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,1,0,,,See also references of WO 8908643A1,EXPIRED
172,AU,B2,AU 731291 B2,074-319-221-550-292,2001-03-29,2001,AU 1998/077967 A,1998-05-18,US 86816297 A;;US 7660698 A;;US 9810104 W,1997-06-02,Prion protein modulator factor (PPMF) and prion resistant animals,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/074-319-221-550-292,Granted Patent,no,0,0,8,9,0,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,1,1,065-423-927-132-846,10.1006/nbdi.1997.0130;;9173930,"NEUROBIOLOGY OF DISEASE, 3, PP 339-355 (1997)",EXPIRED
173,US,A,US 5028693 A,127-839-199-562-536,1991-07-02,1991,US 37911189 A,1989-07-13,US 37911189 A;;US 16808788 A,1988-03-11,Urethane-protected amino acid-N-carboxyanhydrides,"Urethane-protected NCAs and MTAs are prepared by reacting an NCA or NTA with a haloformate in an inert diluent, under anhydrous conditions and in the presence of a tertiary nitrogen-containing base having an atom or functional group sufficiently electron rich and positioned relative to the nitrogen of said base so as to render said atom or group capable of complexing with the H--N&lt; group of said N-carboxyanhydride or N-thiocarboxyanhydride but able to generate N-carboxyanhydride or N-thiocarboxyanhydride anionic complexes capable of reacting with the haloformate.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL P;;NAIDER FRED R;;GOODMAN MURRAY,BIORESEARCH INC (1989-11-03),https://lens.org/127-839-199-562-536,Granted Patent,yes,0,9,1,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/44;;C07K1/04;;C07K1/023;;C07D277/34,C07D263/44;;C07D277/34;;C07K1/02;;C07K1/04,530/335;;530/333;;530/334;;530/337;;548/227;;548/183;;548/188;;544/97;;544/54;;540/488,7,1,000-691-222-196-893,5573721;;10.1021/ja00740a027,"Benoiton, N., et al., Int. J. Peptide Protein Reg., 31: 577 580, 1988.;;Chen, F., et al., Con. J. Chem., 65(3): 619 653, 1987.;;Ahiyama, M., Tetrahedron Letters, 28: 2599 2600, 1979.;;Shimizu, K., Bull. Chem. Soc. Jpn., 57: 495 499, 1984.;;Hirschmann, R., JACS, 93(11): 2746 2754, 1971.;;Halstrom, J., Peptides (Eur. Peptide Symp., 12th, 1972), 1973.;;Bodanszky, M., Principles of Peptide Synthesis, Springer Verlag, N.Y.; 85 86, 1984.",EXPIRED
174,EP,B1,EP 0357750 B1,084-026-255-499-206,1994-07-13,1994,EP 89903412 A,1989-03-03,US 8900875 W;;US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES.,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/084-026-255-499-206,Granted Patent,yes,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,2,2,179-899-288-668-878;;055-345-237-844-834,10.1002/macp.1977.021780401;;10.1007/978-3-642-71586-0,"Kricheldorf, Makromolecular Chemie, vol. 178, 1977, pp. 905-939;;Kricheldorf, Alpha-aminoacid-N-carboxy-anhydrides and related heterocycles, 1987, pp. 8-9",EXPIRED
175,CZ,A3,CZ 148989 A3,049-400-241-843-115,1997-11-12,1997,CS 148989 A,1989-03-10,US 16808788 A,1988-03-11,N-CARBOXYANHYDRIDES OR N-THIOCARBOXYANHYDRIDES OF AMINO ACID PROTECTED AS URETHANE AND PROCESS FOR PREPARING THEREOF,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/049-400-241-843-115,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,PENDING
176,US,A,US 5962669 A,125-260-942-939-323,1999-10-05,1999,US 86816297 A,1997-06-02,US 86816297 A,1997-06-02,Nucleic acid encoding prion protein variant,"A protein designated Prion Protein Modulator Factor (PPMF) is disclosed which protein is an auxiliary factor in prion replication. PPMF is primarily characterized by its ability to bind to PrP.sup.C and facilitate a conformational change from PrP.sup.C to PrP.sup.Sc. A discontinuous epitope on PrP.sup.C comprising residues 172, 215 and 219 of human PrP.sup.C binds PPMF which is encoded by a nucleotide sequence derived from an organism selected from the group consisting of cow, sheep, mouse, hamster and human. In converting PrP.sup.C to PrP.sup.Sc the PPMF forms a PrP.sup.C /PrP.sup.Sc complex and is a rate limiting compound in the formation of that complex. Molecules, including antibodies, which bind PPMF or its epitope on PrP.sup.C are useful in the treatment of prion disease. Pharmacophores of the PrP.sup.C epitope are disclosed as are useful therapeutics and pharmacophores of the PPMF surface which binds PrP.sup.C. Animals resistant to prion disease are taught as are genes for producing such animals. Assay systems are disclosed which use PPMF to amplify PrP.sup.Sc is a sample being tested.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1997-12-05),https://lens.org/125-260-942-939-323,Granted Patent,yes,11,13,1,9,24,A61K31/7048;;A61K31/7048;;A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A61K31/417;;A61K31/4178;;A61K38/00;;C07H21/00;;C07K1/04;;C07K14/47,536/23.5;;536/23.1;;536/23.72;;435/69.1;;435/252.3;;435/320.1,78,75,092-872-964-318-60X;;050-067-114-608-605;;073-471-639-279-380;;094-151-950-903-210;;014-148-181-267-301;;017-577-990-503-583;;045-852-186-095-143;;008-361-725-760-125;;032-409-974-407-058;;080-437-968-996-57X;;071-772-765-956-684;;153-368-234-494-423;;079-975-646-187-852;;051-983-761-228-799;;043-451-517-284-388;;030-933-004-144-056;;030-675-552-399-704;;089-650-916-710-883;;022-200-622-890-023;;092-243-535-113-700;;016-460-593-452-975;;005-660-743-204-705;;007-728-271-452-065;;054-717-385-142-277;;072-140-853-530-414;;004-240-752-404-568;;176-338-940-727-172;;009-514-385-736-17X;;041-774-823-698-339;;027-996-048-989-093;;013-707-716-398-589;;008-313-176-340-390;;017-080-594-688-105;;026-113-275-066-629;;043-141-030-792-715;;057-365-548-975-242;;029-357-080-653-794;;064-775-014-978-559;;024-267-323-523-978;;011-420-014-056-604;;050-218-564-306-685;;035-149-682-232-082;;003-755-575-954-951;;004-170-279-690-27X;;145-273-325-748-677;;045-506-781-213-130;;028-998-298-813-221;;084-688-053-652-033;;032-690-517-241-213;;015-165-550-157-820;;021-727-523-534-140;;068-344-586-358-356;;119-192-657-487-71X;;094-974-313-169-217;;037-424-958-277-000;;071-653-349-970-151;;016-387-612-950-657;;017-710-636-685-708;;005-812-809-438-732;;013-632-974-151-972;;038-570-893-121-612;;056-110-055-044-019;;048-742-579-132-293;;102-923-007-442-383;;021-728-485-230-975;;006-615-048-543-477;;037-305-418-325-620;;091-992-099-413-919;;050-236-579-426-339;;049-983-360-679-626;;133-220-740-974-327;;013-825-882-367-654;;013-264-510-765-830;;013-611-786-677-405;;065-423-927-132-846,10.1007/bf01718334;;8645112;;10.1099/0022-1317-74-7-1451;;7687651;;1674080;;10.1016/0140-6736(91)92953-y;;10.1093/infdis/154.3.518;;3090160;;2873895;;10.1016/0092-8674(86)90662-8;;10.1212/wnl.43.1_part_1.205;;8423886;;10.1126/science.6815801;;6815801;;1351607;;10.1016/0140-6736(92)92431-e;;2025705;;pmc1669149;;10.1136/bmj.302.6780.824;;8100741;;10.1016/0092-8674(93)90360-3;;1373228;;10.1038/356577a0;;10.1016/0092-8674(86)90875-5;;3015416;;10.1016/s0140-6736(61)92008-6;;10.1136/jnnp.55.11.1094;;1469410;;pmc1015303;;2222355;;10.1111/j.1445-5994.1990.tb01322.x;;10.1016/0140-6736(91)93128-v;;1675319;;2199610;;10.1136/jnnp.53.6.459;;pmc1014203;;pmc41951;;7753817;;10.1073/pnas.92.10.4397;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;142303;;10.1126/science.142303;;8419831;;10.1056/nejm199302043280520;;10.1126/science.1439789;;1439789;;10.1073/pnas.87.7.2476;;1969635;;pmc53712;;10.1099/0022-1317-72-1-201;;1671225;;pmc52362;;10.1073/pnas.88.17.7664;;1715573;;1672446;;10.1038/350243a0;;8400968;;pmc1678637;;10.1136/bmj.307.6903.517;;10.1101/gad.6.7.1213;;1628828;;10.1038/338342a0;;2564168;;1674116;;10.1212/wnl.41.5.681;;10.1212/wnl.40.12.1820;;2247227;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;3897861;;10.1056/nejm198509193131206;;3755672;;10.1089/dna.1986.5.315;;1383401;;10.1099/0022-1317-73-10-2757;;10.1006/bbrc.1993.2373;;7902706;;pmc386505;;10.1073/pnas.83.17.6372;;3462700;;pmc335873;;1108016;;10.1073/pnas.73.1.223;;356055;;10.1073/pnas.75.7.3432;;pmc392791;;6414721;;10.1016/0092-8674(83)90207-6;;pmc6151859;;1346338;;10.1056/nejm199202133260704;;pmc1886534;;1376559;;10.1001/jama.261.8.1118b;;2644460;;10.1001/jama.261.8.1118;;10.1038/352547a0;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;10.1002/ana.410110406;;6808890;;10.1021/bi00269a050;;6818988;;10.1016/0092-8674(83)90168-x;;6418385;;10.1016/0092-8674(90)90134-z;;1977523;;1675487;;10.1126/science.1675487;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;10.1093/infdis/167.3.602;;8440932;;10.1146/annurev.ne.17.030194.001523;;8210178;;10.1128/jvi.66.10.6155-6163.1992;;pmc283664;;1356161;;10.1016/0140-6736(93)90413-b;;8094877;;1719082;;2574076;;10.1016/0092-8674(89)90608-9;;1338978;;pmc2142161;;10.1002/pro.5560010804;;8098995;;10.1016/0092-8674(93)90275-u;;10.1212/wnl.40.1.110;;1967489;;1350920;;10.1021/bi00136a600;;pmc49762;;1354357;;10.1073/pnas.89.16.7620;;10.1093/oxfordjournals.bmb.a072656;;8137138;;382976;;10.1002/ana.410050616;;3054015;;10.3171/jns.1988.69.5.0766;;10.1128/mcb.11.3.1402;;pmc369413;;10.1128/mcb.11.3.1402-1408.1991;;1996101;;10.1101/gad.8.8.959;;7926780;;10.1016/0092-8674(94)90177-5;;8287472;;10.1136/jnnp.54.10.940;;1744660;;pmc1014592;;pmc23307;;9294164;;10.1073/pnas.94.19.10069;;10.1016/0092-8674(95)90236-8;;7553876;;10.1016/s0092-8674(00)81163-0;;9590169;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;7909169;;10.1126/science.7909169;;10.1006/nbdi.1997.0130;;9173930,"Yokoyama et al. (1996) Archives of Virology 141 (3 4):763 769 (abstract), 1996.;;Groschup et al. (1993) Journal of General Virology 74/7:1451 1456 (abstract), 1993.;;Baker, H.F., et al. Aminoacid Polymorphism in Human Prion Protein and Age at Death in Inherited Prion Disease, Lancet (1991) 337:1286.;;Barry, R.A., et al., Monoclonal Antibodies to the Cellular and Scrapie Prion Proteins, J. Infect. Dis. (1986) 154(3):518 521.;;Basler et al., Scrapie and Cellular PrP Isoforms Are Encoded by the Same Chromosomal Gene, Cell , (1986) 46:417 28.;;Berger, J.R., et al., Creutzfeldt Jakob disease in a physician: A review of the disorder in health care workers , Neurology , (1993) 43:205 206.;;Bolton et al., Identification of a Protein That Purifies with the Scrapie Prion, Science (1982) 218: 1309 11.;;Brown et al., Friendly Fire in Medicine: Hormones, Homografts, and Cruetzfeldt Jakob Disease, Lancet (1992) 340:24 27.;;Buchanan et al., Mortality, Neoplasia, and Creutzfeld Jakob Disease in Patients Treated with Human Pituitary Growth Hormone in the United Kingdom , BMJ (1991) 302:824 828.;;Bueler et al., Mice Devoid of PrP are Resistant to Scrapie, Cell (1993) 73:1339 1347.;;Bueler et al., Normal Development and behavior of Mice Lacking the Neuronal Cell surface PrP Protein, Nature (1992) 356:577 582.;;Carlson et al., Linkage of Protein and Scrapie Incubation Time Genes, Cell (1986) 46:503 511.;;Chandler, Encephaolpathy in Mice Produced by Inoculation with Scrapie Brain Material, Lancet (1961) 1:1378 79.;;Cochius et al, Creutzfeldt Jakob Disease in a Recipient of Human Pituitary Derived Gonadotrophin: A Second Case, J. Neurol. Neurosurg. Psychiatry (1992) 55:1094 1095.;;Cochius et al., Creutzfeldt Jakob Disease in a Recipient of Human Pituitary Derived Gonadotrophin, Aust. N.Z. J. Med. (1990) 20:592 593.;;Collinge et al., Genetic Predisposition to Latrogenic Creutzfeldt Jakob Disease, Lancet (1991) 337:1441 1442.;;Cousens, S.N., et al., Geographical distribution of cases of Creutzfeldt Jakob disease in England and Wales 1970 84 , J. Neurol. Neurosurg. Psychiatry (1990) 53:459 465.;;Farlie, P.G., et al., bcl 2 Transgene expression can protect neurons against developmental and induced cell death , Proc. Natl. Acad. Sci. USA (1995) 92:4397 4401.;;Gabriel et al., Molecular Cloning of a Candidate Chicken Prion Protein, Proc. Natl. Acad. Sci. USA (1992) 89:9097 9101.;;Gajdusek, D.C., Unconventional Viruses and the Origin and Disappearance of Kuru, Science (1977) 197:943 960.;;Gibbs, Jr. et al., Creutzfeldt Jakob Disease Infectivity of Growth Hormone Derived from Human Pituitary Glands, N.Engl. J. Med. (1993) 328:358 359.;;Goldfarb et al, Fatal Familial Insomnia and Familial Creutzfeldt Jakob Disease: Disease Phenotype Determined by a DNA Polymorphism, Science (1992) 258:806 808.;;Goldmann et al., Two Alleles of a Neural Protein Gene Linked to Scrapie in Sheep, Proc. Natl. Acad. Sci. USA (1990) 87:2476 2480.;;Goldmann et al., Different Forms of the Bovine PrP Gene Have Five or Six Copies of a Short, G C Rich Element within the protein coding Exon, J. Gen. Virol. (1991) 72:201 204.;;Harris et al., A Prion like Protein from Chicken Brain Copurifies with an Acetylcholine Receptor Inducing Activity, Proc. Natl. Acad. Sci. USA (1991) 88:7664 7668.;;Hasty, P., et al., Introduction of a subtle mutation into the Hox 2.6 locus in embryonic stem cells , Nature (1991) 350:243 246.;;Healy et al., Creutzfeldt Jakob Disease After Pituitary Gonadotrophins: The Prion is the Problem, BMJ (1993) 307:517 518.;;Hecker et al., Replication of Distinct Scrapie Prion Isolates is Region Specific in Brains of Transgenic Mice and Hamsters, Genes Dev. (1992) 6:1213 1228.;;Hsaio et al., Linkage of a Prion Protein Missense Variant to Gerstmann Straussler Syndrome, Nature (1989) 383:342 345.;;Hsaio et al., A Prion Protein Variant in a Family with the Telencephalic Form of Gerstmann Strussler Scheinker Syndrome, Neurology (1991) 41:681 684.;;Hsaio et al., Inherited Human Prion Disease, Neurology (1990) 40:1820 1827.;;Kascasak, R.J., et al., Mouse Polyclonal and Monoclonal Antibody to Scrapie Associated Fibril Proteins, J. Virol. (1987) 61(12):3688 3693.;;Koch et al., Creutzfeldt Jakob Disease in a Young Adult with Idiopathic Hypopituitarism, N. Engl. J. Med. (1985) 313:731 733.;;Kretzschmar et al., Molecular Cloning of a Human Prion Protein cDNA, DNA (1986) 5:315 324.;;Kretzschmar et al., Molecular Cloning of a Mink Prion Protein Gene, J.Gen.Virol. (1992) 73:2757 2761.;;Lasmezas et al., Recombinant Human Hormone and Insulin Like Growth Factor I Induce PRP Gene Expression in PC12 Cell, Biochem. Biophys. Res.Commun. (1993) 196:1163 1169.;;Locht et al., Molecular Cloning and Complete Sequence of Prion Protein cDNA from Mouse Brain Infected with the Scrapie Agent, Proc. Natl. Acad. Sci. USA (1986) 83:6372 6376.;;Manuelidis et al., Serial Propagation of Creutzfeldt Jakob Disease in Guinea Pigs, Proc. Natl. Acad. Sci. USA (1976) 73:223 227.;;Manuelidis et al., Interspecies Transmission of Creutzfeldt Jakob Disease to Syrian Hamsters with Reference to Clinical Syndromes and Strain of Agent, Proc. Natl. Acad. Sci. USA (1978) 75:3432 3436.;;McKinley et al, A Protease Resistant Protein is a Structural Component of the Scrapie Prion, Cell (1983) 35:57 62.;;Medori et al., Fatal Familial Insomnia, a Prion Disease with a Mutation at Codon 178 of the Prion Protein Gene, N. Engl.J. Med. (1992) 326:444 449.;;Muramoto, T., et al., The Sequential Development of Abnormal Prion Protein Accumulation in Mice with Creuzfeldt Jakob Disease, Am. J. Pathol. (1992) 140(6):1411 1420.;;Nisbet et al., Creutzfeldt Jakob Disease in a Second Patient Who Received a Cadaveric Dura mater Graft, J.Am. Med.Assoc. (1989) 261:1118.;;Palmer, M.S., et al., Homozygous Prion Protein Genotype Predisposes to Sporadic Creutzfeldt Jakob Disease , Nature (1991) 352:340 342.;;Patel, France Reels at Latest Medical Scandal, New Scientist , Jul. 31, 1993, p.4.;;Patel, Placenta Donors to be Screened for Brain Disease, 0 New Scientist , Nov. 20, 1993, p. 10.;;Pan, K.M., et al., Conversion of sheets features in the formation of the scrapie prion proteins , Proc. Natl. Acad. Sci. USA (1993) 90:10962 10966.;;Prusiner et al., Measurement of the Scrapie Agent Using an Incubation Time Interval Assay, Annals. Neurol. (1982) 11(4):353 358.;;Prusiner et al., Further Purification and Characterization of Scrapie Prions, Biochemistry (1982) 21:6942 50.;;Prusiner, S.B., et al., Scrapie Prions Aggregate to Form Amyloid like Birefringent Rods, Cell (1983) 35:349 358.;;Prusiner et al., Transgenic Studies Implicate Interactions Between Homologous PrP Isoforms in Scrapie Prion Replication, Cell (1990) 63:673 686.;;Prusiner et al., Molecular Biology of Prion Diseases, Science (1991) 252:1515 1522.;;Prusiner et al., Ablation of the Prion Protein (PrP) Gene in Mice Prevents Scrapie and Facilitates Production of Anti PrP Antibodies, Proc. Natl. Acad. Sci. USA (1993) 90:10608 10612.;;Prusiner, S.B., et al., Immunologic and Molecular Biological Studies of Prion Proteins in Bovine Spongiform Encephalopathy, J. Infect. Dis. (1993) 167:602 613.;;Prusiner et al., Prion Diseases and Neurodegeneration, Ann.Rev.Neurosci. (1994) 17:311 339.;;Raeber et al., Attempts to Convert the Cellular Prion Protein into the Scrapie Isoform in Cell Free Systems, J. Virol. (1992) 66:6155 6163.;;Ridley et al., Lancet Occupational Risk of Creufeldt Jakob Disease, (1993) 341:641 2.;;Rogers, M. et al., Epitope Mapping of the Syrian Hamster Prion Protein Utilizing Chimeric and Mutant Genes in a Vaccinia Virus Expression System, J. immunol. (1991) 147(10):3568 3574.;;Scott, M., et al, Transgenic Mice Expressing Hamster Prion Protein Produce Species Specific Infectivity and Amyloid Plaques, Cell (1989) 59:847 857.;;Scott et al, Chimeric Prion Protein Expression in Cultured Cells and Transgenic Mice, Protein Sci. (1992) 1:986 97.;;Scott et al, Propagation of Prions with Artificial Properties in Transgenic Mice Expressing Chimeric PrP Genes, Cell (1993) 73:979 988.;;Serban, D., et al. Rapid detection of Creutzfeldt Jakob disease and scrapie prion proteins , Neurology (1990) 40:110 117.;;Stahl et al., Glycosylinositol Phospholipid Anchors of the Scrapie and Cellular Prion Proteins Contain Sialic Acid, Biochemistry (1992) 31:5043 5053.;;Taraboulos et al., Regional Mapping of Prion Proteins in Brain, Proc. Natl. Acad. Sci. USA (1992) 89:7620 7624.;;Tateishi, J. and Kitamoto, T., Developments in Diagnosis for Prion Diseases, Br. Med. Bull. (1993) 49(4):971 979.;;Tateishi et al., Transmission of Chronic Spongiform Encephalopathy with Kuru Plaques from Humans to Small Rodents, Ann.Neurol. (1979) 5:581 584.;;Thadani et al., Creutzfeldt Jakob Disease Probably Acquired From a Cadaveric Dura Mater Graft, J. Neurosurg. (1988) 69:766 769.;;Valancius, V. and Smithies, O., Testing and In Out Targeting Procedure for Making Subtle Genomic Modifications in Mouse Embryonic Stem Cells , Mol. Cell Biol. (1991) 11(3):1402 1408.;;Westaway et al., Homozygosity for Prion Protein Alleles Encoding Glutamine 171 Renders Sheep Susceptible to Natural Scrapie,: Genes Dev. (1994) 8:959 969.;;Westaway et al., Degeneration of Skeletal Muscle, Peripheral Nerves, and the Central Nervous System in Transgenic Mice Overexpressing Wild Type Prion Proteins, Cell 76:117 129.;;Willison et al., Creutzfeldt Jakob Disease Following Cadaveric Dura Mater Graft, Neurosurg. Psychiatric (1991) 54:940.;;Wilesmith, J.W., The epidemiology of bovine spongiform encephalopathy , Acad. Press. (1991) 2:239 245.;;Kaneko, K. et al., Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie protein propagation, Proc Natl Acad USA (Sep. 1977) 94:10069 10074.;;Telling, G.C. et al., Prion Propagation in Mice Expressing Human and Chimeric PrP Transgenes Implicates the Interaction of Cellular PrP with Another Protein, Cell (Oct. 6, 1995) 83:79 90.;;Prusiner, S.B., et al., Prion Protein Biology, Cell (May 1, 1998) 93:337 348.;;Telling, G.C., et al., Transmission of Creutzfeldt Jakob disease from humans to transgenic mice expressing chimeric human mouse prion protein, Proc Natl Acad Sci USA (Oct. 1994) 91:9936 9940.;;Cohen, F.E., et al., Structural Clues to Prion Replication, Science (Apr. 22, 1994) 264:530 531.;;Yehiely, F., et al., Identification of candidate proteins binding to prion proteins, Neurobiology of Disease 3(4):339 355 (1997) (Abstract).",EXPIRED
177,FI,B1,FI 102379 B1,181-175-252-512-52X,1998-11-30,1998,FI 895382 A,1989-11-10,US 16808788 A;;US 8900875 W,1988-03-11,Uretaanisuojattuja aminohappo-N-karboksianhydridejä,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/181-175-252-512-52X,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D277/20;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
178,EP,A1,EP 0357750 A1,049-778-481-687-304,1990-03-14,1990,EP 89903412 A,1989-03-03,US 8900875 W;;US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES.,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/049-778-481-687-304,Patent Application,yes,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
179,IN,B,IN 176071 B,089-045-666-242-89X,1996-01-13,1996,IN 188CA1989 A,1989-03-07,IN 188CA1989 A,1989-03-07,A method of preparing urethane-protected amino acid N-carboxyanhydrides or N-thiocarboxy-anhydrides,,BIORES INC,FULLER WILLIAM DEAN;;COHEN MICHAEL PHILLIP;;NAIDER FRED ROBERT;;GOODMAN MURRAY,,https://lens.org/089-045-666-242-89X,Granted Patent,no,0,0,1,1,0,,C07D263/44;;C07D265/10;;C07D267/06;;C07D277/24;;C07D279/04;;C07D281/02,,0,0,,,,EXPIRED
180,AU,A,AU 2001/051863 A,090-787-541-607-515,2001-11-08,2001,AU 2001/051863 A,2001-06-12,AU 2001/051863 A,2001-06-12,Prion protein modulator factor (PPMF) and prion resistant animals,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/090-787-541-607-515,Patent Application,no,0,0,1,1,0,,A61K31/20;;A61K31/415;;A61K38/00;;C07H21/00;;C07K1/04;;C07K14/47,,0,0,,,,PENDING
181,WO,A1,WO 2001/087911 A1,153-116-521-839-294,2001-11-22,2001,US 0115832 W,2001-05-15,US 57298000 A,2000-05-16,METHOD OF IDENTIFYING CRITICAL POINTS WITHIN PROTEIN-PROTEIN INTERACTIONS,A method is disclosed for identifying compound defined by pharmacophores which compound affect protein-protein interactions. The method involves determining functional residues of at least one protein of a protein-protein interaction of interest. Three-dimensional structures are then developed based on the positions of the functional residues. The three-dimensional structures are then compared against compounds which have calculatable tertiary structures in order to identify compounds having a spatial orientation consistent with functionally relevant portions of a protein of the protein-protein interaction of interest.,UNIV CALIFORNIA;;PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/153-116-521-839-294,Patent Application,yes,0,1,3,3,0,C12N15/1055;;C07H17/00;;C07K14/47;;G01N33/6896,C07H17/00;;C07K14/47;;C12N15/10;;G01N33/68,,4,4,022-200-622-890-023;;051-179-598-789-379;;133-220-740-974-327;;049-983-360-679-626,10.1073/pnas.89.19.9097;;pmc50072;;1409608;;10.1128/jvi.71.12.9685-9689.1997;;pmc230278;;9371634;;10.1016/0092-8674(95)90236-8;;7553876;;pmc23307;;9294164;;10.1073/pnas.94.19.10069,"GABRIEL J.-M. ET AL.: ""Molecular cloning of a candidate chicken prion protein"", PROC. NATL. ACAD. SCI. USA, vol. 89, October 1992 (1992-10-01), pages 9097 - 9101, XP002948406;;DEMAIMAY R. ET AL.: ""Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals"", J. VIROLOGY, vol. 71, no. 12, December 1997 (1997-12-01), pages 9685 - 9689, XP002948407;;TELLING G.C. ET AL.: ""Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein"", CELL, vol. 83, 6 October 1995 (1995-10-06), pages 79 - 90, XP002948408;;KANEKO K. ET AL.: ""Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation"", PROC. NATL. ACAD. SCI. USA, vol. 94, September 1997 (1997-09-01), pages 10069 - 10074, XP002948409",PENDING
182,WO,A1,WO 1998/055132 A1,162-771-372-901-417,1998-12-10,1998,US 9810104 W,1998-05-18,US 86816297 A;;US 7660698 A,1997-06-02,PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS,"A protein designated Prion Protein Modulator Factor (PPMF) is disclosed which protein is an auxiliary factor in prion replication. PPMF is primarily characterized by its ability to bind to PrPC and facilitate a conformational change from PrP?C to PrPSc¿. A discontinuous epitope on PrPC comprising residues 172, 215 and 219 of human PrPC binds PPMF which is encoded by a nucleotide sequence derived from an organism selected from the group consisting of cow, sheep, mouse, hamster and human. In converting PrP?C to PrPSc¿ the PPMF forms a PRPC/PrPSc complex and is a rate limiting compound in the formation of that complex. Molecules, including antibodies, which bind PPMF or its epitope on PrPC are useful in the treatment of prion disease. Pharmacophores of the PrPC epitope are disclosed as are useful therapeutics and pharmacophores of the PPMF surface which binds PrPC. Animals resistant to prion disease are taught as are genes for producing such animals. Assay systems are disclosed which use PPMF to amplify PrPSc in sample being tested.",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/162-771-372-901-417,Patent Application,yes,0,7,8,9,0,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,7,6,049-983-360-679-626;;133-220-740-974-327;;013-825-882-367-654;;013-264-510-765-830;;013-611-786-677-405;;065-423-927-132-846,pmc23307;;9294164;;10.1073/pnas.94.19.10069;;10.1016/0092-8674(95)90236-8;;7553876;;10.1016/s0092-8674(00)81163-0;;9590169;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;7909169;;10.1126/science.7909169;;10.1006/nbdi.1997.0130;;9173930,"KANEKO K., ET AL.: ""EVIDENCE FOR PROTEIN X BINDING TO A DISCONTINUOUS EPITOPE ON THE CELLULAR PRION PROTEIN DURING SCRAPIE PRION PROPAGATION."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 94., 1 September 1997 (1997-09-01), US, pages 10069 - 10074., XP002912098, ISSN: 0027-8424, DOI: 10.1073/pnas.94.19.10069;;TELLING G. C., ET AL.: ""PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHEMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN."", CELL, CELL PRESS, US, vol. 83., 6 October 1995 (1995-10-06), US, pages 79 - 90., XP002912099, ISSN: 0092-8674, DOI: 10.1016/0092-8674(95)90236-8;;PRUSINER S. B., ET AL.: ""PRION PROTEIN BIOLOGY."", CELL, CELL PRESS, US, vol. 93., 1 May 1998 (1998-05-01), US, pages 337 - 348., XP002912100, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(00)81163-0;;TELLING G. C., ET AL.: ""TRANSMISSION OF CREUTZFELD-JAKOB DISEASE FROM HUMANS TO TRANSGENIC MICE EXPRESSING CHIMERIC HUMAN-MOUSE PRION PROTEIN."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 91., 1 October 1994 (1994-10-01), US, pages 9936 - 9940., XP002912101, ISSN: 0027-8424, DOI: 10.1073/pnas.91.21.9936;;COHEN F. E., ET AL.: ""STRUCTURAL CLUES TO PRION REPLICATION."", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 264., 22 April 1994 (1994-04-22), US, pages 530/531., XP002912102, ISSN: 0036-8075, DOI: 10.1126/science.7909169;;YEHIELY F., ET AL.: ""IDENTIFICATION OF CANDIDATE PROTEINS BINDING TO PRION PROTEIN."", NEUROBIOLOGY OF DISEASE., BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 03., no. 04., 1 January 1997 (1997-01-01), GB, pages 339 - 355., XP002912103, ISSN: 0969-9961, DOI: 10.1006/nbdi.1997.0130;;See also references of EP 0986396A4",PATENTED
183,AU,B2,AU 616054 B2,177-245-945-374-015,1991-10-17,1991,AU 1989/041887 A,1989-03-03,US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/177-245-945-374-015,Granted Patent,no,1,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
184,DE,D1,DE 68916722 D1,085-319-706-207-432,1994-08-18,1994,DE 68916722 T,1989-03-03,US 8900875 W;;US 16808788 A,1988-03-11,URETHAN GESCHÜTZTE AMINOSÄUREN-N-CARBOXYANHYDRIDE.,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/085-319-706-207-432,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D277/20;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
185,DK,D0,DK 564489 D0,176-384-478-907-284,1989-11-10,1989,DK 564489 A,1989-11-10,US 16808788 A;;US 8900875 W,1988-03-11,URETHANBESKYTTEDE AMINOSYRE-N-CARBOXYANHYDRIDER,,BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/176-384-478-907-284,Patent Application,no,0,0,2,39,0,,C07D263/44;;C07D277/34;;C07K1/04;;C07K1/06,,0,0,,,,EXPIRED
186,NZ,A,NZ 228282 A,196-571-296-499-565,1990-10-26,1990,NZ 22828289 A,1989-03-09,US 16808788 A,1988-03-11,URETHANE PROTECTED AMINO ACID-N-(THIO) CARBOXYANHYDRIDES AND USE IN POLYPEPTIDE SYNTHESIS,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;NAIDER FRED R;;COHEN MICHAEL PHILLIP;;GOODMAN MURRAY,,https://lens.org/196-571-296-499-565,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D277/20;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,PENDING
187,US,B1,US 6365359 B1,006-325-805-347-567,2002-04-02,2002,US 43992199 A,1999-11-12,US 43992199 A;;US 86816297 A;;US 7660698 A,1997-06-02,Inhibitors of prion formation,"
    Molecules are disclosed that interact with the cellular components involved in conversion of PrP ^{ C } to PrP ^{ Sc } . The molecules disclosed can be small molecules, peptides or protein analogs, e.g. analogs of PrP ^{ C } . In one embodiment, these molecules interfere with prion formation and/or replication, e.g. by preventing interactions of proteins involved in a prion complex or by interfering with -sheet formation. In another embodiment, the molecules of the invention promote PrP ^{ C } conversion to PrP ^{ Sc } , e.g. by binding to PrP ^{ C } and facilitating a conformational change from PrP ^{ C } to PrP ^{ Sc } . 
",UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2000-01-27),https://lens.org/006-325-805-347-567,Granted Patent,yes,6,2,8,9,0,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,435/7.1;;574/2;;530/350,78,75,051-179-598-789-379;;149-290-145-602-267;;073-471-639-279-380;;094-151-950-903-210;;014-148-181-267-301;;017-577-990-503-583;;045-852-186-095-143;;008-361-725-760-125;;032-409-974-407-058;;080-437-968-996-57X;;071-772-765-956-684;;153-368-234-494-423;;079-975-646-187-852;;051-983-761-228-799;;043-451-517-284-388;;013-611-786-677-405;;030-933-004-144-056;;030-675-552-399-704;;089-650-916-710-883;;022-200-622-890-023;;092-243-535-113-700;;016-460-593-452-975;;005-660-743-204-705;;007-728-271-452-065;;054-717-385-142-277;;072-140-853-530-414;;004-240-752-404-568;;176-338-940-727-172;;009-514-385-736-17X;;041-774-823-698-339;;027-996-048-989-093;;013-707-716-398-589;;049-983-360-679-626;;008-313-176-340-390;;017-080-594-688-105;;026-113-275-066-629;;043-141-030-792-715;;057-365-548-975-242;;029-357-080-653-794;;064-775-014-978-559;;024-267-323-523-978;;011-420-014-056-604;;050-218-564-306-685;;035-149-682-232-082;;003-755-575-954-951;;004-170-279-690-27X;;145-273-325-748-677;;045-506-781-213-130;;028-998-298-813-221;;084-688-053-652-033;;032-690-517-241-213;;015-165-550-157-820;;021-727-523-534-140;;068-344-586-358-356;;119-192-657-487-71X;;013-825-882-367-654;;094-974-313-169-217;;037-424-958-277-000;;071-653-349-970-151;;016-387-612-950-657;;017-710-636-685-708;;005-812-809-438-732;;013-632-974-151-972;;038-570-893-121-612;;056-110-055-044-019;;048-742-579-132-293;;102-923-007-442-383;;133-220-740-974-327;;013-264-510-765-830;;021-728-485-230-975;;006-615-048-543-477;;037-305-418-325-620;;091-992-099-413-919;;050-236-579-426-339;;065-423-927-132-846,10.1128/jvi.71.12.9685-9689.1997;;pmc230278;;9371634;;7479957;;pmc40591;;10.1073/pnas.92.24.11160;;1674080;;10.1016/0140-6736(91)92953-y;;10.1093/infdis/154.3.518;;3090160;;2873895;;10.1016/0092-8674(86)90662-8;;10.1212/wnl.43.1_part_1.205;;8423886;;10.1126/science.6815801;;6815801;;1351607;;10.1016/0140-6736(92)92431-e;;2025705;;pmc1669149;;10.1136/bmj.302.6780.824;;8100741;;10.1016/0092-8674(93)90360-3;;1373228;;10.1038/356577a0;;10.1016/0092-8674(86)90875-5;;3015416;;10.1016/s0140-6736(61)92008-6;;10.1136/jnnp.55.11.1094;;1469410;;pmc1015303;;2222355;;10.1111/j.1445-5994.1990.tb01322.x;;7909169;;10.1126/science.7909169;;10.1016/0140-6736(91)93128-v;;1675319;;2199610;;10.1136/jnnp.53.6.459;;pmc1014203;;pmc41951;;7753817;;10.1073/pnas.92.10.4397;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;142303;;10.1126/science.142303;;8419831;;10.1056/nejm199302043280520;;10.1126/science.1439789;;1439789;;10.1073/pnas.87.7.2476;;1969635;;pmc53712;;10.1099/0022-1317-72-1-201;;1671225;;pmc52362;;10.1073/pnas.88.17.7664;;1715573;;1672446;;10.1038/350243a0;;8400968;;pmc1678637;;10.1136/bmj.307.6903.517;;10.1101/gad.6.7.1213;;1628828;;10.1038/338342a0;;2564168;;1674116;;10.1212/wnl.41.5.681;;10.1212/wnl.40.12.1820;;2247227;;pmc23307;;9294164;;10.1073/pnas.94.19.10069;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;3897861;;10.1056/nejm198509193131206;;3755672;;10.1089/dna.1986.5.315;;1383401;;10.1099/0022-1317-73-10-2757;;10.1006/bbrc.1993.2373;;7902706;;pmc386505;;10.1073/pnas.83.17.6372;;3462700;;pmc335873;;1108016;;10.1073/pnas.73.1.223;;356055;;10.1073/pnas.75.7.3432;;pmc392791;;6414721;;10.1016/0092-8674(83)90207-6;;pmc6151859;;1346338;;10.1056/nejm199202133260704;;pmc1886534;;1376559;;10.1001/jama.261.8.1118b;;2644460;;10.1001/jama.261.8.1118;;10.1038/352547a0;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;10.1002/ana.410110406;;6808890;;10.1021/bi00269a050;;6818988;;10.1016/0092-8674(83)90168-x;;6418385;;10.1016/0092-8674(90)90134-z;;1977523;;1675487;;10.1126/science.1675487;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;10.1093/infdis/167.3.602;;8440932;;10.1146/annurev.ne.17.030194.001523;;8210178;;10.1016/s0092-8674(00)81163-0;;9590169;;10.1128/jvi.66.10.6155-6163.1992;;pmc283664;;1356161;;10.1016/0140-6736(93)90413-b;;8094877;;1719082;;2574076;;10.1016/0092-8674(89)90608-9;;1338978;;pmc2142161;;10.1002/pro.5560010804;;8098995;;10.1016/0092-8674(93)90275-u;;10.1212/wnl.40.1.110;;1967489;;1350920;;10.1021/bi00136a600;;pmc49762;;1354357;;10.1073/pnas.89.16.7620;;10.1093/oxfordjournals.bmb.a072656;;8137138;;382976;;10.1002/ana.410050616;;10.1016/0092-8674(95)90236-8;;7553876;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;3054015;;10.3171/jns.1988.69.5.0766;;10.1128/mcb.11.3.1402;;pmc369413;;10.1128/mcb.11.3.1402-1408.1991;;1996101;;10.1101/gad.8.8.959;;7926780;;10.1016/0092-8674(94)90177-5;;8287472;;10.1136/jnnp.54.10.940;;1744660;;pmc1014592;;10.1006/nbdi.1997.0130;;9173930,"Demaimay et al. 1997. J. Virology 71(12): 9685-9689.*;;Kaneko et al. 1995. PNAS 92: 11160-11164.*;;Baker, H.F., et al. ""Aminoacid Polymorphism in Human Prion Protein and Age at Death in Inherited Prion Disease,"" Lancet (1991) 337:1286.;;Barry, R.A., et al., ""Monoclonal Antibodies to the Cellular and Scrapie Prion Proteins,"" J. Infect. Dis. (1986) 154(3):518-521.;;Basler et al., ""Scrapie and Cellular PrP Isoforms Are Encoded by the Same Chromosomal Gene,""0 Cell, (1986) 46:417-28.;;Berger, J.R., et al., ""Creutzfeldt-Jakob disease in a physician: A review of the disorder in health care workers"", Neurology, (1993) 43:205-206.;;Bolton et al., ""Identification of a Protein That Purifies with the Scrapie Prion,"" Science (1982) 218: 1309-11.;;Brown et al., ""Friendly Fire' in Medicine: Hormones, Homografts, and Cruetzfeldt-Jakob Disease,"" Lancet (1992) 340: 24-27.;;Buchanan et al., ""Mortality, Neoplasia, and Creutzfeld-Jakob Disease in Patients Treated with Human Pituitary Growth Hormone in the United Kingdom"", BMJ (1991) 302:824-828.;;Bueler et al., ""Mice Devoid of PrP are Resistant to Scrapie,"" Cell (1993) 73:1339-1347.;;Bueler et al., ""Normal Development and Behavior of Mice Lacking the Neuronal Cell-surface PrP Protein,"" Nature (1992) 356:577-582.;;Carlson et al., ""Linkage of Protein and Scrapie Incubation Time Genes,"" Cell (1986) 46:503-511.;;Chandler, ""Encephaolpathy in Mice Produced by Inoculation with Scrapie Brain Material,"" Lancet (1961) 1:1378-79.;;Cochius et al, ""Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin: A Second Case,"" J. Neurol. Neurosurg. Psychiatry (1992) 55:1094-1095.;;Cochius et al., ""Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin,"" Aust. N.Z. J. Med. (1990) 20:592-593.;;Cohen, F.E., et al., ""Structural Clues to Prion Replication,"" Science (Apr. 22, 1994) 264:530-531.;;Collinge et al., ""Genetic Predisposition to Latrogenic Creutzfeldt-Jakob Disease,"" Lancet (1991) 337:1441-1442.;;Cousens, S.N., et al., ""Geographical distribution of cases of Creutzfeldt-Jakob disease in England and Wales 1970-84"", J. Neurol. Neurosurg. Psychiatry (1990) 53:459-465.;;Farlie, P.G., et al., ""bcl-2 Transgene expression can protect neurons against developmental and induced cell death"", Proc. Natl. Acad. Sci. USA (1995) 92:4397-4401.;;Gabriel et al., ""Molecular Cloning of a Candidate Chicken Prion Protein,"" Proc. Natl. Acad. Sci. USA (1992) 89:9097-9101.;;Gajdusek, D.C., ""Unconventional Viruses and the Origin and Disappearance of Kuru,"" Science (1977) 197:943-960.;;Gibbs, Jr. et al., ""Creutzfeldt-Jakob Disease Infectivity of Growth Hormone Derived from Human Pituitary Glands,"" N.Engl. J. Med. (1993) 328:358-359.;;Goldfarb et al, ""Fatal Familial Insomnia and Familial Creutzfeldt-Jakob Disease: Disease Phenotype Determined by a DNA Polymorphism,"" Science (1992) 258:806-808.;;Goldmann et al., ""Two Alleles of a Neural Protein Gene Linked to Scrapie in Sheep,"" Proc. Natl. Acad. Sci. USA (1990) 87:2476-2480.;;Goldmann et al., ""Different Forms of the Bovine PrP Gene Have Five or Six Copies of a Short, G-C Rich Element within the protein-coding Exon,"" J. Gen. Virol. (1991) 72:201-204.;;Harris et al., ""A Prion-like Protein from Chicken Brain Copurifies with an Acetylcholine Receptor-Inducing Activity,"" Proc. Natl. Acad. Sci. USA (1991) 88:7664-7668.;;Hasty, P., et al., ""Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells"", Nature (1991) 350:243-246.;;Healy et al., ""Creutzfeldt-Jakob Disease After Pituitary Gonadotrophins: The Prion is the Problem,"" BMJ (1993) 307:517-518.;;Hecker et al., ""Replication of Distinct Scrapie Prion Isolates is Region Specific in Brains of Transgenic Mice and Hamsters,"" Genes Dev. (1992) 6:1213-1228.;;Hsaio et al.,""Linkage of a Prion Protein Missense Variant to Gerstmann-Straussler Syndrome,"" Nature (1989) 383:342-345.;;Hsaio et al., ""A Prion Protein Variant in a Family with the Telencephalic Form of Gerstmann-Strussler-Scheinker Syndrome,"" Neurology (1991) 41:681-684.;;Hsaio et al., ""Inherited Human Prion Diseases,"" Neurology (1990) 40:1820-1827.;;Kaneko, K. et al., ""Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation,"" Proc Natl Acad Sci USA (Sep. 1977) 94:10069-10074.;;Kascsak, R.J., et al., ""Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins,"" J. Virol. (1987) 61(12):3688-3693.;;Koch et al.,""Creutzfeldt-Jakob Disease in a Young Adult with Idiopathic Hypopituitarism,"" N. Engl. J. Med. (1985) 313:731-733.;;Kretzschmar et al., ""Molecular Cloning of a Human Prion Protein cDNA,"" DNA (1986) 5:315-324.;;Kretzschmar et al., ""Molecular Cloning of a Mink Prion Protein Gene,"" J.Gen.Virol. (1992) 73:2757-2761.;;Lasmezas et al.,""Recombinant Human Growth Hormone and Insulin-Like Growth Factor I Induce PRP Gene Expression in PC12 Cell,"" Biochem. Biophys. Res.Commun. (1993) 196:1163-1169.;;Locht et al.,""Molecular Cloning and Complete Sequence of Prion Protein cDNA from Mouse Brain Infected with the Scrapie Agent,"" Proc. Natl. Acad. Sci USA (1986) 83:6372-6376.;;Manuelidis et al., ""Serial Propagation of Creutzfeldt-Jakob Disease in Guinea Pigs,"" Proc. Natl. Acad. Sci. USA (1976) 73:223-227.;;Manuelidis et al., ""Interspecies Transmission of Creutzfeldt-Jakob Disease to Syrian Hamsters with Reference to Clinical Syndromes and Strain of Agent,"" Proc. Natl. Acad. Sci USA (1978) 75:3432-3436.;;McKinley et al, ""A Protease-Resistant Protein is a Structural Component of the Scrapie Prion,"" Cell (1983) 35:57-62.;;Medori et al., ""Fatal Familial Insomnia, a Prion Disease with a Mutation at Codon 178 of the Prion Protein Gene,"" N. Engl.J. Med. (1992) 326:444-449.;;Muramoto, T., et al., ""The Sequential Development of Abnormal Prion Protein Accumulation in Mice with Creuzfeldt-Jakob Disease,"" Am. J. Pathol. (1992) 140(6):1411-1420.;;Nisbet et al., ""Creutzfeldt-Jakob Disease in a Second Patient Who Received a Cadaveric Dura mater Graft,"" J.Am. Med.Assoc. (1989) 261:1118.;;Palmer, M.S., et al., ""Homozygous Prion Protein Genotype Predisposes to Sporadic Creutzfeldt-Jakob Disease"", Nature (1991) 352:340-342.;;Patel, ""France Reels at Latest Medical Scandal,"" New Scientist, Jul. 31, 1993, p. 4.;;Patel, ""Placenta Donors to be Screened for Brain Disease,"" New Scientist, Nov. 20, 1993, p. 10.;;Pan, K.M., et al., ""Conversion of beta-sheets features in the formation of the scrapie prion proteins"", Proc. Natl. Acad. Sci. USA (1993) 90:10962-10966.;;Prusiner et al., ""Measurement of the Scrapie Agent Using an Incubation Time Interval Assay,"" Annals. Neurol. (1982) 11(4):353-358.;;Prusiner et al., ""Further Purification and Characterization of Scrapie Prions,"" Biochemistry (1982) 21:6942-50.;;Prusiner, S.B., et al., ""Scrapie Prions Aggregate to Form Amyloid-like Birefringent Rods,"" Cell (1983) 35:349-358.;;Prusiner et al., ""Transgenic Studies Implicate Interactions Between Homologous PrP Isoforms in Scrapie Prion Replication,"" Cell (1990) 63:673-686.;;Prusiner et al., ""Molecular Biology of Prion Diseases,"" Science (1991) 252:1515-1522.;;Prusiner et al., ""Ablation of the Prion Protein (PrP) Gene in Mice Prevents Scrapie and Facilitates Production of Anti-PrP Antibodies,"" Proc. Natl. Acad. Sci. USA (1993) 90:10608-10612.;;Prusiner, S.B., et al., ""Immunologic and Molecular Biological Studies of Prion Proteins in Bovine Spongiform Encephalopathy,"" J. Infect. Dis. (1993) 167:602-613.;;Prusiner et al., ""Prion Diseases and Neurodegeneration,"" Ann.Rev.Neurosci. (1994) 17:311-339.;;Prusiner, S.B., et al., ""Prion Protein Biology,"" Cell (May 1, 1998) 93:337-348.;;Raeber et al., ""Attempts to Convert the Cellular Prion Protein into the Scrapie Isoform in Cell-Free Systems,"" J. Virol. (1992) 66:6155-6163.;;Ridley et al., Lancet Occupational Risk of Creuzfeldt-Jakob Disease, (1993) 341:641-2.;;Rogers, M. et al., ""Epitope Mapping of the Syrian Hamster Prion Protein Utilizing Chimeric and Mutant Genes in a Vaccinia Virus Expression System,"" J. Immunol. (1991) 147(10):3568-3574.;;Scott, M., et al, ""Transgenic Mice Expressing Hamster Prion Protein Produce Species-Specific Infectivity and Amyloid Plaques,"" Cell (1989) 59:847-857.;;Scott et al, ""Chimeric Prion Protein Expression in Cultured Cells and Transgenic Mice,"" Protein Sci. (1992) 1:986-97.;;Scott et al, ""Propagation of Prions with Artificial Properties in Transgenic Mice Expressing Chimeric PrP Genes,"" Cell (1993) 73:979-988.;;Serban, D., et al. ""Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins"", Neurology (1990) 40:110-117.;;Stahl et al., ""Glycosylinositol Phospholipid Anchors of the Scrapie and Cellular Prion Proteins Contain Sialic Acid,"" Biochemistry (1992) 31:5043-5053.;;Taraboulos et al., ""Regional Mapping of Prion Proteins in Brain,"" Proc. Natl. Acad. Sci. USA (1992) 89:7620-7624.;;Tateishi, J. and Kitamoto, T., ""Developments in Diagnosis for Prion Diseases,"" Br. Med. Bull. (1993) 49(4):971-979.;;Tateishi et al.,""Transmission of Chronic Spongiform Encephalopathy with Kuru Plaques from Humans to Small Rodents,"" Ann.Neurol. (1979) 5:581-584.;;Telling, G.C. et al., ""Prion Propagation in Mice Expressing Human and Chimeric PrP Transgenes Implicates the Interaction of Cellular PrP with Another Protein,"" Cell (Oct. 6, 1995) 83:79-90.;;Telling, G.C., et al., ""Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein,"" Proc Natl Acad Sci USA (Oct. 1994) 91:9936-9940.;;Thadani et al., ""Creutzfeldt-Jakob Disease Probably Acquired From a Cadaveric Dura Mater Graft,"" J. Neurosurg. (1988) 69:766-769.;;Valancius, V. and Smithies, O., ""Testing and ""In-Out"" Targeting Procedure for Making Subtle Genomic Modifications in Mouse Embryonic Stem Cells"", Mol. Cell Biol. (1991) 11(3):1402-1408.;;Westaway et al., Homozygosity for Prion Protein Alleles Encoding Glutamine-171 Renders Sheep Susceptible to Natural Scrapie,: Genes Dev. (1994) 8:959-969.;;Westaway et al., ""Degeneration of Skeletal Muscle, Peripheral Nerves, and the Central Nervous System in Transgenic Mice Overexpressing Wild-Type Prion Proteins,"" Cell (1994) 76:117-129.;;Willison et al., ""Creutzfeldt-Jakob Disease Following Cadaveric Dura Mater Graft,"" Neurosurg. Psychiatric (1991) 54:940.;;Wilesmith, J.W., ""The epidemiology of bovine spongiform encephalopathy"", Acad. Press. (1991) 2:239-245.;;Yehiely, F., et al., ""Identification of candidate proteins binding to prion proteins,"" Neurobiology of Disease (1977) 3(4):339-355.",EXPIRED
188,EP,A4,EP 0986396 A4,024-678-357-627-173,2003-05-02,2003,EP 98926042 A,1998-05-18,US 9810104 W;;US 86816297 A;;US 7660698 A,1997-06-02,PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/024-678-357-627-173,Search Report,no,1,0,8,9,0,A61K31/417;;A61K31/417;;A61K31/4178;;A61K31/4178;;A61K31/7048;;A61K31/7048;;A61K31/7076;;A61K31/7076;;A61K38/00;;A61K38/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07H21/00;;C07K1/045;;C07K1/045;;C07K1/047;;C07K1/047;;C07K14/47;;C07K14/47;;Y02P20/582;;Y02P20/582,A01K67/027;;A61K31/4164;;A61K31/417;;A61K31/4172;;A61K31/4178;;A61K31/662;;A61K31/7064;;A61K31/7076;;A61K31/7084;;A61K38/00;;A61K45/00;;A61P25/00;;A61P43/00;;C07H21/00;;C07K1/04;;C07K14/47;;C07K16/18;;C12N5/10;;C12N15/09;;C12Q1/02;;G01N33/53,,3,2,133-220-740-974-327;;065-423-927-132-846,10.1016/0092-8674(95)90236-8;;7553876;;10.1006/nbdi.1997.0130;;9173930,"TELLING G C ET AL: ""PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHIMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN"", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 1, 6 October 1995 (1995-10-06), pages 79 - 90, XP000674450, ISSN: 0092-8674;;YEHIELY F ET AL: ""IDENTIFICATION OF CANDIDATE PROTEINS BINDING TO PRION PROTEIN"", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 3, no. 4, 1997, pages 339 - 355, XP002912103, ISSN: 0969-9961;;See also references of WO 9855132A1",DISCONTINUED
189,AU,A,AU 2001/061671 A,065-665-724-929-339,2001-11-26,2001,AU 2001/061671 A,2001-05-15,US 57298000 A;;US 0115832 W,2000-05-16,Method of identifying critical points within protein-protein interactions,,UNIV CALIFORNIA,PRUSINER STANLEY B;;COHEN FRED E;;JAMES THOMAS L;;KANEKO KIYOTOSHI,,https://lens.org/065-665-724-929-339,Patent Application,no,0,0,3,3,0,C12N15/1055;;C07H17/00;;C07K14/47;;G01N33/6896,C07H17/00;;C07K14/47;;C12N15/10;;G01N33/68,,0,0,,,,PENDING
190,CA,C,CA 1321280 C,172-719-391-051-168,1993-08-10,1993,CA 592823 A,1989-03-06,US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,"1027-2 A urethane-protected amino acid-N-carboxyanhydride or N-thiocarboxyanhydride having the structure: <IMG> wherein R and R' are hydrogen, alkyl, cycloalkyl, substituted alkyl substituted cycloalkyl, aryl, or substituted aryl and at least one of R and R' is other than hydrogen; R"" is alkyl, aryl, substituted alkyl or substituted aryl; Z is oxygen or sulfur; and n is 0, 1, or 2. These compounds find use in polypeptide synthesis.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL P;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/172-719-391-051-168,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,D3530000106  M;;26002446   S;;2600304    S;;26003101   S;;26003117   S,0,0,,,,EXPIRED
191,AU,A,AU 1989/041887 A,198-000-691-807-832,1989-10-05,1989,AU 1989/041887 A,1989-03-03,US 16808788 A,1988-03-11,URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES,,BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/198-000-691-807-832,Patent Application,no,0,1,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D277/20;;C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
192,NO,B1,NO 306304 B1,022-393-948-644-192,1999-10-18,1999,NO 894503 A,1989-11-10,US 16808788 A;;US 8900875 W,1988-03-11,Uretan-beskyttede aminosyre-N-karboksyanhydrider,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/022-393-948-644-192,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
193,FI,B,FI 102379 B,043-102-745-410-571,1998-11-30,1998,FI 895382 A,1989-11-10,US 16808788 A;;US 8900875 W,1988-03-11,Uretaanisuojattuja aminohappo-N-karboksianhydridejä,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORES INC,FULLER WILLIAM D;;COHEN MICHAEL PHILIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/043-102-745-410-571,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D277/20;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
194,US,A,US 4946942 A,185-487-346-721-881,1990-08-07,1990,US 16808788 A,1988-03-11,US 16808788 A,1988-03-11,Urethane-protected amino acid-N-carboxyanhydrides,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL P;;NAIDER FRED R;;GOODMAN MURRAY,BIORESEARCH INC (1988-06-27),https://lens.org/185-487-346-721-881,Granted Patent,yes,2,76,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D277/20;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,530/335;;530/334;;530/337;;530/333;;548/227;;548/183;;544/97;;544/54;;540/488,7,3,086-343-758-794-559;;000-691-222-196-893;;179-899-288-668-878,10.1016/s0040-4039(01)86359-0;;5573721;;10.1021/ja00740a027;;10.1002/macp.1977.021780401,"Akiyama, M., Tetrahedron Letters, 28: 2599 2600, 1979.;;Shimizu, K., Bull. Chem. Soc. Jpn., 57: 495 499, 1984.;;Hirschmann, R., JACS, 93 (11): 2746 2754, 1971.;;Halstrom, J., Peptides (Eur. Peptide Symp., 12th, 1972), 1973.;;Bodanszhy, M., Principles of Peptide Synthesis, Springer Verlag, N.Y.: 25 86, 1984.;;Blacklock, T. J., The Peptides, 9: 39 102, 1987.;;Kricheldorf, Makromol. Chem., 178: 905 939, 1977.",EXPIRED
195,PT,A,PT 89961 A,047-737-184-324-415,1989-11-10,1989,PT 8996189 A,1989-03-09,US 16808788 A,1988-03-11,PROCESSO PARA A PREPARACAO DE N-CARBOXIANIDRIDOS DE AMINOACIDOS PROTEGIDOS POR URETANO,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/047-737-184-324-415,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D277/20;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
196,HK,A1,HK 1007744 A1,000-038-328-756-834,1999-04-23,1999,HK 98106869 A,1998-06-26,US 16808788 A;;US 8900875 W,1988-03-11,Urethane-protected amino acid-n-carboxyanhydrides,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/000-038-328-756-834,Patent Application,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D277/20;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,DISCONTINUED
197,IE,B1,IE 65149 B1,021-438-274-763-610,1995-10-04,1995,IE 77889 A,1989-03-10,US 16808788 A,1988-03-11,Urethane-protected amino acid-N-carboxyanhydrides,"The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide and protein synthesis. Disclosed herein is the preparation and use of these novel compounds.",BIORESEARCH INC,FULLER WILLIAM D;;COHEN MICHAEL PHILLIP;;NAIDER FRED R;;GOODMAN MURRAY,,https://lens.org/021-438-274-763-610,Granted Patent,no,0,0,36,39,0,C07D263/44;;C07D277/34;;C07K1/023;;C07K1/04;;C07D263/26;;C07D277/36;;C07D263/44;;C07K1/04;;C07D277/34;;C07K1/023,C07D263/16;;C07D263/44;;C07D265/06;;C07D267/06;;C07D269/02;;C07D277/20;;C07D277/34;;C07D279/06;;C07D281/02;;C07D283/02;;C07D413/04;;C07D413/12;;C07D417/04;;C07D417/12;;C07K1/00;;C07K1/02;;C07K1/04;;C07K1/06;;C07K1/113;;C07K5/06;;C07K5/062;;C07K5/08;;C07K5/083,,0,0,,,,EXPIRED
198,CA,A1,CA 2253262 A1,130-119-559-875-37X,1997-12-11,1997,CA 2253262 A,1997-05-29,US 66062696 A;;US 9709289 W,1996-06-06,TRANSGENIC ANIMALS EXPRESSING ARTIFICIAL EPITOPE-TAGGED PROTEINS,"DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitopetagged protein are provided, including transgenic animals expressing epitopetagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided.",UNIV CALIFORNIA,SCOTT MICHAEL R;;TELLING GLENN C;;PRUSINER STANLEY B;;COHEN FRED E,,https://lens.org/130-119-559-875-37X,Patent Application,no,0,0,10,10,13,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,0,0,,,,DISCONTINUED
199,US,A,US 6150583 A,068-103-749-443-874,2000-11-21,2000,US 3116898 A,1998-02-26,US 3116898 A;;US 66062696 A;;US 52199295 A;;US 50926195 A;;US 24218894 A,1994-05-13,Transgenic animals expressing artificial epitope-tagged proteins,"DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided.",UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/068-103-749-443-874,Granted Patent,yes,9,6,10,10,13,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,800/4;;800/3;;800/6;;435/69.1;;435/7.1;;435/320.1;;536/23.1,24,23,014-148-181-267-301;;045-852-186-095-143;;068-073-845-477-068;;071-772-765-956-684;;022-200-622-890-023;;009-514-385-736-17X;;035-976-233-926-571;;008-313-176-340-390;;133-154-290-763-393;;164-155-340-466-717;;011-420-014-056-604;;022-002-828-578-345;;145-273-325-748-677;;021-727-523-534-140;;015-165-550-157-820;;003-786-150-572-757;;065-678-110-707-195;;115-351-475-493-545;;068-425-905-837-800;;016-387-612-950-657;;133-220-740-974-327;;013-264-510-765-830;;091-992-099-413-919,2873895;;10.1016/0092-8674(86)90662-8;;10.1126/science.6815801;;6815801;;1968466;;pmc2116048;;10.1083/jcb.110.3.743;;1373228;;10.1038/356577a0;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;10.1101/gad.6.7.1213;;1628828;;10.1016/0168-1656(94)90062-0;;7764960;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;7530459;;1374385;;10.1016/s0021-9258(19)50394-5;;6414721;;10.1016/0092-8674(83)90207-6;;7485969;;10.1006/abio.1995.1399;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;1675487;;10.1126/science.1675487;;10.1126/science.2499927;;2499927;;10.1126/science.2821619;;2821619;;3029962;;10.1016/0042-6822(87)90334-5;;10.1016/0021-9673(94)80434-6;;7921186;;2574076;;10.1016/0092-8674(89)90608-9;;10.1016/0092-8674(95)90236-8;;7553876;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;10.1016/0092-8674(94)90177-5;;8287472,"Basler, K., et al., (1986) Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene , Cell 46:417 428.;;Bolton, D.C., et al., (1982) Identification of a protein that purifies with the scrapie prion , Science vol. 218:1309 1311.;;Borchelt, D.R., et al., (1990) Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J. Cell Biol . 110:743 52.;;Bueler, H., et al., (1992) Normal development and behavior of mice lacking the neuronal cell surface PrP protein , Nature 356.;;Gabriel, J. M., et al., (1992) Molecular cloning of a candidate chicken prion protein , Proc. Natl. Acad. Sci. USA 89:9097 9101.;;Hecker, R., et al., Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters , Genes and Development 6:1213 1228.;;Houdebine, Louis Marie, (1994) Production of Pharmaceutical Proteins from Transgenic Animals , J. of Biotechnology 34:269 287.;;Kascsak, R.J., et al., (1987) Mouse polyclonal and monoclonal antibody to scrapie associated fibril proteins , J. Virol . 61:3688 93.;;Knappik, A., and Pluckthun, A., (1994) An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments , Biotechniques 17:754 61.;;Kunz, D., et al., (1992) The human leukocyte platelet activating factor receptor , J. Biol. Chem . 267:9101 6.;;McKinley, P., et al., (1983) A protease resistant protein is a structural component of the scrapie prion , Cell 36:57 62.;;Murray, P.J., et al., (1995) Epitope tagging of the human endoplasmic reticulum HSP70 protein, BiP, to facilitate Analysis of BiP substrate interactions , Anal Biochem . 229:170 9.;;Pan, K. M., et al., (1993) Conversion of helicies into sheets features in the formation of the scrapie prion proteins , Proc. Natl. Acad. Sci. USA 90:10962 6.;;Prusiner, et al., (1993) Ablation of the Prion Protein (PrP) Gene in Mice Prevents Scrapie and Facilitates Production of Anti PrP Antibodies , Proc. Natl. Acad. Sci. USA 90:10608 12.;;Prusiner, S.B., et al., (1991) Molecular Biology of prion diseases , Science 252:1515 1522.;;Pursel, et al., (1989) Genetic Engineering Livestock , Science 244:1281 8.;;Ruoslahti, E., and Pierschbacher, M.D., (1987) New perspectives in cell adhesion: RGD and integrins , Science 238:491 7.;;Salter, et al., (1987) Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line , Virol . 157:236 40.;;Schmidt, T.G.M., and Skerra, A., (1994) One step affinity purification of bacterially produced proteins by means of the Strep tag and immobilized recombinant core streptavidin , J. Chromatography 676:337 45.;;Scott, M.R., et al., (1989) Chimeric prion protein expression in cultured cells and transgenic mice , Cell 59:847 57.;;Scott, M., et al., (1992) Transgenic mice expressing hamster prion protein produce species specific scrapie infectivity and amyloid plaques , Protein Sci . 1:986 997.;;Telling, G.C., et al.,(1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , Cell 83:79 90.;;Telling et al., (1994) Transmission of Creutzfeldt Jakob Disease from Humans to Transgenic Mice Expressing Chimeric Human Mouse Prion Protein , Proc. Natl. Acad. Sci. USA 91:9936 40.;;Westway. D., et al., (1994) Degeneration of Skeletal Muscle, Peripheral Nerves, and the Central Nervous system in transgenic mice overexpressing wild type prion proteins , Cell 76:117 29.",EXPIRED
200,WO,A1,WO 1997/046572 A1,172-100-995-767-555,1997-12-11,1997,US 9709289 W,1997-05-29,US 66062696 A,1996-06-06,TRANSGENIC ANIMALS EXPRESSING ARTIFICIAL EPITOPE-TAGGED PROTEINS,"DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided.",UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/172-100-995-767-555,Patent Application,yes,2,3,10,10,0,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,3,2,059-093-825-752-685;;017-710-636-685-708,7688567;;10.1021/bi00081a018;;1338978;;pmc2142161;;10.1002/pro.5560010804,"BIOCHEMISTRY, 1993, Vol. 32, No. 30, GROVE et al., ""Regulation of an Epitope-Tagged Recombinant Rsk-1 S6 Kinase by Phorbol Ester and Erk/MAP Kinase"", pages 7727-7738.;;PROTEIN SCIENCE, 1992, Vol. 1, SCOTT et al., ""Chimeric Prion Protein Expression in Cultured Cells and Transgenic Mice"", pages 986-997.;;See also references of EP 0915902A4",PENDING
201,EP,A1,EP 0915902 A1,029-859-440-370-924,1999-05-19,1999,EP 97927865 A,1997-05-29,US 9709289 W;;US 66062696 A,1996-06-06,TRANSGENIC ANIMALS EXPRESSING ARTIFICIAL EPITOPE-TAGGED PROTEINS,,UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/029-859-440-370-924,Patent Application,yes,0,0,10,10,13,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,0,0,,,,DISCONTINUED
202,AU,A,AU 1997/032221 A,179-823-922-039-788,1998-01-05,1998,AU 1997/032221 A,1997-05-29,US 66062696 A;;US 9709289 W,1996-06-06,Transgenic animals expressing artificial epitope-tagged proteins,,UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/179-823-922-039-788,Patent Application,no,0,0,10,10,0,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,0,0,,,,EXPIRED
203,EP,A4,EP 0915902 A4,126-007-889-444-213,2004-06-30,2004,EP 97927865 A,1997-05-29,US 9709289 W;;US 66062696 A,1996-06-06,TRANSGENIC ANIMALS EXPRESSING ARTIFICIAL EPITOPE-TAGGED PROTEINS,,UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/126-007-889-444-213,Search Report,no,0,0,10,10,0,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,4,3,015-165-550-157-820;;145-273-325-748-677;;133-220-740-974-327,1675487;;10.1126/science.1675487;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;10.1016/0092-8674(95)90236-8;;7553876,"PRUSINER S B: ""MOLECULAR BIOLOGY OF PRION DISEASES"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 252, no. 5012, 14 June 1991 (1991-06-14), pages 1515 - 1522, XP001156296, ISSN: 0036-8075;;PAN K-M ET AL: ""CONVERSION OF ALPHA-HELICES INTO BETA-SHEETS FEATURES IN THE FORMATION OF THE SCRAPIE PRION PROTEINS"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, December 1993 (1993-12-01), pages 10962 - 10966, XP000918938, ISSN: 0027-8424;;TELLING G C ET AL: ""PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHIMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN"", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 1, 6 October 1995 (1995-10-06), pages 79 - 90, XP000674450, ISSN: 0092-8674;;See also references of WO 9746572A1",DISCONTINUED
204,US,A,US 5789655 A,013-508-405-958-671,1998-08-04,1998,US 66062696 A,1996-06-06,US 66062696 A;;US 52199295 A;;US 50926195 A;;US 24218894 A,1994-05-13,Transgenic animals expressing artificial epitope-tagged proteins,"DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided.",UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,UNIVERSITY OF CALIFORNIA THE REGENTS OF THE (1996-08-07),https://lens.org/013-508-405-958-671,Granted Patent,yes,8,38,10,10,13,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,800/2;;435/172.3;;424/9.1;;424/9.2,24,23,014-148-181-267-301;;045-852-186-095-143;;068-073-845-477-068;;071-772-765-956-684;;022-200-622-890-023;;009-514-385-736-17X;;008-313-176-340-390;;133-154-290-763-393;;164-155-340-466-717;;011-420-014-056-604;;022-002-828-578-345;;145-273-325-748-677;;015-165-550-157-820;;065-678-110-707-195;;068-425-905-837-800;;133-220-740-974-327;;091-992-099-413-919;;115-351-475-493-545;;035-976-233-926-571;;003-786-150-572-757;;021-727-523-534-140;;013-264-510-765-830;;017-710-636-685-708,2873895;;10.1016/0092-8674(86)90662-8;;10.1126/science.6815801;;6815801;;1968466;;pmc2116048;;10.1083/jcb.110.3.743;;1373228;;10.1038/356577a0;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;10.1101/gad.6.7.1213;;1628828;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;7530459;;1374385;;10.1016/s0021-9258(19)50394-5;;6414721;;10.1016/0092-8674(83)90207-6;;7485969;;10.1006/abio.1995.1399;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;1675487;;10.1126/science.1675487;;10.1126/science.2821619;;2821619;;10.1016/0021-9673(94)80434-6;;7921186;;10.1016/0092-8674(95)90236-8;;7553876;;10.1016/0092-8674(94)90177-5;;8287472;;3029962;;10.1016/0042-6822(87)90334-5;;10.1016/0168-1656(94)90062-0;;7764960;;10.1126/science.2499927;;2499927;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;1338978;;pmc2142161;;10.1002/pro.5560010804,"Basler, K., et al., (1986) Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene , Cell 46 :417 428.;;Bolton, D.C., et al., (1982) Identification of a protein that purifies with the scrapie prion , Science vol. 218 :1309 1311.;;Borchelt, D.R., et al., (1990) Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells J. Cell Biol. 110 :743 52.;;Bueler, H., et al., (1992) Normal development and behavior of mice lacking the neuronal cell surface PrP protein , Nature 356.;;Gabriel, J. M., et al., (1992) Molecular cloning of a candidate chicken prion protein , Proc. Natl. Acad. Sci. USA 89 :9097 9101.;;Hecker, R., et al., Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters , Genes and Development 6 :1213 1228.;;Kascsak, R.J., et al., (1987) Mouse polyclonal and monoclonal antibody to scrapie associated fibril proteins , J. Virol. 61 :3688 93.;;Knappik, A., and Pluckthun, A., (1994) An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments , Biotechniques 17 :754 61.;;Kunz, D., et al., (1992) The human leukocyte platelet activating factor receptor , J. Biol. Chem. 267 :9101 6.;;McKinley, P., et al., (1983) A protease resistant protein is a structural component of the scrapie prion , Cell 36 :57 62.;;Murray, P.J., et al., (1995) Epitope tagging of the human endoplasmic reticulum HSP70 protein, BiP, to facilitate Analysis of BiP substrate interactions , Anal Biochem. 229 :170 9.;;Pan, K. M., et al., (1993) Conversion of helicies into sheets features in the formation of the scrapie prion proteins , Proc. Natl. Acad. Sci. USA 90 :10962 6.;;Prusiner, S.B., et al., (1991) Molecular Biology of prion diseases , Science 252 :1515 1522.;;Ruoslahti, E., and Pierschbacher, M.D., (1987) New perspectives in cell adhesion: RGD and integrins , Science 238 :491 7.;;Schmidt, T.G.M., and Skerra, A., (1994) One step affinity purification of bacterially produced proteins by means of the Strep tag and immobilized recombinant core streptavidin , J. Chromatography 676 :337 45.;;Scott, M.R., et al., (1989) Chimeric prion protein expression in cultured cells transgenic mice , Cell 59 :847 57.;;Telling, G.C., et al., (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , Cell 83 :79 90.;;Westway. D., et al., (1994) Degeneration of Skeletal Muscle, Peripheral Nerves, and the Central Nervous system in transgenic mice overexpressing wild type prion proteins , Cell 76 :117 29.;;Salter, et al. Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line, Virol. vol. 157, pp. 236 240, 1987.;;Houdebine, Louis Marie, Production of Pharmaceutical Proteins from Transgenic Animals, Journal of Biotechnology, vol. 34, pp. 269 287, 1994.;;Pursel, et al. Genetic Engineering of Livestock, Science, vol. 244, pp. 1281 1288, Jun. 16, 1989.;;Prusiner et al. Ablation of the Prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti PrP antibodies. PNAS vol. 90, pp. 10608 10612, Nov. 1993.;;Telling et al. Transmission of Creutzfeldt Jakob Disease from humans to transgenic mice expressing chimeric human mouse prion protein. PNAS vol. 91, pp. 9936 9940, Oct. 1994.;;Scott et al. Chimeric Prion Protein expression in cultured cells and transgenic mice. Protein Science. vol. 1 No. 8, pp. 986 997, Aug. 1992.",EXPIRED
205,US,B1,US 6602672 B1,102-617-069-958-128,2003-08-05,2003,US 66951600 A,2000-09-25,US 66951600 A;;US 3116898 A;;US 66062696 A;;US 52199295 A;;US 50926195 A;;US 24218894 A,1994-05-13,Recombinant construct encoding epitope tagged PrP protein,"
    DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided. 
",UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/102-617-069-958-128,Granted Patent,yes,9,7,10,10,15,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,435/7.1;;435/69.1;;435/320.1;;435/325;;435/252.3;;536/23.1;;530/350,24,23,014-148-181-267-301;;045-852-186-095-143;;068-073-845-477-068;;071-772-765-956-684;;022-200-622-890-023;;009-514-385-736-17X;;035-976-233-926-571;;008-313-176-340-390;;133-154-290-763-393;;164-155-340-466-717;;011-420-014-056-604;;022-002-828-578-345;;145-273-325-748-677;;021-727-523-534-140;;015-165-550-157-820;;003-786-150-572-757;;065-678-110-707-195;;115-351-475-493-545;;068-425-905-837-800;;016-387-612-950-657;;133-220-740-974-327;;013-264-510-765-830;;091-992-099-413-919,2873895;;10.1016/0092-8674(86)90662-8;;10.1126/science.6815801;;6815801;;1968466;;pmc2116048;;10.1083/jcb.110.3.743;;1373228;;10.1038/356577a0;;10.1073/pnas.89.19.9097;;pmc50072;;1409608;;10.1101/gad.6.7.1213;;1628828;;10.1016/0168-1656(94)90062-0;;7764960;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;7530459;;1374385;;10.1016/s0021-9258(19)50394-5;;6414721;;10.1016/0092-8674(83)90207-6;;7485969;;10.1006/abio.1995.1399;;10.1073/pnas.90.23.10962;;7902575;;pmc47901;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;1675487;;10.1126/science.1675487;;10.1126/science.2499927;;2499927;;10.1126/science.2821619;;2821619;;3029962;;10.1016/0042-6822(87)90334-5;;10.1016/0021-9673(94)80434-6;;7921186;;2574076;;10.1016/0092-8674(89)90608-9;;10.1016/0092-8674(95)90236-8;;7553876;;pmc44932;;10.1073/pnas.91.21.9936;;7937921;;10.1016/0092-8674(94)90177-5;;8287472,"Basler, K., et al., (1986) ""Scrapie and cellular PrP isoforms are encoded by the same chromosmal gene"", Cell 46:417-428.;;Bolton, D.C., et al., (1982) ""Identification of a protein that purifies with the scrapie prion"", Science vol. 218:1309-1311.;;Borchelt, D.R., et al., (1990) ""Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells."" J. Cell Biol. 110:743-52.;;Bueler, H., et al., (1992) ""Normal development and behavior of mice lacking the neuronal cell-surface PrP protein"", Nature 356.;;Gabriel, J.-M., et al., (1992) ""Molecular cloning of a candidate chicken prion protein"", Proc. Natl. Acad. Sci. USA 89:9097-9101.;;Hecker, R., et al., ""Replication of distinct scarpie prion isolates is region specific in brains of transgenic mice and hamsters"", Genes and Development 6:1213-1228.;;Houdebine, Louis-Marie, (1994), ""Production of Pharmaceutical Proteins from Transgenic Animals"", J. of Biotechnology 34:269-287.;;Kascsak, R.J., et al., (1987) ""Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins"", J. Virol. 61:3688-93.;;Knappik, A., and Pluckthun, A., (1994) ""An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments"", Biotechniques 17:754-61.;;Kunz, D., et al., (1992) ""The human leukocyte platelet-activating factor receptor"", J. Biol. Chem. 267:9101-6.;;McKinley, P., et al., (1983) ""A protease-resistant protein is a structural component of the scrapie prion"", Cell 36:57-62.;;Murray, P.J., et al., (1995) ""Epitope tagging of the human endoplasmic reticulum HSP70 protein, BiP, to facilitate Analysis of BiP-substrate interactions"", Anal Biochem. 229:170-9.;;Pan, K.-M., et al., (1993) ""Conversion of alpha-helicies into beta-sheets features in the formation of the scrapie prion proteins"", Proc. Natl. Acad. Sci. USA 90:10962-6.;;Prusiner, et al., (1993) ""Ablation of the Prion Protein (PrP) Gene in Mice Prevents Scrapie and Facilitates Production of Anti-PrP Antibodies"", Proc. Natl. Acad. Sci. USA 90:10608-12.;;Prusiner, S.B., et al., (1991) ""Molecular Biology of prion diseases"", Sciences 252:1515-1522.;;Pursel, et al., (1989) ""Genetic Engineering Livestock"", Science 244:1281-8.;;Ruoslahti, E., and Pierschbacher, M.D., (1987) ""New perspectives in cell adhesion: RGD and integrins"", Science 238:491-7.;;Salter, et al., (1987) ""Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line"", Virol. 157:236-40.;;Schmidt, T.G.M., and Skerra, A., (1994) ""One-step affinity purification of bacterially produced proteins by means of the ""Strep tag"" and immobilized recombinant core streptavidin"", J. Chromatography 676:337-45.;;Scott, M.R., et al., (1989) ""Chimeric prion protein expression in cultured cells and transgenic mice"", Cell 59:847-57.;;Scott, M., et al., (1992) ""Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques"", Protein Sci. 1:986-997.;;Telling, G.C., et al., (1995) ""Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein"", Cell 83:79-90.;;Telling et al., (1994) ""Transmission of Creutzfeldt-Jakob Disease from Humans to Transgenic Mice Expressing Chimeric Human-Mouse Prion Protein"", Proc. Natl. Acad. Sci. USA 91:9936-40.;;Westway. D., et al., (1994) ""Degeneration of Skeletal Muscle, Peripheral Nerves, and the Central Nervous system in transgenic mice overexpressing wild-type prion proteins"", Cell 76:117-29.",EXPIRED
206,AU,B2,AU 714775 B2,109-199-614-567-321,2000-01-13,2000,AU 1997/032221 A,1997-05-29,US 66062696 A;;US 9709289 W,1996-06-06,Transgenic animals expressing artificial epitope-tagged proteins,,UNIV CALIFORNIA,PRUSINER STANLEY B;;TELLING GLENN C;;COHEN FRED E;;SCOTT MICHAEL R,,https://lens.org/109-199-614-567-321,Granted Patent,no,2,0,10,10,0,A01K67/0275;;A01K67/0275;;A01K2207/15;;A01K2207/15;;A01K2217/00;;A01K2217/00;;A01K2217/05;;A01K2217/05;;A01K2217/075;;A01K2217/075;;A01K2227/105;;A01K2227/105;;A01K2267/0318;;A01K2267/0318;;A01K2267/0337;;A01K2267/0337;;A01K2267/0343;;A01K2267/0343;;A61K47/645;;A61K47/645;;A61K49/0008;;A61K49/0008;;C12N15/8509;;C12N15/8509;;C07K14/42;;C07K14/42;;C07K14/47;;C07K14/47;;G01N2800/2828;;G01N2800/2828,A01K67/027;;A61K47/48;;A61K49/00;;C07K14/42;;C07K14/47;;C12N5/10;;C12N15/09;;C12N15/85,,0,0,,,,EXPIRED
207,AU,A1,AU 2003/279088 A1,109-929-351-248-59X,2005-04-27,2005,AU 2003/279088 A,2003-09-30,US 50203203 P;;US 0331057 W,2003-09-10,PRION CHIMERAS AND USES THEREOF,,CHIRON CORP,HU CELINE YUAN-HWEI;;PHELPS BRUCE;;ABRIGNANI SERGIO;;COHEN FRED;;MICHELITSCH MELISSA D,,https://lens.org/109-929-351-248-59X,Patent Application,no,0,0,2,2,0,A61K2039/505;;C07K16/2872;;G01N33/6896;;G01N2800/2828,C07K16/28;;G01N33/68,,0,0,,,,DISCONTINUED
208,US,B1,US 6182059 B1,040-633-727-323-523,2001-01-30,2001,US 85307497 A,1997-05-08,US 85307497 A;;US 4249497 P;;US 4265697 P,1997-04-03,Automatic electronic message interpretation and routing system,"A method for automatically interpreting an electronic message, including the steps of (a) receiving the electronic message from a source; (b) interpreting the electronic message using a rule base and case base knowledge engine; and (c) classifying the electronic message as at least one of (i) being able to be responded to automatically; and (ii) requiring assistance from a human operator. The method for automatically interpreting an electronic message may also include the step of retrieving one or more predetermined responses corresponding to the interpretation of the electronic message from a repository for automatic delivery to the source.",BRIGHTWARE INC,ANGOTTI ANTHONY A;;PICCOLO ROSANNA M;;COHEN FRED R;;HSU JULIE;;RICE AMY,FIREPOND INC (2003-02-14);;BRIGHTWARE INC (1998-04-08);;CHASE MANHATTAN BANK THE (1997-08-14);;BRIGHT RESPONSE LLC (2006-02-06);;CIRCINUS IP LLC (2004-08-30);;ORION IP LLC DE LIMITED LIABILITY COMPANY (2004-02-22);;ORION IP LLC (2004-08-26),https://lens.org/040-633-727-323-523,Granted Patent,yes,13,253,3,3,0,G06N5/04;;G06Q10/107;;G06N5/04;;G06Q10/107,G06N5/04;;G06Q10/10,706/45;;706/46;;706/47,16,12,006-039-627-250-318;;020-147-408-518-412;;143-196-138-762-706;;012-182-092-216-066;;061-708-485-593-154;;028-202-706-538-93X;;118-249-768-185-587;;049-880-485-677-454;;151-835-360-911-790;;077-952-005-396-414;;008-012-415-592-116;;115-128-485-317-084,10.1145/319151.319152;;10.1145/62548.62642;;10.1145/143457.143464;;10.1145/15847.15848;;10.1145/238355.238456;;10.1145/22899.22903;;10.1145/291080.291090;;10.1145/240080.240230;;10.1145/143164.143244;;10.1145/280765.280791;;10.1145/45945.214327;;10.1109/caia.1994.323683,"Saito et al, Managebility, availability and performance in porcupine: a highly scalable, cluster based mail service, SOSP ACM, pp 1-15, Feb. 1999.;;Malone et al, ""The information lens: an intelligent system for infromation sharing in organization"", ACM pp 1-8, 1986.;;Thyberg, ""Advisor an electronic mail consultng service"", ACM SIGUCCS XVI, pp 247-255, 1988.;;Goldberg et al, ""Active mail a framework for implementing groupware"", CSCW ACW pp 75-83, Jul. 1992.;;Gold, ""Envoys in electronic mail systems"", ACM pp 2-10, Jan. 1986.;;Hall, ""INFOMOD a knowledge based moderator for elecetronic mail help lists"", ACM CIKM pp 107-114, 1996.;;Malone et al., Intelligent information sharing systems, Comm. of the ACM, vol. 30, No. 5, pp 390-402, May 1987.;;Satoh et al, ""Documentation know how sharing by automatic process tracking"", ACM IUI, pp 49-56, 1999.;;Marx et al, ""CLUES Dynamic personalized message filering"", ACM CSCW, pp 113-121, 1996.;;Freund, ""Brining email services to the desktop"", ACM SIGUCCS, pp 101-103, 1992.;;Boone, Concept features in Reagent an intelligent email agent, ACM, Autonomus Agents, pp 141-148, 1998.;;Pollock, A rule based message filering system, ACM trans. on office Inf. syst. vol. 6, No. 3, pp 232-245, Jul. 1988.;;Sahin, K., and Sawyer, K. 1989. The Intelligent Banking System: Natural Language Processing for Finanical Communications. In Innovative Applications of Artifical Intelligence, AAAI Press.;;Compton, M. and Wolfe, S. 1994. Intelligent Validation and Routing of Electronic Forms in a Distributed Work Flow Environment. The Tenth Conference On Artificial Intelligence For Applications.;;Goodman, M. Prism. 1991. A Case-Based Telex Classifier. In Innovative Applications of Artificial Intelligence, vol. 2:AAAI Press.;;Taylor, D.; Mehta. B.; and Wurster, T. 1996. Online Delivery & the Information Superhighway; Searching for Retail Strategies. Bank Management 72(I):22-29.",EXPIRED
209,US,B1,US 6411947 B1,073-996-591-745-435,2002-06-25,2002,US 5423398 A,1998-04-02,US 5423398 A;;US 4249497 P;;US 4265697 P;;US 85307497 A,1997-04-03,Automatic message interpretation and routing system,"
    A method for automatically interpreting an electronic message, including the steps of (a) receiving the electronic message from a source; (b) interpreting the electronic message using a rule base and case base knowledge engine; and (c) classifying the electronic message as at least one of (i) being able to be responded to automatically; and (ii) requiring assistance from a human operator. The method for automatically interpreting an electronic message may also include the step of retrieving one or more predetermined responses corresponding to the interpretation of the electronic message from a repository for automatic delivery to the source. 
",BRIGHTWARE INC,RICE AMY;;HSU JULIE;;ANGOTTI ANTHONY M;;PICCOLO ROSANNA M;;COHEN FRED R,FIREPOND INC (2003-02-14);;BRIGHTWARE INC (1998-06-19);;BRIGHT RESPONSE LLC (2006-02-06);;CIRCINUS IP LLC (2004-08-30);;ORION IP LLC DE LIMITED LIABILITY COMPANY (2004-02-22),https://lens.org/073-996-591-745-435,Granted Patent,yes,8,148,3,3,0,G06N5/04;;G06Q10/107;;G06N5/04;;G06Q10/107,G06N5/04;;G06Q10/10,706/47;;706/46;;706/49,5,3,008-012-415-592-116;;022-797-137-195-013;;077-952-005-396-414,10.1145/45945.214327;;10.1145/191246.191322;;10.1145/280765.280791,"Microsoft Corporation, Getting Results with Microsoft Office 97, 375-81, Jun. 1995.*;;Pollock, A rule based message filtering system, ACM TOIS, pp 232-254, vo. 6, No. 3, Jul. 1988.*;;Finin et al, ""KQML as an agent communication lanaguage"", ACM CIKM, pp 456-463, Mar. 1994.*;;Thomas et al, ""Using agents to personlize th eweb"", ACM IUI, pp. 53-60, Aug. 1996.*;;Boone, ""Concept features in re-agent an intelligent email agent"", ACM AA, pp 141-148, Jan. 1998.",EXPIRED
210,WO,A1,WO 2005/034995 A1,186-367-710-995-468,2005-04-21,2005,US 0331057 W,2003-09-30,US 50203203 P,2003-09-10,PRION CHIMERAS AND USES THEREOF,"The invention relates to prions chimeras, antibodies specific to prions, polynucleotides encoding these chimeras and antibodies, and to methods of generating antibodies using chimeras. The invention further relates to methods of using such chimeras and antibodies to detect the presence of pathogenic prions in a biological sample and to methods of using such antibodies, chimeras and/or polynucleotides as components of a therapeutic or prophylactic vaccine.",CHIRON CORP;;ABRIGNANI SERGIO;;COHEN FRED;;MICHELITSCH MELISSA D;;HU CELINE YUAN-HWEI;;PHELPS BRUCE,ABRIGNANI SERGIO;;COHEN FRED;;MICHELITSCH MELISSA D;;HU CELINE YUAN-HWEI;;PHELPS BRUCE,,https://lens.org/186-367-710-995-468,Patent Application,yes,3,5,2,2,0,A61K2039/505;;C07K16/2872;;G01N33/6896;;G01N2800/2828,C07K16/28;;G01N33/68,,0,0,,,,PENDING
211,US,A1,US 2002/0095361 A1,097-910-283-995-062,2002-07-18,2002,US 76057601 A,2001-01-16,US 76057601 A,2001-01-16,Method and system for securitizing a future obligation to purchase goods or services,"
   A company with underperforming assets sells these assets to a trading house in exchange for value and a promise to make future purchases from the trading house. The value is provided by a financial institution. A portion of the money received by the trading house from the future purchases is given to the financial institution to pay back the value plus interest. To securitize the promise to make future purchases, the financial institution creates a special purpose entity which, in turn, creates a trust. Investors provide money to the special purpose entity which is used to purchase low risk assets that are placed in the trust. The special purpose entity then makes an agreement with the financial institution that if the company with underperforming assets defaults on its promise to purchase, the financial institution can take money from the trust. In exchange, the financial institution agrees to give the special purpose entity, and thus the investors, a large portion of the interest it receives as a result of future purchases made by the company with underperforming assets. 
",TRENK MICHAEL;;KAPLAN JUDAH E.;;COHEN STEVEN;;LEWIS JAMES E.;;SLAVIN FRED;;DONELIAN STEPHAN V.,TRENK MICHAEL;;KAPLAN JUDAH E;;COHEN STEVEN;;LEWIS JAMES E;;SLAVIN FRED;;DONELIAN STEPHAN V,CHASE MANHATTAN BANK THE (2001-01-11),https://lens.org/097-910-283-995-062,Patent Application,yes,3,26,1,1,0,G06Q40/00;;G06Q40/04;;G06Q40/00;;G06Q40/04,G06Q40/00,705/35,0,0,,,,DISCONTINUED
212,DE,D1,DE 69725878 D1,100-091-619-733-542,2003-12-11,2003,DE 69725878 T,1997-08-13,US 2386796 P;;US 9714465 W,1996-08-13,ZUSAMMENSETZUNGEN ZUR POLYNUKLEOTIDABGABE,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS A;;MURPHY E;;COHEN FRED;;UNO TETSUO,"NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US (2009-05-07)",https://lens.org/100-091-619-733-542,Granted Patent,no,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,EXPIRED
213,US,A1,US 2002/0095365 A1,132-192-313-106-857,2002-07-18,2002,US 76057701 A,2001-01-16,US 76057701 A,2001-01-16,Corporate products trading marketplace,"
   A company transfers underperforming assets (UPA's) to a second party in return for a cash and/or asset payment. The company obligates itself to earn a variable number of consumption points for an agreed to consumption period by making future purchases of assets. Each purchase has a known number of consumption points associated therewith. The number of consumption points to be earned varies as a function of a periodically applied interest rate. A computerized, preferably web-based, system is used to carry out the foregoing process. 
",CHASE MANHATTAN BANK NAT ASS,SLAVIN FRED G;;DONELIAN STEPHAN V;;COHEN STEVEN;;TRENK MICHAEL;;KAPLAN JUDAH;;LEWIS JAMES E,CHASE MANHATTAN BANK THE (2001-01-05),https://lens.org/132-192-313-106-857,Patent Application,yes,4,34,1,1,0,G06Q30/0226;;G06Q30/0239;;G06Q40/04;;G06Q40/04;;G06Q30/0239;;G06Q30/0226,G06Q30/02,705/37;;705/14;;705/1,0,0,,,,DISCONTINUED
214,EP,A1,EP 0752813 A1,021-649-123-365-586,1997-01-15,1997,EP 93921592 A,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITORS OF METAZOAN PARASITE PROTEASES,,UNIV CALIFORNIA,COHEN FRED;;MCKERROW JAMES;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE;;LI ZHE,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/021-649-123-365-586,Patent Application,yes,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
215,ES,T3,ES 2183940 T3,037-474-526-544-49X,2003-04-01,2003,ES 96908797 T,1996-03-13,US 41333795 A,1995-03-30,INHIBIDORES DE PROTEASAS DE PARASITOS METAZOARIOS.,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING,,https://lens.org/037-474-526-544-49X,Granted Patent,no,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,EXPIRED
216,EP,A4,EP 0752813 A4,111-059-355-327-362,1997-08-20,1997,EP 93921592 A,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITORS OF METAZOAN PARASITE PROTEASES,,UNIV CALIFORNIA,COHEN FRED;;MCKERROW JAMES;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE;;LI ZHE,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/111-059-355-327-362,Search Report,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,6,3,008-267-222-030-891;;004-497-708-925-060;;074-091-879-354-820,1544632;;10.1002/hep.1840150323;;10.1021/je00054a044;;10.1016/0304-4165(88)90197-3;;3167093,"BAKER E. ET AL: ""Evaluation of the Iron Chelation Potential of Hydrazones of Pyridoxal, Salicylaldehyde and 2-Hydroxy-1-Naphthylaldehyde using Hepatocyte in Culture"", HEPATOLOGY (ST. LOUIS), vol. 15, no. 3, 1992, pages 492 - 501, XP000654330;;EDWARD J.T. ET AL: ""Synthesis of New Acylhydrazones as Iron-Chelating Compounds"", J. CHEM. ENG. DATA, vol. 33, no. 4, 1988, pages 538 - 540, XP000654339;;PONKA P. ET AL: ""Effect of Pyridoxal Isonicotinyl Hydrazone and Other Hydrazones on Iron Release from Macrophages, Reticulocytes and Hepatocytes"", BIOCHIM. BIOPHYS. ACTA, vol. 967, no. 1, 1988, pages 122 - 129, XP000654310;;CHEMICAL ABSTRACTS, vol. 107, no. 9, 1987, Columbus, Ohio, US; abstract no. 77393r, GAIDUKEVICH A.N. ET AL: ""Synthesis and Biological Activity of Derivatives of 2,4-Dichloro-5-Nitrobenzoic Acid"" page 663; XP002032259;;CHEMICAL ABSTRACTS, vol. 95, no. 5, 1981, Columbus, Ohio, US; abstract no. 35421b, HIRAYAMA T. ET AL: ""Anti-tumor Activities of Some Heterocyclic and Nitrogen-containing Compounds"" XP002032260;;See also references of WO 9406280A1",EXPIRED
217,US,B1,US 8458018 B1,027-698-145-929-046,2013-06-04,2013,US 69509300 A,2000-10-24,US 69509300 A,2000-10-24,Electronic trading system and method for marketing products and services,"A consumer is provided with a first asset in return for a promise to earn an agreed to number of points over an agreed to redemption period. The consumer subsequently earns the points by purchasing one or more second assets. At least one of the second assets is different than the first asset. Each purchase has an associated point value, at least one of the point values being different than at least one other point value. An electronic trading system includes a first set of web sites where a consumer can select a first asset it wants to obtain in return for a promise to earn points by making future purchases of one or more second assets. The number of points which the consumer must earn varies as a function of which of the first assets is selected by the consumer. The consumer can fulfill its obligation to earn the stated number of points by purchasing one or more second assets at a second set of web sites. Each of the second assets has an associated point value.",DONELIAN STEPHAN V;;COHEN STEVEN;;SLAVIN FRED G;;TRENK MICHAEL;;KAPLAN JUDAH;;LEWIS JAMES E;;JPMORGAN CHASE BANK NA,DONELIAN STEPHAN V;;COHEN STEVEN;;SLAVIN FRED G;;TRENK MICHAEL;;KAPLAN JUDAH;;LEWIS JAMES E,JPMORGAN CHASE BANK NATIONAL ASSOCIATION (2004-11-13);;CHASE MANHATTAN BANK THE (2001-01-17);;JPMORGAN CHASE BANK N.A (2008-02-05),https://lens.org/027-698-145-929-046,Granted Patent,yes,5,5,4,4,0,G06Q30/0207;;G06Q30/0207;;G06Q30/0226;;G06Q30/0226,G06Q30/00,705/14.1;;705/14.23;;705/14.34;;705/26.1;;705/26.35;;705/26.62,23,0,,,"Dialog file 20, # 10279554 ""Offerr: Book Yourself Free cassettes"" Mar. 25, 2000, Birmingham Post, p. 16.;;""Accounting for Transactions Involving Barter Credits"" The CPA Journal, Jul. 1999 issue.;;""Internet Barter Signs Maytag, Carl Sandburg College in Innovative Barter Transactions,"" ""3-Way Agreement Lets Maytag Sell Refrigerators and Train Employees, College Makes Physical Plant Improvements Using BarterTrust Dollars,"" Business Wire, Inc., Mar. 27, 2000.;;""Corporate Trading Rids Firms of Last Year's Merchandise,"" Journal of Commerce, Inc. Global Commerce, Gordon Platt, Author, Dec. 1, 1999.;;""Bank to Redeem Barter Credits,"" Journal of Commerce, Inc., Global Commerce, Gordon Platt, Author, Oct. 20, 1999.;;""Solutions/The Problem:/Can Bartering Help Your Comapny, and What Do You Need to Get Started,"" Newsday, Inc., Executive Edition, Laura Koss-Feder, Author, Jul. 19, 1999.;;""Accounting for Transactions Involving Barter Credits,"" Bell & Howell Information and Learning, CPA Journal,vol. 69, No. 7, p. 56, Joel Steinberg, CPA, American Express Tax and Business Services, Author, Jul. 1999.;;Corporate Barter Firms Can Swap Your Product or Service for Almost Anything You Need (Let's Make a Deal), UMI, Inc. ABI/Inform, Bill Communications Successful Meetings, vol. 47, No. 13, pp. 71-72, Robert Carey, Author, Dec. 1998.;;""Business-to-business Bartering"" UMI, Inc. ABI/Inform, Office Systems Magazine Corp. Office Systems, vol. 15, No. 11, pp. 13-16, Jean Buchanan, Author, Nov. 1998.;;""Barter Companies Thriving in Tough Economic Climate Manufacturers Find Canceled Orders Bring Good Prices Paid in Trade Credits,"" Journal of Commerce, Inc. Global Commerce, p. 7A, Rosalind McLymont, Author, Oct. 19, 1998.;;""Barter Companies Thriving in Tough Economic Climate Manufacturers Find Canceled Orders Bring Good Prices Paid in Trade Credits,"" vol. 18, No. 36, p. 26, UMI Inc., Copyright P&L Publications Inc., Business Dateline, Boston Business Journal, Small Business, Roberta Holland, Oct. 16-22, 1998.;;""Merger Creates North American Barter Giant,"" Business Editors, Dec. 23, 1999.;;""Barter Companies Thriving in Tough Economic Climate,"" Journal of Commerce, Inc., Rosalind McLymont, Oct. 19, 1998.;;Tapping New Markets Through Barter; Atwood Richards Inc. Conducts an International Bartering Service for Business; Brief Article, Information Access Company, a Thompson Corporation Company, ASAP, Bill Communications Inc. Sales & Marketing Management, Tricia Campbell, Author, Oct. 1, 1998, p. 41.;;""Barter Paying Off for Firms Like Tyson Ore-Ida,"" Information Access Company, a Thompson Corporation Company, ASAP, Maclean Hunter Media Inc., Frozen Food Age, May 1998, vol. 46, Section 10, p. 54.;;""More Hoteliers Hit Room-Bartering Bonanza"" Information Access Company, a Thompson Corporation Company, ASAP, Advanstar Communications Inc., Hotel & Motel Management, Marty Whitford, Author, Apr. 6, 1998, vol. 213, Section 6, p. 56.;;""The Booming Barter Business,"" Journal of Commerce, Inc., p. 1A; News Section, Apr. 1, 1997, Paula L. Green, Author.;;""When Barter is Better; Corporate Bartering"" Information Access Company, a Thompson Corporation Company, ASAP, American Management Association Management Review, vol. 85, No. 2, p. 58, Angela Briggins, Author, Feb. 1996.;;""The Business of Barter,"" Business and Industry, What an Accountant Should Know About it, The Business of Barter, Mar. 1998, Phyllis Malitz, Author.;;""Why is Corporate Barter?"" Business Economics, Information Access Company, A Thompson Corporation Company, ASAP, Copyright 1996 National association of Business Economists, No. 2, vol. 31, p. 36, Apr. 1996, Nigel M. Healey, Author.;;""Trade You for a Hotel Room: Barter is Like Having a No-Interest Credit Card, Businessman Says,"" The Gazette (Montreal), Copyright 2000 Southam Inc., Jun. 10, 2000.;;""Land a Deal Down Under,"" Smart Cash, Bell & Howell Information and Learning, Far East Trade Press Ltd., Asian Business, vol. 36, No. 6, p. 49, Jun. 1, 2000.;;Discussion of prior art.",ACTIVE
218,DE,T2,DE 69725878 T2,091-998-649-391-951,2004-07-29,2004,DE 69725878 T,1997-08-13,US 2386796 P;;US 9714465 W,1996-08-13,ZUSAMMENSETZUNGEN ZUR POLYNUKLEOTIDABGABE,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS A;;MURPHY E;;COHEN FRED;;UNO TETSUO,"NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US (2009-05-07)",https://lens.org/091-998-649-391-951,Granted Patent,no,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,EXPIRED
219,US,B1,US 6548521 B1,021-140-705-609-235,2003-04-15,2003,US 62808000 A,2000-07-28,US 62808000 A;;US 80197 A;;US 41333795 A;;US 94392592 A,1992-09-11,Inhibitors of metazoan parasite proteases,"
    Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula I 

    AXB 

    wherein A is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1 subsites; B is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S1, S1 and S2 subsites; and X is CCC(O). These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases. 
",UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/021-140-705-609-235,Granted Patent,yes,5,7,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,514/354;;514/248;;514/307;;514/311;;514/399;;514/355;;514/419;;514/457,13,9,077-363-946-748-009;;001-799-035-777-124;;027-169-973-427-881;;005-109-335-316-80X;;090-321-821-192-233;;053-964-422-972-627;;110-598-662-276-581;;033-938-069-269-759;;171-441-700-244-108,10.1021/jm00110a022;;1676428;;3556407;;106908;;10.1002/bit.260210307;;10.1248/cpb.18.1408;;4318253;;7979274;;pmc284578;;10.1128/aac.38.7.1470;;10.1073/pnas.90.8.3583;;pmc46345;;8475107;;pmc295650;;1939639;;10.1172/jci115456;;3058128;;10.1016/0006-2952(88)90606-5;;4849285;;4152971,"Gazit et al., J. Med. Chem. 34(6), 1896-907 (1991) (abstract).*;;Agnihotri et al., Exp. Clin. Endocrinol., 88(2), 185-92 (1986) (abstract).*;;Kuan et al., Biotechnol. Bioeng., 21(3), 443-59 (1979) (abstract).*;;Irikura et al., Chem. Pharm. Bull., 18(7), 1408-13 (1970) (abstract).*;;Chen, et al. ""Licochalcone A, a New Antimalarial Agent, Inhibits In Vitro Growth of the Human Malaria Parasite Plasmodium falciparum and Protects Mice from P. yoelii Infection"" Antimicrobial Agents and Chemotherapy (Jul. 1994) vol. 38(7), pp. 1470-1475.;;Ring, et al. ""Structure-based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents"" Proc. Natl. Acad. Sci. USA (Apr. 1993) vol. 90, pp. 3583-3587.;;Rosenthal, et al. ""Antimalarial Effects of Peptide Inhibitors of a Plasmodium falciparum Cysteine Proteinase"" J. Clin. Invest. (1991) vol. 88, pp. 1467-1472.;;Silfen, et al. ""Bioflavonoid Effects on In Vitro Cultures of Plasmodium Falciparum"" Biochemical Pharmacology (1988) vol. 37(22), pp. 4269-4276.;;Santi, et al. ""Burger's Medicinal Chemistry"" Fourth Edition, Part II. Published by John Wiley & Sons (N.Y.) (1981), pp. 350-351.;;Chemical Abstracts, vol. 115, No. 4, Issued 1991, Rheinberger Et Al. ""Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue,"" See Abstract No. 142380, GER. OFFEN, DE 3939998.;;Chemical Abstracts, vol. 81 No. 12, Issued 1974, Mucke, H., ""Possibilities of Coloring Peracetic Acid for Skin Disinfection"" See Abstract No. 68513, Pharmazie 29(3), 206-7.;;Chemical Abstracts, vol. 113, No. 22, Issued 1989, Kino and Kato, ""Hair Dyes Taining Water-Soluble Dyes, Carbon Black, and Nonionic Surfactants,"" See Abstract No. 197653, JP 01242518.;;Sweeney Et Al. ""Burger's Medicinal Chemistry"" Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 342-345).",EXPIRED
220,EP,A4,EP 0817624 A4,126-431-516-049-029,1999-03-10,1999,EP 96908797 A,1996-03-13,US 9603445 W;;US 41333795 A,1995-03-30,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/126-431-516-049-029,Search Report,no,5,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,1,1,009-149-737-468-525,10.1021/jm00026a010;;8544179,"LI, R. ET AL.: ""In Vitro Antimalarial Activity of Chalcones and Their Derivatives"", J. MED. CHEM, vol. 38, no. 26, 1995, pages 5031 - 5037, XP002089127",EXPIRED
221,CA,A1,CA 2215245 A1,171-945-537-360-465,1996-10-03,1996,CA 2215245 A,1996-03-13,US 41333795 A,1995-03-30,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of general formula (I): A - X B, wherein A is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases.",UNIV CALIFORNIA,LI ZHE;;KENYON GEORGE L;;MCKERROW JAMES H;;GONG BAOQING;;CHEN XIAOWU;;COHEN FRED E;;LI RONGSHI,,https://lens.org/171-945-537-360-465,Patent Application,no,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,DISCONTINUED
222,EP,A1,EP 0817624 A1,033-665-396-926-495,1998-01-14,1998,EP 96908797 A,1996-03-13,US 9603445 W;;US 41333795 A,1995-03-30,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/033-665-396-926-495,Patent Application,yes,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,EXPIRED
223,EP,A2,EP 0941122 A2,030-533-627-550-576,1999-09-15,1999,EP 97938367 A,1997-08-13,US 9714465 W;;US 2386796 P,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;TETSUO UNO,"NOVARTIS VACCINES & DIAGNOSTICS, INC. (2008-02-29)",https://lens.org/030-533-627-550-576,Patent Application,yes,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,EXPIRED
224,EP,B1,EP 0941122 B1,108-732-663-613-300,2003-10-29,2003,EP 97938367 A,1997-08-13,US 9714465 W;;US 2386796 P,1996-08-13,COMPOSITIONS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;UNO TETSUO,"NOVARTIS VACCINES & DIAGNOSTICS, INC. (2008-02-29)",https://lens.org/108-732-663-613-300,Granted Patent,yes,1,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,EXPIRED
225,EP,B1,EP 0817624 B1,021-381-253-635-391,2002-10-02,2002,EP 96908797 A,1996-03-13,US 9603445 W;;US 41333795 A,1995-03-30,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/021-381-253-635-391,Granted Patent,yes,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,1,1,113-356-400-289-97X,10.1016/0223-5234(90)90012-r,"COMPREHENSIVE MEDICINAL CHEMISTRY, vol. 4, 1990, pages 426",EXPIRED
226,WO,A3,WO 1998/006437 A3,047-712-280-464-679,1998-02-19,1998,US US9714465,1997-08-13,"US 60/0/023,867",1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORPORATION,"ZUKERMANN, Ronald;;DUBOIS-STRINGFELLOW, Nathalie;;DWARKI, Varavani;;INNIS, Michael, A.;;MURPHY, John, E.;;COHEN, Fred;;TETSUO, Uno",,https://lens.org/047-712-280-464-679,Search Report,yes,0,0,1,1,0,,A61K47/48;;A61K48/00;;C12N15/87,,0,0,,,,UNKNOWN
227,CA,C,CA 2264012 C,053-706-518-195-525,2011-04-26,2011,CA 2264012 A,1997-08-13,US 2386796 P;;US 9714465 W,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUCKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;UNO TETSUO,,https://lens.org/053-706-518-195-525,Granted Patent,no,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,C12N15/87;;A61K31/70;;A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/16;;A61K47/30;;A61K47/34;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00,,0,0,,,,EXPIRED
228,US,A,US 5739170 A,119-365-870-366-725,1998-04-14,1998,US 41333795 A,1995-03-30,US 41333795 A;;US 9308708 W;;US 38776095 A;;US 94392592 A,1992-09-11,Inhibitors of metazoan parasite proteases,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula I A--X--B wherein A is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S1', S1 and S2 subsites; and X is --C.dbd.C--C(.dbd.O)--. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1995-04-25),https://lens.org/119-365-870-366-725,Granted Patent,yes,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,514/685;;514/646;;514/676,9,5,090-321-821-192-233;;033-938-069-269-759;;053-964-422-972-627;;171-441-700-244-108;;110-598-662-276-581,7979274;;pmc284578;;10.1128/aac.38.7.1470;;3058128;;10.1016/0006-2952(88)90606-5;;10.1073/pnas.90.8.3583;;pmc46345;;8475107;;4849285;;4152971;;pmc295650;;1939639;;10.1172/jci115456,"Chen et al., Antimicrobial Agents and Chemotheraph, Licochalone A, a New Antimalarial Agent, Inhibits in Vitro Growth of the Human Malaria Parasite Plasmidium falciparum and Protects Mice from P. yoelii infection , 38:1470 75, 1994.;;Chemical Abstracts, Biofioflavonoid effects on in vitro cultures of Plasmodium falciparum. Inhibition of permeation pathways induced in the host cell membrane by intraerythrocytic parasite , 110(11)18, column 2, abstract No. 87987p, Biochem. Parmacol., 37(22):4269 76, 1989.;;Proceedings of the National Academy of Sciences, vol. 90, Issued Apr. 1993, Ring et al Structural Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents pp. 3583 3587.;;Chemical Abstracts, vol. 115, No. 14, Issued 1991, Rheinberger et al. Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue, 0 See Abstract No. 142380, Ger. Offen, DE 3939998.;;Chemical Abstracts, vol. 81 No. 12, Issued 1974, Mucke, H., Possibilities of Coloring Peracetic Acid for Skin Disinfection See Abstract No. 68513, Pharmazie 29(3), 206 7.;;Chemical Abstracts, vol. 113, No. 22, Issued 1989, Kino and Kato, Hair Dye Taining Water Soluble Dyes, Carbon Black, and Nonionic Surfactants, See Abstract No. 197653, JP 01242518.;;Sweeney et al. Burger s Medicinal Chemistry Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 342 345).;;Santi et al. Burger s Medicinal Chemistry Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 350 351.;;Rosenthal et al. The American Society for Clinical Investigation, Inc. Antimalarial Effectis of Peptide Inhibitors of Plasmodium falciparum Cysteine Proteinase vol. 88, Nov. 1991, 1467 1472.",EXPIRED
229,AT,T1,AT E252914 T1,198-333-661-522-989,2003-11-15,2003,AT 97938367 T,1997-08-13,US 2386796 P;;US 9714465 W,1996-08-13,ZUSAMMENSETZUNGEN ZUR POLYNUKLEOTIDABGABE,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;UNO TETSUO,,https://lens.org/198-333-661-522-989,Granted Patent,no,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,DISCONTINUED
230,US,A1,US 2013/0246152 A1,019-279-921-291-326,2013-09-19,2013,US 201313855161 A,2013-04-02,US 201313855161 A;;US 69509300 A;;US 83422307 A;;US 201313850876 A,2000-10-24,Electronic Trading System and Method for Marketing Products and Services,"A consumer is provided with a first asset in return for a promise to earn an agreed to number of points over an agreed to redemption period. The consumer subsequently earns the points by purchasing one or more second assets. At least one of the second assets is different than the first asset. Each purchase has an associated with point value, at least one of the point values being different than at least one other point value. A trading system includes a first set of websites where a consumer can select and obtain a first asset in return for a promise to earn points by making future purchases of one or more second assets. The consumer can fulfill its obligation to earn the stated number of points by purchasing one or more second assets at a second set of websites. Each of the second assets has an associated point value.",JPMORGAN CHASE BANK NA,DONELIAN STEPHAN V;;COHEN STEVEN G;;SLAVIN FRED G;;TRENK MICHAEL H;;KAPLAN JUDAH;;LEWIS JAMES E,,https://lens.org/019-279-921-291-326,Patent Application,yes,1,0,4,4,0,G06Q30/0207;;G06Q30/0207;;G06Q30/0226;;G06Q30/0226,G06Q30/02,705/14.27,0,0,,,,DISCONTINUED
231,DK,T3,DK 0817624 T3,033-312-790-152-180,2002-10-28,2002,DK 96908797 T,1996-03-13,US 41333795 A;;US 9603445 W,1995-03-30,Inhibitorer af metazoparasitproteaser,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,,https://lens.org/033-312-790-152-180,Granted Patent,no,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,EXPIRED
232,JP,A,JP 2006257088 A,052-015-315-881-518,2006-09-28,2006,JP 2006086765 A,2006-03-27,US 2386796 P,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"<P>PROBLEM TO BE SOLVED: To provide compositions and methods for increasing the uptake of polynucleotides into cells. <P>SOLUTION: A compound represented by the formula and exhibiting a clear positive charge at physiological pH, wherein Ta and Tc are each a terminal group. The compound is capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides. <P>COPYRIGHT: (C)2006,JPO&NCIPI",CHIRON CORP,ZUCKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;UNO TETSUO,,https://lens.org/052-015-315-881-518,Patent Application,no,0,1,17,17,4,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K47/48;;A61K9/127;;A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/09;;C12N15/87,,0,0,,,,DISCONTINUED
233,WO,A3,WO 1998/006437 A3,094-149-449-402-970,1998-08-27,1998,US 9714465 W,1997-08-13,US 2386796 P,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;TETSUO UNO,,https://lens.org/094-149-449-402-970,Search Report,yes,5,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,5,4,016-265-122-983-119;;175-833-149-417-043;;118-843-647-887-744;;035-886-556-173-632,7873664;;10.1021/bc00030a017;;10.1016/0168-3659(96)01537-4;;10.1016/0960-894x(95)00187-x;;9001404;;10.1016/s0014-5793(96)01397-x,"MERWIN J R ET AL: ""TARGETED DELIVERY OF DNA USING YEE(GALNACAH)3, A SYNTHETIC GLYCOPEPTIDE LIGAND FOR THE ASIALOGLYCOPROTEIN RECEPTOR"", BIOCONJUGATE CHEMISTRY, vol. 5, no. 6, 1 November 1994 (1994-11-01), pages 612 - 620, XP000484176;;TOMLINSON E ET AL: ""Controllable gene therapy Pharmaceutics of non-viral gene delivery systems"", JOURNAL OF CONTROLLED RELEASE, vol. 39, no. 2, May 1996 (1996-05-01), pages 357-372, XP004037341;;RICHTER L S ET AL: ""SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNA) BY SUBMONOMER SOLID-PHASE SYNTHESIS"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 11, 1 January 1995 (1995-01-01), pages 1159 - 1162, XP000566512;;BEHR J. P.: ""The proton sponge: a trick to enter cells the viruses did not exploit"", CHIMIA, vol. 51, no. 1/2, 1997, pages 34 - 36, XP002067584;;HONG K. ET AL: ""Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly (ethylene glycol)-phospholipid conjugates for efficient in vivo gen delivery"", FEBS LETTERS, vol. 400, 1997, pages 233 - 237, XP002067585",PATENTED
234,PT,E,PT 817624 E,046-059-095-684-201,2003-02-28,2003,PT 96908797 T,1996-03-13,US 41333795 A,1995-03-30,INIBIDORES DE PROTEASES DE PARASITAS METAZOARIOS,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,KENYON GEORGE L;;COHEN FRED E;;MCKERROW JAMES H;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,,https://lens.org/046-059-095-684-201,Granted Patent,no,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,EXPIRED
235,AT,T1,AT E225170 T1,097-183-290-721-571,2002-10-15,2002,AT 96908797 T,1996-03-13,US 41333795 A;;US 9603445 W,1995-03-30,INHIBITOREN DER METAZOENPARASITEN-PROTEASEN,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula Iwherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,,https://lens.org/097-183-290-721-571,Granted Patent,no,0,0,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,0,0,,,,DISCONTINUED
236,CA,A1,CA 2264012 A1,005-312-587-325-714,1998-02-19,1998,CA 2264012 A,1997-08-13,US 2386796 P;;US 9714465 W,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUCKERMANN RONALD;;MURPHY JOHN E;;COHEN FRED;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;UNO TETSUO,,https://lens.org/005-312-587-325-714,Patent Application,no,0,0,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,EXPIRED
237,US,B1,US 6194421 B1,024-628-026-798-562,2001-02-27,2001,US 80197 A,1997-12-30,US 80197 A;;US 41333795 A;;US 38776095 A,1995-03-28,Inhibitors of metazoan parasite proteases,"Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula I A--X--B wherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is --C.dbd.C--C(.dbd.O)--. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,,https://lens.org/024-628-026-798-562,Granted Patent,yes,5,9,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,514/277;;514/248;;514/307;;514/311;;514/415;;514/457,20,9,031-889-731-333-76X;;053-964-422-972-627;;171-441-700-244-108;;110-598-662-276-581;;090-321-821-192-233;;033-938-069-269-759;;170-785-733-265-098;;031-889-731-333-76X;;009-149-737-468-525,1867460;;10.1073/pnas.90.8.3583;;pmc46345;;8475107;;4849285;;4152971;;pmc295650;;1939639;;10.1172/jci115456;;7979274;;pmc284578;;10.1128/aac.38.7.1470;;3058128;;10.1016/0006-2952(88)90606-5;;10.1002/jhet.5570110511;;1867460;;10.1021/jm00026a010;;8544179,"Southwick et al., J. Heterocycl. Chem., 11(5), 723-30 (abstract), 1974.;;Ebeid et al., Egypt. J. Pharm. Sci., 32(3-4), 767-73 (abstract), 1991.;;Berthelot et al., Ann. Pharm. Fr., 49(1), 31-9 (abstract), 1991.;;Batra et al., Indian J. Chem., Sect. B, 29B(11), 1051-5 (abstract), 1990.;;Niwas et al., Indian J. Chem., Sect. B, 24B(7), 747-53 (abstract), 1985.;;Proceeding of the Nationa Academy of Sciences, vol. 90, Issued Apr. 1993, Ring et al., ""Structural-Based Inhibitor Design by using Protein Models for the Development of Antiparasitic Agents"", pp. 3583-3587, see entire Document Especially p. 3584 Figures.;;Chemical Abstracts, vol. 115, No. 4, Issued 1991, Rheinberger et al., ""Incorporated of Flourescent Substances into Dental Materials for Differentiation from Surronding Tissue,"" see abstract No. 142380, Ger. Offen, DE 3939998.;;Chemical Abstracts, vol. 81 No. 12, Issued 1974, Mucke, H., ""Possibilities of Coloring Peracetic Acid for Skin Disinfection"" See Abstract No. 38513, Pharmazie 29(3), 206-7.;;Chemical Abstracts, vol. 113, No. 22,, Issued 1989, Kino and Kato, ""Hair Dye Taining Water-Soluble Dyes, Carbon Black, and Nonionic Surfactants,"" See Abstract No. 197653, JP 0124518.;;Sweeney et al., ""Burger Medicinal Chemistry"", Fourth Edition, Part II, Published 1981 by John Wiley & Sons (N.Y.), pp. 342-345.;;Santi et al., ""Burger's Medicinal Chemistry"", Fourth Edition, Part II, Published 1981 by John Wiley & Sons(N.Y.), pp. 350-351.;;Rosenthal et al., The American Society for Clinical Investigation Inc., ""Antimalarial Effects of Peptide Inhibitors of Plasmodium Falciparum Cysteine Proteinase"", vol. 88, Nov., 1991, 1467-1472.;;Chen, et al., ""Licochalone A, a New Antimalarial Agent, Inhibits In Vitro Growth of the Human Malaria Parasite Plasmodium falciparum and Protects Mice from P. yeolii infection"",Antimicrobial Agents And Chemotheorym 38(7):1470-1475 (1994).;;Silfen, et al., ""Bioflavoniod effects on in vitro cultures of Plasmodium falciparum. Inhibition of permeation pathways induced in the host cell membrane by intraerythrocytic parasite"", Chemical Abstracts, 110(11):18, Col. 2, Abstract 87987p (1989).;;Southwick, et al., Synthesis of Antifols Related to 2,4-Diamino-6,7-dihydro-5H-pyrrolo-[3,4-d] pyrimidine. enchancement of Antiparasitic Selectivity by Nitrogen-Linked Mono- and Dichlorobenzoyl Groups or the 3,4-Dichlorophenylthiocarbamoyl Group (1), J. Heterocycl. Chem., 11(5):723-30 (1994).;;Niwas et al., Syntheses & Anthelmintic Activity of 5 (6)-Substituted-benzimidazole-2carbamates & N1 , N2 Dimethoxycarbonyl-N3-(p-substituted penyl)guanidines, Indian Journal of Chemistry, 24B:747-753 ( Jul. 1995).;;Batra and Sharma, Studies in antiparasitic agents: Part 15-Synthesis of 4,6-disubstitued tetrahy-dropyrimidine-2-thiones as potential leishmanicides, Indian Journal of Chemistry, 29B:1051-1055 ( Nov. 1990).;;Berthelot et al., Synthesis of various oximes, hydrazones and dichloroacetamides, Ann. pharmaceutiques francaises, 49(1):31-39, (1991).;;Ebeid et al., New 5-Nitrothiazolyl Heterocycles of Possible Schistosomicidal Activity, Egypt J. Pharm. Sci., 32(3-4): 767-773 (1991).;;Li et al., In Vitro Antimalarial Activity of Chalcones and Their Derivatives, J. Med. Chem. 38: 5031-5037 (1995).",EXPIRED
238,US,A,US 5610192 A,074-414-626-647-450,1997-03-11,1997,US 38776095 A,1995-03-28,US 38776095 A;;US 94392592 A;;US 9308708 W,1992-09-11,Inhibitors of metazoan parasite proteases,"Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease. The compositions comprise at least one metazoan protease inhibitor which binds to the S2 subsite and at least one of the S1 and S1' subsites of the metazoan parasite protease. The methods comprise administration to a patient infected with a metazoan parasite of at least one metazoan protease inhibitor in an amount effective to inhibit the protease of the metazoan parasite, thereby killing the parasite.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;RING CHRISTINE S;;ROSENTHAL PHILIP J;;KENYON GEORGE L;;LI ZHE,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1995-03-14),https://lens.org/074-414-626-647-450,Granted Patent,yes,0,15,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,514/614;;514/639,10,6,090-321-821-192-233;;033-938-069-269-759;;053-964-422-972-627;;171-441-700-244-108;;110-598-662-276-581;;043-199-636-910-36X,7979274;;pmc284578;;10.1128/aac.38.7.1470;;3058128;;10.1016/0006-2952(88)90606-5;;10.1073/pnas.90.8.3583;;pmc46345;;8475107;;4849285;;4152971;;pmc295650;;1939639;;10.1172/jci115456;;5773786;;10.1021/jm00301a006,"Chen, et al., Licochalone A, a New Antimalarial Agent, Inhibits In Vitro Growth of the Human Malaria Parasite Plasmodium falciparum and Protects Mice from P. yoelii infection , Antimicrobial Agents and Chemotherapy , 38(7):1470 1475 (1994).;;Silfen, et al., Bioflavonoid effects on in vitro cultures of Plasmodium falciparum . Inhibition of permeation pathways induced in the host cell membrane by intraerythrocytic parasite , Chemical Abstracts , 110(11):18, Col. 2, Abstract 87987p (1989).;;Proceedings of the National Academy of Sciences, vol. 90, Issued Apr. 1993, Ring et al Structural Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents pp. 3583 3587, See Entire Document Especially p. 3584 Figures.;;Chemical Abstracts, vol. 115, No. 4, Issued 1991, Rheinberger et al. Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue, See Abstract No. 142380, Ger. Offen. DE 3939998.;;Chemical Abstracts, vol. 81, No. 12, Issued 1974, Mucke, H., Possibilities of Coloring Peracetic Acid for Skin Disinfection See Abstract No. 68513, Pharmazie 29(3), 206 7.;;Chemical Abstracts, vol. 113, No. 22, Issued 1989, Kino and Kato, Hair Dyes Taining Water Soluble Dyes, Carbon Black, and Nonionic Surfactants, See Abstract No. 197653, JP 01242518.;;Sweeney et al. Burger s Medicinal Chemistry Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 342 345).;;Santi et al. Burger s Medicinal Chemistry Fourth Edition, Part II. Published 1981 by John Wiley & Sons (N.Y.) pp. 350 351.;;Rosenthal et al. The American Society for Clinical Investigation, Inc. Antimalarial Effectis of Peptide Inhibitors of Plasmodium Falciparum Cysteine Proteinase vol. 88, Nov. 1991, 1467 1472.;;DoAmaral et al., J. Med. Chem. (12), pp. 21 25, Jan., 1969.",EXPIRED
239,WO,A2,WO 1998/006437 A2,038-696-790-212-769,1998-02-19,1998,US 9714465 W,1997-08-13,US 2386796 P,1996-08-13,COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY,"This invention relates to compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUKERMANN RONALD;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED;;TETSUO UNO,,https://lens.org/038-696-790-212-769,Patent Application,no,0,50,17,17,4,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,,0,0,,,,PATENTED
240,WO,A1,WO 1996/030004 A1,109-388-974-009-019,1996-10-03,1996,US 9603445 W,1996-03-13,US 41333795 A,1995-03-30,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of general formula (I): A - X - B, wherein A is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic or heteroaromatic ring system comprising one to three rings which binds to at least one of the S1', S1 and S2 subsites; and X is -C=C-C(=O)-. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases.",UNIV CALIFORNIA,COHEN FRED E;;MCKERROW JAMES H;;KENYON GEORGE L;;LI ZHE;;CHEN XIAOWU;;GONG BAOQING;;LI RONGSHI,,https://lens.org/109-388-974-009-019,Patent Application,yes,0,5,14,14,0,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12;;Y02A50/30;;A61K31/472;;A61K31/50;;A61K31/365;;A61K31/195;;A61K31/165;;A61K31/40;;A61K31/4178;;A61K31/36;;A61K31/136;;A61K31/135;;A61K31/35;;A61K31/4406;;A61K31/47;;A61K31/60;;A61K31/17;;A61K31/4164;;A61K31/44;;A61K31/12;;A61K31/505;;A61K31/34;;A61K31/415;;A61K31/4402;;Y02A50/30,A61K31/12;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/02;;A61P33/06;;A61P33/12,,2,2,090-321-821-192-233;;033-938-069-269-759,7979274;;pmc284578;;10.1128/aac.38.7.1470;;3058128;;10.1016/0006-2952(88)90606-5,"ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Volume 38, No. 7, issued July 1994, CHEN et al., ""Licochalone A, a New Antimalarial Agent, Inhibits in Vitro Growth of the Human Malaria Parasite Plasmodium Falciparum and Protects Mice from P. Yoelii Infection"", pages 1470-75.;;CHEMICAL ABSTRACTS, Volume 110, Number 11, issued 13 March 1989, SILFEN et al., ""Bioflavonoid Effects on in Vitro Cultures of Plasmodium Falciparum. Inhibition of Permeation Pathways Induced in the Host Cell Membrane by Intraerythrocytic Parasite"", page 18, Abstract No. 87987p; & BIOCHEM. PHARMACOL., 37(22), pages 4269-76.",PATENTED
241,US,A1,US 2013/0268329 A1,003-816-456-893-451,2013-10-10,2013,US 201313856066 A,2013-04-03,US 201313856066 A;;US 69509300 A;;US 83422307 A;;US 201313850876 A,2000-10-24,Electronic Trading System and Method for Marketing Products and Services,"A consumer is provided with a first asset in return for a promise to earn an agreed to number of points over an agreed to redemption period. The consumer subsequently earns the points by purchasing one or more second assets. At least one of the second assets is different than the first asset. Each purchase has an associated with point value, at least one of the point values being different than at least one other point value. A trading system includes a first set of websites where a consumer can select and obtain a first asset in return for a promise to earn points by making future purchases of one or more second assets. The consumer can fulfill its obligation to earn the stated number of points by purchasing one or more second assets at a second set of websites. Each of the second assets has an associated point value.",JPMORGAN CHASE BANK NA,DONELIAN STEPHAN V;;COHEN STEVEN G;;SLAVIN FRED G;;TRENK MICHAEL H;;KAPLAN JUDAH;;LEWIS JAMES E,,https://lens.org/003-816-456-893-451,Patent Application,yes,1,0,4,4,0,G06Q30/0207;;G06Q30/0207;;G06Q30/0226;;G06Q30/0226,G06Q30/02,705/14.1,0,0,,,,DISCONTINUED
242,US,A1,US 2013/0238415 A1,190-301-961-797-207,2013-09-12,2013,US 201313850876 A,2013-03-26,US 201313850876 A;;US 69509300 A;;US 83422307 A,2000-10-24,Electronic Trading System and Method for Marketing Products and Services,"A consumer is provided with a first asset in return for a promise to earn an agreed to number of points over an agreed to redemption period. The consumer subsequently earns the points by purchasing one or more second assets. At least one of the second assets is different than the first asset. Each purchase has an associated point value, at least one of the point values being different than at least one other point value. An electronic trading system includes a first set of web sites where a consumer can select a first asset it wants to obtain in return for a promise to earn points by making future purchases of one or more second assets. The number of points which the consumer must earn varies as a function of which of the first assets is selected by the consumer.",DONELIAN STEPHAN V;;COHEN STEVEN G;;SLAVIN FRED G;;TRENK MICHAEL H;;KAPLAN JUDAH;;LEWIS JAMES E;;JPMORGAN CHASE BANK NA,DONELIAN STEPHAN V;;COHEN STEVEN G;;SLAVIN FRED G;;TRENK MICHAEL H;;KAPLAN JUDAH;;LEWIS JAMES E,,https://lens.org/190-301-961-797-207,Patent Application,yes,0,1,4,4,0,G06Q30/0207;;G06Q30/0207;;G06Q30/0226;;G06Q30/0226,G06Q30/02,705/14.27,0,0,,,,DISCONTINUED
243,ES,T3,ES 2183817 T3,105-672-477-678-10X,2003-04-01,2003,ES 93921592 T,1993-09-13,US 94392592 A,1992-09-11,INIBIDORES DE PROTEASAS DE PARASATISO METAZOARIOS.,"COMPOSICIONES Y METODOS PARA TRATAR A UN PACIENTE INFECTADO POR UN PARASITO METAZOICO MEDIANTE LA INHIBICION DE LA ACCION ENZIMATICA DE LA PROTEASA DEL PARASITO METAZOICO. ESTAS COMPOSICIONES Y METODOS TIENEN PARTICULAR UTILIDAD EN EL TRATAMIENTO DE LA ESQUISTOSOMIASIS, MALARIA Y OTRAS ENFERMEDADES INFECCIOSAS. LAS COMPOSICIONES CONTIENEN AL MENOS UN COMPUESTO INHIBIDOR DE LA PROTEASA METAZOICA QUE CONTIENE ELEMENTOS ESTRUCTURALES ESPECIFICOS QUE SE UNEN A LA SUBPOSICION S2 Y A AL MENOS UNA DE LOS SUBPOSICIONES S1 Y S1'' DE LAS PROTEASAS DEL PARASITO METAZOICO. LOS INHIBIDORES DE LA PRESENTE INVENCION GENERALMENTE INCLUYEN AL MENOS DOS SISTEMAS DE ANILLO HOMOAROMATICOS O HETEROAROMATICOS, CADA UNO DE LOS CUALES COMPRENDE DE UNO A TRES ANILLOS, UNIDOS ENTRE SI MEDIANTE LOS ENLACES APROPIADOS. EL TRATAMIENTO DE UN PACIENTE INFECTADO POR UN PARASITO METAZOICO INCLUYE LA ADMINISTRACION DE UNA COMPOSICION QUE CONTENGA AL MENOS UN INHIBIDOR DE LA PROTEASA METAZOICA EN UNA CANTIDAD EFECTIVA PARA INHIBIR LA PROTEASA DEL PARASITO METAZOICO Y DE ESTE MODO MATAR AL PARASITO.",UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/105-672-477-678-10X,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
244,OA,A,OA 10132 A,106-888-236-944-904,1996-12-18,1996,OA 60620 A,1995-03-07,US 94392592 A,1992-09-11,Inhibitors of metazoan parasite proteases,,UNIV CALIFORNIA,EHRENKRANZ COHEN FRED;;JAMES HOBSON MCKERRON;;SUN YOUNG RING CHRISTINE;;ROSENTHAL PHILIP JON;;LOMMEL KENYON GEORGE;;ZHE LI,,https://lens.org/106-888-236-944-904,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
245,EP,B1,EP 0752813 B1,190-632-796-881-320,2002-12-11,2002,EP 93921592 A,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITORS OF METAZOAN PARASITE PROTEASES,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1999-12-08),https://lens.org/190-632-796-881-320,Granted Patent,yes,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,11,0,,,"HEPATOLOGY (ST. LOUIS), vol. 15, no. 3, 1992, pages 492-501, XP000654330 BAKER E. ET AL: ""Evaluation of the Iron Chelation Potential of Hydrazones of Pyridoxal, Salicylaldehyde and 2-Hydroxy-1-Naphthylaldehyde using Hepatocyte in Culture"";;J. CHEM. ENG. DATA, vol. 33, no. 4, 1988, pages 538-540, XP000654339 EDWARD J.T. ET AL: ""Synthesis of New Acylhydrazones as Iron-Chelating Compounds"";;BIOCHIM. BIOPHYS. ACTA, vol. 967, no. 1, 1988, pages 122-129, XP000654310 PONKA P. ET AL: ""Effect of Pyridoxal Isonicotinyl Hydrazone and Other Hydrazones on Iron Release from Macrophages, Reticulocytes and Hepatocytes"";;CHEMICAL ABSTRACTS, vol. 107, no. 9, 1987 Columbus, Ohio, US; abstract no. 77393r, GAIDUKEVICH A.N. ET AL: ""Synthesis and Biological Activity of Derivatives of 2,4-Dichloro-5-Nitrobenzoic Acid"" page 663; XP002032259 & FARM. ZH. (KIEV), vol. 1, 1987, page 69;;CHEMICAL ABSTRACTS, vol. 95, no. 5, 1981 Columbus, Ohio, US; abstract no. 35421b, HIRAYAMA T. ET AL: ""Anti-tumor Activities of Some Heterocyclic and Nitrogen-containing Compounds"" XP002032260 & YAKUGAKU ZASSHI, vol. 100, no. 12, 1980, pages 1225-1234,;;PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Vol. 90, issued April 1993, RING et al., ""Structure-Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents"", pages 3583-3587.;;CHEMICAL ABSTRACTS, Volume 115, No. 4, issued 1991, RHEINBERGER et al., ""Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue"", see Abstract No. 142380; & DE,A,39 39 998.;;CHEMICAL ABSTRACTS, Volume 81, No. 12, issued 1974, MUCKE, H., ""Possibilities of Coloring Peracetic Acid for Skin Disinfection"", see Abstract No. 68513; & PHARMAZIE, 29(3), 206-7.;;CHEMICAL ABSTRACTS, Volume 113, No. 22, issued 1989, KINO AND KATO, ""Hair Dyes Containing Water-Soluble Dyes, Carbon Black, and Nonionic Surfactants"", see Abstract No. 197653; & JP,A,01 242 518.;;SWEENEY et al., ""Burger's Medicinal Chemistry"", Fourth Edition, part II, Published 1981, by JOHN WILEY & SONS (N.Y.), pages 342-345.;;SANTI et al., ""Burger's Medicinal Chemistry"", Fourth Edition, part I. Published 1981, by JOHN WILEY & SONS (N.Y.), pages 350-351.",EXPIRED
246,WO,A1,WO 1994/006280 A1,112-831-388-518-98X,1994-03-31,1994,US 9308708 W,1993-09-13,US 94392592 A,1992-09-11,INHIBITORS OF METAZOAN PARASITE PROTEASES,"Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases. The compositions contain at least one metazoan protease inhibitor compound containing specific structural elements which bind to the S2 subsite and at least one of the S1 and S1' subsites of the metazoan parasite protease. The protease inhibitors of the present invention generally include at least two homoaromatic or heteroaromatic ring systems, each comprising one to three rings, joined together by suitable linkers. Treatment of a patient infected by a metazoan parasite involves administration of a composition containing at least one metazoan protease inhibitor in an amount effective to inhibit the protease of the metazoan parasite and thus kill the parasite.",UNIV CALIFORNIA;;COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/112-831-388-518-98X,Patent Application,yes,0,23,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,7,2,053-964-422-972-627;;171-441-700-244-108,10.1073/pnas.90.8.3583;;pmc46345;;8475107;;4849285;;4152971,"PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Vol. 90, issued April 1993, RING et al., ""Structure-Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents"", pages 3583-3587.;;CHEMICAL ABSTRACTS, Volume 115, No. 4, issued 1991, RHEINBERGER et al., ""Incorporation of Fluorescent Substances into Dental Materials for Differentiation from Surrounding Tissue"", see Abstract No. 142380; & DE,A,39 39 998.;;CHEMICAL ABSTRACTS, Volume 81, No. 12, issued 1974, MUCKE, H., ""Possibilities of Coloring Peracetic Acid for Skin Disinfection"", see Abstract No. 68513; & PHARMAZIE, 29(3), 206-7.;;CHEMICAL ABSTRACTS, Volume 113, No. 22, issued 1989, KINO AND KATO, ""Hair Dyes Containing Water-Soluble Dyes, Carbon Black, and Nonionic Surfactants"", see Abstract No. 197653; & JP,A,01 242 518.;;SWEENEY et al., ""Burger's Medicinal Chemistry"", Fourth Edition, part II, Published 1981, by JOHN WILEY & SONS (N.Y.), pages 342-345.;;SANTI et al., ""Burger's Medicinal Chemistry"", Fourth Edition, part I. Published 1981, by JOHN WILEY & SONS (N.Y.), pages 350-351.;;See also references of EP 0752813A4",PATENTED
247,DE,D1,DE 69332567 D1,095-140-398-834-372,2003-01-23,2003,DE 69332567 T,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITOREN VON METAZOAN-PARASIT-PROTEASEN,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/095-140-398-834-372,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
248,DK,T3,DK 0752813 T3,185-297-588-713-465,2003-01-06,2003,DK 93921592 T,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,Hæmmere af metozoan-parasit-proteaser,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/185-297-588-713-465,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
249,DE,T2,DE 69332567 T2,154-665-482-896-12X,2003-04-17,2003,DE 69332567 T,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITOREN VON METAZOAN-PARASIT-PROTEASEN,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/154-665-482-896-12X,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
250,PT,E,PT 752813 E,081-930-939-095-460,2003-04-30,2003,PT 93921592 T,1993-09-13,US 94392592 A,1992-09-11,INIBIDORES DE PROTEASES DE PARASITAS METAZOARIOS,,UNIV CALIFORNIA,LI ZHE;;COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL,,https://lens.org/081-930-939-095-460,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,EXPIRED
251,AU,A,AU 1993/049230 A,006-625-758-527-155,1994-04-12,1994,AU 1993/049230 A,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,Inhibitors of metazoan parasite proteases,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/006-625-758-527-155,Patent Application,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,PENDING
252,AT,T1,AT E229331 T1,132-210-175-644-986,2002-12-15,2002,AT 93921592 T,1993-09-13,US 94392592 A;;US 9308708 W,1992-09-11,INHIBITOREN VON METAZOAN-PARASIT-PROTEASEN,,UNIV CALIFORNIA,COHEN FRED EHRENKRANZ;;MCKERROW JAMES HOBSON;;RING CHRISTINE SUN YOUNG;;ROSENTHAL PHILIP JON;;KENYON GEORGE LOMMEL;;LI ZHE,,https://lens.org/132-210-175-644-986,Granted Patent,no,0,0,14,14,0,A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/35;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/4725;;A61K31/50;;A61K31/505;;A61K31/60;;A61P33/00;;A61P33/02;;A61P33/06;;A61P43/00;;Y02A50/30;;A61K31/60;;A61K31/365;;A61K31/415;;A61K31/135;;A61K31/44;;A61K31/505;;A61K31/195;;A61K31/136;;A61K31/4406;;A61K31/47;;A61K31/36;;A61K31/4164;;A61K31/4725;;A61K31/35;;A61K31/472;;A61K31/17;;A61K31/34;;A61K31/50;;A61K31/165;;A61K31/4402;;A61K31/40;;A61K31/4178;;Y02A50/30,C07D237/34;;A61K31/135;;A61K31/136;;A61K31/165;;A61K31/17;;A61K31/195;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/352;;A61K31/357;;A61K31/36;;A61K31/365;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/44;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/60;;A61K45/00;;A61P33/00;;A61P33/02;;A61P43/00;;C07C233/09;;C07C233/56;;C07C243/30;;C07C251/18;;C07C251/86;;C07C251/88;;C07C281/06;;C07C335/04;;C07D209/14;;C07D209/80;;C07D215/12;;C07D215/22;;C07D215/38;;C07D217/02;;C07D217/22;;C07D307/68;;C07D311/80;;C07D317/60;;C07D471/06,,0,0,,,,DISCONTINUED
253,US,B2,US 7462592 B2,159-521-471-821-80X,2008-12-09,2008,US 27875102 A,2002-10-22,US 27875102 A;;US 9714465 W;;US 62092500 A;;US 91064797 A;;US 2386796 P,1996-08-13,Compositions and methods for polynucleotide delivery,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",NOVARTIS VACCINES & DIAGNOSTIC,ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,,https://lens.org/159-521-471-821-80X,Granted Patent,yes,20,8,17,17,4,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K9/14;;A01N37/18;;A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,514/2;;424/486;;530/300,30,24,019-810-335-711-889;;038-490-918-925-431;;114-517-649-646-486;;059-172-353-640-68X;;038-206-696-631-102;;096-317-125-842-948;;050-885-886-277-521;;035-886-556-173-632;;072-395-547-617-233;;004-456-464-309-219;;022-200-580-308-452;;012-595-233-448-094;;001-596-965-870-798;;155-997-957-806-763;;016-265-122-983-119;;166-492-343-373-663;;078-403-096-840-094;;088-686-971-255-340;;118-843-647-887-744;;175-833-149-417-043;;009-416-320-508-847;;157-947-201-686-965;;011-307-053-684-81X;;071-211-641-209-775,9579858;;7584089;;10.1021/bc00029a002;;7849066;;9669880;;10.1016/s1359-0278(98)00030-3;;8750010;;8547238;;10.1021/bi952436a;;10.1007/bf02789334;;7552693;;9001404;;10.1016/s0014-5793(96)01397-x;;10.1021/bc00031a002;;7711106;;10.1016/0169-409x(96)00002-6;;10.1089/hum.1995.6.9-1129;;8527471;;9026036;;10.1021/bc960076d;;10.1074/jbc.270.42.24864;;7559609;;8607031;;8629036;;7873664;;10.1021/bc00030a017;;7584085;;7619428;;10.1016/1045-1056(95)90004-7;;7878052;;pmc42596;;10.1073/pnas.92.5.1744;;10.1016/0960-894x(95)00187-x;;10.1016/0168-3659(96)01537-4;;9305836;;10.1038/38410;;10.1021/bc00010a006;;1772904;;1518816;;pmc49829;;10.1073/pnas.89.17.7934;;10.1016/0005-2736(95)00256-1;;8634302,"Canadian patent application No. 2,264,012, Examination Report mailed Jan. 11, 2007.;;Japan patent application No. 10-508319, Office Action mailed Mar. 18, 2008.;;Anderson et al., Human gene therapy, Apr. 30, 1998, Nature, vol. 392, pp. 25-30.;;Batra et al., ""Receptor-Mediated Gene Delivery Emplyong Lectin-Binding Specificity"" Gene Therapy 1:255-260, 1994.;;Behr et al., ""Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy"" Bioconjugate Chem. 5:382-389, 1994.;;Behr et al., ""The Proton Sponge: a Trick to Enter Cells the Viruses did not Exploit"" Chimia 51:34-36 (1997).;;Chiu et al., Optimizing energy potentials for success in protein tertiary sturcture prediction, May 7, 1998, Folding & Design, vol. 3, pp. 223-228.;;Gao and Huang, ""Cationic Liposome-Mediated Gene Transfer"" Gene Therapy 2:710-722, 1995.;;Gao and Huang, ""Potentiation of Cationic Liposome-Mediated Gene Transfer Delivery by Polycations"" Biochemistry 35:1027-1036, 1996.;;Guy et al., ""Delivery of DNA into Mammalian Cells by Receptor-Mediated Endocytosis and Gene Therapy"" Molecular Biology 3:237-248, 1995.;;Hong et al., ""Stabilization of Cationic Liposome-Plasmid DNA Complexes by Polyamines and . . . "" FEBS Letters 400:233-237, 1997.;;Kabanov and Kabanov, ""DNA Complexes with Polycations for the Delivery of Genetic Material into Cells"" Bioconjugate Chem. 6:7-20, 1995.;;Lasic and Tenpleton, ""Liposomes in Gene Therapy"" Advanced Drug Delivery Reviews 20:221-226, 1996.;;Ledley, ""Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products"" Human Gene Ther. 6:1129-1144, Sep. 1995.;;Legendre et al., ""Dioleoylmelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells"" Bioconjugate Chem. 8:57-63, 1997.;;Liu et al., ""Cationic Liposome-Mediated Intravenous Gene Delivery"" J. Biological Chemistry 270(42):24864-24870, 1995.;;Mastrangelo et al., ""Gene Therapy for Human Cancer: an Essay for Clinicians"" Seminars in Oncology 23:4-21, 1996.;;Merwin et al., ""Targeted Delivery of DNA Using Yee(GalNacAH).sub.3, a Synthetic Glycopeptide Ligand . . . "" Bioconjugate Chemistry 5(6):612-620, 1994.;;Michael and Curiel, ""Strategies to Achieve Targeted Gene Delivery via the Receptor-Mediated Endocytosis Pathway"" Gene Therapy 1:223-232, 1994.;;Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Parasdox, 1994, vol. 14, pp. 492-495.;;Ngo et al., in: The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et ., (ed)., Birkhauser, Boston, MA, pp. 433 and 492-495.;;Phillips, ""Receptor-Mediated DNA Delivery Approaches to Human Gene Therapy"" Biologicals 23:13-16, 1995.;;Raz et al., Cationic Lipids Inhibit Intradermal Genetic Vaccination, 1994, pp. 71-75.;;Remy et al., ""Targeted Gene Transfer into Hepatoma Cells With Lipopolyamine-Condensed DNA Particles . . . "" PNAS USA 92:1744-1748, 1995.;;Richter and Zuckerman, ""Synthesis of Peptide Nucleic Acids (PNA) by Submonomer Solid-Phase Synthesis"" 5(11) : 1159-1162 (1995).;;Tomlinson and Rolland, ""Controllable Gene Therapy Pharmaceutics of Non-Viral Gene Delivery Systems"" J. Controlled Release 39:357-372, 1996.;;Verma et al., Gene therapy-promises, problems and prospects, Sep. 18, 1997, Nature, vol. 389, pp. 239-242.;;Wagner et al., ""DNA-Binding Transferrin Conjugates as Functional Gene-Delivery Agents: . . . "" Bioconjugate Chem. 2:226-231, 1991.;;Wagner et al., ""Influenza Virus Hemagglutinin HA-2 N-terminal Fusogenic Peptides Augment Gene Transfer by . . . "" PNAS USA 89:7934-7938, 1992.;;Wheeler et al., ""Converting an Alcohol to an Amine in a Cationic Lipid Dramatically Alters the Co-Lipid Requirement, . . . "" Biochim. et Biophsica Acta. 1280:1-11, 1996.",EXPIRED
254,US,A9,US 2008/0089938 A9,177-424-644-764-312,2008-04-17,2008,US 27875102 A,2002-10-22,US 27875102 A;;US 9714465 W;;US 62092500 A;;US 91064797 A;;US 2386796 P,1996-08-13,Compositions and methods for polynucleotide delivery,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,,https://lens.org/177-424-644-764-312,Amended Application,yes,7,5,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K48/00;;A61K9/14;;A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,424/484;;514/8;;530/324;;530/325;;530/327;;530/326;;514/44,0,0,,,,EXPIRED
255,US,B1,US 6468986 B1,004-997-933-238-225,2002-10-22,2002,US 62092500 A,2000-07-21,US 62092500 A;;US 91064797 A;;US 2386796 P,1996-08-13,Compositions and methods for polynucleotide delivery,"
    This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides. 
",CHIRON CORP,ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,,https://lens.org/004-997-933-238-225,Granted Patent,yes,19,37,17,17,4,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,514/44;;424/486;;424/450;;435/320.1;;435/325;;435/91.4;;435/455,28,24,019-810-335-711-889;;009-416-320-508-847;;059-172-353-640-68X;;157-947-201-686-965;;011-307-053-684-81X;;038-490-918-925-431;;114-517-649-646-486;;166-492-343-373-663;;096-317-125-842-948;;038-206-696-631-102;;050-885-886-277-521;;072-395-547-617-233;;035-886-556-173-632;;016-265-122-983-119;;118-843-647-887-744;;022-200-580-308-452;;071-211-641-209-775;;155-997-957-806-763;;001-596-965-870-798;;078-403-096-840-094;;028-650-332-166-498;;004-456-464-309-219;;175-833-149-417-043;;012-595-233-448-094,9579858;;9305836;;10.1038/38410;;9669880;;10.1016/s1359-0278(98)00030-3;;10.1021/bc00010a006;;1772904;;1518816;;pmc49829;;10.1073/pnas.89.17.7934;;7584089;;10.1021/bc00029a002;;7849066;;7584085;;8547238;;10.1021/bi952436a;;8750010;;10.1007/bf02789334;;7552693;;10.1021/bc00031a002;;7711106;;9001404;;10.1016/s0014-5793(96)01397-x;;7873664;;10.1021/bc00030a017;;10.1016/0960-894x(95)00187-x;;10.1089/hum.1995.6.9-1129;;8527471;;10.1016/0005-2736(95)00256-1;;8634302;;8607031;;8629036;;10.1074/jbc.270.42.24864;;7559609;;7619428;;10.1016/1045-1056(95)90004-7;;10.1016/0168-9525(95)90478-6;;10.1016/0169-409x(96)00002-6;;10.1016/0168-3659(96)01537-4;;9026036;;10.1021/bc960076d,"Raz et al., Cationic Lipids Inhibit Intradermal Genetic Vaccination, 1994, pp. 71-75.*;;Anderson et al., Human gene therapy, Apr. 30, 1998, Nature, vol. 392, pp. 25-30.*;;Verma et al., Gene therapy-promises, problems and prospects, Sep. 18, 1997, Nature, vol. 389, pp. 239-242.*;;Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Parasdox, 1994, vol. 14, pp. 492-495.*;;Chiu et al., Optimizing energy potentials for success in protein tertiary sturcture prediction, May 7, 1998, Folding & Design, vol. 3, pp. 223-228.*;;Wagner et al., ""DNA-Binding Transferrin Conjugates as Functional Gene-Delivery Agents: Synthesis by Linkage of Polylysine or Ethidium Homodimer to the Transferrin Carbohydrate Moiety"" Bioconjugate Chem. 2(4) :226-231, 1991.;;Wagner et al., ""Influenza Virus Hemagglutinin HA-2 N-terminal Fusogenic Peptides Augment Gene Transfer by Transferrin-Polylysine-DNA Complexes: Toward a Synthetic Virus-Like Gene-Transfer Vehicle"" Proc. Natl. Acad. Sci. USA 89:7934-7938, Sep., 1992.;;Batra et al., ""Receptor-Mediated Gene Delivery Emplyong Lectin-Binding Specificity"" Gene Therapy 1:255-260, 1994.;;Behr et al., ""Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy"" Bioconjugate Chem. 5:382-389, 1994.;;Michael and Curiel, ""Strategies to Achieve Targeted Gene Delivery via the Receptor-Mediated Endocytosis Pathway"" Gene Therapy 1:223-232, 1994.;;Gao and Huang, ""Potentiation of Cationic Liposome-Mediated Gene Transfer Delivery by Polycations"" Biochemistry 35:1027-1036, 1996.;;Gao and Huang, ""Cationic Liposome-Mediated Gene Transfer"" Gene Therapy 2:710-722, 1995.;;Guy et al., ""Delivery of DNA into Mammalian Cells by Receptor-Mediated Endocytosis and Gene Therapy"" Molecular Biology 3:237-248, 1995.;;Kabanov and Kabanov, ""DNA Complexes with Polycations for the Delivery of Genetic Material into Cells"" Bioconjugate Chem. 6:7-20, 1995.;;Behr et al., ""The Proton Sponge: a Trick to Enter Cells the Viruses did not Exploit"" Chimia 51:34-36 (1997).;;Hong et al., ""Stabilization of Cationic Liposome-Plasmid DNA Complexes by Polyamines and Poly(ethylene glycol) -phospholipid Conjugates for Efficient in vivo Gene Delivery"" FEBS Letters 400:233-237 (1997).;;Merwin et al., ""Targeted Delivery of DNA Using Yee(GalNacAH)3 , a Synthetic Glycopeptide Ligand for the Asialoglycoprotein Receptor"" Bioconjugate Chemistry 5(6):612-620 (1994).;;Richter and Zuckerman, ""Synthesis of Peptide Nucleic Acids (PNA) by Submonomer Solid-Phase Synthesis"" 5(11) : 1159-1162 (1995).;;Ledley, ""Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products"" Human Gene Ther. 6:1129-1144, Sep. 1995.;;Wheeler et al., ""Converting an Alcohol to an Amine in a Cationic Lipid Dramatically Alters the Co-Lipid Requirement, Cellular Transfection Activity and The Ultrastructure of DNA-Cytofectin Complexes"" Biochim. et Biophsica Acta. 1280:1-11, 1996.;;Mastrangelo et al., ""Gene Therapy for Human Cancer: an Essay for Clinicians"" Seminars in Oncology 23:4-21, 1996.;;Ngo et al., in: The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et ., (ed)., Birkhauser, Boston, MA, pp. 433 and 492-495.;;Liu et al., ""Cationic Liposome-Mediated Intravenous Gene Delivery"" J. Biological Chemistry 270(42):24864-24870, 1995.;;Phillips, ""Receptor-Mediated DNA Delivery Approaches to Human Gene Therapy"" Biologicals 23:13-16, 1995.;;Remy et al., ""Targeted Gene Transfer into Hepatoma Cells With Lipopolyamine-Condensed DNA Particles Presenting Galactose Ligands: a Stage Toward Artificial Viruses"" Proc. Natl. Acad. Sci. USA 92:1744-1748, Feb., 1995.;;Lasic and Tenpleton, ""Liposomes in Gene Therapy"" Advanced Drug Delivery Reviews 20:221-226, 1996.;;Tomlinson and Rolland, ""Controllable Gene Therapy Pharmaceutics of Non-Viral Gene Delivery Systems"" J. Controlled Release 39:357-372, 1996.;;Legendre et al., ""Dioleoylmelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells"" Bioconjugate Chem. 8:57-63, 1997.",EXPIRED
256,US,B1,US 6251433 B1,117-066-478-824-290,2001-06-26,2001,US 91064797 A,1997-08-13,US 91064797 A;;US 2386796 P,1996-08-13,Polycationic polymers,"This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.",CHIRON CORP,ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,CHIRON CORPORATION (1997-09-22),https://lens.org/117-066-478-824-290,Granted Patent,yes,17,45,17,17,4,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,424/486;;424/450;;530/300;;530/333;;435/320.1;;525/54.1;;525/420,23,21,157-947-201-686-965;;011-307-053-684-81X;;038-490-918-925-431;;114-517-649-646-486;;166-492-343-373-663;;096-317-125-842-948;;038-206-696-631-102;;050-885-886-277-521;;072-395-547-617-233;;001-596-965-870-798;;078-403-096-840-094;;028-650-332-166-498;;004-456-464-309-219;;175-833-149-417-043;;012-595-233-448-094;;035-886-556-173-632;;016-265-122-983-119;;118-843-647-887-744;;022-200-580-308-452;;071-211-641-209-775;;155-997-957-806-763,10.1021/bc00010a006;;1772904;;1518816;;pmc49829;;10.1073/pnas.89.17.7934;;7584089;;10.1021/bc00029a002;;7849066;;7584085;;8547238;;10.1021/bi952436a;;8750010;;10.1007/bf02789334;;7552693;;10.1021/bc00031a002;;7711106;;10.1074/jbc.270.42.24864;;7559609;;7619428;;10.1016/1045-1056(95)90004-7;;10.1016/0168-9525(95)90478-6;;10.1016/0169-409x(96)00002-6;;10.1016/0168-3659(96)01537-4;;9026036;;10.1021/bc960076d;;9001404;;10.1016/s0014-5793(96)01397-x;;7873664;;10.1021/bc00030a017;;10.1016/0960-894x(95)00187-x;;10.1089/hum.1995.6.9-1129;;8527471;;10.1016/0005-2736(95)00256-1;;8634302;;8607031;;8629036,"Ngo et al., in: The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.;;Wagner et al., ""DNA-Binding Transferrin Conjugates as Functional Gene-Delivery Agents: Synthesis by Linkage of Polylysine or Ethidium Homodimer to the Transferrin Carbohydrate Moiety"" Bioconjugate Chem. 2(4):226-231, 1991.;;Wagner et al., ""Influenza Virus Hemagglutinin HA-2 N-terminal Fusogenic Peptides Augment Gene Transfer by Transferrin-Polylysine-DNA Complexes: Toward a Synthetic Virus-Like Gene-Transfer Vehicle"" Proc. Natl. Acad. Sci. USA89 :7934-7938, Sep., 1992.;;Batra et al., ""Receptor-Mediated Gene Delivery Emplyong Lectin-Binding Specificity"" Gene Therapy1 :255-260, 1994.;;Behr et al., ""Gene Transfer With Synthetic Cationic Amphiphiles: Prospects for Gene Therapy"" Bioconjugate Chem. 5:382-389, 1994.;;Michael and Curiel, ""Strategies to Achieve Targeted Gene Delivery via the Receptor-Mediated Endocytosis Pathway"" Gene Therapy 1:223-232, 1994.;;Gao and Huang, ""Potentiation of Cationic Liposome-Mediated Gene Transfer Delivery by Polycations"" Biochemistry 35 :1027-1036, 1996.;;Gao and Huang, ""Cationic Liposome-Mediated Gene Tranfer"" Gene Therapy 2 :710-722, 1995.;;Guy et al., ""Delivery of DNA into Mammalian Cells by Receptor-Mediated Endocytosis and Gene Therapy"" Molecular Biology 3:237-248, 1995.;;Kabanov and Kabanov, ""DNA Complexes with Polycations for the Delivery of Genetic Material into Cells"" Bioconjugate Chem. 6 :7-20, 1995.;;Liu et al., ""Cationic Liposome-Mediated Intravenous Gene Delivery"" J. Biological Chemistry 270 (42):24864-24870, 1995.;;Phillips, ""Receptor-Mediated DNA Delivery Approaches to Human Gene Therapy"" Biologicals 23 :13-16, 1995.;;Remy et al., ""Targeted Gene Transfer into Hepatoma Cells With Lipopolyamine-Condensed DNA Particles Presenting Galactose Ligands: a Stage Toward Artificial Viruses"" Proc. Natl. Acad. Sci. USA 92 :1744-1748, Feb., 1995.;;Lasic and Tenpleton, ""Liposomes in Gene Therapy"" Advanced Drug Delivery Reviews 20:221-226, 1996.;;Tomlinson and Rolland, ""Controllable Gene Therapy Pharmaceutics of Non-Viral Gene Delivery Systems"" J. Controlled Release 39 :357-372, 1996.;;Legendre et al., ""Dioleoylmelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells"" Bioconjugate Chem. 8 :57-63, 1997.;;Behr et al., ""The Proton Sponge: a Trick to Enter Cells the Viruses did not Exploit"" Chimia 51 :34-36 (1997).;;Hong et al., ""Stabilization of Cationic Liposome-Plasmid DNA Complexes by Polyamines and Poly(ethylene glycol)-phospholipid Conjugates for Efficient in vivo Gene Delivery"" FEBS Letters400 :233-237 (1997).;;Merwin et al., ""Targeted Delivery of DNA Using YEE(GalNAcAH)3, a Synthetic Glyopeptide Ligand for the Asialoglycoprotein Receptor"" Bioconjugate Chemistry 5 (6):612-620 (1994).;;Richter and Zuckermann, ""Synthesis of Peptide Nucleic Acids (PNA) by Submonomer Solid-Phase Synthesis"" 5(11):1159-1162 (1995).;;Ledley (Human Gene Ther. (1995) 6:1129-1144).*;;Wheeler et al. (Biochim. et Biophsica Acta 1280, 1996, 1-11).*;;Mastrangelo et al. (Seminars in Oncology, vol. 23, 1:4-21, 1996).*",EXPIRED
257,US,A1,US 2003/0185890 A1,020-436-902-374-662,2003-10-02,2003,US 27875102 A,2002-10-22,US 27875102 A;;US 9714465 W;;US 62092500 A;;US 91064797 A;;US 2386796 P,1996-08-13,Compositions and methods for polynucleotide delivery,"
   This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides. 
",ZUCKERMANN RONALD N.;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A.;;MURPHY JOHN E.;;COHEN FRED E.;;UNO TETSUO,ZUCKERMANN RONALD N;;DUBOIS-STRINGFELLOW NATHALIE;;DWARKI VARAVANI;;INNIS MICHAEL A;;MURPHY JOHN E;;COHEN FRED E;;UNO TETSUO,,https://lens.org/020-436-902-374-662,Patent Application,yes,7,15,17,17,0,A61K38/1816;;A61K38/2264;;A61K48/00;;A61K48/0008;;A61K48/0041;;C07K7/08;;C07K14/001;;C12N15/87;;C12N2810/858;;A61K47/645;;A61P11/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;A61P3/06;;A61P7/00;;A61P7/04;;A61P7/06;;A61P9/10;;A61P3/10;;A61K38/2264;;A61K48/00;;A61K48/0041;;A61K48/0008;;C07K7/08;;C07K14/001;;A61K38/1816;;C12N2810/858;;C12N15/87;;A61K47/645,A61K31/711;;A61K38/00;;A61K38/18;;A61K38/22;;A61K47/30;;A61K47/48;;A61K48/00;;A61P3/06;;A61P3/10;;A61P7/00;;A61P7/06;;A61P9/10;;A61P29/00;;A61P31/00;;A61P31/12;;A61P35/00;;C07K7/08;;C07K14/00;;C12N15/87,424/484;;514/8;;530/324;;530/325;;530/327;;530/326;;514/44,0,0,,,,EXPIRED
258,AU,A1,AU 2021/337589 A1,013-889-199-696-245,2023-03-30,2023,AU 2021/337589 A,2021-09-01,US 202063074241 P;;US 2021/0048588 W,2020-09-03,Diol desymmetrization by nucleophilic aromatic substitution,Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R,AMGEN INC,BEAVER MATTHEW G;;DENNIS JOSEPH;;DORNAN PETER K;;MENNEN STEVEN;;TEDROW JASON S;;LANGILLE NEIL FRED;;COHEN CAROLYN;;ROTHELI ANDREAS RENE,,https://lens.org/013-889-199-696-245,Patent Application,no,0,0,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07D519/00;;C07C205/59;;C07D267/12;;C07D513/10,,0,0,,,,PENDING
259,WO,A1,WO 2022/051317 A1,056-744-778-595-580,2022-03-10,2022,US 2021/0048588 W,2021-09-01,US 202063074241 P,2020-09-03,DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION,"Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R 1 is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof, compound A2, and salts and solvates thereof, and compound A3 and salts and solvates thereof. [INSERT COMPOUNDS HERE]",AMGEN INC,BEAVER MATTHEW G;;DENNIS JOSEPH;;DORNAN PETER K;;MENNEN STEVEN;;TEDROW JASON S;;LANGILLE NEIL FRED;;COHEN CAROLYN;;ROTHELI ANDREAS RENE,,https://lens.org/056-744-778-595-580,Patent Application,yes,5,2,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07D519/00;;C07C205/59;;C07D267/12;;C07D513/10,,0,0,,,,PENDING
260,CA,A1,CA 3193132 A1,069-552-712-077-073,2022-03-10,2022,CA 3193132 A,2021-09-01,US 202063074241 P;;US 2021/0048588 W,2020-09-03,DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION,"Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R1 is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof, compound A2, and salts and solvates thereof, and compound A3 and salts and solvates thereof. [INSERT COMPOUNDS HERE]",AMGEN INC,BEAVER MATTHEW G;;DENNIS JOSEPH;;DORNAN PETER K;;MENNEN STEVEN;;TEDROW JASON S;;LANGILLE NEIL FRED;;COHEN CAROLYN;;ROTHELI ANDREAS RENE,,https://lens.org/069-552-712-077-073,Patent Application,no,0,0,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07C205/59;;C07D267/12;;C07D513/10;;C07D519/00,,0,0,,,,PENDING
261,CL,A1,CL 2023000605 A1,067-962-675-519-651,2023-08-11,2023,CL 2023000605 A,2023-03-02,US 202063074241 P,2020-09-03,Desimetrización de diol mediante sustitución aromática nucleófila,"Se proporcionan en la presente procesos para sintetizar inhibidores de Mcl-1 y productos intermedios tales como el compuesto Y que pueden usarse para prepararlos, donde el R1 variable es tal como se define en la presente. En particular, se proporcionan en la presente procesos para sintetizar el compuesto A1, y sales o solvatos del mismo, el compuesto A2, y sales y solvatos del mismo, y el compuesto A3 y sales y solvatos del mismo.",AMGEN INC,JASON S TEDROW;;MATTHEW G BEAVER;;NEIL FRED LANGILLE;;JOSEPH DENNIS;;PETER K DORNAN;;STEVEN MENNEN;;CAROLYN COHEN;;ANDREAS RENE ROTHELI,,https://lens.org/067-962-675-519-651,Patent Application,no,0,0,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07C205/59;;C07D267/12;;C07D513/10;;C07D519/00,,0,0,,,,PENDING
262,KR,A,KR 20230058694 A,103-722-731-557-531,2023-05-03,2023,KR 20237010991 A,2021-09-01,US 202063074241 P;;US 2021/0048588 W,2020-09-03,친핵성 방향족 치환에 의한 디올 탈대칭화,"Mcl-1 억제제 및 이를 제조하는 데 사용될 수 있는 화합물 Y와 같은 중간체의 합성 방법이 본원에 제공되고, 변수 R1은 본원에 정의된 바와 같다. 특히, 화합물 A1 및 이의 염 또는 용매화물, 화합물 A2 및 이의 염 및 용매화물, 및 화합물 A3 및 이의 염 및 용매화물의 합성 방법이 본원에 제공된다. JPEGpct00226.jpg8794",AMGEN INC,BEAVER MATTHEW G;;DENNIS JOSEPH;;DORNAN PETER K;;MENNEN STEVEN;;TEDROW JASON S;;LANGILLE NEIL FRED;;COHEN CAROLYN;;ROTHELI ANDREAS RENE,,https://lens.org/103-722-731-557-531,Patent Application,no,0,0,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10,,0,0,,,,PENDING
263,EP,A1,EP 4208467 A1,020-443-383-184-386,2023-07-12,2023,EP 21778303 A,2021-09-01,US 202063074241 P;;US 2021/0048588 W,2020-09-03,DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION,,AMGEN INC,BEAVER MATTHEW G;;DENNIS JOSEPH;;DORNAN PETER K;;MENNEN STEVEN;;TEDROW JASON S;;LANGILLE NEIL FRED;;COHEN CAROLYN;;ROTHELI ANDREAS RENE,,https://lens.org/020-443-383-184-386,Patent Application,yes,0,0,10,10,0,C07D519/00;;C07D513/10;;C07D267/12;;C07C2602/10;;C07C201/12;;C07D519/00;;C07C201/12;;C07C2602/10;;C07D267/12;;C07D513/10;;C07C205/59;;C07C201/12;;C07C205/59;;C07D267/12;;C07D513/10;;C07C2602/10;;C07B2200/07;;C07D513/10;;C07D519/00,C07D519/00;;C07C205/59;;C07D267/12;;C07D513/10,,0,0,,,,PENDING
264,US,A1,US 2022/0110975 A1,128-724-585-980-775,2022-04-14,2022,US 202117499157 A,2021-10-12,US 202117499157 A;;US 202063090539 P,2020-10-12,METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS,"This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and a microRNA are provided herein. Also provided are methods of treating an autoimmune disease that include administering these T cells.",KYVERNA THERAPEUTICS INC,LEVINSON SARAH;;LEE JOHN;;TSAI JORDAN;;FLANDEZ JEANNE;;MAHNE ASHLEY;;WU FAYE;;FARINA SASHA;;SRIVASTAVA HARSH;;PARK JOSEPH;;GREVE JEFFREY;;COHEN FRED,KYVERNA THERAPEUTICS INC (2021-10-31),https://lens.org/128-724-585-980-775,Patent Application,yes,0,2,2,2,53,A61K35/17;;C12N5/0637;;C12N2310/141;;C12N2501/60;;C12N2510/00;;C07K14/4702;;C07K14/71;;A61K35/17;;C07K14/4702;;C07K14/71;;C12N5/0636;;C12N15/113;;C12N15/86;;C12N2310/141;;C12N2510/00;;C12N2740/15043,A61K35/17;;C07K14/47;;C07K14/71;;C12N5/0783;;C12N15/113;;C12N15/86,,0,0,,,,DISCONTINUED
265,WO,A1,WO 2022/081530 A1,013-336-260-600-151,2022-04-21,2022,US 2021/0054504 W,2021-10-12,US 202063090539 P,2020-10-12,A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS,"This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and a microRNA are provided herein. Also provided are methods of treating an autoimmune disease that include administering these T cells.",KYVERNA THERAPEUTICS INC,LEVINSON SARAH;;LEE JOHN;;TSAI JORDAN;;FLANDEZ JEANNE;;MAHNE ASHLEY;;WU FAYE;;FARINA SASHA;;SRIVASTAVA HARSH;;PARK JOSEPH;;GREVE JEFFREY;;COHEN FRED,,https://lens.org/013-336-260-600-151,Patent Application,yes,2,0,2,2,53,A61K35/17;;C12N5/0637;;C12N2310/141;;C12N2501/60;;C12N2510/00;;C07K14/4702;;C07K14/71;;A61K35/17;;C07K14/4702;;C07K14/71;;C12N5/0636;;C12N15/113;;C12N15/86;;C12N2310/141;;C12N2510/00;;C12N2740/15043,C12N5/0783;;A61K35/17,,13,10,071-483-273-360-314;;017-015-078-738-224;;031-117-123-575-298;;123-209-660-962-414;;003-587-642-570-190;;016-357-117-432-062;;130-453-865-029-933;;149-411-029-485-225;;003-587-642-570-190;;079-354-653-132-583,30927737;;10.1016/j.intimp.2019.03.009;;pmc2637310;;19098714;;10.1038/embor.2008.224;;10.1016/j.jaut.2020.102438;;32184036;;29445371;;10.3389/fimmu.2018.00057;;pmc5797736;;10.1093/intimm/dxp095;;19737784;;10.1126/science.1079490;;12522256;;pmc6276865;;28910978;;10.1093/abbs/gmx079;;29119056;;pmc5665854;;10.1093/intimm/dxp095;;19737784;;10.1016/j.cyto.2015.07.005;;26165923;;pmc4969074,"CHAO GAO ET AL: ""MiR-155 controls follicular Treg cell-mediated humoral autoimmune intestinal injury by inhibiting CTLA-4 expression"", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 71, 28 March 2019 (2019-03-28), NL, pages 267 - 276, XP055881968, ISSN: 1567-5769, DOI: 10.1016/j.intimp.2019.03.009;;BO HUANG ET AL: ""miR-142-3p restricts cAMP production in CD4(+)CD25(-) T cells and CD4(+)CD25(+) T-REG cells by targeting AC9 mRNA"", EMBO REPORTS, NATURE PUBLISHING GROUP, LONDON, GB, vol. 10, no. 2, 1 February 2009 (2009-02-01), pages 180 - 185, XP002679659, ISSN: 1469-221X, [retrieved on 20081219], DOI: 10.1038/EMBOR.2008.224;;ZHANG LIAN ET AL: ""Clinical significance of miRNAs in autoimmunity"", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 109, 14 March 2020 (2020-03-14), XP086125312, ISSN: 0896-8411, [retrieved on 20200314], DOI: 10.1016/J.JAUT.2020.102438;;HIPPEN KELI L. ET AL: ""Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease"", FRONTIERS IN IMMUNOLOGY, vol. 9, 31 January 2018 (2018-01-31), XP055881986, DOI: 10.3389/fimmu.2018.00057;;SAKAGUCHI ET AL., M 7 IMM ., vol. 21, no. 10, 2009, pages 1105 - 1111;;HORT ET AL., SCIENCE, vol. 299, 2003, pages 1057 - 1061;;LI ET AL., ACTA BIOCHIM. BIOPHYSC. SILL., vol. 49, no. 9, 2017, pages 792 - 99;;ANANDAGODA ET AL., J. CLIL . INVEST, vol. 129, no. 3, 1 March 2019 (2019-03-01), pages 1257 - 1271;;HAN, AM. J. CANCER RES., vol. 7, no. 10, 2017, pages 2081 - 2090;;LI ET AL., J. TRATIS!1. AFED., vol. 13, 2015, pages 271;;SAKAGUCHI ET AL., INT'1 IMMI N., vol. 21, no. 10, 2009, pages 1105 - 1111;;PANDIYAN ET AL., CYTOKINE, vol. 76, no. 1, 2015, pages 13 - 24;;""NCBI"", Database accession no. NP O5472β.2",PENDING
266,UA,C2,UA 101676 C2,124-112-577-758-485,2013-04-25,2013,UA A201102282 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND USES THEREOF","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR)., (I)",GENENTECH INC,COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/124-112-577-758-485,Limited Patent,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,EXPIRED
267,CA,A1,CA 2729045 A1,079-861-628-631-459,2010-02-04,2010,CA 2729045 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/079-861-628-631-459,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D487/04;;A61K31/519;;A61K31/529;;A61K31/5377;;A61K31/5383;;A61K31/55;;A61P35/00;;C07D471/04;;C07D471/14;;C07D471/18;;C07D498/14,,0,0,,,,DISCONTINUED
268,BR,A2,BR PI0911688 A2,054-372-453-832-915,2015-07-28,2015,BR PI0911688 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"""compostos de pirimidina, composições e métodos de uso""",,GENENTECH INC,BERGERON PHILIPPE;;ESTRADA ANTHONY;;LY CUONG;;ORTWINE DANIEL FRED;;COHEN FREDERICK;;LYSSIKATOS JOSEPH P;;LAU KEVIN HON LUEN;;KOEHLER MICHAEL F T;;ZHAO XIANRUI;;PEI ZHONGHUA,,https://lens.org/054-372-453-832-915,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,DISCONTINUED
269,WO,A1,WO 2010/014939 A1,150-570-416-991-981,2010-02-04,2010,US 2009/0052469 W,2009-07-31,US 8530908 P,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC;;BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/150-570-416-991-981,Patent Application,yes,5,46,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,1,0,,,See also references of EP 2318377A4,PENDING
270,MX,A,MX 2011001196 A,165-211-288-353-773,2011-05-30,2011,MX 2011001196 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC,PEI ZHONGHUA;;ORTWINE DANIEL FRED;;COHEN FREDERICK;;LYSSIKATOS JOSEPH P;;BERGERON PHILIPPE;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;ZHAO XIANRUI,,https://lens.org/165-211-288-353-773,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
271,AU,A1,AU 2009/276339 A1,190-612-206-362-857,2010-02-04,2010,AU 2009/276339 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"Pyrimidine compounds, compositions and methods of use",,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/190-612-206-362-857,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,INACTIVE
272,CN,A,CN 102171194 A,110-089-018-871-624,2011-08-31,2011,CN 200980139005 A,2009-07-31,US 2009/0052469 W;;US 8530908 P,2008-07-31,"Pyrimidine compounds, compositions and methods of use","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC,PHILIPPE BERGERON;;FREDERICK COHEN;;ANTHONY ESTRADA;;KOEHLER MICHAEL F T;;LUEN LAU KEVIN HON;;CUONG LY;;LYSSIKATOS JOSEPH P;;FRED ORTWINE DANIEL;;ZHONGHUA PEI;;XIANRUI ZHAO,,https://lens.org/110-089-018-871-624,Patent Application,no,5,1,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,DISCONTINUED
273,EP,A4,EP 2318377 A4,083-631-545-115-02X,2012-05-09,2012,EP 09803674 A,2009-07-31,US 2009/0052469 W;;US 8530908 P,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/083-631-545-115-02X,Search Report,no,1,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
274,AU,B2,AU 2009/276339 B2,164-499-052-217-870,2012-06-07,2012,AU 2009/276339 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"Pyrimidine compounds, compositions and methods of use","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/164-499-052-217-870,Granted Patent,no,4,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,INACTIVE
275,EP,B1,EP 2318377 B1,023-687-721-967-78X,2013-08-21,2013,EP 09803674 A,2009-07-31,US 2009/0052469 W;;US 8530908 P,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/023-687-721-967-78X,Granted Patent,yes,6,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
276,AU,A8,AU 2009/276339 A8,085-236-029-469-991,2011-03-03,2011,AU 2009/276339 A,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"Pyrimidine compounds, compositions and methods of use",,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/085-236-029-469-991,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,INACTIVE
277,MA,B1,MA 32580 B1,192-394-649-765-313,2011-08-01,2011,MA 33637 A,2011-02-22,US 8530908 P;;US 2009/0052469 W,2008-07-31,مركبات بيريميدين، التراكيب وطرق الاستعمال,يتعلق الاختراع بمركبات الصيغة الأولى، تضم المتزامرات الفراغية، المتزامرات الهندسية،التاوتوميرات،المذيبات، مواد أيضية وأملاح مقبولة صيدليا لها، والتي هي مفيدة لتعديل إشارة كيناز في علاقة مع pikk ،مثلا mtor، ولعلاج الأمراض (مثل السرطان) المعززة على الأقل في جزء منها من خلال اختلال مسار إشارة كيناز في علاقة مع pikk ،على سبيل المثال mtor .,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/192-394-649-765-313,Granted Patent,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
278,CO,A2,CO 6311051 A2,011-352-859-862-040,2011-08-22,2011,CO 11022828 A,2011-02-24,US 8530908 P,2008-07-31,"COMPUESTOS DE PIRIMIDINA, COMPOSICIONES Y METODOS DE USO","Se describen compuestos de la fórmula I, incluso sus estereoisómeros, isómeros geométricos, tautómeros, solvatos, metabolitos y sales farmacéuticamente aceptables, que son de utilidad en la modulación de la señalización de las quinasas relacionadas con PIKK, por ejemplo, mTOR y para el tratamiento de enfermedades (por ejemplo, cáncer) que son mediadas al menos en parte por la desregulación de la vía de señalización de PIKK (por ejemplo, mTOR).",GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ZHAO XIANRUI;;PEI ZONGHUA;;ORTWINE DANIEL FRED;;LYSSIKATOS P JOSEPH;;LY CUONG;;LAU KEVIN HON LUEN;;KOEHLER F T MICHAEL;;ESTRADA ANTHONY,,https://lens.org/011-352-859-862-040,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,DISCONTINUED
279,ES,T3,ES 2432821 T3,007-706-246-940-369,2013-12-05,2013,ES 09803674 T,2009-07-31,US 8530908 P;;US 2009/0052469 W,2008-07-31,"Compuestos de pirimidina, composiciones y métodos de utilización","Compuesto de fórmula I **Fórmula** o una sal farmacéuticamente aceptable del mismo, en el que en la fórmula I, A es un anillo heterocíclico de 5 a 8 miembros que tiene de 1 a 3 heteroátomos seleccionados independientementeentre N, O y S como vértices del anillo, y que tiene de 0 a 2 dobles enlaces; fusionado opcionalmente al anilloheterocíclico de A está un anillo arilo de 6 miembros o un anillo heteroarilo de 5 ó 6 miembros que tiene de 1 a 3heteroátomos seleccionados entre N, O y S; y en el que el anillo A, y si están presentes, el anillo arilo de 6 miembroso el anillo heteroarilo de 5 ó 6 miembros fusionados al mismo, están adicionalmente sustituidos con de 0 a 5sustituyentes RA seleccionados del grupo que consiste en -C(O)ORa,-C(O)NRaRb, -NRaRb, -OC(O)Rc, -ORa, -SRa, -S(O)2Rc, -S(O)Rc, -Rc, -(CH2)1-4-NRaRb, -(CH2)1-4-NRaC(O)Rc, -(CH2)1-4-ORa, -(CH2)1-4-SRa, -(CH2)1-4-S(O)2Rc25 , -(CH2)1-4-S(O)Rc, halógeno, F, Cl, Br, I, -NO2, -CN y -N3, en los que Ra y Rb se seleccionan independientemente entrehidrógeno, alquilo C1-6, haloalquilo C1-6, heteroalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, fenilo y -(CH2))1-4(fenilo), y opcionalmente Ra y Rb, junto con el átomo de nitrógeno al que está unido cada uno, se combinanpara formar un anillo heterocíclico de 3 a 7 miembros que comprende de 1 a 2 heteroátomos seleccionados entre N,O y S; Rc se selecciona entre alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, fenilo y -(CH2)1-4(fenilo), y cualquiera de dos sustituyentes unidos al mismo átomo en el anillo heterocíclico de 5 a 8 miembrosse combinan opcionalmente para formar un anillo carbocíclico de 3 a 5 miembros o un anillo heterocíclico de 3 a 5miembros sustituidos con 0-3 sustituyentes RA; R1 y R2 se combinan con los átomos a los que se unen para formar un anillo heterocíclico saturado de 5 a 8miembros que comprende -N(W)- como uno de los vértices del anillo, en el que W está representado por la fórmula i",GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/007-706-246-940-369,Granted Patent,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
280,EP,A1,EP 2318377 A1,054-211-943-433-311,2011-05-11,2011,EP 09803674 A,2009-07-31,US 2009/0052469 W;;US 8530908 P,2008-07-31,"PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",,GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/054-211-943-433-311,Patent Application,yes,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,ACTIVE
281,EC,A,EC SP11010796 A,168-717-177-624-929,2011-02-28,2011,EC SP11010796 A,2011-01-31,US 8530908 P,2008-07-31,"COMPUESTOS DE PIRIMIDINA, COMPOSICIONES Y MÉTODOS DE USO","Se describen compuestos de la fórmula I, incluso sus estereoisómeros, isómeros geométricos, tautómeros, solvatos, metabolitos y sales farmacéuticamente aceptables, que son de utilidad en la modulación de la señalización de las quinasas relacionadas con PIKK, por ejemplo, mTOR y para el tratamiento de enfermedades (por ejemplo, cáncer) que son mediadas al menos en parte por la desregulación de la vía de señalización de PIKK (por ejemplo, mTOR).",GENENTECH INC,LYSSIKATOS JOSEPH PETER;;BERGERON PHILIPPE;;ORTWINE DANIEL FRED;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;PEI ZHONGHUA;;ZHAO XIANRUI,,https://lens.org/168-717-177-624-929,Patent Application,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D239/02,,0,0,,,,PENDING
282,TW,A,TW 201018681 A,013-836-501-552-076,2010-05-16,2010,TW 98125944 A,2009-07-31,US 8530908 P,2008-07-31,"Pyrimidine compounds, compositions and methods of use","Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).",GENENTECH INC,BERGERON PHILIPPE;;COHEN FREDERICK;;ESTRADA ANTHONY;;KOEHLER MICHAEL F T;;LAU KEVIN HON LUEN;;LY CUONG;;LYSSIKATOS JOSEPH P;;ORTWINE DANIEL FRED;;PEI ZHONGHUA;;ZHAO XIAN-RUI,,https://lens.org/013-836-501-552-076,Patent of Addition,no,0,0,30,30,0,C07D471/14;;C07D471/18;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;C07D413/14;;A61K31/519;;C07D471/18;;C07D471/14,C07D471/04;;A61K31/506;;A61K31/519;;A61K31/5377;;A61P35/00;;C07D413/10;;C07D413/14;;C07D487/04;;C07D487/12;;C07D498/12,,0,0,,,,PENDING
283,CN,A,CN 116888638 A,176-335-806-223-455,2023-10-13,2023,CN 202280016761 A,2022-02-25,US 202163153723 P;;US 2022/0017840 W,2021-02-25,Patient response based biomarker topology quantification and assessment for multiple tissue types,"Methods and computer systems for classifying CD8T cell topologies using a patient response based linear truncation model are described herein. A plurality of histological images of tissue samples of a plurality of patients are received by a computer system. An image analysis is performed on the plurality of histological images to obtain CD8 + T cell abundance in tumor parenchyma and matrix in each of the plurality of histological images. A true inflammation score and a tumor infiltration score are determined based on polar coordinate transformation of CD8 + T cell abundance in the tumor parenchyma and matrix. A feature space is generated based on the true inflammation score and the tumor infiltration score, and a linear bound or a linear truncation between a plurality of classifications in the feature space is identified based on the true inflammation score, the tumor infiltration score, and patient response data.",BRISTOL MYERS SQUIBB CO,LI GUOQING C;;EDWARDS RICHARD;;ERI SIGRID;;COHEN DAVID N;;WOYCHIK JOHN B;;BASSI VIRGINIA A;;PANDYA DHAVAL;;TRILLO-TINOCO JORGE;;CHEN BRYAN J;;FISCHER ANTON;;GRAY FRED,,https://lens.org/176-335-806-223-455,Patent Application,no,0,0,7,7,0,G06V10/42;;G06V10/7715;;G06V20/698;;G06T7/0014;;G06T2207/10016;;G06T2207/10056;;G06T2207/30024;;G06T2207/30096;;G06V10/42;;G06V10/7715;;G06T2207/30024;;G06T2207/10056;;G06T7/0014;;G06T2207/10016;;G06V20/698;;G06T2207/30096;;G06V20/698;;G06V10/42;;G06V10/7715;;G06T7/0014;;G06T2207/10016;;G06T2207/10056;;G06T2207/30024;;G06T2207/30096,G06V10/42,,0,0,,,,PENDING
284,CN,A,CN 116529781 A,033-967-242-622-898,2023-08-01,2023,CN 202180072287 A,2021-08-31,US 202063072662 P;;US 2021/0048507 W,2020-08-31,Biomarker topology quantification and assessment of multiple tissue types,"Methods and computer systems for topologically classifying CD8T cells using artificial intelligence and machine learning are described herein. A plurality of histological images of tissue samples of a plurality of patients are received by a computer system. An image analysis is performed on the plurality of histological images to obtain CD8 + T cell abundance in tumor parenchyma and matrix in each of the plurality of histological images. A machine learning algorithm is then trained using the results of the image analysis and the CD8 + T cell abundance in the tumor parenchyma and matrix. Based on the training, a machine learning feature space containing a plurality of classifications is generated, and boundaries between the plurality of classifications in the machine learning feature space are identified.",BRISTOL MYERS SQUIBB CO,LI GUOQING C;;EDWARDS RICHARD;;ERI SIGRID;;COHEN DAVID N;;WOYCHIK JOHN B;;BASSI VIRGINIA A;;PANDYA DHAVAL;;TRILLO-TINOCO JORGE;;CHEN BRYAN J;;FISCHER ANTON;;GRAY FRED,,https://lens.org/033-967-242-622-898,Patent Application,no,0,0,11,11,0,G06V20/695;;G06F18/213;;G06F18/24323;;G06V20/695;;G06F18/213;;G06F18/24323;;G06V20/695;;G06V20/698;;G06V10/82;;G06V10/776;;G06N20/00;;G06T2207/30096;;G06V20/698;;G06T7/0012;;G06T2207/20081;;G06T2207/30096,G06V10/764;;G06N3/08;;G06T7/00;;G06V10/40;;G06V10/82;;G06V20/69,,0,0,,,,PENDING
